


20
20

Multimomics and Precision Medicine Joint Conference

多體學及精準醫學聯合會議

11/14 Sat
11/15 Sun

 長庚大學

主辦單位：台灣蛋白質學會 / 長庚大學

協辦單位：台灣生物資訊與系統生物學會

台灣基因醫學暨生物標記學會


台灣演化暨計算生物學學會

台灣精準醫學學會

台灣胞外體學會

科技部

Abcam 成立於1998年，至今已行銷超過130個國家，抗體品項目前多達66,500種，除了優質抗體以外，Abcam也擁有超過24,000種的高品質Proteins和Peptides產品，在各個研究領域Abcam一直都期望提供給研究人員最優質的產品，同時還提供最完善、全面、快速的服務與高效率的技術支援。



Primary Antibody

76,000+ 一級抗體；包含
19,000+ RabMAb® 兔單株抗體



Secondary Antibody

20,000+ 二級抗體；包含
240+ Alexa Fluor® 螢光二抗



ELISA Kit

1,400+ ELISA 免疫分析套組；
包含 900+ SimpleStep ELISA®



IHC & ICC Kit

300+ IHC & ICC 分析套組



Peptide & Protein

29,000+ 胜肽及重組蛋白



Small Molecules

5,700+ 小分子化合物



Cellular & Biochemical Kit

1,300+ 細胞與生化分析套組



Cell Lysates

500+ 細胞溶解物



Multiplex Kit

採用專利 FirePlex®
particle 技術

全方位免疫實驗研究試劑與服務解決方案 www.abcam.com



目錄 Content

大會主席歡迎詞 Welcome Remarks	4
籌備暨執行委員會 Organizing and Executive Committees	5
工作人員 Congress Staffs	7
注意事項 General Information	8
會議議程 Conference Program	9
特別演講 Keynote Speeches	12
特別演講 I Keynote Lecture I	13
特別演講 II Keynote Lecture II	23
特別演講 III Keynote Lecture III	31
受邀演講 Invited Speeches	39
台灣蛋白體學會 (TPS) 台灣胞外體學會 (TSEV)	39
台灣演化與計算生物學會 (TSECB) 台灣生物資訊與系統生物學會 (TBSB)	93
台灣基因醫學暨生物標記學會 (TGMBS) 台灣精準醫學學會 (TPMS)	141
科技新知分享 New Frontiers in the Development of Science and Biotechnology	190
學會資訊 Information of Societies	195
交通地圖 Maps	203
贊助廠商 Sponsors	209

大會主席歡迎詞 Welcome Remarks

由於知識的累積與科技的進步，生物現象的片面了解已無法滿足研究者的期待。近年來興起的生物分子高通量分析技術（high-throughput technologies）已廣泛地應用於核酸、蛋白質、代謝物小分子等研究領域，發展出各種定性與定量的體學（omics）分析平台，包括：基因體、轉錄體、蛋白質體、代謝體等。經由高通量分析技術產出的巨量數據又須仰賴生物資訊的工具開發與數據分析，才能將數據（data）轉換為訊息（information），進而被有效整合與精確解讀。此一多體學整合研究策略徹底顛覆了以往的單一體學的研究思維，讓研究人員更有機會探勘出以往無法得知的新線索。而（多）體學的分析與整合又以人類疾病相關研究居多，這些體學數據除了提供更全面更完整的資訊增加研究者對疾病的了解，更是找出新的致病機轉、用藥指標、與診斷或監控疾病的生物標誌的重要工具。



基於推廣多體學研究的初衷，國內三個體學相關學會(台灣生物資訊暨系統生物學會、台灣蛋白質學會、與台灣基因醫學暨生物標記學會)，首度於2019年12月7~8日聯合舉辦「2019多體學及精準醫學聯合會議」，為國內第一個多體學領域之聯合學術會議，成功的讓與會者快速獲知國內外多體學之最新進展與趨勢，獲得相當迴響與肯定。有了成功第一步的經驗，今年籌備委員會進一步邀請台灣演化與計算生物學會、台灣精準醫學學會、與台灣胞外體學會加入，共同籌辦「2020多體學及精準醫學聯合會議」，讓會議的成員擴及基因體、蛋白質體、代謝體、胞外體、生物資訊及後端的精準醫學臨床應用，更為完整豐富。希望結合六個學會的專業與力量，讓會議內容更多元精采，讓台灣的學子對新興的多體學與精準醫學領域有更多的了解，更促成不同領域之間的研究人員有更多交流與合作的機會。此次會議籌辦過程中遇到新冠病毒肆虐全球，因應此突發疫情，聯合會議隨即調整為現場直播的線上會議型式，但也提高了會議舉辦的複雜度與工作份量。在此要特別感謝所有來自各學會全力投入籌備會議的工作同仁、國內外受邀演講的專家學者及熱情贊助聯合會議的生技公司與廠商，並預祝聯合會議順利圓滿成功，參與會議的學員能透過線上直播及錄影重播觀看方式，完整掌握聯合會議所要傳遞的重要資訊，為多體學及精準醫學研究注入新的活水動力。



2020 多體學及精準醫學聯合會議 大會主席
台灣蛋白質學會 理事長

籌備暨執行委員會 Organizing and Executive Committees

總召集人：余兆松

總策畫：朱俐潔

籌備委員：

台灣蛋白體學會：余兆松理事長、朱俐潔秘書長

台灣生物資訊與系統生物學會：孫孝芳理事長、陳琮明秘書長

台灣基因醫學暨生物標記學會：鄭添祿理事長、莊智弘秘書長

台灣演化與計算生物學會：丁照棟理事長、王弘毅秘書長

台灣精準醫學學會：盧章智理事長、陳冀寬秘書長

台灣胞外體學會：沈湯龍理事長、周涵怡秘書長

總執行：蕭永晉

執行委員：

學術組：朱俐潔、陳琮明、莊智弘、王弘毅、陳冀寬、周涵怡、游佳融、
紀朗明

招商組：吳治慶、陳怡婷

會議直播組：簡昆鎰、張益峯、廖威超
啓迪國際 (<https://www.ginnet.com.tw>)

庶務組：蕭永晉、謝雅如

網站設計製作：朱俐潔
Embraced Studio (<https://www.embraced.co>)

大會秘書處：蔡淑娟

Chairman: Jau-Song Yu

Curator: Lichieh Julie Chu

Preparatory Committees:

Taiwan Proteomics Society

President Jau-Song Yu and Secretary-general L. Julie Chu

Taiwan Bioinformatics and Systems Biology Society

President H. Sunny Sun and Secretary-general Tsung-Ming Chen

Taiwan Genomic Medicine and Biomarker Society

President Tain-Lu Cheng and Secretary-general Chih-Hung Chuang

Taiwan Society of Evolution and Computational Biology

President Chau-Ti Ting and Secretary-general Hurng-Yi Wang

Taiwan Precision Medicine Society

President Jang-Jih Lu and Secretary-general Chi-Kuan Chen

Taiwan Society for Extracellular Vesicles

President Tang-Long Shen and Secretary-general Han-Yi E. Chou

Executive: Yung-Chin Hsiao

Executive Committees:

Academic Society: L. Julie Chu, Tsung-Ming Chen, Chih-Hung Chuang, Hurng-Yi Wang, Chi-Kuan Chen, Han-Yi E. Chou, Chia-Jung Yu, and Lang-Ming Chi

Sponsor Promotion: Chih-Ching Wu and Yi-Ting Chen

Livestream Affairs: Kun-Yi Chien, Ian Yi-Feng Chang, Wei-Chao Liao, and Global Intelligence Network (<https://www.ginnet.com.tw>)

General Affairs: Yung-Chin Hsiao and Ya-Ju Hsieh

Website Design and Construction: L. Julie Chu and Embraced Studio (<https://www.embraced.co>)

Secretariat: Shu-Chuan Tsai

工作人員 Congress Staff

吳 嘉 群	Chia-Chun Wu	黃 黎 莘	Jie-Xin Huang
林 育 存	Yu-Tsun Lin	劉 建 均	Chien-Chun Liu
洪 承 裕	Cheng-Yu Hung	劉 若 娟	Jo-Chuan Liu
涂 瑋 儒	Wei-Ju Tu	蕭 鼎 峰	Ting-Feng Hsiao
王 怡 媚	Yi-Mei Wang	張 榮 興	Rong-Shing Chang
王 怡 雯	Yi-Wen Wang	陳 思 帆	Szu-Fan Chen
王 柏 蓉	Po-Jung Wang	陳 盈 利	Yin-Li Chen
王 薇 淳	Wei-Shun Wang	陳 致 儒	Chih-Ju Chen
吳 淑 芳	Shu-Fang Wu	陳 筱 蕨	Hsiao-Wei Chen
李 怡 萱	Yi-Shiuan Li	陳 正 翰	Jen-Han Chen
周 孟 楷	Meng-Kai Chou	馮 香 菩	Hsiang-Pu Feng
周 采 瑩	Tsai-Ying Chou	黃 郁 盛	Yu-Sheng Huang
林 孟 瑾	Meng-Chin Lin	詹 琇 雅	Xiu-Ya Chan
林 怡 佩	Yi-Pei Lin	劉 巧 柔	Chiao-Rou Liu
林 書 帆	Shu-Fan Lin	劉 育 伶	Yu-Ling Liu
林 詩 語	Shih-Yu Lin	劉 昱 暄	Yu-Syuan Liou
林 岱 緣	Tai-Yuan Lin	劉 倚 姝	Yi-Wen Liu
洪 佳 瑜	Jia-Yu Ang	劉 晏 君	Yen-Chun Liu
洪 菊 米	Chu-Mi Hung	歐 陽 瑋 婷	Wei-Ting Ou Yang
徐 崧 鈞	Sung-Chun Hsu	蔡 佳 蓉	Chia-Jung Tsai
張 文 瑜	Wen-Yu Chang	鄧 乃 瑄	Nai-Hsuan Teng
張 育 勳	Yu-Xun Chang	顏 詩 穎	Shih-Ying Yen
張 欣 慈	Hsin-Tzu Chang	羅 御 伶	Yu-Ling Lo
張 峻 銘	Jun-Ming Chang	羅 際 勝	Ji-Sheng Lo
張 鈺	Yu Chang		

注意事項 General Information

會場

長庚大學 第二醫學大樓 B1 第一~三會議廳 (本次會議不開放觀眾進場)

網路

會場提供免費 Wi-Fi

名稱：mopm2020；密碼：20201114

名稱：mopm2020_1；密碼：20201114

報到櫃台

11/14 (六) 8:30-17:30

11/15 (日) 8:30-13:50

會議廳內

配合現場直播，發問請至演講台前特定位置

禁止飲食、手機請開靜音、全程配戴口罩

線上直播

凡報名繳費者，可用相同的帳號進入三間會議室，請從會議網站點擊直播連結。親臨會場之與會貴賓可掃描現場海報上的 QR code 進入會議室。登入帳號為註冊會議之 e-mail，密碼為@前的英文字母

例如：使用 tps@gate.sinica.edu.tw 註冊本次會議

帳號：tps@gate.sinica.edu.tw 密碼：tps

第一會議室



第二會議室



第三會議室



會議網站

會議首頁：<https://bit.ly/2020mopm>

會議議程：<https://reurl.cc/4mjEZ2>

會議結束後一週，每場演講均會剪輯為影片置於會議網站，請以網站註冊之帳號密碼登入觀看

晚宴

時間：11/14 (六) 17:00

地點：長庚高爾夫俱樂部 -- 桃園市龜山區舊路里長庚球場路 66 號

接駁車 16:30 自長庚大學台塑文物館旁發車 ([p.205](#))，前往長庚高爾夫俱樂部

19:30 自長庚高爾夫俱樂部發車，先返回長庚大學，再停靠機捷 A8 站

- ❖ 校園禁止吸菸
- ❖ 請配合現場量體溫、噴酒精、全程配戴口罩等防疫措施

會議議程 Conference Program Day 1

Nov. 14 th 2020 (Day one)	TPS & TSEV 第一會議廳	TSECB & TBSB 第二會議廳	TGMBS & TPMS Lectures in Chinese 第三會議廳 (中文演講)
08:40 - 09:10	來賓報到		
09:10 - 09:20	開幕式 (第一會議廳)		
09:20 - 10:10	特別演講 I (第一會議廳) 主持人：張玉生 特聘教授 (Dr. Yu-Sun Chang) 長庚大學 生物醫學研究所 講員：Dr. Henry Rodriguez Director of Office of Cancer Clinical Proteomics Research, NCI, NIH, USA 題目: Beyond Cancer Genomics: Toward Precision Medicine		
10:10 - 10:40	團體照 / 中場休息		
Section I	Multiomics 主持人：余兆松 主任 (Dr. Jau-Song Yu) 長庚大學 分子醫學研究中心	Population Genomics 主持人：王弘毅 教授 (Dr. Hung-Yi Wang) 國立台灣大學 臨床醫學研究所	Cell & Immune Therapy 主持人：蔡婉琪 副教授 (Dr. Wan-Chi Tsai) 高雄醫學大學 醫學檢驗生物技術學系
10:40 - 11:05	陳玉如 特聘研究員 (Dr. Yu-Ju Chen) 中央研究院化學研究所 Taiwan Cancer Proteogenomics Moonshot : Pathway to Next Generation Precision Medicine in Cancer	蔡懷寬 研究員 (Dr. Huai-Kuang Tsai) 中央研究院 資訊科學研究所 Deciphering the Multiple Facets of Gene Regulation via Multi-omics Data Integration and Analysis	林泰元 副教授 (Dr. Thai-Yen Ling) 國立臺灣大學 藥理學科 細胞治療的藥理觀點 The Pharmacology of Cellular Therapy
11:10 - 11:35	陳昌熙 教授 (Dr. Chang-Shi Chen) 國立成功大學 基礎醫學研究所 A Multiomic Analysis Reveals the Role of Fumarate in Regulating the Virulence of Enterohemorrhagic Escherichia Coli	吳育璋 副教授 (Dr. Yu-Wei Wu) 臺北醫學大學 醫學資訊研究所 Predicting Antimicrobial Resistance Activities from the Bacterial Pan-genomes Using Machine Learning Algorithms	莊國祥 副教授 (Dr. Kuo-Hsiang Chuang) 臺北醫學大學 生藥學研究所 Novel Anti-cancer Armed T Cell Therapeutic Technology
11:40 - 12:05	高承源 副研究員 (Dr. Cheng-Yuan Kao) 國家衛生研究院 免疫中心 A Multi-omics Analysis Reveals Novel Insights of Gut Microbiota Shaping and Inflammation Control	王禹超 副教授 (Dr. Yu-Chao Wang) 國立陽明大學 生物醫學資訊研究所 Identification of Genomic Predictors for Treatment Response to Cancer Immunotherapy Using Omics Data Analysis	陳寬寬 執行長 (Dr. Chi-Kuan Chen) 光晟生技研發中心 Pitfalls in Autologous Cellular Immunotherapy
12:10 - 12:35	TPS 線上時間	TSECB 線上時間	TGMBS 線上時間
科技新知分享			
12:40 - 13:20	台灣賽默飛世爾科技股份有限公司 Orbitrap Exploris™ Mass Spectrometry – The Preferred Platform for Proteomics	六學會理事長專訪 學會的回顧與展望	科睿唯安 Clarivate 使用AI工具加速研究創新
13:20 - 13:30			
13:30 - 14:20	特別演講 II (第一會議廳) 主持人：沈湯龍 教授 (Dr. Tang-Long Shen) 國立臺灣大學 植物病理與微生物學系 講員：Dr. Koji Ueda Project Leader, Cancer Precision Medicine Center, The Cancer Institute of JFCR, Japan 題目: Proteogenomic Approaches in Development of Cancer Liquid Biopsy and Precision Immunotherapy		
14:20 - 14:40	中場休息		
Section II	New Technology 主持人：陳逸然 副研究員 (Dr. Yet-Ran Chen) 中央研究院 農業生物科技研究中心	Bioinformatics 主持人：蔡正 講座教授 (Dr. Shaw-Jenq Tsai) 國立成功大學 生理學科暨研究所	Microbiota 主持人：黃啟儀 教授 (Dr. Ming-Yii Huang) 高雄醫學大學 醫學系
14:40 - 15:05	賴品光 助理研究員 (Dr. Pin-Kuang Lai) 中央研究院 原子與分子科學研究所 Multi-resolution Imaging of Cancer-derived Extracellular Vesicles and Exomers Identifies Distinct Biodistribution Profiles with Redirected Tropism	楊欣洲 研究員 (Dr. Hsin-Chou Yang) 中央研究院 統計科學研究所 Population Pharmacogenomics: Enrichment of Ancestry-informative Markers in Pharmacogenetic Loci	吳俊穎 教授/主任 (Dr. Chun-Ying Wu) 臺北榮民總醫院 醫學研究部轉譯研究科 Gut Microbiota, FMT and Human Diseases
15:10 - 15:35	許觀達 助理教授 (Dr. Guan-Da Syu) 國立成功大學 生物科技與產業科學系 Application of Functional Protein Microarray in Research and Drug Development	呂曉沛 助理教授 (Dr. Hsiao-Pei Lu) 國立成功大學 生物科技與產業科學系 The Application of Metagenomics, Metatranscriptomics, and Metabolomics on Ecological Issues	曾景鴻 總經理 (Dr. Ching-Hung Tseng) 微菌方舟生物科技股份有限公司 The Gut Microbiome in Human Health and Diseases, a Recent Perspective
15:40 - 16:05	簡昆鎰 副教授 (Dr. Kun-Yi Chien) 長庚大學 生化暨分子生物學科 A NanoLC-MS System for Single-cell Proteomic Analysis	江士昇 助理研究員 (Dr. Shih-Sheng Jiang) 國家衛生研究院 癌症研究所 Dissecting Tumor Microenvironment Using Gene Expression Profiling Data for Prognostic Biomarkers of OSCC	許庭源 醫師 (Dr. Ting-Yuan Hsu) 安未診所 Integrative Treatments of Advanced Cancers by Combined Both Cytokine-induced Killer Cells and Personalized Probiotic Therapy
16:20 - 16:30	集合乘坐接駁車		
17:00 - 19:30	晚宴 長庚高爾夫俱樂部餐廳		

會議議程 Conference Program Day 2

Nov. 15 th 2020 (Day two)	TPS & TSEV 第一會議廳	TSECB & TBSB 第二會議廳	TGMBS & TPMS Lectures in Chinese 第三會議廳 (中文演講)
08:40 - 09:10	來賓報到		
09:10 - 10:00	<p>特別演講 III (第一會議廳)</p> <p>主持人：丁照棟 教授 (Dr. Chau-Ti Ting) 國立臺灣大學 生態學與演化生物學研究所</p> <p>講員：Dr. Sarah A. Tishkoff</p> <p>David and Lyn Silfen University Professor, Department of Genetics, Perelman School of Medicine and Department of Biology, School of Arts and Sciences, University of Pennsylvania</p> <p>題目: Genomic Evolution and Adaptation in Africa: Implications for Health and Disease</p>		
10:00 - 10:30	中場休息		
Section III	<p>Extracellular Vesicles</p> <p>主持人：蔡少正 講座教授 (Dr. Shaw-Jenq Tsai)</p> <p>國立成功大學 生理學科暨研究所</p>	<p>Artificial Intelligence</p> <p>主持人：孫孝芳 主任 (Dr. H. Sunny Sun)</p> <p>國立成功大學 分子醫學研究所</p>	<p>Precision Medicine</p> <p>主持人：周輝政 副院長 (Dr. Hei-Jen Jou)</p> <p>臺安醫院</p>
10:30 - 10:55	<p>李華容 副研究員 (Dr. Hua-Jung Li)</p> <p>國家衛生研究院 細胞及系統醫學研究所</p> <p>Exosomes in Stem Cell Homeostasis, Cancer, and Regeneration Medicine</p>	<p>阮雪芬 特聘教授 (Dr. Hsueh-Fen Juan)</p> <p>國立臺灣大學 生命科學系</p> <p>AI for Drug Repositioning</p>	<p>王子豪教授紀念講座</p> <p>Memorial Lecture for Prof. Tzu-Hao Wang</p> <p>賴鴻政 副院長 (Dr. Hung-Cheng Lai)</p> <p>衛生福利部雙和醫院</p> <p>FemTech: Precision Women Health</p>
11:00 - 11:25	<p>王竹安 助理研究員 (Dr. Chu-An Wang)</p> <p>國立成功大學 分子醫學研究所</p> <p>The Function and Regulation of EV-VEGF-C in Pancreatic Cancer Early Metastasis</p>	<p>陳倩瑜 教授 (Dr. Chien-Yu Chen)</p> <p>國立臺灣大學 生物機電工程學系</p> <p>Whole Genome Sequencing Data Analysis Using Deep Learning</p>	<p>李妮鍾 醫師 (Dr. Ni-Chung Lee)</p> <p>台大醫院 基因醫學部暨小兒部</p> <p>兒童罕病的精準醫療 – 機會與挑戰</p> <p>Precision Medicine for Critically Ill Children – Opportunities and Challenges</p>
11:30 - 11:55	<p>徐瑋萱 助理教授 (Dr. Wei-Hsuan Hsu)</p> <p>國立成功大學 食品安全衛生暨風險管理研究所</p> <p>Development and Application of Extracellular Vesicles Derived from Probiotics</p>	<p>張家銘 助理教授 (Dr. Jia-Ming Chang)</p> <p>國立政治大學 資訊科學系</p> <p>Computational Protein Function Prediction</p>	<p>張璧月 主任 (Dr. Pi-Yueh Chang)</p> <p>林口長庚紀念醫院 檢驗醫學部</p> <p>我會得癌症嗎? 遺傳性癌症基因檢測經驗分享</p> <p>Am I Susceptible to Cancer?</p>
12:00 - 12:25	TSEV 線上時間	TBSB 線上時間	TPMS 線上時間
科技新知分享			
12:30 - 13:10	<p>法德利科技股份有限公司</p> <p>全球疫情帶來的醫藥產業新秩序 – 數據為王、有「它」就強!</p>	<p>六學會理事長專訪</p> <p>學會的回顧與展望</p>	<p>凱杰生物科技有限公司</p> <p>QIAGEN實現NGS樣本定序到數據分析解決方案</p>
13:10 - 13:30	Section IV		
Section IV	<p>Disease Biomarker & Mechanism</p> <p>主持人：周涵怡 副教授 (Dr. Han-Yi E. Chou)</p> <p>國立臺灣大學 口腔生物科學研究所</p>	<p>Genomics of Pathogens</p> <p>主持人：丁照棟 教授 (Dr. Chau-Ti Ting)</p> <p>國立臺灣大學 生態學與演化生物學研究所</p>	<p>Target Therapy</p> <p>主持人：盧章智 理事長 (Dr. Jang-Jih Lu)</p> <p>台灣精準醫學學會</p>
13:30 - 13:55	<p>徐丞志 副教授 (Dr. Cheng-Chih Hsu)</p> <p>國立臺灣大學 化學系</p> <p>Ambient Mass Spectrometry and Machine Learning for Disease Diagnosis</p>	<p>王弘毅 教授 (Dr. Hurng-Yi Wang)</p> <p>國立臺灣大學 臨床醫學研究所</p> <p>The Origin and Underlying Driving Forces of SARS-CoV-2 Outbreak</p>	<p>嚴成文 教授 (Dr. Chen-Wen Yen)</p> <p>國立中山大學 機械與機電工程學系</p> <p>睡眠醫學遇上機器學習</p> <p>When Sleep Medicine Meets Machine Learning</p>
14:00 - 14:25	<p>郭文宏 醫師 (Dr. Wen-Hung Kuo)</p> <p>台大醫院 一般外科</p> <p>Clinical Application of Circulation Extracellular mi-RNA in Breast Cancer</p>	<p>林明德 副教授 (Dr. Ming-Der Lin)</p> <p>慈濟大學 分子生物暨人類遺傳學系</p> <p>The Genome of Prohrihotermes Flavus: A Termite Species with High Salinity Tolerance</p>	<p>楊品安 主任 (Dr. Chin-An Yang)</p> <p>中國醫藥大學附設醫院 竹北分院</p> <p>精準用藥：從高維度次世代定序資訊分析談起</p> <p>Drug Selection Using High-dimensional NGS Data Analysis</p>
14:30 - 14:55	<p>吳子珩 執行長 (Dr. Tzu-Heng Wu)</p> <p>PlasmonicTron</p> <p>Engineered Aptamer Based Plasmonic Sensing Toward Exosome Liquid Biopsy and Beyond</p>	<p>顧銓 助研究員 (Dr. Chuan Ku)</p> <p>中央研究院 植物暨微生物學研究所</p> <p>Genome Content Evolution in Giant Viruses of Eukaryotes</p>	<p>楊博鈞 副總經理 (Dr. Eric P. Yang)</p> <p>奎克生技光電股份有限公司</p> <p>The Various Diagnostic Technologies for Precision Target Therapy</p>
15:10 - 15:30	閉幕式 (第一會議廳)		



HiFi Sequencing

For Highly Accurate Long-Read Sequencing

>99.9% High Accuracy:
A typical 20 kb HiFi read has ~8 incorrect bases



HiFi Sequencing




6000+ Publications



Latest updates


Benefits of the HiFi Reads:

- ✓ Long read lengths up to 25 kb
- ✓ High read accuracy >99.9%
- ✓ Easy library preparation
- ✓ Low coverage requirements to save valuable sample
- ✓ Small file sizes to minimize compute time
- ✓ A single technology solution for a range of applications



HiFi reads are generated by combining multiple consecutive observations of a DNA molecule (subreads), driving the accuracy of individual HiFi reads over >99.9%.

With PacBio® HiFi reads, you No Longer Need to Compromise between long read lengths and high accuracy sequencing.



A Single Technology Solution for A Range of Applications!

VARIANT DETECTION

WHOLE GENOME SEQUENCING

COMPLEX POPULATIONS

RNA SEQUENCING

TARGETED SEQUENCING

EPIGENETICS



特別演講

Keynote Speeches



Keynote Speeches – Moderator

Lecture I 11/14 9:20-10:00

Yu-Sun Chang, Ph.D. (張玉生)

Current position and professional experiences

- | | |
|------------------|---|
| 2020/2 ~ Present | Visiting Professor , Molecular Medicine Research Center, Chang Gung University |
| 2014 ~ 2020 | Chair Professor , Graduate Institute of Biomedical Sciences, Chang Gung University |
| 2005 ~ 2016 | Director , Molecular Medicine Research Center, Chang Gung University |
| 1999 ~ 2001 | Professor and Director , Graduate Institute of Basic Medical Sciences, Chang Gung University |



Research interest

1. Epstein-Barr virus and nasopharyngeal carcinoma
2. Cancer biology
3. Molecular medicine (biomarkers/biosignatures)

Short research summary

Dr. Chang received her Ph.D. degree from the graduate program of Microbiology, University of California at Davis. She has started her career in Chang Gung University since 1986, started by setting up the Department of Microbiology. Her research interest has been focused on

(1) Nasopharyngeal carcinoma/Epstein-Barr virus

The long term and continued research interest of her team is to understand the role of Epstein-Barr virus (EBV) in the development of nasopharyngeal carcinoma (NPC), and to study candidate biomarkers for early detection, prognosis and therapy of NPC. Her team has contributed few pioneered research including a) discovery multiple NPC-associated loci within the HLA region at Chromosome 6p21.3 by genome-wide association study (GWAS); b) Discovery and verification of NPC biomarkers for translational study; c) Functional studies of EBV-encoded oncogene latent membrane protein 1 (LMP1); and d) Biological and clinical role of inflammasomes in NPC.

(2) Cancer Biomarkers and translational application

Dr. Chang has initiated the cancer biomarker studies since 2003 mainly through collaboration with clinical colleagues: a) Collaboration with colleagues or groups from Chang Gung Molecular Medicine Research Center/Chang Gung Memorial Hospital on cancer biomarkers-directed translational research; b) Collaboration with National Cancer Institute, NIH, USA and International Cancer Proteogenome Consortium (associated with the US Cancer Moonshot project) on oral squamous cell carcinoma.

Publications

1. Chang PY, Chen CC, Chang YS, Tsai WS, You JF, Lin GP, Chen TW, Chen JS, Chan EC. 2016. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. *Oncotarget* 7(9):10663-75.
2. Wu CS, Chang KP, OuYang CN, Kao HK, Hsueh C, Chen LC, Cheng HY, Liang Y, Liou W, Liang CL, *Chang YS. 2016. ASC contributes to metastasis of oral cavity squamous cell carcinoma.

Keynote Speeches – Moderator

Lecture I 11/14 9:20-10:00

- Oncotarget 7(31):50074-50085.
- Chen H, Hsiao YC, Chiang SF, Wu CC, Lin YT, Liu H, Zhao H, Chen JS, Chang YS, Yu JS. 2016. Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. *Anal Chim Acta.* 933:144-55.
 - Wang HM, Lin TL, Kuo YC, Li HP, Chang KP, Lin CY, Fan HC, Lin AC, Hsieh CH, Tsang NM, Lee LY, Chan SC, Lui KW, Chang YS, Hsu CL. 2016. Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. *Oncotarget* 7(33):53217-53229
 - Fan PC, Chen CC, Chen YC, Chang YS, Chu PH. 2016. MicroRNAs in acute kidney injury. *Hum Genomics.* 10(1):29. (Review)
 - Yu JS, Chen YT, Chiang WF, Hsiao YC, Chu LJ, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Chia SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, *Chang YS, *Hartwell LH. 2016. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. *Proc Natl Acad Sci U S A.* 113(41):11549-11554.
 - Chung IC, OuYang CN, Yuan SN, Li HP, Chen JT, Shieh HR, Chen YJ, Ojcius D, Chu CL, Yu JS, Chang YS, and Lih-Chyang Chen. 2016. Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. *Scientific Reports* 6:36214.
 - Chen YT, Chen HW, Wu CF, Chu LJ, Chiang WF, Wu CC, Yu JS, Tsai CH, Liang KH, Chang YS, Wu M, OuYang WT. 2017. Development of a Multiplexed Liquid Chromatography Multiple-Reaction-Monitoring Mass Spectrometry (LC-MRM/MS) Method for Evaluation of Salivary Proteins as Oral Cancer Biomarkers. *Mol Cell Proteomics.* 2017 May;16(5):799-811.
 - Chuang WY, Chang H, Chang GJ, Wang TH, Chang YS, Wang TH, Yeh CJ, Ueng SH, Chien HP, Chang CY, Wan YL, Hsueh C. 2017. Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. *Histopathology* 70(6):986-999.
 - Hsiao YC, Chi LM, Chien KY, Chiang WF, Chen SF, Chuang YN, Lin SY, Wu CC, Chang YT, Chu LJ, Chen YT, Chia SL, Chien CY, Chang KP, Chang YS, Yu JS. 2017. Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. *Mol Cell Proteomics* 16(10):1829-1849
 - Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Po-Huang PJ, Wang J, Chang IYF, Yeh YM, Chen CD, Li HP, Luo JD, Tan BCM, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang KWF, Rodriguez H, Cheng MH, Myers JN, Chang KP, *Chang YS. 2017. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. *Nat Commun.*;8(1):465.
 - Hsiao YC, Chu LJ, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, Yu JS. 2018. Variability Assessment of 90 Salivary Proteins in Intra-Day and Inter-Day Samples from Healthy Donors by Multiple Reaction Monitoring-Mass Spectrometry. *Proteomics Clin Appl.* 2018 Mar; 12(2). doi: 10.1002/prca.201700039.
 - Li HP, Peng CC, Wu CC, Chen CH, Shih MJ, Huang MY, Lai YR, Chen YL, Chen TW, Tang P, Chang YS, Chang KP, Hsu CL. 2018. Inactivation of the tight junction gene CLDN11 by aberrant hypermethylation modulates tubulins polymerization and promotes cell migration in nasopharyngeal carcinoma. *J Exp Clin Cancer Res.* 37(1):102.
 - Li HP, Hsu CL, *Chang YS. 2018. Screening of nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA for at-risk population. *Annals of Nasopharynx Cancer.* (Editorial) doi: 10.21037/anpc.2018.03.01
 - Hsu CL, Lui KW, Chi LM, Kuo YC, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Huang MY, Lai YR, Yeh YM, Fan HC, Lin AC, Lu YJ, Hsieh CH, Chang KP, Tsang NM, Wang HM, Chang AY, Chang YS, Li HP.

Keynote Speeches – Moderator

Lecture I 11/14 9:20-10:00

2018. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma. *J Exp Clin Cancer Res.* 20;37(1):233.
16. Chung IC, Yuan SN, OuYang CN, Lin HC, Huang KY, Chen YJ, Chung AK, Chu CL, Ojcius DM, Chang YS, Chen LC. 2018. Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation. *Cell Death Dis.* 9(11):1109.
 17. Liu SC, Hsu T, Chang YS, Jiang SS, Chung AK, OuYang CN, Hsueh C, Yuh CH, Liu YP, Tsang NM. 2018. Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. *Nature Communications* 9:5105.
 18. Lee CC, Hsieh YJ, Chen SW, Fu SH, Hsu CW, Wu CC, Han W, Li Y, Tao H, Chang YS, Yu JS, Li L, Chang CH, Chen YT. 2018. Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. *Scientific Reports* 8(1):17774.
 19. Lin WC, Chakraborty A, Huang SC, Wang PY, Hsieh YJ, Chien KY, Lee YH, Chang CC, Tang HY, Lin YT, Tung CS, Luo JD, Chen TW, Lin TY, Cheng ML, Chen YT, Yeh CT, Liu JL, Sung LY, Shiao MS, Yu JS, Chang YS, Pai LM. 2018. Histidine-Dependent Protein Methylation Is Required for Compartmentalization of CTP Synthase. *Cell Rep.* 24(10):2733-2745.
 20. Tsai CH, Chen YT, Chang YH, Hsueh C, Liu CY, Chang YS, Chen CL, Yu JS. 2018. Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens. *Oncotarget.* 9(56):30731-30747.
 21. Hsu CW, Chen YT, Hsieh YJ, Chang KP, Hsueh PC, Chen TW, Yu JS, Chang YS, Li L, Wu CC. 2019. Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. *Analytica Chimica Acta.* 1050:113-122.
 22. Chung IC, OuYang CN, Yuan SN, Lin HC, Huang KY, Wu PS, Liu CY, Tsai KJ, Loi LK, Chen YJ, Chung AK, Ojcius DM, *Chang YS, Chen LC. 2019. Pretreatment with a Heat-Killed Probiotic Modulates the NLRP3 Inflammasome and Attenuates Colitis-Associated Colorectal Cancer in Mice. *Nutrients.* 11(3). 11(3), 516.
 23. Fan PC, Chen CC, Peng CC, Chang CH, Yang CH, Yang C, Chu LJ, Chen YC, Yang CW, Chang YS, Chu PH. 2019. A circulating miRNA signature for early diagnosis of acute kidney injury following acute myocardial infarction. *Journal of Translational Medicine* 17:139.
 24. Chung AK, OuYang CN, Liu H, Chao M, Luo JD, Lee CY, Lu YJ, Chung IC, Chen LC, Wu SM, Tsang NM, Chang KP, Hsu CL, Li HP, *Chang YS. 2019. Targeted sequencing of cancer-related genes in nasopharyngeal carcinoma identifies mutations in the TGF- β pathway. *Cancer Med.* 8(11):5116-5127.
 25. Chung IC, Chen LC, Tsang NM, Chuang WY, Liao TC, Yuan SN, OuYang CN, Ojcius DM, Wu CC, *Chang YS. 2020. Mitochondrial oxidative phosphorylation complex regulates NLRP3 inflammasome activation and predicts patient survival in nasopharyngeal carcinoma. *Mol Cell Proteomics.* 19 (1) 142-154.
 26. Chung IC, Yuan SN, Chun-Nan OuYang CN, Hu SI, Lin HC, Huang KY, Lin WN, Chuang YT, Chen YJ, Ojcius DM, Chang YS, Chen LC. 2020. EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment. *Cytokine.* 2019 Dec 11;127:154951.
 27. Chen CC, Peng CC, Fan PC, Chu PH, Chang YS, Chang CH. 2020. Practical Procedures for Improving Detection of Circulating miRNAs in Cardiovascular Diseases. *Journal of Cardiovascular Translational Research*, published on line May 2020.
 28. Lin HC, Chen YJ, Wei YH, Chuang YT, Hsieh SH, Hsieh JY, Hsieh YL, Ojcius DM, Huang KY, Chung IC, Yuan SN, Chang YS, Chen LC. 2020. Cbl negatively regulates NLRP3 inflammasome activation through GLUT1-dependent glycolysis inhibition. *International Journal of Molecular Sciences* 21(14):5104.
 29. Yang CY, Liu CR, Chang IYF, OuYang CN, Hsieh CH, Huang YL, Wang CI, Jan FW, Wang WL, Tsai TL,

Keynote Speeches – Moderator

Lecture I 11/14 9:20-10:00

Liu H, Tseng CP, Chang YS, Wu CC, Chang KP.2020. Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. *Cancers*. *Cancers*, 12, 1726.

30. Wu CS, Chang YF, Hung JL, Liao WC, Lai YR, Chang KP, Li HP, *Chang YS. 2020. ASC modulates HIF-1 stability and induces cell mobility in OSCC. *Cell Death and Disease* 11(9):721.

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

Henry Rodriguez, Ph.D., M.S., MBA

Current position and professional experiences

- | | |
|----------------|---|
| 2006 ~ Present | Director , Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health; Bethesda, Maryland |
| 2008 ~ Present | Director , Antibody Characterization Program, National Cancer Institute, National Institutes of Health; Bethesda, Maryland |
| 2009 ~ Present | Senior Scientific Officer , National Cancer Institute, National Institutes of Health |
| 2016 ~ Present | Visiting Scholar (Professor) , Academia Sinica, Taipei, Taiwan |



Research interest

1. Precision oncology
2. Cancer biology
3. Genomics and proteomics metrology
4. Technology development

Short research summary

Dr. Henry Rodriguez is the founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), National Institutes of Health (NIH), and a member of the NCI Senior Leadership where he assists in the development of strategies and priorities to achieve the mission and goals of the NCI. Previously, Dr. Rodriguez served as at the Acting Deputy Director of the Center for Strategic Scientific Initiatives at the NCI, and held multiple roles at the National Institute of Standards and Technology, including Director of a research group and Health Sciences Program/Policy Analyst in the Office of the Director that involved coordination with the Department of Commerce Office of Financial Management, Congress, and the Department of Health and Human Services Secretary's Advisory Committee on Genetic, Health and Society.

Dr. Rodriguez has over 25 years of management and research experience, with a focus on understanding mechanisms of cancer and age-related diseases, including development of molecular-based technologies in basic and clinical science. Dr. Rodriguez is a member of several organizations, and is a recipient of numerous honors. Dr. Rodriguez has authored more than 140 original research papers, including co-editing a best-selling book on oxidative stress and aging. Dr. Rodriguez received his B.S. in biology/chemistry and M.S. in biology/toxicology from Florida International University, Ph.D. in cell and molecular biology from Boston University, and M.B.A. in finance and management from Johns Hopkins University Carey Business School. Fellowships were conducted at the Scripps Research Institute and City of Hope Comprehensive Cancer Center.

Publications

1. Xu Ze, Wu C; Xie F, Slysz G, Tolić N, Monroe M, Petyuk V, Payne S, Fujimoto G, Moore R, Fillmore T, Schepmoes A, Levine D, Townsend R, Davies S, Li S, Ellis M, Boja E, Rivers R, Rodriguez H, Rodland K, Liu T, Smith R. Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes. *J. Proteome Res.*, 2015, 14 (1), pp 422–433.

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

2. Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, MacLean B, Albertolle M, Allen S, Burgess M, Cusack MP, Ghosh M, Hedrick V, Held JM, Inerowicz D, Jackson A, Keshishian H, Kinsinger CR, Lyssand J, Makowski L, Mesri M, Rodriguez H, Rudnick P, Sadowski P, Sedransk N, Shaddox K, Skates SJ, Smith D, Whiteaker JR, Whitwell, Zhang S, Borchers CH, Fisher SJ, Gibson BW, Liebler C, MacCoss MJ, Neubert TA, Paulovich AG, Regnier FE, Tempst P, Carr SA. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. *Mol Cell Proteomics*, 2015 Oct 26. pii: mcp.M114.047480.
3. Ntai I, LeDuc RD, Fellers RT, Gilmore P, Davies S, Malone J, Early BP, Thomas PM, Ellis MJC, Fenyo, D, Boja ES, Rodriguez H, Townsend RR, Kelleher NL. Integrated Bottom-up and Top-down Proteomics of Patient-derived Breast Tumor Xenografts. *Mol Cell Proteomics*, 2015 Oct 26. pii: mcp.M114.047480.
4. Ruggles K, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan M, Clauser K, Tabb D, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena H, Xie L, Liu T, Zhou JY, Sun S, Hoadley K, Perou C, Chen X, Davies S, Maher C, Kinsinger C, Rodland K, Zhang H, Zhang Z, Ding L, Townsend R, Rodriguez H, Chan D, Smith R, Liebler D, Carr S, Payne S, Ellis M. An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. *Mol Cell Proteomics*, 2015 Dec 2. pii: mcp.M115.056226.)
5. Tabb D, Wang X, Carr S, Clauser K, Mertins P, Chambers M, Holman Jerry, Wang J, Zhang B, Zimmerman L, Chen X, Gunawardena H, Davies S, Ellis M, Li S, Townsend R, Boja E, Ketchum K, Kinsinger C, Mesri M, Rodriguez H, Liu T, Kim S, McDermott J, Payne S, Petyuk V, Rodland K, Smith R, Yang F, Chan D, Zhang B, Zhang H, Zhang Z, Zhou J-Y, Liebler D. Reproducibility of differential proteomic technologies in CPTAC fractionated xenografts. *J. Proteome Res.* 2016, 15 (3), pp 691–706.
6. Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, Townsend RR, Zimmerman LJ, Boja E, Chen J, Crimmins DL, Davies SR, Gao Y, Hiltke TR, Ketchum KA, Kinsinger CR, Mesri M, Meyer MR, Qian W-J, Schoenherr RM, Scott MG, Shi T, Whiteley GR, Wrobel JA, Wu C, Ackermann BL, Aebersold R, Barnidge DR, Bunk DM, Clarke N, Fishman JB, Grant RP, Kusebauch U, Kushnir MM, Lowenthal MS, Moritz RL, Neubert H, Patterson SD, Rockwood AL, Rogers J, Singh RJ, Van Eyk JE, Wong SH, Zhang S, Chan DW, Chen X, Ellis MJ, Liebler DC, Rodland KD, Rodriguez H, Smith RD, Zhang Z, Zhang H, and Paulovich AG. Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays. *Clinical Chemistry* 2016; v. 62, p.48-69.
7. Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, Wrobel JA, Kennedy J, Mani DR, Zimmerman LJ, Meyer MR, Mesri M, Boja E, Carr SA, Chan DW, Chen X, Chen J, Davies SR, Ellis MJ, Fenyo D, Hiltke T, Ketchum KA, Kinsinger C, Kuhn E, Liebler DC, Liu T, Loss M, MacCoss MJ, Qian WJ, Rivers R, Rodland KD, Ruggles KV, Scott MG, Smith RD, Thomas S, Townsend RR, Whiteley G, Wu C, Zhang H, Zhang Z, Rodriguez H, Paulovich AG. Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. *Methods Mol Biol.* 2016;1410:223-236.
8. Rudnick PA, Markey SP, Roth R, Mirokhin Y, Yan X, Tchekhovskoi D, Edwards NJ, Thangudu RR, Ketchum KA, Kinsinger CR, Mesri M, Rodriguez H, Stein SE. A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline. *J. Proteome Res.*, 2016, 15 (3), pp 1023–1032.
9. Mertins P, Mani DR, Ruggles K, Gillette M, Clauser K, Wang P, Wang X, Qiao J, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei J, Gatz M, Wilkerson M, Perou C, Yellapantula V, Huang KL, Lin C, McLellan M, Yan P, Davies S, Townsend R, Skates S, Wang J, Zhang B, Kinsinger C, Mesri M, Rodriguez H, Ding L, Paulovich A, Fenyo D, Ellis M, Carr SA & the NCI CPTAC. Proteogenomics connects somatic mutations to signaling in breast cancer. *Nature* (2016) May 25;534(7605):55-

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

- 62.
10. Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, Zhou J-Y, Petyuk VA, Chen L, Ray D, Sun S, Yang F, Chen L, Wang J, Shah P, Cha SW, Aiyetan P, Woo S, Tian Y, Gritsenko MA, Clauss TR, Choi C, Monroe ME, Thomas S, Nie S, Wu C, Moore RJ, Yu K-H, Tabb DL, Fenyö D, Bafna V, Wang Y, Rodriguez H, Boja ES, Hiltke T, Rivers R, Sokoll L, Zhu H, Shih I-M, Cope L, Pandey A, Zhang B, Snyder MP, Levine DA, Smith RD, Chan DW, Rodland KD, and the CPTAC investigators. Integrated proteogenomic characterization of human high grade serous ovarian cancer. *Cell* (2016) Jun 28. pii: S0092-8674(16)30673-0.
 11. Uhlen M, Bandrowski A, Bradbury A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T. A Proposal for Validation of Antibodies. *Nature Methods* (2016) doi:10.1038/nmeth.3995
 12. Wang J, Ma Z, Carr SA, Mertins P, Zhang H, Zhang Z, Chan D, Ellis MJ, Townsend RR, Smith RD, McDermott JE, Chen X, Paulovich AG, Boja ES, Mesri M, Kinsinger CR, Rodriguez H, Rodland KD, Liebler DC, Zhang B. Proteome profiling outperforms transcriptome profiling for co-expression based gene function prediction. *Mol Cell Proteomics*, 2016 Nov 11. pii: mcp.M116.060301. Epub 2016 Nov 11
 13. Fiore LD, Rodriguez H, Shriver CD. Collaboration to Accelerate Proteogenomics Cancer Care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics Organizational and Learning (APOLLO) Network. *Clin Pharmacol Ther*. 18 April 2017;Vol: 101, Pages: 619–621 DOI: 10.1002/cpt.658
 14. Huang K-I, Li S, Mertins P, Gunawardena HP, Cao S, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski M, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Kawaler E, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Townsend RR, Chen X, Carr SA, Ellis MJ, Ding L. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. *Nature Communications*, 2017; 8:14864 DOI: 10.1038/ncomms14864
 15. Chen T-W, Lee C-C, Liu H, Wu C-S, Pickering C, Huang P-J, Wang J, Chang I, Yeh Y-M, Chen C-D, Li H-P, Luo J-D, Tan B, Chan TEH, Hsueh C, Chu L, Chen Y-T, Zhang B, Yang C-Y, Wu C-C, Hsu C-W, See L-C, Tang P, Yu J-S, Liao W-C, Chiang K, Rodriguez H, Myers J, Chang K-P, Chang Y-S. APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. *Nature Communications*, 2017; Sep 6;8(1):465
 16. Zhou J-Y, Chen L, Zhang B, Tian Y, Liu T, Thomas S; Chen L, Boja E, Hiltke T, Kinsinger C, Rodriguez H, Davis S, Li S, Snider J, Erdmann-Gilmore P, Tabb D, Townsend R, Ellis M, Rodland K, Smith R, Carr S, Zhang Z, Chan D, Zhang H. Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. *J Proteome Res*. 2017 Dec 1;16(12):4523-4530.
 17. Aebersold R, Agar JN, Amster IJ, Baker MS, Bertozzi CR, Boja ES, Costello CE, Cravatt BF, Fenselau C, Garcia BA, Ge Y, Gunawardena J, Hendrickson RC, Hergenrother PJ, Huber CG, Ivanov AR, Jensen ON, Jewett MC, Kelleher NL, Kiessling LL, Krogan NJ, Larsen MR, Loo JA, Loo RO, Lundberg E, MacCoss MJ, Mallick P, Mootha VK, Mrksich M, Muir TW, Patrie SM, Pesavento JJ, Pitteri SJ, Rodriguez H, Saghatelian A, Sandoval W, Schlüter H, Sechi S, Sheeley DM, Slavoff SA, Smith LM, Snyder MP, Thomas PM, Uhlén M, van Eyk JE, Vidal M, Walt DR, White FM, Williams ER, Wohlschläger T, Wysocki VH, Yates NA, Young NL, Zhang B. How Many Human Proteoforms Are There? *Nat Chem Biol*. 2018 Feb 14;14(3):206-214.
 18. Ntaia I, Fornelli L, LeDua RD, Hutton JE, Doubleday PF, van Nispen AJ, Fellers RT, Whiteley G, Boja ES, Rodriguez H, and Kelleher NL. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification crosstalk. *Proc Natl Acad Sci U S A*. 2018 Apr 17;115(16):4140-4145.
 19. Qiu J, LaBaer J, Rodriguez H, Paulovich AG. Advancing Cancer Immunotherapy with

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

- Proteomics. The Global Forum, 2018, URL:<https://globalforum.diaglobal.org/issue/february-2018/advancing-cancer-immunotherapy-with-proteomics>
20. Rodriguez H and Pennington S. Revolutionizing Precision Oncology Through Collaborative Proteogenomics and Data Sharing. *Cell*, 2018 Apr 19;173(3):535-539.
 21. Piehowski PD, Petyuk VA, Sontag RL, Gritsenko MA, Weitz KK, Fillmore TL, Makhoul H, Chuaqui RF, Boja ES, Rodriguez H, Lee JSH, Smith RD, Carrick DM, Liu T, and Rodland KD. Residual Tissue Repositories as a Resource for Population-based Cancer Proteomic Studies. *Clinical Proteomics*, 2018;15:26.
 22. Boja E, Tezak Z, Zhang B, Wang P, Johanson E, Hinton D, Rodriguez H. Right Data for Right Patient – A PrecisionFDA NCI-CPTAC Multi-omics Mislabeling Challenge. *Nature Medicine*, volume 24, p. 1301–1302 (2018)
 23. Mun D-G, Bhin J, Kim S, Kim H, Jung JH, Jung Y, Jang YE, Park JM, Kim H, Jung Y, Lee H, Bae J, Back S, Kim S, Kim S-J, Park H, Li H, Hwang K-B, Park YS, Yook JH, Kim BS, Kwon SY, Ryu SW, Park DY, Jeon TY, Kim DH, Lee J-H, Han S-U, Song KS, Park D, Park JW, Rodriguez H, Kim J, Lee H, Kim KP, Yang EG, Kim HK, Paek E, Lee S, Lee S-W, Hwang D. Proteogenomic Characterization of Human Early-Onset Gastric Cancer. *Cancer Cell*, Jan 14, 2019, volume 35, issue 1, P111-124.E10
 24. Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, McDermott JE, Clauss TR, Moore RJ, Zhao R, Monroe ME, Wang YT, Chambers MC, Slebos RJC, Lau KS, Mo Q, Ding L, Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. *Cell*, 2019 May 2;177(4):1035-1049.
 25. Bradshaw RA, Hondermarck H, Rodriguez H. Cancer Proteomics and the Elusive Diagnostic Biomarkers. *Proteomics*, 2019 Nov;19(21-22):e1800445; PMID: 31172665.
 26. Schoenherr RM, Huang D, Voytovich UJ, Ivey RG, Kennedy JJ, Saul RG, Colantonio S, Roberts RR, Knotts JG, Kaczmarczyk JA, Perry C, Hewitt S, Bocik W, Whiteley GR, Hiltke T, Boja ES, Rodriguez H, Whiteaker JR, Paulovich AG. A Dataset Describing a Suite of Novel Antibody Reagents for the RAS Signaling Network. *Scientific Data*, volume 6, Article number: 160 (2019).
 27. Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja ES, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-related Hepatocellular Carcinoma. *Cell*, 2019 Oct 3;179(2):561-577.
 28. Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih T-S, Chang H-Y, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho K-C, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geizler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H, and the NCI CPTAC Investigators. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. *Cell*, 2019 Oct 31;179(4):964-983.
 29. Dou Y, Kawaler EA, Zhou DC, Gritsenko MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Satpathy S, Liu W, Wu Y, Tsai C-F, Wen B, Li Z, Cao S, Moon J, Shi Z, Cornwell M, Wyczalkowski MA, Chu RK, Vasaikar S, Zhou H, Gao Q, Moore RJ, Li K, Sethuraman S, Monroe ME, Zhao R, Heiman D, Krug K, Clauser K, Kothadia R, Maruvka Y, Pico AR, Oliphant AE, Hoskins EL, Pugh SL, Beecroft SJI, Adams DW, Jarman JC, Kong A, Chang H-Y, Reva B, Liao Y, Rykunov D, Colaprico A, Chen XS, Czeakański A, Jędryka M, Matkowski R, Wiznerowicz M, Hiltke T, Boja E,

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

- Kinsinger CR, Mesri M, Robles AI, Rodriguez H, Mutch D, Fuh K, Ellis MJ, DeLair D, Thiagarajan M, Mani DR, Getz G, Noble M, Nesvizhskii AI, Wang P, Anderson ML, Levine DA, Smith RD, Payne SH, Ruggles KV, Rodland KD, Ding L, Zhang B, Liu T, Fenyö D, and the Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Characterization of Endometrial Carcinoma. *Cell*, 2020 Feb 20;180(4):729-748.e26
30. Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar S, Krug K, Petralia F, Li Y, Liang W-W, Reva B, Krek A, Ji J, Song X, Liu W, Hong R, Yao L, Blumenberg L, Savage SR, Wendl M, Wen B, Li K, Tang LC, MacMullan MA, Avanesian SC, Kane MH, Newton C, Cornwell M, Kothadia RB, Ma W, Yoo S, Mannan R, Vats P, Kumar-Sinha C, Kawaler E, Omelchenko T, Colaprico A, Geffen Y, Maruvka Y, Leprevost FDV, Veluswamy R, Hostetter G, Heiman D, Wyczalkowski MA, Kinsinger CR, Boja ES, Omenn GS, Chinnaiyan AM, Rodriguez H, Li QK, Jewell S, Thiagarajan M, Getz G, Zhang B, Fenyö D, Ruggles K, Cieslik M, Robles AI, Clauser KC, Govindan R, Wang P, Nesvizhskii AI, Ding L, Mani DR, Carr SA, Clinical Proteomic Tumor Analysis Consortium. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. *Cell*, 2020 Jul 9;182(1):200-225.e35
31. Chen Y-J, Roumeliotis TI, Chang Y-H, Chen C-T, Han C-L, Lin M-H, Chen H-W, Chang G-C, Chang Y-L, Wu C-T, Lin M-W, Hsieh M-S, Wang Y-T, Chen Y-R, Jonassen I, Ghavidel FZ, Lin Z-S, Lin K-T, Chen C-W, Xu P-Y, Hung C-T, Huang K-C, Yang H-C, Lin P-Y, Yen T-C, Lin Y-W, Wang J-H, Ragha L, Lin C-Y, Chen Y-S, Wu P-S, Lai C-T, Weng S-H, Su K-Y, Chang W-H, Tsai P-Y, Robles AI, Rodriguez H, Hsiao Y-J, Chang W-H, Sung T-Y, Chen J-S, Yu S-L, Choudhary JS, Chen H-Y, Yang PC, Chen Y-J. Proteogenomic Landscape of Early Stage Non-smoking Lung Adenocarcinoma in East Asia. *Cell*, 2020 Jul 9;182(1):226-244.e17Published online February 13, 2020)

Keynote Speeches – Speaker

Lecture I 11/14 9:20-10:00

Beyond Cancer Genomics: Toward Precision Medicine

Henry Rodriguez

National Cancer Institute, National Institutes of Health, USA

Although recent genomic landscape studies have provided a comprehensive map of the genetic alterations associated with human cancers, the direct consequences of these alterations on the functional proteome are not well understood. So while genomic markers can be used to determine predisposition to tumor development, unfortunately, molecularly targeted treatment strategies are not widely available for most cancers. Integration of proteomic data with genomic data (proteogenomics) facilitates to advance our understanding of the causes of cancer and narrow target selection for potential therapeutic intervention by providing increased granularity regarding cancer-relevant pathways triggered by somatic DNA variants or DNA copy number alterations. In particular, the analysis of phosphorylation and other post-translational modifications by mass spectrometry-based proteomics provides pathway insights not obtainable from genomic analysis alone. As such, proteogenomics provides an opportunity to generate new insights by melding the complexity of cancer genomics with cancer proteomics to more completely understand how somatic genomes activate aberrant signal transduction events that drive cancer pathogenesis, with the potential to fast become an essential part of laboratory medicine. This seminar will discuss how genomics, transcriptomics, and proteomics are being combined in the quest to understand the etiology of cancer – in basic clinical sample studies and translational research (clinical trials).

Keynote Speeches – Moderator

Lecture II 11/14 13:30-14:20

Tang-Long Shen, Ph.D. (沈湯龍)

Current position and professional experiences

Director, Center of Industry-Academia Cooperation, National Taiwan University

Director, Center for Biotechnology, National Taiwan University

Professor, Department of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan

Professor, Program of Genomics and Systems Biology, National Taiwan University, Taipei, Taiwan

President, Taiwan Society for Extracellular Vesicles (TSEV)



Research interest

1. Signal transduction (migration/cell cycle)
2. Pre-metastatic niche/exosomes/organotropism
3. Neurodegenerative and aging
4. Microbial secondary metabolites
5. Molecular plant-microbe interactions

Awards and honors

1. The American Society for Cell Biology (ASCB) 2001 annual meeting Predoctoral Travel Awards. 2001
2. Liu Memorial Award in Cornell University for an excellent progress in graduate program and high potential for a successful academic career. 2002
3. American Heart Association Postdoctoral Fellowship, USA 2003-2005
4. Blind Prevention Foundation Scholar Travel Award, USA 2010
5. The 6th Breast Cancer Outstanding Research Award, Breast cancer prevention foundation, Taiwan

Short research summary

Prof. Tang-Long Shen received his BS and MS degrees from National Taiwan University in the Department of Plant Pathology in 1991 and 1994, respectively, and obtained his PhD from Cornell University in the Department of Molecular Medicine in 2002. After his postdoc training in American Heart Association, Prof. Shen joined the Department of Plant Pathology and Microbiology at the National Taiwan University since 2004. His research explores varied subjects, including microbes, plants to human, to understand the basic mechanisms of various pathologic complications as well as how to utilize the microbial metabolites or natural product for human health. By using molecular biology, biochemistry and cellular biology approaches as well as animal models, Prof. Shen deciphers the molecular mechanism of cancer progression, especially how cancer cells interact with tumor microenvironment in cell migration, the formation of pre-metastatic niches and metastatic organotropism. Several key targets, including integrins, receptor tyrosine kinases (e.g. EGFR), non-receptor tyrosine kinases (e.g. FAK, Src), adaptor proteins (e.g. Grb7, C35) and cytokines as well as extracellular vesicles (e.g. exosomes), are main focuses. Additionally, Shen lab is also seeking useful natural products and de novo protein components in human cells including critical secondary metabolites from traditional Chinese medicinal fungi, *Cordyceps* spp, *Antrodia cinnamomea*, and metallothioneins, to apply for anti-cancer, anti-aging or other therapeutics.

Publications

Keynote Speeches – Moderator

Lecture II 11/14 13:30-14:20

1. Yu-Ling Tai, Pei-Yu Chu, I-Rui Lai, Hui-Yuan Tseng, Jun-Yang Liou, Jun-Lin Guan, Tang-Long Shen* (2015) An EGFR/Src-dependent $\beta 4$ Integrin/FAK complex contributes to the malignancy of breast cancer. *Scientific Reports* 5, 16408; doi: 10.1038/srep16408
2. Pei-Yu Chu, Tsia-Kun Li, Shih-Torng Ding, I-Rue Lai, Tang-Long Shen* (2010) EGF-induced Grb7 activation promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. *Journal Biological Chemistry* 285(38):29279-85
3. I-Rue Lai, Pei-Yu Chu, Hsiao-Sheng Lin, Jun-Yang Liou, Yee-Jee Jan, Jen-Chieh Lee, Tang-Long Shen* (2010) Autophosphorylation of Tyr-397 of focal adhesion kinase in gastric carcinoma and its clinical significance. *American Journal of Pathology* 177(4):1629-37 (This article is highlighted by *Nature Reviews Gastroenterology and Hepatology* 7, 592)
4. Bruno Costa-Silva, Nicole M. Aiello, Swarnima Singh, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Ayuko Hoshino, Milica Tešić Mark, Henrik Molina, Jenny Xiang, Tuo Zhang, Till-Martin Theilen, Guillermo García-Santos, Caitlin Williams, Yonathan Ararso, Yujie Huang, Gonçalo Rodrigues, Tang-Long Shen, et. al. (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nature Cell Biol.* 17(6):816-26.
5. Ayuko Hoshino*, Bruno Costa-Silva*, Tang-Long Shen*, et. al. (2015) Tumor exosome integrins determine organotropic metastasis. *Nature* 527(7578):329-35 (*co-first authors)
6. Yu-Ling Tai, I-Rue Lai, Yu-Ju Peng, Shih-Torng Ding, Tang-Long Shen* (2016) Activation of focal adhesion kinase through an interaction with $\beta 4$ integrin contributes to colon cancer progression. *FEBS letters* 590(12):1826-37
7. Huang CW, Hong TW, Wang YJ, Chen KC, Pei JC, Chuang TY, Lai WS, Tsai SH, Chu R, Chen WC, Sheen LY, Takahashi S, Ding ST, Shen TL* (2016) Ophiocordyceps formosana extract improves hyperglycemia and depression in an STZ-induced mouse model *BMC Complementary and Alternative Medicine* 16(1):310
8. Yu-Ling Tai, Li-Hsuan Tung, Yu-Chi Lin, Pei-Jung Lu, Pei-Yu Chu, Ming-Yang Wang, Wei-Pang Huang, Ko-Chien Lin, Hsinyu Lee, Tang-Long Shen* (2016) Grb7 Protein Stability Modulated by Pin1 in Association with Cell Cycle Progression. *PLoS One* 11(9):e0163617
9. Yu-Ling Tai, Ko-Chien Chen, Jer-Tsong Hsieh, Tang-Long Shen* (2018) Exosomes in cancer development and clinical applications. *Cancer Science* 109(8):2364-2374. doi: 10.1111/cas.13697.
10. Yueh-Chien Lin, Chien-Chin Chen, Wei-Min Chen, Kuan-Ying Lu, Tang-Long Shen, Yeong-Chin Jou, Cheng-Huang Shen, Norihiko Ohbayashi, Yasunori Kanaho, Yuan-Li Huang, Hsinyu Lee (2018) LPA1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer. *BBA - Molecular and Cell Biology of Lipids* 1863(10):1305-1315.
11. Tai YL, Chu PY, Lee BH, Chen KC, Yang CY, Kuo WH, Shen TL*. (2019) Basics and applications of tumor-derived extracellular vesicles. *J Biomed Sci.* 26(1):35.
12. Chu PY, Tai YL, Shen TL*. (2019) Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. *Cells* 8(5). doi: 10.3390/cells8050435.
13. Wu PY, Yu IS, Lin YC, Chang YT, Chen CC, Lin KH, Tseng TH, Kargren M, Tai YL, Shen TL, Liu YL, Wang BJ, Chang CH, Chen WM, Juan HF, Huang SF, Chan YY, Liao YF, Hsu WM, Lee H. (2019) Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma. *Cancer Res.* 79(21):5550-5562
14. Chun-Jung Lin, Eun-Jin Yun, U-Ging Lo, Yu-Ling Tai, Su Deng, Elizabeth Hernandez, Andrew Dang, Yu-An Chen, Debabrata Saha, Ping Mu, Ho Lin, Tsai-Kun Li, Tang-Long Shen, Chih-Ho Lai and Jer-Tsong Hsieh (2019) The Paracrine Induction of Prostate Cancer Progression by Caveolin-1. *Cell Death & Disease* 10(11):834. doi: 10.1038/s41419-019-2066-3.
15. Gao YL, Wang YJ, Chung HH, Chen KC, Shen TL, Hsu CC. Molecular networking as a dereplication strategy for monitoring metabolites of natural product treated cancer cells. (2019) *Rapid Commun Mass Spectrom.* doi: 10.1002/rcm.8549

Keynote Speeches – Moderator

Lecture II 11/14 13:30-14:20

16. Kuo TH, Chung HH, Chang HY, Lin CW, Wang MY, Shen TL, Hsu CC. (2019) Deep Lipidomics and Molecular Imaging of Unsaturated Lipid Isomers: A Universal Strategy Initiated by mCPBA Epoxidation. *Anal Chem.* 91(18):11905-11915. doi: 10.1021/acs.analchem.9b02667.
17. Chu PY, Tai YL, Shen TL. (2019) Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. *Cells.* 8(5). pii: E435. doi: 10.3390/cells8050435.
18. Li-En Lin; Chih-Lin Chen; Ying-Chen Huang; Hsin-Hsiang Chung; Chiao-Wei Lin; Ko-Chien Chen; Yu-Ju Peng; Shih-Torng Ding; Ming-Yang Wang; Tang-Long Shen; Cheng-Chih Hsu (2019) Precision Biomarker Discovery Powered by High Spatial Resolution Ambient Ionization Mass Spectrometry Imaging Using Microscopy Image Fusion. *Analytica Chimica Acta* 1100:75-87
19. I-Chen Hung, Tsung-Ming Chen, Jing-Ping Lin, Yu-Ling Tai, Tang-Long Shen and Shyh-Jye Lee (2020) Wnt5b integrates Fak1a to mediate gastrulation cell movements via Rac1 and Cdc42. *Open Biology* 10(2) :190273
20. Tai YL, Lin CJ, Li TK, Shen TL, Hsieh JT, Chen BPC. (2020) The role of extracellular vesicles in prostate cancer with clinical applications. *Endocr Relat Cancer.* pii: ERC-20-0021.R1. doi: 10.1530/ERC-20-0021.


Keynote Speeches – Speaker

Lecture II 11/14 13:30-14:20

Koji Ueda, Ph.D. (植田幸嗣)

Current position and professional experiences

2015 ~ Present **Group Leader,**
Cancer Proteomics Group
Project Leader,
Project for Realization of Personalized Cancer
Medicine
Cancer Precision Medicine Center,
Japanese Foundation for Cancer Research (JFCR)



Research interest

1. Proteogenomics
2. Cancer early detection
3. Cancer liquid biopsy
4. Cancer immunology

Short research summary

Dr. Koji Ueda is a Group Leader of Cancer Proteomics Group at Japanese Foundation for Cancer Research (JFCR). Dr. Ueda received his Ph.D degree from the University of Tokyo and has been involved in cancer genomics and proteomics researches for the past 15 years. His research interest focuses on the development of innovative proteomic technologies and application of them to establish novel cancer diagnosis. Especially, in recent years, he has worked on development of technologies for cancer liquid biopsy using extracellular vesicles. In Cancer Precision Medicine Center, JFCR, he also leads basic and translational research teams for cancer immunotherapy.

He has served as a council member of Japanese Cancer Association, a board member of Japanese Proteomics Society, and a board member of Japanese Society for Extracellular Vesicles.

Publications

1. Pathological processes in aqueous humor due to iris atrophy predispose to early corneal graft failure in humans and mice. Yamaguchi T, Higa K, Yagi-Yaguchi Y, Ueda K, Noma H, Shibata S, Nagai T, Tomida D, Yasu-Mimura R, Ibrahim O, Matoba R, Tsubota K, Hamrah P, Yamada J, Kanekura K, Shimazaki J*, Sci Adv (2020);6:eaz5195
2. Multiresolution Imaging Using Bioluminescence Resonance Energy Transfer Identifies Distinct Biodistribution Profiles of Extracellular Vesicles and Exosomes with Redirected Tropism. Wu AYT, Sung YC, Chen YJ, Chou STY, Guo V, Chien CY, Ko JJS, Yang AL, Huang HC, Chuang JC, Wu S, Ho MR, Ericsson M, Lin WW, Cheung CHY, Juan HF, Ueda K, Chen Y, Lai CPK*, Adv Sci (2020):in press
3. Proteomic Analysis of Extracellular Vesicles for Cancer Diagnostics. Wu AY, Ueda K, Lai CP*, Proteomics (2019);19:e1800162
4. Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N*, Thorac Cancer (2019);10:395-400
5. INKA2, a novel p53 target that interacts with the serine/threonine kinase PAK4. Liu YY, Tanikawa C, Ueda K, Matsuda K*, Int J Oncol (2019);54:1907-20
6. Leukocyte-associated immunoglobulin-like receptor 1 promotes tumorigenesis in RCC. Jingushi K, Uemura M, Nakano K, Hayashi Y, Wang C, Matsuzaki K, Kato T, Kawashima A, Ujike T, Nagahara

Keynote Speeches – Speaker

Lecture II 11/14 13:30-14:20

- A, Fujita K, Ueda K, Tsujikawa K, Nonomura N*, *Oncol Rep* (2019);41:1293-303
7. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA. Haga Y, Uemura M, Baba S, Inamura K, Takeuchi K, Nonomura N, Ueda K*, *Anal Chem* (2019);91:2247
 8. Citrullination of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and ALS Susceptibility. Tanikawa C, Ueda K, Suzuki A, Iida A, Nakamura R, Saichi N, Momozawa Y, Kamatani Y, Kubo M, Yamamoto K, Nakamura Y, Matsuda K*, *Cell Rep* (2018);22:1473-83
 9. Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin. Jingushi K, Uemura M, Ohnishi N, Nakata W, Fujita K, Naito T, Fujii R, Saichi N, Nonomura N, Tsujikawa K, Ueda K*, *Int J Cancer* (2018);142:607-17
 10. Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells. Deng B, Tarhan YE, Ueda K, Ren L, Katagiri T, Park JH, Nakamura Y*, *Neoplasia* (2018);20:1038-44
 11. Regulation of tubular recycling endosome biogenesis by the p53-MICALL1 pathway. Takahashi Y, Tanikawa C, Miyamoto T, Hirata M, Wang G, Ueda K, Komatsu T, Matsuda K*, *Int J Oncol* (2017);51:724-36
 12. EPSIN 3, A Novel p53 Target, Regulates the Apoptotic Pathway and Gastric Carcinogenesis. Mori J, Tanikawa C, Ohnishi N, Funauchi Y, Toyoshima O, Ueda K, Matsuda K*, *Neoplasia* (2017);19:185-95
 13. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Miyamoto T, Lo PHY, Saichi N, Ueda K, Hirata M, Tanikawa C, Matsuda K*, *Sci Adv* (2017);3:e1603204
 14. p53-independent p21 induction by MELK inhibition. Matsuda T, Kato T, Kiyotani K, Tarhan YE, Saloura V, Chung S, Ueda K, Nakamura Y, Park JH*, *Oncotarget* (2017);8:57938-47
 15. GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition. Lin J, Chung S, Ueda K, Matsuda K, Nakamura Y, Park JH*, *Neoplasia* (2017);19:43-53
 16. Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. Tarhan YE, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y, Park JH*, *Neoplasia* (2016);18:265-72
 17. Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors. Nakakido M, Tamura K, Chung S, Ueda K, Fujii R, Kiyotani K, Nakamura Y*, *Int J Oncol* (2016);49:868-76
 18. A plasma diagnostic model of human T-cell leukemia virus-1 associated myelopathy. Ishihara M, Araya N, Sato T, Saichi N, Fujii R, Yamano Y, Ueda K*, *Ann Clin Transl Neurol* (2015);2:231-40

Keynote Speeches – Speaker

Lecture II 11/14 13:30-14:20

Proteogenomic Approaches in Development of Cancer Liquid Biopsy and Precision Immunotherapy

Koji Ueda

Japanese Foundation for Cancer Research, Japan

Recent development and clinical application of liquid biopsy technologies have moved cancer diagnosis into a new stage. Indeed, a variety of liquid biopsy tools (cfDNA, extracellular vesicles (EVs), CTC, etc.) have been established and tested. However, a modality utilizing mutated proteins has been rarely assessed yet, mainly due to difficulties in comprehensive and sensitive detection. Here we present our approach to develop a diagnostic model based on a mutated protein panel in circulating EVs.

To globally identify mutated EV proteins, we constructed a mutated proteome database for mass spectrometric analysis, in which publicly-available 1,066,470 cancer-associated mutations were listed as peptide sequences. We extracted EVs from viable tissue samples (normal mucosa, primary colon cancer, and liver metastasis, $n = 17$) and performed proteome analysis using Orbitrap Fusion Lumos-FAIMS Pro LC/MS and the in-house mutated proteome database. Whole exome sequence analysis was also performed for the identical set of tissue samples. As the second part, EV mutated protein panel diagnostics for colon cancer was established using the multiple reaction monitoring (MRM) method on LCMS-8060 and a set of isotope labeled mutated peptide standards.

The LC/MS analysis identified 5,543 EV proteins including, importantly, 207 mutated proteins (FDR < 0.01). From this analysis, in addition to 31 common mutations in primary colon cancer and liver metastasis, 32 primary cancer-specific mutations, 58 metastasis-specific mutations were identified. Based on this list, results of whole exome analysis, and allele frequency information in public database, our challenge to establish EV mutated protein panel diagnostics for colon cancer will be shared in this presentation, for which 96-well automated EV isolation robot and the high throughput mass spectrometric absolute quantification method are employed.

On the other hand, immunotherapy has really revolutionized the treatment of cancer. Human leukocyte antigen (HLA) binding peptide (HLAp) with somatic mutation, recognized as a neoantigen, is considered as a key initiation factor of these cancer-specific immunological reactions. However, the global analysis of neoantigens remains difficult due to a technical limitation that a large amount of sample (> 1 g of a tissue block) is needed for in-depth analysis (> 5,000 HLAp identification).

To overcome this technological task, we optimized experimental conditions for isolation of MHC complexes and employed a leading-edge LC/MS system equipped with the high-field asymmetric ion mobility spectrometry (FAIMS) ion source. By use of this method, 11 neoantigens out of 6,767 HLAs were identified from 1.5×10^7 cells of HCT116 cells. For neoantigen identification, tailored protein data base was established from whole exome sequencing data individually and searched for HLAp with mutation. Here we present pairwise HLAp maps acquired from colon cancer tissues and adjacent normal mucosa ($n = 17$), identifying 44,499 non-redundant HLAs including 2 neoantigens. These methodology and knowledgebase could contribute to establishment of future innovative cancer immunotherapy.

樣品配置



SpectroArt 200
蛋白質/核酸定量 分光光譜儀



凝膠電泳



V-GES system / Power Supply
垂直電泳槽 / 電源供應器



Yrdimes Semi-Dry Blotter
半乾轉漬器



E-Blotter system
濕式轉漬器

轉漬



抗體偵測

TAYA 100XE
全自動西方墨點工作站



顯影拍照



KETA CLX
高感度冷光儀



封閉膜



Keynote Speeches – Moderator

Lecture III 11/15 9:10-10:00

Chau-Ti Ting, Ph.D. (丁照棣)

Current position and professional experiences

2020 ~ Present	Professor , Department of Life Science, National Taiwan University, Taiwan
2006 ~ 2020	Associate Professor , Department of Life Science, National Taiwan University, Taiwan
2004 ~ 2006	Associate Professor , Department of Life Science, National Tsing Hua University, Taiwan
2000 ~ 2004	Assistant Professor , Department of Life Science, National Tsing Hua University, Taiwan



Research interest

1. Molecular evolution
2. Population genetics and genomics
3. Speciation
4. *Drosophila* genetics

Short research summary

Dr. Chau-Ti Ting is a Professor of Department of Life Science at the National Taiwan University, Taiwan. Dr. Ting received her Ph.D. degree from the National Taiwan University and has been involved in population genetics and genomics researches for more than 20 years. Dr. Ting's research interest focuses on the genetics changes during species formation and her team has applied advanced molecular genetic techniques to investigate the phenotypic consequences and fitness differences. Her work on population genomics has also revealed the evolutionary dynamics of segmental duplications and the evolutionary forces acting on these segmental duplications. In addition to her primary role in research and teaching, Dr. Ting is also the Director of Center for International Academic Exchanges in College of Life Science.

Publications

1. Burlyaeva M, Vishnyakova M, Gurkina M, Konstanin K, Lee CR, Ting CT, Schafleitner R, Nuzhdin S, Samsonova M, von Wettberg E. 2019 Collections of Mungbean [*Vigna radiata*] (L.) R. Wilczek and urdbean [*V. mungo* (L.) Hepper] in Vavilov Institute (VIR): traits diversity and trends in the breeding process over the last 100 years. *Genet Resour Crop Evol* 66: 767–781. (doi.org/10.1007/s10722-019-00760-2).
2. Li J, Jiang L, Wu CI, Lu X*, Fang S*, and Ting CT*. 2019. Small segmental duplications in *Drosophila*—High rate of emergence and elimination. *Genome Biol Evol* 11: 486–496. (doi.org/10.1093/gbe/evz011)
3. Chen, C K, Yu CP, Li SC, Wu SM, Lu MJ, Chen JH, Chen RD, Ng SC, Ting CT*, and Li WH*. 2017. Identification and evolutionary analysis of long non-coding RNAs in zebra finch. *BMC Genomics* 18: 117. (doi: 10.1186/s12864-017-3506-z)
4. Chen CK, Ng CS, Wu SM, Chen JJ, Cheng PL, Wu P, Lu MJ, Chen DR, Chuong CM, Cheng HC*, Ting CT* and Li WH*. 2016. Regulatory differences in natal down development between altricial zebra finch and precocial chicken. *Mol Biol Evol* 33: 2030–2043.
5. Yang H, He B, Ma H, Tsaor SC, Ma C, Wu Y, Ting CT, Zhang YE*. 2015. Expression profile and gene age jointly shaped the genome-wide distribution of premature termination codons in *Drosophila* populations. *Mol Biol Evol* 32: 216–28

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

Sarah A. Tishkoff, Ph.D.

Current position and professional experiences

- 2012 ~ Present **David and Lyn Silfen University Professor**, Department of Genetics, Perelman School of Medicine and Department of Biology, School of Arts and Sciences, University of Pennsylvania (Penn Integrates Knowledge Professor)
- 2008 ~ 2012 **David and Lyn Silfen University Associate Professor**, Department of Genetics, Perelman School of Medicine and Department of Biology, School of Arts and Sciences, University of Pennsylvania (Penn Integrates Knowledge Associate Professor)
- 2005 ~ 2007 **Associate Professor**, University of Maryland, Department of Biology
- 2000 ~ 2005 **Assistant Professor**, University of Maryland, Department of Biology



Research interest

1. African integrative evolutionary genomics
2. African genomic and phenotypic diversity project
3. The genetic basis of resistance to infectious disease
4. The genetic basis of adaptation in humans

Short research summary

Dr. Tishkoff studies genomic and phenotypic variation in ethnically diverse Africans. Her research combines field work, laboratory research, and computational methods to examine African population history and how genetic variation can affect a wide range of traits – for example, why humans have different susceptibility to disease, how they metabolize drugs, and how they adapt through evolution. Dr. Tishkoff is a member of the National Academy of Sciences and a recipient of an NIH Pioneer Award, a David and Lucile Packard Career Award, a Burroughs/Wellcome Fund Career Award, an ASHG Curt Stern award, and a Penn Integrates Knowledge (PIK) endowed chair. She is a member of the Scientific Advisory Panel for the Packard Fellowships for Science and Engineering and the Board of Global Health at the National Academy of Sciences and is on the editorial boards at PLOS Genetics, Genome Research Journal, G3 (Genes, Genomes, and Genetics), and Cell.

Publications

1. Hunt SC, Hansen MEB, Verhulst S, McQuillan MA, Beggs W, Lai TP, Mokone GG, Mpoloka SW, Meskel DW, Belay G, Nyambo TB, Abnet CC, Yeager M, Chanock SJ, Province MA, Williams SM, Aviv A, Tishkoff SA. Genetics and Geography of Leukocyte Telomere Length in Sub-Saharan Africans. *Hum Mol Genet.* 2020 Aug 21:ddaa187. 2020
2. Mosbrugger TL, Dinou A, Duke JL, Ferriola D, Mehler H, Pagkrati I, Damianos G, Mbunwe E, Sarmady M, Lyratzakis I, Tishkoff SA, Dinh A, Monos DS. Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing. *Hum Immunol.* Aug;81(8):413-422. 2020.
3. Rubel MA, Abbas A, Taylor LJ, Connell A, Tanes C, Bittinger K, Ndze VN, Fonsah JY, Ngwang E, Essiane A, Fokunang C, Njamnshi AK, Bushman FD, Tishkoff SA. Lifestyle and the presence of helminths is associated with gut microbiome composition in Cameroonians. *Genome Biol.* May 25;21(1):122. doi: 10.1186/s13059-020-02020-4. 2020.

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

4. Gouveia MH, Borda V, Leal TP, Moreira RG, Bergen AW, Kehdy FSG, Alvim I, Aquino MM, Araujo GS, Araujo NM, Furlan V, Liboredo R, Machado M, Magalhaes WCS, Michelin LA, Rodrigues MR, Rodrigues-Soares F, Sant Anna HP, Santolalla ML, Scliar MO, Soares-Souza G, Zamudio R, Zolini C, Bortolini MC, Dean M, Gilman RH, Guio H, Rocha J, Pereira AC, Barreto ML, Horta BL, Lima-Costa MF, Mbulaiteye SM, Chanock SJ, Tishkoff SA, Yeager M, Tarazona-Santos E. Origins, admixture dynamics and homogenization of the African gene pool in the Americas. *Mol Biol Evol.* Mar 3. pii: msaa033. doi: 10.1093/molbev/msaa033. [Epub ahead of print], 2020.
5. McHenry ML, Bartlett J, Igo RP Jr, Wampande EM, Benchek P, Mayanja-Kizza H, Fluegge K, Hall NB, Gagneux S, Tishkoff SA, Wejse C, Sirugo G, Boom WH, Joloba M, Williams SM, Stein CM. Interaction between host genes and Mycobacterium tuberculosis lineage can affect tuberculosis severity: evidence for coevolution? *PLoS Genet.* Apr 30;16(4):e1008728. 2020.
6. Gouveia MH, Cesar CC, Santolalla ML, Anna HPS, Scliar MO, Leal TP, Araújo NM, Soares-Souza GB, Magalhães WCS, Mata IF, Ferri CP, Castro-Costa E, Mbulaiteye SM, Tishkoff SA, Shriner D, Rotimi CN, Tarazona-Santos E, Lima-Costa MF. Genetics of cognitive trajectory in Brazilians: 15 years of follow-up from the Bambuí-Epigen Cohort Study of Aging. *Sci Rep.* Dec 2;9(1):18085. 2019.
7. Lona-Durazo F, Hernandez-Pacheco N, Fan S, Zhang T, Choi J, Kovacs MA, Loftus SK, Le P, Edwards M, Fortes-Lima CA, Eng C, Huntsman S, Hu D, Gómez-Cabezas EJ, Marín-Padrón LC, Grauholm J, Mors O, Burchard EG, Norton HL, Pavan WJ, Brown KM, Tishkoff S, Pino-Yanes M, Beleza S, Marcheco-Teruel B, Parra EJ.. Meta-analysis of GWA studies provides new insights on the genetic architecture of skin pigmentation in recently admixed populations. *BMC Genet.* Jul 17;20(1):59, 2019.
8. Shaohua Fan, Derek E. Kelly, Marcia H. Beltrame, Matt EB. Hansen, Swapan Mallick, Thomas Nyambo, Sabah Omar, Dawit Wolde Meskel, Gurja Belay, Alain Froment, Nick Patterson, David Reich, Sarah A. Tishkoff. African evolutionary history inferred from whole genome sequence data, *Genome Biology*, 2Apr 26;20(1):82. 2019.
9. Scheinfeldt L , Sameer Soi, Charla Lambert, Wen-Ya Ko, Aoua Coulibaly, Alessia Ranciaro, Simon Thompson, Jibril Hirbo, William Beggs, Muntaser Ibrahim, Thomas Nyambo, Sabah Omar, Dawit Woldemeskel, Gurja Belay, Alain Froment, Junhyong Kim, Sarah Tishkoff. Genomic evidence for shared common ancestry of East African hunting-gathering populations and insights into local adaptation, *Proc Natl Acad Sci U S A*, Feb 19. pii: 201817678. doi: 10.1073/pnas.1817678116. [Epub ahead of print] PMID:30782801, 2019.
10. Gouveia MH, Bergen AW, Borda V, Nunes K, Leal TP, Ogwang MD, Yeboah ED, Mensah JE, Kinyera T, Otim I, Nabalende H, Legason ID, Mpoloka SW, Mokone GG, Kerchan P, Bhatia K, Reynolds SJ, Birtwum RB, Adjei AA, Tettey Y, Tay E, Hoover R, Pfeiffer RM, Biggar RJ, Goedert JJ, Prokunina-Olsson L, Dean M, Yeager M, Lima-Costa MF, Hsing AW, Tishkoff SA, Chanock SJ, Tarazona-Santos E, Mbulaiteye SM. Genetic signatures of gene flow and malaria-driven natural selection in sub-Saharan populations of the "endemic Burkitt Lymphoma belt. *PLoS Genet.* Mar 8;15(3):e1008027. doi: 10.1371. 2019.
11. Matthew EB Hansen, Meagan A. Rubel, Aubrey G. Bailey, Alessia Ranciaro, Simon R. Thompson, Michael C. Campbell, William Beggs, Jaanki R. Dave, Gaonyadiwe G. Mokone, Sununguko Wata Mpoloka, Thomas Nyambo, Christian Abnet, Stephen J. Chanock, Frederic D. Bushman & Sarah A. Tishkoff*. Population structure of human gut bacteria in a diverse cohort from rural Tanzania and Botswana. *Genome Biology*, Jan 22;20(1):16. doi: 10.1186. 2019.
12. Bamford CGG, Aranday-Cortes E, Filipe IC, Sukumar S, Mair D, Filipe ADS, Mendoza JL, Garcia KC, Fan S, Tishkoff SA, McLauchlan J. A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages. *PLoS Pathog.* Oct 11;14(10):e1007307. doi: 10.1371/journal.ppat.1007307. 2018
13. Hey J, Chung Y., Sethuraman A., Lachance J., Tishkoff S, Sousa V.C., Wang Y. Phylogeny

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

- Estimation by Integration over Isolation with Migration Models. *Mol Biol Evol.* Aug 20. doi: 10.1093/molbev/msy162. [Epub ahead of print]. 2018.
14. Lachance J, Berens AJ, Hansen MEB, Teng AK, Tishkoff SA, Rebbeck TR. Genetic Hitchhiking and Population Bottlenecks Contribute to Prostate Cancer Disparities in Men of African Descent. *Cancer Res.* 2018 May 1;78(9):2432-2443. doi: 10.1158/0008-5472.CAN-17-1550. Epub Feb 8 2018
 15. Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. *Am J Med Genet B Neuropsychiatr Genet.* 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub Feb 20 2018
 16. Loy DE, Rubel MA, Avitto AN, Liu W, Li Y, Learn GH, Ranciaro A, Mbunwe E, Fokunang C, Njamnshi AK, Sharp PM, Tishkoff SA, Hahn BH. Investigating zoonotic infection barriers to ape *Plasmodium* parasites using faecal DNA analysis. *Int J Parasitol.* Jun;48(7):531-542. 2018.
 17. Crawford N, Prendergast D, Oehlert JW, Shaw GM, Stevenson DK, Rappaport N, Sirota M, Tishkoff SA, Sondheimer N. Divergent Patterns of Mitochondrial and Nuclear Ancestry Are Associated with the Risk for Preterm Birth. *J Pediatr.* Dec 13. Mar;194:40-46. 2018
 18. Crawford NG, Kelly DE, Hansen MEB, Beltrame MH, Fan S, Bowman SL, Jewett E, Ranciaro A, Thompson S, Lo Y, Pfeifer SP, Jensen JD, Campbell MC, Beggs W, Hormozdiari F, Mpoloka SW, Mokone GG, Nyambo T, Meskel DW, Belay G, Haut J; NISC Comparative Sequencing Program, Rothschild H, Zon L, Zhou Y, Kovacs MA, Xu M, Zhang T, Bishop K, Sinclair J, Rivas C, Elliot E, Choi J, Li SA, Hicks B, Burgess S, Abnet C, Watkins-Chow DE, Oceana E, Song YS, Eskin E, Brown KM, Marks MS, Loftus SK, Pavan WJ, Yeager M, Chanock S, Tishkoff SA. Loci associated with skin pigmentation identified in African populations. *Science*, Nov 17;358(6365). 2017.
 19. McQuillan MA, Zhang C, Tishkoff SA, Platt A. The importance of including ethnically diverse populations in studies of quantitative trait evolution. *Curr Opin Genet Dev.* Jun 27;62:30-35. 2020
 20. Kelly, D.E., Hansen, M.E.B, Tishkoff, S.A. Global variation in gene expression and the value of diverse sampling. *Curr Opin Syst Biol.* Feb;1:102-108. 2017
 21. Nielsen R, Akey JM, Jakobsson M, Pritchard JK, Tishkoff S, Willerslev E. Tracing the peopling of the world through genomics. *Nature.* Jan 18;541(7637):302-310. 2017
 22. McGuire AL, Gabriel S, Tishkoff SA, Wonkam A, Chakravarti A, Furlong EEM, Treutlein B, Meissner A, Chang HY, López-Bigas N, Segal E, Kim JS. The road ahead in genetics and genomics. *Nat Rev Genet.* Aug 24;1-16. 2020
 23. Sirugo, G, Williams Scott M, and Tishkoff SA*, The missing diversity in human genetic studies, *Cell*, Mar 21;177(1):26-31. doi: 10.1016. 2019.
 24. Tishkoff S and Ellegren H (guest editors). Evolutionary Genomics Issue, *Genome Biology.* volume 20, Article number: 10. 2019
 25. Kowal E, Llamas B, Tishkoff S. Consent: Data-sharing for indigenous peoples. *Nature.* Jun 21;546(7659):474. 2017.
 26. Yudell M, Roberts D, DeSalle R, Tishkoff S. Science and Society: Taking race out of human genetics, *Science*, Feb 5;351(6273):564-5. 2016
 27. Yudell M, Roberts D, DeSalle R, Tishkoff S (2016) Science and Society. Taking race out of human genetics. *Science* 351(6273):564-565. PMID: 26912690
 28. Fan S, Hansen ME, Lo Y, Tishkoff SA* (2016) Going global by adapting local: A review of recent human adaptation. *Science* 354:(6308):54-59.PMID: 27846491
 29. Beltrame MH, Rubel MA, Tishkoff SA* (2016) Inferences of African evolutionary history from genomic data. *Curr Opin Genet Dev.* 41:159-166. PMID: 27810637

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

30. Stone RC, Horvath K, Kark JD, Susser E, Tishkoff SA, Aviv A (2016) Telomere length and the cancer-atherosclerosis trade-off. *PLoS Genet.* 12(7):e1006144. PMID: 27386863
31. Hansen ME, Hunt SC, Stone RC, Horvath K, Herbig U, Ranciaro A, Hirbo J, Beggs W, Reiner AP, Wilson JG, Kimura M, De Vivo I, Chen MM, Kark JD, Levy D, Nyambo T, Tishkoff SA,* Aviv A.* (2016) Shorter telomere length in Europeans than in Africans due to polygenetic adaptation. *Hum Mol Genet.* 25(11):2324-2330. *Co-Senior Author PMID: 26936823
32. Pagani L, Lawson DJ, Jagoda E, Mörseburg A, Eriksson A, Mitt M, Clemente F, Hudjashov G, DeGiorgio M, Saag L, Wall JD, Cardona A, Mägi R, Sayres MA, Kaewert S, Inchley C, Scheib CL, Järve M, Karmin M, Jacobs GS, Antao T, Iliescu FM, Kushniarevich A, Ayub Q, Tyler-Smith C, Xue Y, Yunusbayev B, Tambets K, Mallick CB, Saag L, Pocheshkhova E, Andriadze G, Muller C, Westaway MC, Lambert DM, Zoraqi G, Turdikulova S, Dalimova D, Sabitov Z, Sultana GN, Lachance J, Tishkoff S, Momyinaliev K, Isakova J, Damba LD, Gubina M, Nymadawa P, Evseeva I, Atramentova L, Utevska O, Ricaut FX, Brucato N, Sudoyo H, Letellier T, Cox MP, Barashkov NA, Škaro V, Mulahasanovic L, Primorac D, Sahakyan H, Mormina M, Eichstaedt CA, Lichman DV, Abdullah S, Chaubey G, Wee JT, Mihailov E, Karunas A, Litvinov S, Khusainova R, Ekomasova N, Akhmetova V, Khidiyatova I, Marjanović D, Yepiskoposyan L, Behar DM, Balanovska E, Metspalu A, Derenko M, Malyarchuk B, Voevoda M, Fedorova SA, Osipova LP, Lahr MM, Gerbault P, Leavesley M, Migliano AB, Petraglia M, Balanovsky O, Khusnutdinova EK, Metspalu E, Thomas MG, Manica A, Nielsen R, Vilems R, Willerslev E, Kivisild T, Metspalu M (2016) Genomic analyses inform on migration events during the peopling of Eurasia. *Nature* 538(7624):238-242. PMID: 27654910
33. Mallick S, Li H, Lipson M, Mathieson I, Gymrek M, Racimo F, Zhao M, Chennagiri N, Nordenfelt S, Tandon A, Skoglund P, Lazaridis I, Sankararaman S, Fu Q, Rohland N, Renaud G, Erlich Y, Willems T, Gallo C, Spence JP, Song YS, Poletti G, Balloux F, van Driem G, de Knijff P, Romero IG, Jha AR, Behar DM, Bravi CM, Capelli C, Hervig T, Moreno-Estrada A, Posukh OL, Balanovska E, Balanovsky O, Karachanak-Yankova S, Sahakyan H, Toncheva D, Yepiskoposyan L, Tyler-Smith C, Xue Y, Abdullah MS, Ruiz-Linares A, Beall CM, Di Rienzo A, Jeong C, Starikovskaya EB, Metspalu E, Parik J, Vilems R, Henn BM, Hodoglugil U, Mahley R, Sajantila A, Stamatoyannopoulos G, Wee JT, Khusainova R, Khusnutdinova E, Litvinov S, Ayodo G, Comas D, Hammer MF, Kivisild T, Klitz W, Winkler CA, Labuda D, Bamshad M, Jorde LB, Tishkoff SA, Watkins WS, Metspalu M, Dryomov S, Sukernik R, Singh L, Thangaraj K, Pääbo S, Kelso J, Patterson N, Reich D (2016) The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. *Nature* 538(7624):201-206. PMID: 27654912
34. Jacobson DR, Alexander AA, Tagoe C, Garvey WT, Williams SM, Tishkoff S, Modiano D, Sirima SB, Kalidi I, Toure A, Buxbaum JN (2016) The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa. *Mol Genet Genomic Med* 4(5):548-556. PMID: 27652282
35. Sobota RS, Stein CM, Kodaman N, Scheinfeldt LB, Maro I, Wieland-Alter W, Igo RP Jr, Magohe A, Malone LL, Chervenak K, Hall NB, Modongo C, Zetola N, Matee M, Joloba M, Froment A, Nyambo TB, Moore JH, Scott WK, Lahey T, Boom WH, von Reyn CF, Tishkoff SA, Sirugo G, Williams SM (2016) A locus at 5q33.3 confers resistance to tuberculosis in highly susceptible individuals. *Am J Hum Genet.* 98(3):514-524. PMID: 26942285
36. Hsieh P, Veeramah KR, Lachance J, Tishkoff SA, Wall JD, Hammer MF, Gutenkunst RN (2016) Whole-genome sequence analyses of Western Central African Pygmy hunter-gatherers reveal a complex demographic history and identify candidate genes under positive natural selection. *Genome Res.* 26(3):279-290. PMID: 26888263
37. Tishkoff, SA* (2015) Strength in small numbers. *Science* 349(6254):1282-1283. PMID: 26383935
38. 1000 Genomes Project Consortium (2015) A global reference for human genetic variation. *Nature* 526(7571):68-74. PMID: 26432245

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

39. Karmin M, Saag L, Vicente M, Sayres MA, Järve M, Lachance J, Tishkoff S, ..., Thomas MG, Tyler-Smith C, Underhill PA, Willerslev E, Nielsen R, Metspalu M, Villems R, Kivisild T (2015) A recent bottleneck of Y chromosome diversity coincides with a global change in culture. *Genome Res.* 25(4):459-466. PMID: 25770088

Keynote Speeches – Speaker

Lecture III 11/15 9:10-10:00

Genomic Evolution and Adaptation in Africa: Implications for Health and Disease

Sarah A. Tishkoff

University of Pennsylvania, USA

Africa is thought to be the ancestral homeland of all modern human populations. It is also a region of tremendous cultural, environmental and genetic diversity. Differences in diet, climate, and exposure to pathogens among ethnically and geographically diverse African populations have produced divergent selection pressures, resulting in local genetic adaptations, including some that play a role in disease susceptibility. A number of common complex diseases (including hypertension, diabetes, and chronic kidney disease) occur at higher frequency in people of African descent and are rapidly on the rise in urban regions of Africa. And yet, most human genomic studies have focused on non-African populations. The under-representation of ethnically diverse populations impedes our ability to fully understand the genetic and environmental factors influencing complex traits and may exacerbate health inequalities. A comprehensive knowledge of patterns of variation in African genomes is critical for a deeper understanding of human genomic diversity, the identification of functionally important genetic variation, the genetic basis of adaptation to diverse environments and diets, and the origins of modern humans. We use an integrative and functional genomics approach to characterize patterns of genomic variation, ancestry, and local adaptation across ethnically and geographically diverse African populations, leading to identification of novel genetic variants that play a role in immune response, metabolism, and skin pigmentation.



實驗室必備的離心機



3520
桌上型微量冷凍離心機

Angle Rotor
最高轉速: 15,000rpm
最大離心力: 20,630x g
最大處理量: 5 ml x 12



S300T
桌上型泛用離心機

Swing Rotor
最高轉速: 4,000rpm
最大離心力: 2,610x g
最大處理量: 15 ml x 24



液態氮容器
細胞凍存必備的-196°C



-90°C 超低溫冷凍櫃



+4°C 冷藏櫃與-20°C 冷凍櫃



微電腦程式降溫儀
有效提升細胞凍存活率



TEL:02-2278-3223 FAX:02-8512-3975

新北市三重區重新路五段646號4樓 www.deagle.com.tw



雙鷹官方Line
ID:deagle0492



雙鷹官方網站

受邀演講 Invited Speeches

台灣蛋白質學會 (TPS)
Taiwan Proteomics Society

台灣胞外體學會 (TSEV)
Taiwan Society for Extracellular Vesicles

第一會議廳 Lecture Hall I





Trypsin Series

- ◆ Sequencing Grade Modified Trypsin
- ◆ Trypsin Gold, Mass Spectrometry Grade
- ◆ Trypsin Platinum, Mass Spectrometry Grade
- ◆ Trypsin / Lys-C Mix, Mass Spec Grade
- ◆ Rapid Digestion–Trypsin and Rapid Digestion–Trypsin/Lys-C Kits
- ◆ Immobilized Trypsin
- ◆ AccuMAP™ Low pH Protein Digestion Kit

Alternative Protease

- ◆ Arg-C, Sequencing Grade
- ◆ Glu-C, Sequencing Grade
- ◆ Asp-N, Sequencing Grade
- ◆ rAsp-N, Mass Spec Grade
- ◆ Lys-N, Mass Spec Grade
- ◆ Lys-C, Mass Spec Grade
- ◆ rLys-C, Mass Spec Grade
- ◆ ProAlanase, Mass Spec Grade
- ◆ ProAlanase Plus, Mass Spec Grade
- ◆ Chymotrypsin, Sequencing Grade
- ◆ Thermolysin
- ◆ Pepsin
- ◆ Elastase

Glycosidase & IgG-Cleaving Protease

- ◆ PNGase F
- ◆ Endoglycosidase H
- ◆ IdeS Protease
- ◆ IdeZ Protease

GA201001

Jau-Song Yu, Ph.D. (余兆松)

Current position and professional experiences

- 2001/8 ~ Present **Professor**, Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
- 2016/8 ~ Present **Director**, Molecular Medicine Research Center, Chang Gung University, Tao-Yuan, Taiwan
- 2001/8 ~ 2016/7 **Director**, Core Instrument Center, Chang Gung University, Tao-Yuan, Taiwan

**Research interest**

1. Proteomics technology-development and application
2. Cancer biomarker and multiomics
3. Kinase-mediated signal transduction

Short research summary

Dr. Jau-Song Yu is a Professor of Department of Cell and Molecular Biology at Chang Gung University (CGU), Taiwan. Dr. Yu received his Ph.D. degree from the Department of Life Science, National Tsing-Hua University, Taiwan, R.O.C. and has been involved in proteomic researches for the past 20 years. Dr. Yu's research interest focuses on the development and application of Proteomics technologies to identify proteins deregulated in various diseases/cancer, which can be promising biomarkers with high potential for clinical use. In addition to his primary role in the University, Dr. Yu is also the Director of Molecular Medicine Research Center in CGU, in which he leads a team to develop clinically useful cancer biomarkers, investigate cancer multiomics, and provide services for multiomics analysis for basic and clinical researches.

Publications

1. Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS*. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. *Cancers (Basel)*. 12(8):E2273.
2. Lin YH*, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS*, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. *Sensors and Actuators B: Chemical* 322:128607
3. Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. *Analytica Chimica Acta* 1100:118-130.
4. Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP*, Yu JS*. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. *J Proteomics*. 211:103571.
5. Lin Y-H*, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S*. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. *Anal. Bioanal. Chem.* 411(5): 1085-

1094.

6. Liu CC#, Yu JS#, Wang PJ, Hsiao YC, Liu CH, Chen YC, Lai PF, Hsu CP, Fann WC, Lin CC*. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. *PLoS Negl Trop Dis* 12(12): e0007014.
7. Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S*. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. *J. Proteomics* 187:59-68.
8. Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS*. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) *Proteomics-Clin Appl.* 12(2). 1700039.
9. Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS*. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. *Oncotarget* 9(15):12079-12100.
10. Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS*. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. *International Journal of Head and Neck Science* 2(2): 56-68. (Invited review article)
11. Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IYF, Yeh YM, Chen CD, Li HP, Luo JD, Tan BCM, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang KWF, Rodriguez H, Cheng MH, Myers J, Chang KP*, Chang YS*. (2017) Integrated omics analyses identify APOBEC3A as an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. *Nature Communications* 8(1):465.
12. Hsiao YC, Chi LM, Chien KY, Chiang WF, Chen SF, Chuang YN, Lin SY, Wu CC, Chu LJ, Chen YT, Chia SL, Chien CY, Chang KP, Chang YS, and Yu JS*. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. *Mol. Cell. Proteomics* 16(10):1829-1849.
13. Liu CC, You CH, Yu JS*, Huang GJ, Liu CH, Wang PJ, and Lin CC*. (2017) Analysis of the efficacy of Taiwanese freeze-dried neurotoxic antivenom against *Naja kaouthia*, *Naja siamensis* and *Ophiophagus hannah* through proteomics and animal model approaches. *PLOS Neglected Tropical Diseases*. 11(12):e0006138.
14. Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S* (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. *Scientific Reports* 7(1):1370.
15. Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen JT, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu JS, Ding Xue*. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. *Nature* 547, 458–462
16. Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT*, Yu JS*. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. *J. Proteomics* 157:40-51.
17. Hsiao YC#, Chu LJ#, Chen JT, Yeh TS, Yu JS*. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. *Expert Review of Proteomics* 14(9):737-756.
18. Yu JS#, Chen YT#, Chiang WF#, Hsiao YC#, Chu LJ#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS*, Hartwell LH* (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. *Proc Natl Acad Sci USA* 113(41):11549-11554.
19. Chen H#, Hsiao YC#, Chiang SF, Wu CC, Lin YT, Liu H, Zhao H, Chen JS, Chang YS, Yu JS*. (2016)

Invited Speeches

Multiomics – Moderator

(TPS & TSEV) Hall I Section I 11/14 10:40-12:05

Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal Chim Acta 933:144-155.

Yu-Ju Chen, Ph.D. (陳玉如)

Current position and professional experiences

2013/7 ~ Present	Director/ Distinguished Research Fellow, Institute of Chemistry, Academia Sinica
2020/8 ~ 2022/12	Associate Editor, Analytical Chemistry
2020/1 ~ 2020/12	President-Elect, Human Proteome Organization
2021/1 ~ 2022/12	President, Human Proteome Organization
2017/1 ~ 2021/12	Vice President, Asia Oceana Human Proteome Organization
2012/1~2015/12	President, Taiwan Society for Mass Spectrometry
2008/1~2011/12	President, Taiwan Proteomics Society

**Research interest**

1. Biological mass spectrometry
2. Proteomic

Short research summary

Dr. Chen received Ph.D. at the Iowa State University (1997). After postdoctoral work at the Ames Laboratory (1997) and National Tsing Hua University, she joined the Institute of Chemistry, Academia Sinica, Taiwan, and was appointed as Director since 2013. She also holds adjunct professorship at National Taiwan University and National Ocean University. Though being trained as a physical chemist in photoionization mass spectrometry, she switched to the journey of proteomic research and became the pioneering scientist in establishing large-scale mass spectrometry-based proteomics in Taiwan. Dr. Chen's research focuses on developing novel nanomaterial, advanced mass spectrometry and bioinformatics tools towards comprehensive delineation of the membrane proteome and post-translation modifome. In particular, she is passionately interested in revealing the protein system network in cancer and stem cell biology. Her contribution to pioneer interdisciplinary proteomics work has been recognized by domestic and international awards including Distinguished Young Chemists Award from Federation of Asian Chemical Societies and Outstanding Research Award from National Science Council, Taiwan. Dr. Chen is actively serving in the proteomics community by being President of HUPO, Vice President of AOHUPO, and Council Member of "International Mass Spectrometry Foundation". She has been the President of the Taiwan Proteomics Society and Taiwan Society for Mass Spectrometry. Dr. Chen is the Associate Editor of Analytical Chemistry, editorial board member of the Proteomics, European Journal of Mass Spectrometry, and Journal of Proteome Research.

Publications

1. "Proteogenomic Landscape of Early Stage Non-smoking Lung Adenocarcinoma in East Asia ", Yi-Ju Chen+, Theodoros I. Roumeliotis+, Ya-Hsuan Chang+, Ching-Tai Chen, Chia-Li Han*, Miao-Hsia Lin, Huei-Wen Chen, Gee-Chen Chang, Yih-Leong Chang, Chen-Tu Wu, Mong-Wei Lin, Min-Shu Hsieh, Yu-Tai Wang, Yet-Ran Chen, Inge Jonassen, Fatemeh Zamanzad Ghavidel, Ze-Shiang Lin, Kuen-Tyng Lin, Ching-Wen Chen, Pei-Yuan Sheu, Chen-Ting Hung, Ke-Chieh Huang, Hao-Chin Yang, Pei-Yi Lin, Ta-Chi Yen, Yi-Wei Lin, Jen-Hung Wang, Lovely Raghav, Chien-Yu Lin, Yan-Si Chen, Pei-Shan Wu, Chi-Ting Lai, Shao-Hsing Weng, Kang-Yi Su, Wei-Hung Chang, Pang-Yan Tsai, Ana I. Robles, Henry Rodriguez, Ting-Yi Sung*, Jin-Shing Chen*, Sung-Liang Yu*, Jyoti S. Choudhary*, Hsuan-Yu Chen*, Pan-Chyr Yang*, Yu-Ju Chen*, Cell 182, 226-244 (2020) IF:36.216

2. “Standardization and Harmonization of Distributed Multi-National Proteotype Analysis supporting Precision Medicine Studies”, Yue Xuan, Nicholas W. Bateman, Sebastien Gallien, Sandra Goetze, Yue Zhou, Pedro Navarro, Mo Hu, Niyati Parikh, Brian L. Hood, Kelly A. Conrads, Christina Loosse, Reta Birhanu Kitata, Sander R. Piersma, Davide Chiasserini, Hongwen Zhu, Guixue Hou, Muhammad Tahir, Andrew Macklin, Amanda Khoo, Xiuxuan Sun, Ben Crossett, Albert Sickmann, Yu-Ju Chen, Connie R. Jimenez, Hu Zhou, Siqi Liu, Martin R. Larsen, Thomas Kislinger, Zhinan Chen, Benjamin L. Parker, Stuart J. Cordwell, Bernd Wollscheid, Thomas P. Conrads, bioRxiv preprint doi: <https://doi.org/10.1101/2020.03.12.988089> (2020)
3. “Proteomic Analysis Reveals Anti-Fibrotic Effects of Blue Light Photobiomodulation on Fibroblasts”, Lo-Yu Chang, Sabrina Mai-Yi Fan, Yen-Chen Liao, Wei-Hung Wang, Yu-Ju Chen and Sung-Jan Lin*, *Lasers Surg Med*, 52, 358-372 (2020), IF:3.262
4. “Direct Oligosaccharide Profiling using Thin-Layer Chromatography Coupled with Ionic Liquid-Stabilized Nanomatrix-Assisted Laser Desorption-Ionization Mass Spectrometry”, Elias Gizaw, Mernieleta Deressa Tolesa, Ming-Jer Lee, Mei-Chun Tseng and Yu-Ju Chen*, *Anal. Chem.*, DOI: 10.1021/acs.analchem.9b01241 (2019), IF:6.32
5. “Boronate Affinity-based Photoactivatable Magnetic Nanoparticles for the Oriented and Irreversible Conjugation of Fc-fused Lectins and Antibodies”, Chen-Yo Fan, Yi-Ren Hou, Avijit K. Adak, Juanilita T. Waniwan, Mira Anne C. dela Rosa, Penk Yeir Low, Takashi Angata, Kuo-Chu Hwang, Yu-Ju Chen* and Chun-Cheng Lin*, *Chem. Sci.*, DOI: 10.1039/c9sc01613a (2019), IF:9.556
6. “GPER-induced Signaling is Essential for the Survival of Breast Cancer Stem Cells”, Yu-Tzu Chan, Alan C.-Y. Lai, Ruey-Jen Lin, Ya-Hui Wang, Yi-Ting Wang, Wen-Wei Chang, Hsin-Yi Wu, Yu-Ju Lin, Wen-Ying Chang, Jen-Chine Wu, Jyh- Cherng Yu, Yu-Ju Chen*, and Alice L. Yu*, *Int J Cancer*, DOI: 10.1002/ijc.32588 (2019), IF: 7.360
7. “High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells”, Chun-Mei Hu*, Sui-Chih Tien, Ping-Kun Hsieh, Yung-Ming Jeng, Ming-Chu Chang, Yu-Ting Chang, Yi-Ju Chen, Yu-Ju Chen, Eva Y.-H.P. Lee, Wen-Hwa Lee*, *Cell Metab.*, 29, 1–16 , DOI: 10.1016/j.cmet.2019.02.005 (2019) , IF: 20.565
8. “Alteration of Mesenchymal Stem Cells Polarity by Laminar Shear Stimulation Promoting β -catenin Nuclear Localization”, Wei-Ta Chen, Wei-Tse Hsueh, Meng-Hua Yend, Chun A. Changou, Chia-Li Han, Yu-Ju Chen, Ji-Yen Cheng, Tzu-Hao Chang, Oscar Kuang-Sheng Lee*, Jennifer Hui-Chun Hoa*, *Biomaterials*, 190-191, 1–10 , DOI: 10.1016/j.biomaterials. 2018.10.026 (2019) , IF: 8.806
9. “Glycoproteomic Alterations in Drug-Resistant Nonsmall Cell Lung Cancer Cells Revealed by Lectin Magnetic Nanoprobe-Based Mass Spectrometry”, Juanilita T Waniwan, Yi-Ju Chen, Rey Capangpangan, Shao-Hsing Weng, Yu-Ju Chen*, *J Proteome Res.*, 17 (11), 3761-3773, (2018), IF:3.950
10. “Systematic Protein Prioritization for Targeted Proteomics Studies through Literature Mining”, Kun-Hsing Yu, Tsung-Lu Michael Lee, Chi-Shiang Wang, Yu-Ju Chen*, Christopher Re, *J Proteome Res.*17, 1383-1396, (2018), IF:3.950 Samuel C. Kou, Jung-Hsien Chiang, Isaac S. Kohane and Michael Snyder, *J Proteome Res.*,
11. “A Cloud-Based Metabolite and Chemical Prioritization System for the Biology/Disease-Driven Human Proteome Project”, Kun-Hsing Yu, Tsung-Lu Michael Lee, Yu-Ju Chen*, Christopher Re, Samuel C. Kou, Jung-Hsien Chiang, Michael Snyder and Isaac S. Kohane*, *J Proteome Res.*17, 4345-4357, (2018), IF:3.950
12. “Subcellular Proteome Landscape of Human Embryonic Stem Cells Revealed Missing Membrane Proteins”, Mehari Muuz Weldemariam, Chia-Li Han, Faezeh Shekari, Reta Birhanu Kitata, Ching- Yu Chuang, Wei-Ting Hsu, Hung-Chih Kuo, Wai-Kok Choong, Ting-Yi Sung, Fu-Chu

- He, Maxey Ching Ming Chung, Ghasem Hosseini Salekdeh, Yu-Ju Chen*, J Proteome Res., 17 (12), 4138-4151, (2018), IF:3. 950
13. "Evaluating the Possibility of Detecting Variants in Shotgun Proteomics via LeTE-fusion Analysis Pipeline", Tung-Shing Lih, Wai-Kok Choong, Yu-Ju Chen, Ting-Yi Sung*, J. Proteome Res., 17 (9), 2937–2952, (2018), IF:4.268
 14. "Surface Markers of Human Embryonic Stem Cells: Ameta Analysis of Membrane Proteomics Reports", Faezeh Shekari, Chia-Li Han, Jaesuk Lee, Mehdi Mirzaei, Vivek Gupta, Paul A.Haynes, Bonghee Lee, Hossein Baharvand, Yu-Ju Chen, Ghasem HosseiniSalekdeh*, Expert Rev Proteomic, 15(11), 911-922, (2018), IF:3.489
 15. "DNA Demethylation by DNMT3A and DNMT3B in vitro and of Methylated Episomal DNA in Transiently Transfected Cells", Biswanath Chatterjee, Miao-Hsia Lin, Chun-Chang Chen, Kai-Lin Peng, Mu-Sheng Wu, Mei-Chun Tseng, Yu-Ju Chen, Che-Kun James Shen*, BBA-Gene Regul Mech, 1861(11), 1048-1061, (2018), IF:5.179
 16. "Launching the C-HPP neXt-CP50 Pilot Project for Functional Characterization of Identified Proteins with No Known Function", Young-Ki Paik, Lydie Lane, Takeshi Kawamura, Yu-Ju Chen, Je-Yoel Cho, Joshua LaBaer, Jong Shin Yoo, Gilberto Domont, Fernando Corrales, Gilbert S Omenn, Alexander Archakov, Sergio Encarnación-Guevara, Siqi Lui, Ghasem Hosseini Salekdeh, Jin-Young Cho, Chae-Yeon Kim, Christopher M Overall, J Proteome Res., 17(12), 4042-4050, (2018), IF:3. 950
 17. "Inducing Hair Follicle Neogenesis with Secreted Proteins Enriched in Embryonic Skin", Sabrina Mai-Yi Fan, Chia-Feng Tsai, Chien-Mei Yen, Miao-Hsia Lin, Wei-Hung Wang, Chih-Chieh Chan, Chih-Lung Chen, Kyle KL Phua, Szu-Hua Pan, Maksim V Plikus, Sung-Liang Yu, Yu-Ju Chen, Sung-Jan Lin*, Biomaterials, 167, 121-131, (2018), IF:8. 806
 18. "Exploring the Expression Bar Code of SAA Variants for Gastric Cancer Detection", Deng-Chyang Wu, Kai-Yi Wang, Sophie S.W. Wang, Ching-Min Huang, Yi-Wei Lee, Michael Isaac Chen, Szu-An Chuang, Shu-Hua Chen, Ying-Wei Lu, Chun-Cheng Lin, Ka-Wo Lee, Wen-Hung Hsu, Kun-Pin Wu, Yu-Ju Chen*, Proteomics, 17 (11), doi: 10.1002/pmic.201600356, (2017), IF:4.041 (Cover Story)
 19. "One-Pot Two-Nanoprobe Assay Uncovers Targeted Glycoprotein Biosignature", Mira Anne dela Rosa, Wei-Chun Chen, Yi-Ju Chen, Rofeamor Obena, Chih-Hsiang Chang, Rey Capangpangan, Tung-Hung Su, Chi-Ling Chen, Pei-Jer Chen, Yu-Ju Chen*, Anal. Chem. 89, 3973 – 3980, (2017), IF: 5.886
 20. "Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer", Yi-Ting Wang, Szu-Hua Pan, Chia-Feng Tsai, Ting-Chun Kuo, Hsin-Yung Yen, Wai-Kok Choong, Hsin-Yi Wu, Yuan-Ling Hsu, Tse-Ming Hong, Ting-Yi Sung, Pan-Chyr Yang, Yu-Ju Chen*, Sci Rep, 7 ,44021, (2017), IF:5.228
 21. "Role of S-Palmitoylation by ZDHHC13 in Mitochondrial Dysfunction and Metabolic Disequilibrium", Li-Fen Shen, Yi-Ju Chen, Kai-Ming Liu, Amir N. Saleem Haddad, I-Wen Song, Hsiao-Yuh Roan, Li-Ying Chen, Jeffrey J. Y. Yen, Yu-Ju Chen, Jer-Yuarn Wu, Yuan-Tsong Chen*, Sci. Rep. 7: 2182 (2017) , IF:4.259
 22. "Identification of Siglec Ligands Using a Proximity Labeling Method", Lanyi Chang, Yi-Ju Chen, Chan-Yo Fan, Chin-Ju Tang, Yi-Hsiu Chen, Penk-Yeir Low, Albert Ventura, Chun-Cheng Lin, Yu-Ju Chen , and Takashi Angata.*, J Proteome Res. 16(10):3929-3941, doi: 10.1021/acs.jproteome.7b00625, (2017) , IF:4.268
 23. "Decoding the Effect of Isobaric Substitutions on Identifying Missing Proteins and Variant Peptides in Human Proteome", Wai Kok Choong, T. Mamie Lih, Yu-Ju Chen, Ting-Yi Sung *, J Proteome Res., doi: 10.1021/acs.jproteome.7b00342, (2017) , IF:4.268
 24. "iTop-Q: An Intelligent Tool for Top-down Proteomics Quantitation Us-ing DYAMOND Algorithm", Hui-Yin Chang, Ching-Tai Chen, Chu-Ling Ko, Yi-Ju Chen, Yu-Ju Chen, Wen-Lian Hsu, Chiun-Gung Juo, Ting-Yi Sung, Anal. Chem., 89 (24), 13128–13136 (2017), IF:6.32

25. "ROS-Independent ER Stress-Mediated Nrf2 Activation Promotes Warburg Effect to Maintain Stemness-Associated Properties of Cancer-Initiating Cells", Jeng-Fan Lo, Ching-Wen Chang, Yu-Syuan Chen, Yeou-Guang Tsay, Chia-Li Han, Yu-Ju Chen, Cheng-Chieh Yang, Kai-Feng Hung, C.H. Lin, Tsung-Yen Huang, Shou-Yen Kao, and Te-Chang Lee*, *Cell Death Dis*, (2017), IF:5.965
26. "Data for Whole and Mitochondrial Proteome of Human Embryonic Stem Cells", Faezeh Shekari, Hossein Nezari, Yu-Ju Chen, Hossein Baharvand*, Ghasem Hosseini Salekdeh*, *J Proteomics*, 162 (6), 108-118, (2017), IF: 3.914
27. "FAM198B is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression", Chia-Ying Hsu, Gee-Chen Chang, Yi-Ju Chen, Yi-Chiung Hsu, Yi-jing Hsiao, Kang-Yi Su, Hsuan-Yu Chen, Chien-Yu Lin, Jin-Shing Chen, Yu-Ju Chen, Qi-Sheng Hong, Wen-Hui Ku, Chih Ying Wu, Bing-Ching Ho, Ching-Cheng Chiang, Pan-Chyr Yang, and Sung-Liang Yu, *Clin Cancer Res*, (2017) , IF:9.619
28. "Temporal Regulation of Lsp1 O-GlcNAcylation and Phosphorylation During Apoptosis of Activated B Cells", Jung-Lin Wu, Hsin-Yi Wu, Dong-Yan Tsai, Ming-Feng Chiang, Yi-Ju Chen, Shijay Gao, Chun-Cheng Lin, Chun-Hung Lin, Kay-Hooi Khoo, Yu-Ju Chen*, Kuo-I Lin*, *Nat. Commun.*, 7:12526, (2016), IF:11.47
29. "K63-Polyubiquitinated HAUSP Deubiquitinates HIF-1 α and Dictates H3K56 Acetylation Promoting Hypoxia-Induced Tumour Progression", Han-Tsang Wu, Yi-Chih Kuo, Jung-Jyh Hung, Chi-Hung Huang, Wei-Yi Chen, Teh-Ying Chou, Yeh Chen, Yi-Ju Chen, Yu-Ju Chen, Wei-Chung Cheng, Shu-Chun Teng, Kou-Juey Wu*, *Nat. Commun.*, 7,13677, doi:10.1038/ncomms13644, (2016), IF:11.329
30. "Functionalized HgTe Nanoparticles Promote Laser-Induced Solid Phase Ionization/Dissociation for Comprehensive Glycan Sequencing", Indah Primadona, Yin-Hung Lai, Rey Y. Capangpangan, Rofeamor P. Obena, Mei-Chun Tseng, Ming-Feng Huang, Huan-Tsung Chang, Shiou-Ting Li, Chung-Yi Wu, Wei-Ting Chien, Chun-Cheng Lin, Yi-Sheng Wang*, Yu-Ju Chen* , *Analyst*, 141, 6093-6103, (2016), IF: 4.107
31. "Atomic force Microscopy Characterization of Kinase-mediated Phosphorylation of a Peptide Monolayer", Roman Zhuravel, Einav Amit, Shir Elbaz, Dvir Rotem, Yu-Ju Chen, Assaf Friedler, Shlomo Yitzchaik*, Danny Porath*, *Sci. Rep.*, 6: 36793, (2016), IF: 5.228
32. "Chemical Inhibition of Human Thymidylate Kinase and Structural Insights into the Phosphate Binding Loop and Ligand-Induced Degradation", Yi-Hsuan Chen, Hua-Yi Hsu, Ming-Tyng Yeh, Chen-Cheng Chen, Chang-Yu Huang, Ying-Hsuan Chung, Zee-Fen Chang, Wei-Chen Kuo, Nei-Li Chan, Jui-Hsia Weng, Bon-chu Chung, Yu-Ju Chen, Cheng-Bang Jian, Ching-Chieh Shen, Hwan-Ching Tai, Sheh-Yi Sheu*, Jim-Min Fang*, *J. Med. Chem.*, 59 (21), 9906-9918, (2016), IF: 5.589
33. "Untargeted, Spectral Library-Free Analysis of Data Independent Acquisition Proteomics Data Generated Using Orbitrap Mass Spectrometers", Chih-Chiang Tsou, Chia-Feng Tsai, Guoci Teo, Yu-Ju Chen, Alexey I. Nesvizhskii*, *Proteomics*, 16, (15-16), 2257-2271, (2016), IF: 3.807
34. "Download: The Impact of Dupase on Ribonucleotide Reductase-Induced Genome Instability in Cancer Cells", Chih-Wei Chen, Ning Tsao, Lin-Yi Huang, Yun Yen, Xiyong Liu, Christine Lehman, Yuh-Hwa Wang, Mei-Chun Tseng, Yu-Ju Chen, Yi-Chi Ho, Chian-Feng Chen, Zee-Fen Chang*, *Cell Rep.*, 16 (5), 1287-1299, (2016), IF: 7.87
35. "The Shp2-induced Epithelial Disorganization Defect is Reversed by HDAC6 Inhibition Independent of Cdc42", Sui-Chih Tien, Hsiao-Hui Lee, Ya-Chi Yang, Miao-Hsia Lin, Yu-Ju Chen, Zee-Fen Chang*, *Nat. Commun.*, 7, 10420, (2016), IF:11.47
36. "A Photo-Cleavable Biotin Affinity Tag for the Facile Release of a Photo-Crosslinked Carbohydrate-Binding Protein", Tsung-Che Chang, Avijit K. Adak, Ting-Wei Lin, Pei-Jhen Li, Yi-Ju Chen, Chain-Hui Lai, Chien-Fu Liang, Yu-Ju Chen, Chun-Cheng Lin*, *Bioorgan Med Chem.* 24 (6), 1216–1224, (2016), IF:11.47

**Taiwan Cancer Proteogenomics Moonshot:
Pathway to Next Generation Precision Medicine in Cancer**

Yu-Ju Chen

Institute of Chemistry, Academia Sinica, Taiwan

Advances in mass spectrometry-based proteomic technologies have opened the new avenue to identify and quantify thousands of proteins, post-translational modification (PTM) and their system network regulating various biological and physiological functions. Personalized proteomics starts to impact the development of personalized medicine by facilitating discovery of protein biomarkers, molecular signature of disease subtype and response to treatment of individual patients. Combing proteomics with the long standing success of genomics, proteogenomics was recently launched as an emerging tool for full delineation of genomic-to-proteomic network associated with disease. With the aim of accelerating the progress toward prevention, control and treatment for cancer, Taiwan joined the global effort of International Cancer Proteogenome Consortium (ICPC) under Cancer Moonshot initiated by US to apply proteogenomics as a precision approach to delineate the connection of genomic abnormalities and protein alteration in individual cancer patient's tissues. In this talk, I will present the first proteogenomics study on a prospectively collected cohort representing early stage lung adenocarcinomas in Taiwan. We delineated age-dependent mutational signatures as well as the proteogenomic hallmarks of tumor progression and propose a proteomics-informed classification to distinguish the diverse clinical trajectories of patients with EGFR mutation within early stages. Functional annotation of the molecular subtypes by protein network analysis highlights candidate biomarkers for patient stratification and therapeutic opportunity. Our integrative analysis reveals the molecular architecture of lung cancer in East Asia and enables the path for precision medicine.

Chang-Shi Chen, Ph.D. (陳昌熙)

Current position and professional experiences

- | | |
|----------------|--|
| 2017 ~ Present | Professor , Biochemistry and Molecular Biology, National Cheng Kung University, Taiwan |
| 2013 ~ 2017 | Associate Professor , Biochemistry and Molecular Biology, National Cheng Kung University, Taiwan |
| 2008 ~ 2013 | Assistant Professor , Biochemistry and Molecular Biology, National Cheng Kung University, Taiwan |
| 2006 ~ 2008 | Postdoctoral Scholar , Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego |

**Research interest**

1. Bacterial pore-forming toxins
2. Enterohemorrhagic *Escherichia coli*
3. Host-pathogen interactions
4. *Caenorhabditis elegans* biology

Short research summary

Our laboratory studies the genetic bases of the intrinsic cell defense systems against pathogenic bacteria and their virulence factors. We apply chemical genomic, forward/reverse genetic, CRISPR/Cas9 genome editing, molecular and biochemical methodologies, and the model organism *Caenorhabditis elegans* to elucidate the conserved mechanisms in host-pathogen interactions. A rapidly growing number of human and animal microbial pathogens have been shown to infect and kill *C. elegans*. In many cases, microbial genes known to be essential for full virulence in mammalian models have been shown to be similarly required for maximum pathogenicity. Since the innate immune responses are highly conserved among different organisms throughout evolution, understanding the molecular basis of the intrinsic cell defense systems in *C. elegans* should shed light onto some aspects of immunity in human diseases.

Publications

1. Cheng-Rung Huang, Cheng-Ju Kuo, Chih-Wen Huang, Yu-Ting Chen, Bang-Yu Liu, Chung-Ta Lee, Po-Lin Chen, Wen-Tsan Chang, Yun-Wen Chen, Tzer-Min Lee, and Chang-Shi Chen. Host CDK1-formin signal confers microvillar effacement by an attaching and effacing (A/E) pathogen. *Nature Communications*. 2020 Under 2nd revision.
2. Yi-Wei Chen, Wen-Hsuan Yeh, Hung-Jen Tang, Jenn-Wei Chen, Hung-Yu Shu, Yu-Chen Su, Sin-Tian Wang, Cheng-Ju Kuo, Yin-Ching Chuang, Chi-Chung Chen, Wen-Chien Ko, Chang-Shi Chen, and Po-Lin Chen. UvrY Is Required for the Full Virulence of *Aeromonas dhakensis*. *Virulence*. 2020 Dec;11(1):502-520.
3. Wen-Chun Huang, Chung-Yen Lin, Masayuki Hashimoto, Jiunn-Jong Wu, Ming-Cheng Wang, Wei-Hung Lin, Chang-Shi Chen, and Ching-Hao Teng. The role of the bacterial protease Prc in the uropathogenesis of extraintestinal pathogenic *Escherichia coli*. *J Biomed Sci*. 2020 Jan 3;27(1):14.
4. Peter Brown, RELISH Consortium/Chang-Shi Chen, and Yaoqi Zhou. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database (Oxford)*. 2019 Oct 29. doi: 10.1093/database/baz085.

5. Yi-Wei Chen, Wen-Chien Ko, Chang-Shi Chen, and Po-Lin Chen. Evaluating Virulence and Pathogenesis of *Aeromonas* Infection in a *Caenorhabditis elegans* Model. *J Vis Exp*. 2018 Dec 20;(142).
6. Ling-Hsien Tu, Ning-Hsuan Tseng, Ya-Ru Tsai, Yi-Wei Lo, Jien-Lin Charng, Hua-Ting Hsu, Yu-Sheng Chen, Rong-Jie Chen, Ying-Da Wu, Yi-Tsu Chan, Chang-Shi Chen, Jim-Min Fang, and Yun-Ru Chen. Rationally designed divalent caffeic amides inhibit amyloid- β fibrillization, induce fibril dissociation, and ameliorate cytotoxicity. *Eur J Med Chem*. 2018 Oct 5;158:393-404.
7. Yi-Wei Chen, Wen-Chien Ko, Chang-Shi Chen*, and Po-Lin Chen*. RIOK-1 is a suppressor of the p38 MAPK innate immune pathway in *Caenorhabditis elegans*. *Front Immunol*. 2018 Apr 17;9:774. *Corresponding authors.
8. Cheng-Ju Kuo, Sin-Tian Wang, and Chang-Shi Chen. Detection of Enterohemorrhagic *Escherichia coli* Colonization in Murine Host by Non-invasive In Vivo Bioluminescence System. *J Vis Exp*. 2018 Apr 9;(134).
9. Cheng-Ju Kuo, Sin-Tian Wang, Chia-Mei Lin, Hao-Chieh Chiu, Cheng-Rung Huang, Der-Yen Lee, Geen-Dong Chang, Ting-Chen Chou, Jenn-Wei Chen, and Chang-Shi Chen. A multi-omic analysis reveals the role of fumarate in regulating the virulence of Enterohemorrhagic *Escherichia coli*. *Cell Death Dis*. 2018 Mar 7;9(3):381.
10. Chia-Wen Tsai, Rong-Tzong Tsai, Shih-Ping Liu, Chang-Shi Chen, Min-Chen Tsai, Shao-Hsuan Chien, Huey-Shan Hung, Shinn-Zong Lin, Woei-Cherng Shyu, and Ru-Huei Fu. Neuroprotective Effects of Betulin in Pharmacological and Transgenic *C. elegans* Models of Parkinson's Disease. *Cell Transplant*. 2017 Dec;26(12):1903-1918.
11. Huan-Da Chen, Cheng-Yuan Kao, Bang-Yu Liu, Shin-Whei Huang, Cheng-Ju Kuo, Jhen-Wei Ruan, Yen-Hung Lin, Cheng-Rung Huang, Yu-Hung Chen, Horng-Dar Wang, Raffi V. Aroian, and Chang-Shi Chen. HLH-30/TFEB-mediated autophagy functions in a cell-autonomous manner for epithelium intrinsic cellular defense against bacterial pore-forming toxin in *C. elegans*. *Autophagy*. 2017 Feb;13(2):371-385.
12. Po-Lin Chen, Yi-Wei Chen, Chun-Chun Ou, Tzer-Min Lee, Chi-Jung Wu, Wen-Chien Ko, and Chang-Shi Chen. A disease model of muscle necrosis caused by *Aeromonas dhakensis* infection in *Caenorhabditis elegans*. *Front Microbiol*. 2017 Jan 4;7:2058.
13. Cheng-Ju Kuo, Jenn-Wei Chen, Hao-Chieh Chiu, Ching-Hao Teng, Tai-I Hsu, Pei-Jung Lu, Wan-Jr Syu, Sin-Tian Wang, Ting-Chen Chou, and Chang-Shi Chen. Mutation of the enterohemorrhagic *Escherichia coli* core LPS biosynthesis enzyme RfaD confers hypersusceptibility to host intestinal innate immunity in vivo. *Front Cell Infect Microbiol*. 2016 Aug 12;6:82.
14. Han-Sheng Chuang, Wan-Jung Kuo, Chia-Lin Lee, I-Hua Chu, and Chang-Shi Chen. Exercise in an electrotactic flow chamber ameliorates age-related degeneration in *Caenorhabditis elegans*. *Sci Rep*. 2016 Jun 16;6:28064.
15. Han-Chu Chang*, Yu-Ting Huang*, Chang-Shi Chen*, Yi-Wei Chen, Yu-Tsung Huang, Jung-Chen Su, Lee-Jene Teng, Chung-Wai Shiau, and Hao-Chieh Chiu. In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA. *J Antimicrob Chemother*. 2016 Feb;71(2):449-59. *Equal contribution.
16. Po-Lin Chen, Pei-Jane Tsai, Chang-Shi Chen, Ying-Chuan Lu, Hung-Mo Chen, Nan-Yao Lee, Ching-Chi Lee, Chia-Wen Li, Ming-Chi Li, Chi-Jung Wu, and Wen-Chien Ko. *Aeromonas* stool isolates from individuals with or without diarrhea in southern Taiwan: Predominance of *Aeromonas veronii*. *J Microbiol Immunol Infect*. 2015 Dec;48(6):618-24.
17. Hsiang Yu, Huey-Jen Lai, Tai-Wei Lin, Chang-Shi Chen*, and Szecheng John Lo. Loss of DNase II function in the gonad is associated with a higher expression of antimicrobial genes in *C. elegans*. *Biochem J*. 2015 Aug 15;470(1):145-54. *Corresponding authors.
18. Po-Lin Chen, Chi-Jung Wu, Pei-Jane Tsai, Hung-Jen Tang, Nan-Yao Lee, Ching-Chi Lee, Chia-Wen Li, Ming-Chi Li, Chun-Chun Ou, Chang-Shi Chen*, and Wen-Chien Ko. Virulence diversity among

- bacteremic *Aeromonas* isolates: ex vivo, animal, and clinical evidences. PLoS One. 2014 Nov 6;9(11):e111213. *Corresponding authors.
19. Po-Lin Chen, Chi-Jung Wu, Chang-Shi Chen, Pei-Jane Tsai, Hung-Jen Tang, and Wen-Chien Ko. A comparative study of clinical *Aeromonas dhakensis* and *Aeromonas hydrophila* isolates in southern Taiwan: *A. dhakensis* is more predominant and virulent. Clin Microbiol Infect. 2014 Jul;20(7):O428-34.
 20. Ru-Huei Fu, Horng-Jyh Harn, Shih-Ping Liu, Chang-Shi Chen, Wen-Lin Chang, Yue-Mi Chen, Jing-En Huang, Rong-Jhu Li, Sung-Yu Tsai, Huey-Shan Hung, Woei-Cherng Shyu, Shinn-Zong Lin, Yu-Chi Wang. n-Butylidenephthalide Protects against Dopaminergic Neuron Degeneration and α -Synuclein Accumulation in *Caenorhabditis elegans* Models of Parkinson's Disease. PLoS One. 2014 Jan 8;9(1):e85305
 21. Han-Sheng Chuang, Hsiang-Yu Chen, Chang-Shi Chen, Wen-Tai Chiu. Immobilization of the Nematode *Caenorhabditis elegans* with Addressable Light-Induced Heat Knockdown (ALINK). Lab Chip. 2013 Aug 7;13(15):2980-9.
 22. Ya-Luen Yang, Kah-Sin Loh, Bang-Yu Liou, I-Hua Chu, Cheng-Ju Kuo, Huan-Da Chen, and Chang-Shi Chen. SESN-1 is a positive regulator of lifespan in *Caenorhabditis elegans*. Exp Gerontol. 2013 Mar; 48(3):371-9.
 23. Ting-Chen Chou, Hao-Chieh Chiu, Cheng-Ju Kuo, Ching-Ming Wu, Wan-Jr Syu, Wen-Tai Chiu, and Chang-Shi Chen. Enterohaemorrhagic *Escherichia coli* O157:H7 Shiga-like toxin 1 is required for full pathogenicity and activation of the p38 mitogen-activated protein kinase pathway in *Caenorhabditis elegans*. Cell Microbiol. 2013 Jan;15(1):82-97.
 24. Chi-Jung Wu, Hsuan-Chen Wang, Chang-Shi Chen, Hung-Yu Shu, Ai-Wen Kao, Po-Lin Chen, and Wen-Chien Ko. Genome Sequence of a Novel Human Pathogen, *Aeromonas aquariorum*. J Bacteriol. 2012 Aug;194(15):4114-5.

A Multiomic Analysis Reveals the Role of Fumarate in Regulating the Virulence of Enterohemorrhagic *Escherichia coli*

Chang-Shi Chen

Department of Biochemistry and Molecular Biology, College of Medicine,
National Cheng Kung University, Taiwan

The enteric pathogen enterohemorrhagic *Escherichia coli* (EHEC) is responsible for outbreaks of bloody diarrhea and hemolytic uremic syndrome (HUS) worldwide. Several molecular mechanisms have been described for the pathogenicity of EHEC; however, the role of bacterial metabolism in the virulence of EHEC during infection in vivo remains unclear. Here we show that aerobic metabolism plays an important role in the regulation of EHEC virulence in *Caenorhabditis elegans*. Our functional genomic analyses showed that disruption of the genes encoding the succinate dehydrogenase complex (Sdh) of EHEC, including the *sdhA* gene, attenuated its toxicity toward *C. elegans* animals. Sdh converts succinate to fumarate and links the tricarboxylic acid (TCA) cycle and the electron transport chain (ETC) simultaneously. Succinate accumulation and fumarate depletion in the EHEC *sdhA* mutant cells were also demonstrated to be concomitant by metabolomic analyses. Moreover, fumarate replenishment to the *sdhA* mutant significantly increased its virulence toward *C. elegans*. These results suggest that the TCA cycle, ETC, and alteration in metabolome all account for the attenuated toxicity of the *sdhA* mutant, and Sdh catabolite fumarate in particular plays a critical role in the regulation of EHEC virulence. In addition, we identified the tryptophanase (TnaA) as a downstream virulence determinant of SdhA using a label-free proteomic method. We demonstrated that expression of *tnaA* is regulated by fumarate in EHEC. Taken together, our multiomic analyses demonstrate that *sdhA* is required for the virulence of EHEC, and aerobic metabolism plays important roles in the pathogenicity of EHEC infection in *C. elegans*. Moreover, our study highlights the potential targeting of SdhA, if druggable, as alternative preventive or therapeutic strategies by which to combat EHEC infection.

Cheng-Yuan Kao, Ph.D. (高承源)**Current position and professional experiences**

- 2017/9 ~ Present **Associate Investigator**, Immunology Research Center, National Health Research Institutes, Zhunan, Miaoli, Taiwan
- 2012/8 ~ 2017/8 **Assistant Investigator**, Immunology Research Center, National Health Research Institutes, Zhunan, Miaoli, Taiwan

**Research interest**

1. Microbiota
2. Systems biology
3. Gut barrier and mucosal immunity
4. Inflammatory diseases (obesity, metabolic disorder, colitis, etc.)

Short research summary

Dr. Cheng-Yuan Kao completed BS in National Cheng-Kung University and MS in National Yang-Ming University in Taiwan. He received PhD degree from University of California Davis in 2005 and then further worked as a postdoctoral researcher at University of California San Diego and project scientist in University of California Davis from 2005 to 2012. In 2012 he joined the Faculty at Immunology Research Center in National Health Research Institutes, and were promoted to Associate Investigator in 2017. Currently Dr. Kao's lab has been focusing on applying a multi-omics (transcriptomics, proteomics, metabolomics, culturomics and microbiome/metagenome) strategy and complementary in vitro and in vivo approaches to study the roles of microbiota in inflammaging and inflammatory diseases such as obesity/metabolic disorders and colitis.

Publications

- 1 Sarah Statt, Jhen-Wei Ruan, Chih-Ting Huang, Reen Wu and Cheng-Yuan Kao*. Lipidome and transcriptome profiling of pneumolysin intoxication identifies networks involved in statin-conferred protection of airway epithelial cells. *Scientific Reports* 2015 May 29;5:10624.
- 2 Chao-Yang Lai, Da-Wei Yeh, Chih-Hao Lu, Yi-Ling Liu, Li-Rung Huang, Cheng-Yuan Kao, Huan-Yuan Chen, Chi-Ying F. Huang, Chung-Hsing Chang, Yunping Luo, Rong Xiang and Tsung-Hsien Chuang. Identification of Thiostrepton as a novel inhibitor for psoriasis-like inflammation induced by TLR7-9. *The Journal of Immunology* 2015 Oct 15;195(8):3912-21.
- 3 Sarah Statt, Jhen-Wei Ruan, Li-Yin Hung, Ching-Yun Chang, Chih-Ting Huang, Jae Hyang Lim, Jian-Dong Li, Reen Wu, and Cheng-Yuan Kao*. Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells. *American Journal of Respiratory Cell and Molecular Biology* 2015 Nov;53(5):689-702.
- 4 Jhen-Wei Ruan, Sarah Statt, Chih-Ting Huang, Yi-Ting Tsai, Cheng-Chin Kuo, Hong-Lin Chan, Yu-Chieh Liao, Tse-Hua Tan and Cheng-Yuan Kao*. Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice. *Nature Microbiology* 2016 Nov 28;2:16220.
- 5 Huan-Da Chen, Cheng-Yuan Kao, Bang-Yu Liu, Shin-Whei Huang, Cheng-Ju Kuo, Jhen-Wei Ruan, Yen-Hung Lin, Cheng-Rung Huang, Yu-Hung Chen, Horng-Dar Wang, Raffi V. Aroian and Chang-Shi Chen. HLH-30/TFEB-mediated autophagy functions in a cell-autonomous manner for epithelium intrinsic cellular defense against bacterial pore-forming toxin in *C. elegans*.

Autophagy 2017 Feb;13(2):371-385.

- 6 Wei-Chan Hsu, Ming-Yu Chen, Shu-Ching Hsu, Li-Rung Huang, Cheng-Yuan Kao, Wen-Hui Cheng, Chien-Hsiung Pan, Ming-Sian Wu, Guann-Yi Yu, Ming-Shiu Hung, Chuen-Miin Leu, Tse-Hua Tan, and Yu-Wen Su. DUSP6 mediates T cell receptor-engaged glycolysis and restrains TFH cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*. 2018 Aug 21;115(34):E8027-E8036.
- 7 Cherng-Shyang Chang, Jhen-Wei Ruan, and Cheng-Yuan Kao*. An overview of microbiome based strategies on anti-obesity. *The Kaohsiung Journal of Medical Sciences* 2019 Jan;35(1):7-16.
- 8 Cherng-Shyang Chang, and Cheng-Yuan Kao*. Current understanding of the gut microbiome shaping mechanisms. *Journal of Biomedical Science* 2019 Aug 21;26(1):59.
- 9 Chao-Yang Lai, Da-Wei Yeh, Chih-Hao Lu, Yi-Ling Liu, Yu-Chen Chuang, Jhen-Wei Ruan, Cheng-Yuan Kao, Li-Rung Huang and Tsung-Hsien Chuang*. Epigenetic silencing of ubiquitin specific protease 4 by Snail1 contributes to macrophage-dependent inflammation and therapeutic resistance in lung cancer. *Cancers*, 2020 Jan 8;12(1). pii: E148.
- 10 Yi-Ting Tsai, Jhen-Wei Ruan, Cherng-Shyang Chang, Mei-Lan Ko, Hsiu-Chuan Chou, Chi-Chien Lin, Chiao-Mei Lin, Chih-Ting Huang, Yu-Shan Wei, En-Chi Liao, Hsin-Yi Chen, Cheng-Yuan Kao* and Hong-Lin Chan*. *Antrodia cinnamomea* confers obesity resistance and restores intestinal barrier integrity in leptin-deficient obese mice. *Nutrients*, 2020 Mar 10; 12(3), 726.
- 11 Guona Wang, Yi-Chinn Weng, I-Chen Chiang, Yu-Ting Huang, Yi-Chu Liao, Yi-Chun Chen, Cheng-Yuan Kao, Yu-Li Liu, Tsong-Hai Lee, and Wen-Hai Chou*. Neutralization of Lipocalin-2 Diminishes Stroke-Reperfusion Injury. Wang G, Weng YC, Chiang IC, Huang YT, Liao YC, Chen YC, Kao CY, Liu YL, Lee TH, Chou WH. *International Journal of Molecular Sciences*, 2020 Aug 29;21(17):6253.

A Multi-omics Analysis Reveals Novel Insights of Gut Microbiota Shaping and Inflammation Control

Cheng-Yuan Kao

National Health Research institutes, Taiwan

Gut microbiota has been recognized to play essential roles in host physiology and might be critically relevant to many human diseases particularly those associated with inflammation. Many studies have shown that dietary nutrients, pharmacologic treatments and many other environmental factors could modulate the gut microbial compositions. Moreover, some host genetic factors could be playing important roles on shaping the gut microbiota and the microbiome composition is indeed a state of equilibrium resulting from the dynamic crosstalks of intrinsic and external factors. In this talk, we report that a genetic knockout mouse strain could restrain inflammation in various inflammatory disease models. Further combining a multi-omics strategy and complementary in vitro mechanistic approaches, we illustrate how a host factor could shape the gut microbiota. Elucidating the host-microbiota interactions in the gut may not only provide the opportunities to improve host health but may also be used for designing novel strategy for disease therapeutics.

Yet-Ran Chen, Ph.D. (陳逸然)**Current position and professional experiences**

- | | |
|----------------|--|
| 2015 ~ Present | Principle Investigator , Tenured Associate Research Fellow, Agricultural Biotechnology Research Center, Academia Sinica |
| 2016 ~ Present | Joint Associate Professor , Department of Chemistry, National Chiayi University |
| 2015 ~ Present | Joint Associate Professor , Institute of Biotechnology, National Taiwan University |
| 2015 ~ Present | Joint Associate Professor , Biotechnology Center, National Chung Hsing University |
| 2015 ~ Present | Joint Associate Professor , Institute of Bioscience and Biotechnology, National Taiwan Ocean University |
| 2009 ~ Present | Founder and Leader , Academia Sinica Metabolomics Core Facility, Scientific Instrument Service Center, Academia Sinica |

**Research interest**

1. High throughput mass spectrometry-based “omics” platform technologies
2. Early signaling events on the cell surface
3. Peptide hormone signaling involved in plant development and stress defenses
4. Plant damage associated molecular pattern (DAMP) triggered immunity
5. Interplay of biotic and abiotic stresses in plants

Short research summary

Dr. Yet-Ran Chen’s research group aims to overcome current technological limitations in the investigation of the dynamics of inter- and intra-cellular communication events regulated by plant peptides. Their studies started with the development of high-performance analytical technologies to identify novel plant peptide signals induced by stress. With highly integrated advanced analytical technologies as a research platform, they are now able to discover novel signaling peptides for the regulation of plant immune response. The technologies they have developed also helped to further elucidate the signaling mechanisms in proteins and metabolites more sensitively and reliably.

Currently, the use of agrochemicals to control pests and diseases is an efficient and common strategy to increase crop productivity. However, the usage of agrochemicals brings significant impacts on the environment, ecosystem, and human health, thus the need to curb the many negative effects of crop production on the environment is becoming increasingly clear. The development of alternative approaches to improve the crop immunity for better resistance of biotic threats is becoming more and more important now. By the development and application of new molecular profiling approach to identify plant immune peptide and study their regulating mechanisms. Dr. Chen’s group applied a novel peptidomics approach integrated the hypothetical database search to profile plant endogenous peptides and used this approach to discover defense signaling peptides in plants. A novel peptide (CAP-derived peptide1, CAPE1) derived from the PR-1 family was discovered to induce significant antipathogen and minor antiherbivore responses in tomato. The PR-1 is the most canonical protein biomarker for protein immunity but its role in the regulation of immunity was unknown for almost half a century. This discovery identified the role of PR-1 in immune signaling and suggests the potential application of plant endogenous peptides in efforts to defeat biological threats in crop production. As the PR-1 is conserved in not only plants but also animal kingdoms, the CAPEs may also involve in the regulation of innate immunity in diverse

species including humans.

Honors

- 2015 – Present Council Member, Asia Oceania Agricultural Proteomics Organization.
- 2015 – Present Executive Council Member / Chair of Finance Committee / Academic Committee, Taiwan Society for Mass Spectrometry
- 2015 – Present Elected Council Member, Taiwan Society for Mass Spectrometry (3rd Highest Votes in 2015, Top Votes in 2018)
- 2014 – Present Elected Council Member, Taiwan Society for Proteomics (2nd Highest Votes in 2017)
- 2012 – 2015 Chair of Finance Committee / Training Course Committee, Taiwan Society for Mass Spectrometry
- 2012 – 2015 Elected Council Member, Taiwan Society for Mass Spectrometry
- 2011 – 2014 Elected Council Member, Taiwan Society for Proteomics
- 2009 – 2012 Elected Council Member/Training Course Committee, Taiwan Society for Mass Spectrometry
- 2006 - 2009 Elected Council Member, Taiwan Society for Mass Spectrometry

Awards

- 2016 Junior Research Investigators Award, Academia Sinica.
- 2016 Significant Discovery of Academia Sinica in 2015.
- 2016 Career Development Award, Academia Sinica.
- 2015 Professor CY Lin Memorial Award for Innovative Research Program, The Chu-Yung Lin Memorial Foundation and Taiwan Society for Plant Biologists.
- 2015 The Shang-Fa Yang Young Scientist Award, The Shang-Fa Yang Memorial Foundation.
- 2015 Significant Discovery of Academia Sinica in 2014.
- 2013 TSMS Young Scholar Award, Taiwan Society for Mass Spectrometry.
- 2008 Biotechnology Creativity Award, Industrial Development Bureau, Ministry of Economic Affairs.

Publications

1. Y. L. Chen, K. T. Fan, S. C. Hung and Y. R. Chen* "The role of peptides cleaved from protein precursors in eliciting plant stress reactions" *New Phytologist*, 2020, 225(6), 2267. (SCI Category: Plant Science, IF(5-year, 2018):8.344) (On-line on 2019 Sep. and became top download paper of *New Phytologist* in 2018-2019)
2. Y. L. Chen, W. H. Chang, C. Y. Lee, Y. R. Chen* "An Improved Scoring Method for the Identification of Endogenous Peptides based on Mascot MS/MS Ion Search" *Analyst*, 2019, 144, 3045. (SCI Category: Analytical Chemistry, IF(2018):4.019)
3. K. T. Fan, K. H. Wang, W. H. Chang, J. C. Yang, C. F. Yeh, K. T. Cheng, S. C. Hung, Y. R. Chen* "Application of data-independent acquisition approach to study the proteome change from early to later phases of tomato pathogenesis responses." *Int. J. Mol. Sci.*, 2019, 20(4), E863. (SCI Category: Chemistry, Multidisciplinary, IF(5-years 2018):4.331)
4. H. J. Chen, Y. C. Shen, Y. J. Shiao, K. T. Liou, P. H. Hsieh, C. Y. Lee, Y. R. Chen* and Y. L. Lin* "Multiplex Brain Proteomic Analysis Revealed the Difference in Molecular Therapeutic Effects of Tissue plasminogen activator and Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice" *PLOS One*, 2015, 10(10), e0140823. (SCI Category: Multidisciplinary Sciences, IF(5-year):3.702, Category Ranking (excluding review journals):9/57)
5. P. S. Chien, H. G. Nam and Y. R. Chen* "A salt-regulated peptide derived from CAP superfamily

Invited Speeches

New Technology – Moderator

(TPS & TSEV) Hall I Section II 11/14 14:40-16:05

protein negatively regulates salt stress tolerance in Arabidopsis" J. Exp. Bot., 2015, 66(17), 5301. (Invited Submission for Plant Peptide Special Issue) (SCI Category: Plant Science, IF(5-year):6.019, Category Ranking (excluding review journals):3/194)

Charles Pin-Kuang Lai, Ph.D. (賴品光)**Current position and professional experiences**

- 2017 ~ Present **Assistant Research Fellow**, Institute of Atomic and Molecular Sciences, Academia Sinica
- 2018 ~ Present **Assistant Professor (adjunct)**, Genome and Systems Biology Degree Program, Academia Sinica and National Taiwan University
- 2015 ~ 2017 **Assistant Professor**, Institute of Biomedical Engineering, National Tsing Hua University
- 2014 ~ 2015 **Instructor**, Program in Neuroscience, Harvard Medical School
Assistant in Neuroscience, Departments of Neurology, Massachusetts General Hospital

**Research interest**

1. Molecular bioimaging
2. Cell-cell and cell-ECM communications (e.g. extracellular vesicles, exosomes, gap junctions)
3. Gene therapy
4. Cancer cell biology

Short research summary

Dr. Lai received his PhD from the University of British Columbia, Canada, in 2010, where he focused on the role of gap junctions in brain cancer. He thereafter joined Dr. Xandra Breakefield's laboratory for his postdoctoral training and Instructor position in the Department of Neurology at Massachusetts General Hospital and Harvard Medical School. He served as an Assistant Professor of Biomedical Engineering at National Tsing Hua University from 2015 to 2017, and is currently an Assistant Research Fellow at the Institute of Atomic and Molecular Sciences in Academia Sinica, Taiwan. His current work focuses on developing molecular bioimaging methods and elucidating molecular mechanisms of nanosized extracellular vesicles and DNA double-strand break repairs.

Publications

1. Wu, A.Y., Sung, Y., Chen, Y., Chou, S.T., Guo, V., Chien, J.C., Ko, J.J., Yang, A.L., Huang, H., Chuang, J., Wu, S., Ho, M., Ericsson, M., Lin, W., Cheung, C.H.Y., Juan, H., Ueda, K., Chen, Y., Lai, C.P.* (2020). Multiresolution imaging using bioluminescence resonance energy transfer identifies distinct biodistribution profiles of extracellular vesicles and exosomes with redirected tropism. *Advanced Science*. In press.
2. Chien J.C., Pinkham, K., da Hora, C.C., Tabet E., Badr C.E.* , Lai, C.P.* Multiplexed bioluminescent reporter enables real-time tracking of DNA double strand break repair dynamics in vitro and in vivo. *Nucleic Acids Research*. In press. *Co-last authors.
3. Huang, Y., Fan, C., Hsu, N., Chiu, N., Wu, C., Chang, C., Wu, B., Hong, S., Chang, Y., Wu, A.Y., Guo, V., C, Y., Hsu, W., C, L., Lai, C.P., Yeh, C., Lin, Y. (2019). Sonogenetic modulation of cellular activities using an engineered auditory-sensing protein. *Nano Letters*. 20 (2): 1089-1100.
4. Sung, Y., Jin, P., Chu, L., Hsu, F., Wang, M., Chang, C., Chiou, S., Qiu, J.T., Gao, D., Lin, C., Chen, Y., Hsu, Y., Wang, J., Wang, F., Yu, P., Chiang, A., Wu, A.Y., Ko, J.J., Lai, C.P., Lu, T.* , Chen, Y.* (2019). Delivery of nitric oxide with a nanocarrier promotes tumor vessel normalization and

- potentiates anti-cancer therapies. *Nature Nanotechnology*. 14 (12):1160-1169. *Co-last authors.
5. Zaborowski, M.P., Lee, K., Na, Y.J., Sammarco, A., Zhang, X., Iwanicki, M., Cheah, P.S., Lin, H.Y., Zinter, M., Chou, C., Fulci, G., Tannous, B.A., Lai, C.P., Birrer, M.J., Weissleder, R., Lee, H., Breakefield, X.O. (2019). Methods for systematic identification of membrane proteins for specific capture of cancer-derived extracellular vesicles. *Cell Reports*. 27 (1):255-268.e6.
 6. Wu, Y.T., Ueda, K., Lai, C.P.* (2019). Review: Proteomic analysis of extracellular vesicles for cancer diagnostics. *Proteomics*. 19 (1-2): 1800162-12.
 7. Chuo S.T., Chien, J.C., Lai, C.P.* (2018). Review: Imaging extracellular vesicles: current and emerging methods. *Journal of Biomedical Science*. 25 (1):91-100.
 8. Reátegui, E.,* van der Vos, K.E.,* Lai, C.P.,* Zeinali, M., Atai, N.A., Aldikacti, B., Floyd Jr., F.P., Khankhel, A.H., Thapar, V., Hochberg, F.H., Sequist, L.V., Nahed, B.V., Carter, B.S., Toner, M., Balaj, L., Ting, D.T., Breakefield, X.O., Stott, S.L. (2018). Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. *Nature Communications*, 9 (1): 175-186. (IF: 12.121) *Co-first authors.
 9. Sung, Y., Liu, Y., Chao, P., Chang, C., Jin, P., Lin, T., Lin, J., Cheng, H., Wang, J., Lai, C.P., Chen, L., Wu, A.Y., Ho, T., Chiang, T., Gao, D., Duda, D.G., Chen, Y. (2018). Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. *Theranostics*, 8 (4): 894-905.
 10. Reiner, A.T., Witwer, K.W., van Balkom, B.W.M., de Beer, J., Brodie, C., Corteling, R.L., Gabrielsson, S., Gimona, M., Ibrahim, A.G., de Kleijn, D., Lai, C.P., Lötvall, J., Del Portillo, H.A., Reischl, I.G., Riazifar, M., Salomon, C., Tahara, H., Toh, W.S., Wauben, M.H.M., Yang, V.K., Yang, Y., Yeo, R.W.Y., Yin, H., Giebel, B., Rohde, E., Lim, S.K. (2017). Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles. *Stem Cells Translational Medicine*, 6 (8): 1730-1739.
 11. Mateescu, B., Kowal, E.J., van Balkom, B.W., Bartel, S, Bhattacharyya S.N., Buzás, E.I., Buck, A.H., de Candia, P., Chow, F.W., Das, S., Driedonks, T.A., Fernández-Messina, L., Haderk, F., Hill, A.F., Jones, J.C., Van Keuren-Jensen, K.R., Lai, C.P., Lässer, C., Liegro, I.D., Lunavat, T.R., Lorenowicz, M.J., Maas, S.L., Mäger, I., Mittelbrunn, M., Momma S., Mukherjee, K., Nawaz, M., Pegtel, D.M., Pfaffl, M.W., Schiffelers, R.M., Tahara, H., Théry, C., Tosar, J.P., Wauben, M.H., Witwer, K.W., Nolte-'t Hoen, E.N. (2017). Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper. *Journal of Extracellular Vesicles*, 6 (1): 1286095.
 12. Pucci, F., Garris, C., Lai, C.P., Newton, A., Pfirschke, C., Engblom, C., Alvarez, D., Sprachman, M., Evavold, C., Magnuson, A., von Andrian, U.H., Glatz, K., Breakefield, X.O., Mempel, T.R., Weissleder, R., Pittet, M.J. (2016). SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. *Science*, 352 (6282): 242-246.
 13. Hall, J., Prabhakar, S., Balaj, L., Lai, C.P., Cerione, R.A., Breakefield, X.O., (2016). Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. *Cellular and Molecular Neurobiology*, 36 (3): 417-427.
 14. *van der Vos, K.E., *Abels, E.R., *Zhang, X., Lai, C.P., Carrizosa, E., Oakley, D.I., Prabhakar, S., Mardini, O., Crommentuijn, M.H., Skog, J., Krichevsky, A.M., Stemmer-Rachamimov, A., Mempel, T.R., El Khoury, J., Hickman, S.E, Breakefield, X.O. (2016). Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. *Neuro-oncology*, 18 (1): 58-69. *Co-first authors.
 15. Lai, C.P., Kim, E.Y., Badr, C.E., Weissleder R., Mempel, T.R., Tannous, B.A., Breakefield, X.O. (2015). Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. *Nature Communications*, 6: 7029.
 16. Zaborowski, M.P., Balaj, L., Breakefield, X.O., Lai, C.P.* (2015). Extracellular vesicles:

composition, biological relevance and methods of study. *Bioscience*, 65 (8): 783-797.

17. Prabhakar S., Zhang X., Goto J., Han S., Lai C.P., Bronson R., Sena-Esteves M., Ramesh V., Stemmer-Rachamimov A., Kwiatkowski D.J., Breakefield, X.O. (2015). Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. *Neurobiology of Disease*, 82: 22-31.
18. Lai, C.P., Mardini, O., Ericsson, M., Prabhakar, S., Maguire A., Chen, J.W., Tannous, B.A., Breakefield, X.O. (2014). Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. *ACS Nano*, 8 (1): 483-494.

Multi-resolution Imaging of Cancer-derived Extracellular Vesicles and Exomeres Identifies Distinct Biodistribution Profiles with Redirected Tropism

Charles Pin-Kuang Lai

Institute of Atomic and Molecular Sciences, Academia Sinica, Taiwan

Extracellular particles (EPs) including extracellular vesicles (EVs) and exomeres play significant roles in diseases and therapeutic applications. However, their spatiotemporal dynamics *in vivo* have remained largely unresolved in detail due to the lack of a suitable method. Therefore, a bioluminescence resonance energy transfer (BRET)-based reporter, PalmGRET, is created to enable pan-EP labeling ranging from exomeres (<50 nm) to small (<200 nm) and medium and large (>200 nm) EVs. PalmGRET emits robust, sustained signals and allows the visualization, tracking, and quantification of the EPs from whole animal to nanoscopic resolutions under different imaging modalities, including bioluminescence, BRET, and fluorescence. Using PalmGRET, it is shown that EPs released by lung metastatic hepatocellular carcinoma (HCC) exhibit lung tropism with varying distributions to other major organs in immunocompetent mice. It is further demonstrated that gene knockdown of lung-tropic membrane proteins, solute carrier organic anion transporter family member 2A1, alanine aminopeptidase/Cd13, and chloride intracellular channel 1 decreases HCC-EP distribution to the lungs and yields distinct biodistribution profiles. It is anticipated that EP-specific imaging, quantitative assays, and detailed *in vivo* characterization are a starting point for more accurate and comprehensive *in vivo* models of EP biology and therapeutic design.

Guan-Da Syu, Ph.D. (許觀達)

Current position and professional experiences

- 2019/8 ~ Present **Assistant Professor**, Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Taiwan
- 2015 ~ 2019 **Postdoc**, Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, USA
- 2013 ~ 2015 **Postdoc**, Graduate Institute of Systems Biology and Bioinformatics, National Central University, Taiwan
- 2012 ~ 2013 **Postdoc**, Department of Physiology, National Cheng Kung University, Taiwan
- 2005 ~ 2012 **Ph.D.**, Graduate Institute of Basic Medical Science, National Cheng Kung University, Taiwan



Research interest

1. Protein microarray
2. Host and microbial interactions
3. High throughput technology
4. Exercise physiology, virology, and bioinformatics

Short research summary

G protein-coupled receptor (GPCR) is the most important family for signal transduction and drug development. However, the seven transmembrane domains increase the difficulty to purify and study GPCRs. Here, we developed virion-display (VirD) technology to express functional GPCR on the virus envelope and applied to all non-olfactory GPCRs. We used VirD technology to detect specificity of biologicals, measure binding affinity of small molecules, and identified receptors that important in bacterial invasion. We recently published our results in *Journal of the American Chemical Society* and *Nature Communications*.

Publications

- **Syu GD*** (*first and corresponding authors), Johansen E, Zhu H. Virion Display: A High-Throughput Method to Express Functional Membrane Proteins. *Current Protocols*. 2020; In press.
- **Syu GD*** (*first and corresponding authors), Dunn J, Zhu H. Developments and applications of functional protein microarrays. *Mol Cell Proteomics*. 2020; 19:916-927. (SCI; impact factor 5.2; ranking 9/79 = 11.4 % in biomedical research methods)
- **Syu GD**, Wang SC, Ma G, Liu S, Pearce D, Prakash A, Henson B, Weng LC, Ghosh D, Ramos P, Eichinger D, Pino I, Dong X, Xiao J, Wang S, Tao N, Kim KS, Desai P, Zhu H. Development and application of a high-content virion display human GPCR array. *Nat Commun*. 2019; 10:1997. (SCI; impact factor 12.4; ranking 3/64 = 4.7 % in multidisciplinary sciences)
- Ma G*, **Syu GD*** (*co-first author), Shan X, Henson B, Wang S, Desai P, Zhu H, Tao N. Measuring ligand binding kinetics to membrane proteins using virion nano-oscillators. *J Am Chem Soc*. 2018; 140:11495-501. (SCI; impact factor 14.4; ranking 8/171 = 4.7 % in chemistry, multidisciplinary)
- Zhu H, Desai P, **Syu GD***. Virion display (VirD) approach to characterizing non-odorant GPCRs in

- Humans. *Faseb J.* 2018; 32:253.3. (SCI; impact factor 5.6; ranking 8/85 = 9.4 % in biology)
- Kuo HC, Huang YH, Chung FH, Chen PC, Sung TC, Chen YW, Hsieh KS, Chen CS*, **Syu GD*** (*Corresponding authors). Antibody profiling of Kawasaki disease using Escherichia coli proteome microarrays. *Mol Cell Proteomics.* 2018; 17:472-481. (SCI; impact factor 5.2; ranking 9/79 = 11.4 % in biomedical research methods)
 - Hsiao FS, Sutandy FR, **Syu GD**, Chen YW, Lin JM, Chen CS. Systematic protein interactome analysis of glycosaminoglycans revealed YcbS as a novel bacterial virulence factor. *Sci Rep.* 2016; 6:28425. (SCI; impact factor 4.1; ranking 12/64 = 18.8 % in multidiscipline sciences)
 - Fan B, Sutandy FX, **Syu GD**, Middleton S, Yi G, Lu KY, Chen CS, Kao CC. Heterogeneous ribonucleoprotein K (hnRNP K) binds miR-122, a mature liver-specific microRNA required for hepatitis C virus replication. *Mol Cell Proteomics.* 2015; 14:2878-86. (SCI; impact factor 5.2; ranking 9/79 = 11.4 % in biomedical research methods)
 - Chen PC, **Syu GD**, Chung KH, Ho YH, Chung FH, Chen PH, Lin JM, Chen YW, Tsai SY, Chen CS. Antibody profiling of bipolar disorder using Escherichia coli proteome microarrays. *Mol Cell Proteomics.* 2015; 14:510-8. (SCI; impact factor 5.2; ranking 9/79 = 11.4 % in biomedical research methods)

Patient and Tech transfer

- **Syu GD.** Application of coronavirus protein microarray in diagnosis. Nonexclusive tech transfers to CDI laboratories, U.S.A., 2020 (TC-109-052).

Application of Functional Protein Microarray in Research and Drug Development

Guan-Da Syu

Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Taiwan
International Center for Wound Repair and Regeneration, National Cheng Kung University, Taiwan
Research Center of Excellence in Regenerative Medicine, National Cheng Kung University, Taiwan

Functional protein microarrays are crucial tools in the study of proteins in an unbiased and high-throughput manner. The adaptability of this technology has enabled its use in a wide variety of applications, including the study of proteome-wide molecular interactions, analysis of post-translational modifications, identification of novel drug targets, examination of pathogen-host interactions, profiling antibody specificity, and discovery of autoantibody biomarkers. Here, I want to share our recent progress of using coronavirus protein microarray in diagnosis and our new Virion Display (VirD) for expressing membrane proteins.

G protein coupled receptors (GPCRs) are the one of the most important membrane protein families that controls variety of cellular functions and often being designed as drug targets. To date, ~40% of the FDA-approved drugs target GPCRs. Despite the importance of the GPCRs, some ligands GPCRs are unknown and classified as orphan GPCRs. Since the lipid bilayer is required to maintain the conformation of GPCRs, purification attempts often disrupt the GPCR conformation. To overcome this hurdle, we developed VirD technology by replacing a viral envelope gene in herpes simplex virus-1 (HSV-1) with an ORF encoding a human transmembrane protein. The production of this recombinant virus from mammalian cells allowed the human receptor to be embedded in the viral envelope with correct conformation and function.

We used VirD technology and successfully expressed 315 human GPCRs on the virions and fabricated the world's largest functional membrane protein array for the biochemical interrogation. We demonstrated that the GPCR-VirD array is useful to profile specificity of mAbs, ligands, and even pathogen interactions. We believe that the VirD array is a robust platform to profile many different kinds of membrane protein interactions and will speed up the development of antibody and small molecule drugs.

Kun-Yi Chien, Ph.D. (簡昆鎰)**Current position and professional experiences**

- 2013/8 ~ Present **Associate Professor**, Department of Biochemistry and Molecular Biology, Chang Gung University
- 2003/10 ~ 2013/8 **Assistant Professor**, Department of Biochemistry and Molecular Biology, Chang Gung University
- 2002/3 ~ 2003/10 **Assistant Research Professor**, Chang Gung Memorial Hospital

**Research interest**

1. Proteomics
2. Separation science
3. Mass spectrometry
4. Biomarker discovery

Short research summary

Dr. Kun-Yi Chien is an Associate Professor of Department of Biochemistry and Molecular Biology at the Chang Gung University (CGU), Taiwan. Dr. Chien received his Ph.D degree from National Tsing-Hua University, Taiwan, and has been involved in proteomics research for the past ~20 years. Dr. Chien's research interest focuses on the development of separation techniques, especially multidimensional nanoLC systems, for proteome analysis. In addition to his primary role in the University, Dr. Chien is responsible for the maintenance of instruments and providing service in the proteomics core laboratory at CGU.

Publications

- 1 Fang YK, Chien KY, Huang KY, Cheng WH, Ku FM, Lin R, Chen TW, Huang PJ, Chiu CH, Tang P. 2016. Responding to a Zoonotic Emergency with Multi-omics Research: Pentatrichomonas hominis Hydrogenosomal Protein Characterization with Use of RNA Sequencing and Proteomics. OMICS. 20(11):662-669.
- 2 Kung YA, Hung CT, Chien KY, Shih SR. 2017. Control of the negative IRES trans-acting factor KHSRP by ubiquitination. Nucleic Acids Res. 45(1):271-287.
- 3 Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Chen MC, Yeh CT, Yu JS. 2017. Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J Proteomics. 157:40-51.
- 4 Bian XL, Chen HZ, Yang PB, Li YP, Zhang FN, Zhang JY, Wang WJ, Zhao WX, Zhang S, Chen QT, Zheng Y, Sun XY, Wang XM, Chien KY, Wu Q. 2017. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nat Commun. 8:14420.
- 5 Hsieh YJ, Chien KY, Yang IF, Lee IN, Wu CC, Huang TY, Yu JS. 2017. Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Sci Rep. 7(1):1370.
- 6 Hsiao YC, Chi LM, Chien KY, Chiang WF, Chen SF, Chuang YN, Lin SY, Wu CC, Chang YT, Chu LJ, Chen YT, Chia SL, Chien CY, Chang KP, Chang YS, Yu JS. 2017. Development of a Multiplexed Assay

- for Oral Cancer Candidate Biomarkers Using Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry. *Mol Cell Proteomics*. 16(10):1829-1849.
- 7 Tsai HJ, Chien KY, Liao HR, Shih MS, Lin YC, Chang YW, Cheng JC, Tseng CP. 2017. Functional links between Disabled-2 Ser723 phosphorylation and thrombin signaling in human platelets. *J Thromb Haemost*. 15(10):2029-2044.
 - 8 Chen HY, Chang JT, Chien KY, Lee YS, You GR, Cheng AJ. 2018. The Endogenous GRP78 Interactome in Human Head and Neck Cancers: A Deterministic Role of Cell Surface GRP78 in Cancer Stemness. *Sci Rep*. 8(1):536.
 - 9 Hsiao YC, Chu LJ, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, Yu JS. 2018. Variability Assessment of 90 Salivary Proteins in Intraday and Interday Samples from Healthy Donors by Multiple Reaction Monitoring-Mass Spectrometry. *Proteomics Clin Appl*. 12(2). doi: 10.1002/prca.201700039.
 - 10 Li XX, Wang ZJ, Zheng Y, Guan YF, Yang PB, Chen X, Peng C, He JP, Ai YL, Wu SF, Chien KY, Wu Q, Chen HZ. 2018. Nuclear Receptor Nur77 Facilitates Melanoma Cell Survival under Metabolic Stress by Protecting Fatty Acid Oxidation. *Mol Cell*. 69(3):480-492.e7.
 - 11 Chuang CF, King CE, Ho BW, Chien KY*, Chang YC*. 2018. Unbiased Proteomic Study of the Axons of Cultured Rat Cortical Neurons. *J Proteome Res*. 17(5):1953-1966.
 - 12 He JP, Hou PP, Chen QT, Wang WJ, Sun XY, Yang PB, Li YP, Yao LM, Li X, Jiang XD, Chien KY, Zhang ZM, Wu QW, Cowin AJ, Wu Q, Chen HZ. 2018. Flightless-I Blocks p62-Mediated Recognition of LC3 to Impede Selective Autophagy and Promote Breast Cancer Progression. *Cancer Res*. 78(17):4853-4864.
 - 13 Huang TY, Chi LM, Chien KY*. 2018. Size-exclusion chromatography using reverse-phase columns for protein separation. *J Chromatogr A*. 1571:201-212.
 - 14 Lin WC, Chakraborty A, Huang SC, Wang PY, Hsieh YJ, Chien KY, Lee YH, Chang CC, Tang HY, Lin YT, Tung CS, Luo JD, Chen TW, Lin TY, Cheng ML, Chen YT, Yeh CT, Liu JL, Sung LY, Shiao MS, Yu JS, Chang YS, Pai LM. 2018. Histidine-Dependent Protein Methylation Is Required for Compartmentalization of CTP Synthase. *Cell Rep*. 24(10):2733-2745.e7.
 - 15 Tang WF, Huang RT, Chien KY, Tang P, Horng JT. 2019. A large-scale proteomic identification of targets of cellular miR-197 downregulated by enterovirus A71. *J Proteome Res*. 18(1):449-460
 - 16 Chi LM, Hsiao YC, Chien KY, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IY, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP, Yu JS. 2020. Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. *J Proteomics*. 211:103571.
 - 17 Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS. 2020. An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. *Anal Chim Acta*. 1100:118-130.
 - 18 Cheng ML, Chien KY, Lai CH, Li GJ, Lin JF, Ho HY. 2020. Metabolic Reprogramming of Host Cells in Response to Enteroviral Infection. *Cells*. 9(2). pii: E473.
 - 19 Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ. 2020. Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. *Clin Cancer Res*. 26(13):3220-3229.
 - 20 Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang IY, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM. 2020. SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. *J Cell Sci*. 133(9):jcs240200.

A nanoLC-MS System for Single-cell Proteomic Analysis

Kun-Yi Chien

Department of Biochemistry and Molecular Biology, Chang Gung University, Taiwan

Single-cell proteomics has emerged as a powerful approach for getting unique insights into biological processes which cannot be achieved by measuring mixtures of multiple cells owing to the cell heterogeneity. One of the challenges of analyzing a single cell is the difficulty of injecting the components of a single cell into the detection system completely. Sample lost due to the adsorption of proteins/peptides to the wall of processing containers is the major problem in analyzing such tiny amounts of samples. In this study, we make two improvements on a nanoLC system for single-cell proteome analysis. First, the extra column volume of the LC system is minimized by a special design of solvent flow path, starting from the gradient mixer. Second, an injection method which causes a lowest sample lost among tested conditions is obtained. We found that adsorption kinetics of peptides to the contact surface of injection vials is very fast, regardless of what types of vials are used. This phenomenon can be effectively prevented by introducing either detergents or acetonitrile into the samples. Finally, an online SCX-RP nanoLC system which allows dissolving samples in large volumes of acetonitrile-containing solvent for injection is established. The system is an automated, sensitive and scalable nanoLC system which is suitable for analyzing trace amounts of samples. By coupling with a highly sensitive mass spectrometer, ~1000 proteins can be identified from a single human cell. Furthermore, the system is also suitable for analyzing products which are obtained from some low-yield sample preparation processes such as pull-down assays of biotinylated peptides.

Invited Speeches

New Technology – Speaker

(TPS & TSEV) Hall I Section II 11/14 14:40-16:05

Shaw-Jenq Tsai, Ph.D. (蔡少正)

Current position and professional experiences

- 2019 ~ Present **Chair Professor**, Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan
- 2001 ~ Present **Director**, Bioinformatic Center, National Cheng Kung University
- 2016 ~ 2020 **President**, The Chinese Physiological Society
- 2019 ~ Present **President**, Asian Society of Endometriosis and Adenomyosis
- 2011 ~ Present **Ambassador**, World Endometriosis Society



Research interest

1. Hypoxia-mediated epigenome regulation
2. Mechanisms of drug resistance in cancer
3. Endometriosis
4. Translational medicine

Short research summary

Professor Shaw-Jenq (Sean) Tsai received his PhD degree from the University of Wisconsin-Madison, USA in 1997. He then joined the Department of Physiology at the National Cheng Kung University, Taiwan, as an assistant professor in 1998. He was promoted to distinguished professor in 2008 in recognition of his great academic achievements. Professor Tsai also served as the Director-General of Department of Life Sciences, Ministry of Science and Technology, Taiwan during 2014-2017. Professor Tsai's research focuses on investigating molecular mechanisms underlying important human diseases, including cancer, polycystic ovarian syndrome, and endometriosis. He has published more than one hundred papers in prestigious journals such as *Nature*, *Nature Communications*, *Journal of Clinical Investigation*, *Journal of Pathology*, *Cancer Research*, *Nucleic Acids Research*, and *Journal of Clinical Endocrinology & Metabolism*. Those papers have been cited more than 5000 times with an H-index of 46. The outstanding research performance enables Professor Tsai to be awarded the "2014 Distinguished Scientist" by Society for Experimental Biology and Medicine and elected as a fellow in 2018. Professor Tsai serves as editorial board member of many journals including *Journal of Endocrinology*, *Journal of Molecular Endocrinology*, *Reproductive Medicine & Biology*, and is the Asian editor of *Experimental Biology and Medicine*.

Publications

1. WN Li, KY Hsiao, CA Wang, N Chang, PL Hsu, MH Wu*, SJ Tsai* Extracellular vesicle-associated VEGF-C as a novel target for endometriosis. **Proc Natl Acad Sci U S A**, 117 (41):25859-25868, Oct. 13, 2020.
2. PS Chen, WT Chu, PL Hsu, SC Lin, IC Peng, CY Wang, SJ Tsai* Pathophysiological implications of hypoxia in human diseases. **J Biomed Sci** 27: 63, 2020 May 11.
3. CA Wang, YH Chang, PC Hou, YJ Tai, WN Li, PL Hsu, **SR Wu**, CF Li, YS Shan, SJ Tsai* DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination. **J Extracell Vesicles** 9 (1): 1746529, 2020 April 4.
4. TM Chen, MC Lai, YH Li, YL Chan, CH Wu, YM Wang, CW Chien, SY Huang, H. S Sun*, SJ Tsai* hnRNPM induces translation switch under hypoxia to promote colon cancer development. **EBioMedicine** 2019 Mar 6. pii: S2352-3964(19)30138-0. doi: 10.1016/j.ebiom.2019.02.059

5. PL Hsu, J Jou, SJ Tsai* TYRO3: a potential therapeutic target in cancer. **Exp Biol Med** 244: 83–9, 2019
6. SC Lin, HC Lee, CT Hsu, YH Huang, WN Li, PL Hsu, MH Wu*, SJ Tsai* Targeting anthrax toxin receptor 2 ameliorates endometriosis progression. **Theranostics**; 9(3): 620-632, 2019. doi: 10.7150/thno.30655
7. JL Fu, KY Hsiao, HC Lee, WN Li, N Chang, MH Wu*, SJ Tsai* Suppression of COUP-TFII upregulates angiogenin and promotes angiogenesis in endometriosis **Hum Reprod** 33 (8): 1517-27, 2018 Aug 1. doi: 10.1093/humrep/dey220.
8. KY Hsiao, HS Sun, SJ Tsai* Circular RNA - New member of noncoding RNA with novel functions. **Exp Biol Med** (Maywood) 242(11):1136-1141.
9. SC Lin, HC Lee, PC Hou, JL Fu, MH Wu, SJ Tsai* Targeting hypoxia-mediated YAP1 nuclear translocation ameliorates pathogenesis of endometriosis without compromising maternal fertility. **J Pathol** 242: 476–487. doi: 10.1002/path.4922, 2017
10. PC Hou, YH Li, SC Lin, SC Lin, JC Lee, PW Lin, JP Liou, JY Chang, CC Kuo, YM Liu, HS Sun, SJ Tsai* Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. **Cancer Res**, 77 (16): 4305-4316. doi: 10.1158/0008-5472.CAN-16-2990, 2017
11. KY Hsiao, YC Lin, SK Gupta, N Chang, L Yen, H. S Sun*, SJ Tsai* Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. **Cancer Res** 77:2339-2350. May 1, doi: 10.1158/0008-5472.CAN-16-1883, 2017 (Hot paper, high-cite paper)
12. SC Lin, KY Hsiao, N Chang, PC Hou, SJ Tsai* Loss of dual specificity phosphatase-2 promotes angiogenesis and metastasis via upregulation of interleukin-8 in colon cancer. **J Pathol** 241: 638–648, 2017
13. CW Chien, PC Ho, HC Wu, YL Chang, SC Lin, PW Lin, JC Lee, YJ Chang, HS Sun, SJ Tsai* Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. **Oncogene** 35(45):5872-5881, 2016
14. KY Hsiao, MH Wu, N Chang, SH Yang, CW Wu, HS Sun, SJ Tsai* Coordination of AUF1 and miR-148a to destabilize DNA methyltransferase 1 mRNA under hypoxia in endometriosis. **Mol Hum Reprod** 21:894-904, 2015
15. CA Wang, SJ Tsai* 2015 The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. **Exp Biol Med** (Maywood) 240(6):718-24, 2015
16. KY Hsiao, SC Lin, MH Wu*, SJ Tsai* Pathological functions of hypoxia in endometriosis. **Front Biol Sci** 7: 309-321, 2015
17. SC Lin, WL Liao, JC Lee, SJ Tsai* Hypoxia-regulated gene network in drug resistance and cancer progression. **Exp Biol Med** 239:779-792, 2014
18. SC Lin, YH Li, MH Wu, YF Chang, DK Lee, S Tsai, MJ Tsai, and SJ Tsai* Suppression of COUP-TFII by proinflammatory cytokines contributes to the pathogenesis of endometriosis. **J Clin Endocrinol Metab** 99(3): E427-37, 2014.
19. TM Chen, YH Shih, JT Tseng, MC Lai, Ch Wu, YH Li, SJ Tsai*, and HS Sun* Overexpression of FGF9 in colon cancer cells is mediated by hypoxia-induced translational activation. **Nucleic Acids Res** 42:2932-44, 2014
20. HM Chen, YH Lin, YM Cheng, LYC Wing, SJ Tsai* Overexpression of integrin-β1 promotes leiomyomal cell spreading and proliferation. **J Clin Endocrinol Metab** 98:E837-46, 2013.
21. MH Wu, PC Chuang, YJ Lin, SJ Tsai* Suppression of annexin A2 by prostaglandin E₂ impairs phagocytic ability of peritoneal macrophage in women with endometriosis. **Hum Reprod** 28:1045-53, 2013 (recommended by Faculty 1000 of Medicine)
22. J Qin, SP Wu, F Dai, X Xie, CM Cheng, C J Creighton, A Frolov, Gustavo Ayala4, X Lin, XH Feng, MM Ittmann, SJ Tsai, MJ Tsai, S Y Tsai Inhibition of TGF-β-dependent growth barrier by COUP-TFII to promote prostate tumor growth and metastasis. **Nature** 493: 236-240, 2013

Hua-Jung Li, Ph.D. (李華容)

Current position and professional experiences

- 2019/7 ~ Present **Associate Investigator**, Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Taiwan
- 2012 ~ 2019 **Assistant Investigator**, Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Taiwan
- 2009 ~ 2012 **Postdoctoral Fellow**, Whitehead Institute for Biomedical Research/MIT, Boston, MA, USA
- 2007 ~ 2009 **Postdoctoral Fellow**, University of California, Los Angeles (UCLA), CA, USA

**Research interest**

1. Extracellular vesicles
2. Stem cells
3. Regeneration medicine
4. Cancer

Short research summary

Dr. Hua-Jung Li received a PhD degree in Molecular and Medical Pharmacology from University of California, Los Angeles. During the period, Dr. Li studied targeting cancer therapy in Harvey Herschman lab. After receiving the PhD degree, Dr. Li was awarded by Susan G. Komen for the Cure. With the support by Susan G. Komen for the Cure, Dr. Li entered Robert Weinberg Lab at Whitehead Institute. In Weinberg lab, Dr. Li focused on cancer stem cell biology. She investigated the interactions of carcinoma cells and tumor stroma and found that the interaction controlled the tumor behavior via affecting cancer stem cell pools. Dr. Li joined National Health Research Institutes, Taiwan in 2013. Her lab currently works on dissecting the conversion of stem and non-stem cell states.

Publications

- 1 Chen SY, Lin MC, Tsai JS, He PL, Luo WT, Chiu IM, Herschman HR, and Li HJ* Exosomal 2',3'-CNP from mesenchymal stem cells promotes hippocampus CA1 neurogenesis/ neuritogenesis and contributes to rescue of cognition/learning deficiencies of damaged brain. *Stem Cells Translational Medicine* 2020;9:499–517 **FEATURED ARTICLE**
- 2 Chen SY, Lin MC, He PL, Tsai JS, Luo WT, Herschman HR, and Li HJ* EP4 antagonist-elicited extracellular vesicles from mesenchymal stem cells rescue cognition/learning deficiencies by restoring brain cellular functions. *Stem Cells Translational Medicine*. 2019;8(7):707-723 **FEATURED ARTICLE**
- 3 Lin MC, Chen SY, He PL, Herschman HR, and Li HJ* PGE2/EP4 antagonism enhances tumor chemosensitivity by inducing extracellular vesicle-mediated clearance of cancer stem cells. *Int J Cancer*. 2018;143(6):1440-1455 **COVER STORY**
- 4 Lin MC, Chen SY, Tsai HM, He PL, Lin YC, Herschman HR, and Li HJ* PGE2/EP4 signaling controls the transfer of the mammary stem cell state by lipid rafts in extracellular vesicles. *Stem Cells* 2017;35(2):425-444
- 5 Lin MC, Chen SY, He PL, Luo WT, and Li HJ* Transfer of Mammary Gland-forming Ability Between Mammary Basal Epithelial Cells and Mammary Luminal Cells via Extracellular

Vesicles/Exosomes. J. Vis. Exp. 2017; 124, e55736, doi:10.3791/55736

- 6 Li HJ, Reinhardt F, Herschman HR and Weinberg RA*. Cancer stimulated mesenchymal stem cells create a carcinoma stem-cell niche via Prostaglandin E2 signaling. Cancer Discovery 2012;2(9):840-55.
- 7 Li HJ, Everts M, Yamamoto M, Curiel DT, and Herschman HR*. Combined transductional untargeting/retargeting and transcriptional restriction enhance adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Research 2009;69(2):554-64.
- 8 Li HJ, Everts M, Pereboeva L, Komarova S, Idan A, Curiel DT and Herschman HR*. Adenovirus Tumor Targeting and Hepatic Untargeting by a Coxsackie/Adenovirus Receptor Ectodomain Anti-Carcinoembryonic Antigen Bispecific Adapter. Cancer Research 2007;67(11):5354-61

Exosomes in Stem Cell Homeostasis, Cancer, and Regeneration Medicine

Hua-Jung Li

Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan

Extracellular vesicles (EVs) (i.e., exosomes) are responsible for intercellular communication by transferring membrane and cytosolic molecules between cells. Promoting EV release from basal mammary epithelial stem-like cells causes a transition of the cells to a non-stem, more epithelial phenotype. The basal mammary epithelial stem-like cells lose SC properties after releasing the EVs/exosomes. In contrast, uptake of the EVs drives conversion of mammary luminal cells to basal cell-like mammary epithelial stem cells able to form mammary glands. The stem cell EV-mediated stemness transfer provides a new direction for regeneration medicine. For example, adult brains have limited regenerative capacity. Consequently, both brain damage and neurodegenerative diseases often cause functional impairment for patients. Mesenchymal stem cells (MSCs), one type of adult stem cells, can be isolated from various adult tissues; MSCs “have been used in clinical trials to treat human diseases and the therapeutic potentials of the MSC-derived secretome and extracellular vesicles (EVs) have been under investigation. We found that EP4 antagonist-elicited MSC EVs/exosomes exhibit greatly enhanced therapeutic potential, in contrast to the comparatively low efficiency of EVs/exosomes derived from untreated MSCs, to rescue several CNS pathologies; (e.g., neuron degeneration and death, reactive astrogliosis, extensive inflammation, disrupted BBB), which are often associated with brain injury, stroke and many neurodegenerative diseases (e.g., AD and PD). Our study demonstrates EP4-antagonist elicited MSC EVs/exosomes as a regenerative medicine for CNS diseases.

A similar mechanism is observed in cancer. Similar to basal mammary epithelial stem-like cells, breast cancer cells expressing mesenchymal phenotypes are associated with cancer stem cell (CSC) properties and are often resistant to conventional chemotherapy. We can induce a conversion of mesenchymal breast cancer stem cells from a mesenchymal/CSC state to a more epithelial non-CSC state by promoting the release of EVs which remove CSC markers, mesenchymal markers, integrins, and drug efflux transporters from the CSCs. The induced EV release increases chemosensitivity of breast cancer cells, which suggests that, in combination with conventional chemotherapy, such an inhibitor might serve as an effective adjuvant for targeting cancer stem cells. This finding holds implications for the treatment of carcinomas in the oncology clinic.

Chu-An Wang, Ph.D. (王竹安)**Current position and professional experiences**

- 2017 ~ Present **Assistant Investigator**,
Institute of Molecular Medicine, National Cheng Kung
University, Taiwan
- 2014 ~ 2017 **Postdoctoral Fellow**,
Department of Basic Medical Science, National Cheng
Kung University, Taiwan
- 2012 ~ 2014 **Postdoctoral Fellow**,
Department of Pharmacology, University of Colorado
Denver, Anschutz Medical Campus, USA
- 2007 ~ 2012 **Ph.D.**, Molecular and Cancer Biology
University of Colorado Denver, Anschutz Medical Campus, USA

**Research interest**

1. Cancer biology
2. Extracellular vesicle
3. Angiogenesis/lymphangiogenesis

Short research summary

Dr. Wang is an Assistant Investigator at National Cheng Kung University (NCKU), Taiwan. Dr. Wang received her Ph.D. degree from the University of Colorado, Denver in the United State and has been involved in cancer research since her Ph.D. Dr. Wang's research interest focuses on molecular mechanisms of cancer metastasis and the function and regulation of extracellular vesicle in cancer progression.

Publications

1. Meng-Hsing Wu,* Chu-An Wang,* Chen-Chung Lin, Lei-Chin Chen, Wen-Chang Chang, and Shaw-Jenq Tsai. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. *J Clin Endocrinol Metab.* 2005 Jan;90(1):286-95.
2. W. Chen,S.-J. Tsai, C.-A. Wang, J.-C. Tsai, C.C. Zouboulis. Human sebocytes express prostaglandin E2 receptors EP2 and EP4 but treatment with prostaglandin E2 does not affect testosterone production. *Br J Dermatol.* 2009 Sep;161(3):674-7.
3. Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. *Cancer Res.* 2010 Dec 15;70(24):10371-80.
4. Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. *J Clin Invest.* 2012 May 1;122(5):1895-906.
5. Research was highlighted as a short article at: Metastasis: SIX1 of the best. *Nat Rev Cancer.* 2012 May 24;12(5):316.
6. Ritsuko Iwanaga, Chu-An Wang, Douglas S. Micalizzi, Chuck J. Harrell, Paul Jedlicka, Carol Sartorius, Peter Kabos, Andrew P Bradford, Heide L. Ford. Six1 enhances tumor initiating cell activity and predicts poor prognosis in luminal breast cancers. *Breast Cancer Res.* 2012 Jul 5;14(4):R100.
7. Wang CA, Harrell J, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor-C

- promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3. *Breast Cancer Res.* 2014 Oct 30;16(5):462.
8. Wang CA, Drasin DJ, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello J, Tan AC, Ford HL. Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression. *Cancer Res.* 2014 Dec 15;74(24):7357-70.
 9. David J. Drasin , Anna L. Guarnieri , Deepika Neelakantan , Jihye Kim , Joshua H. Cabrera , Chu-An Wang , Vadym Zaberezhnyy , Pierluigi Gasparini , Luciano Cascione , Kay Huebner , Aik Choon Tan, Ford HL. TWIST1-induced microRNA-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. *Cancer Res.* 2015 May 1;75(9):1908-21
 10. Wang CA and Shaw-Jenq Tsai. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. *Exp Biol Med (Maywood).* 2015 Jun;240(6):718-24.
 11. Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein represses translation of p53 via concomitant regulation of RPL26 and microRNA-27a. *Nat Commun.* 2015 Dec 21;6:10077.
 12. Chu-An Wang , Yi-Hern Chang , Pei-Chi Hou , Yu-Jing Tai , Wan-Ning Li, Pei-Ling Hsu, Shang-Rung Wu, Wen-Tai Chiu, Chien-Feng Li , Yan-Shen Shan , Shaw-Jenq Tsai. Targeting DUSP2-mediated extracellular vesicle-VEGF-C secretion ameliorates pancreatic cancer early dissemination. *J Extracell Vesicles.* 2020 Apr 4;9(1):1746529.
 13. Wan-Ning Li, Kuei-Yang Hsiao, Chu-An Wang, Ning Chang, Pei-Ling Hsu, Chung-Hsien Sun, Shang-Rung Wu, Meng-Hsing Wu, Shaw-Jenq Tsai. Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis. *PNAS.* October 13, 2020 117 (41) 25859-25868.

The Function and Regulation of EV-VEGF-C in Pancreatic Cancer Early Metastasis

Chu-An Wang

Institute of Molecular Medicine, National Cheng Kung University, Taiwan

Extracellular vesicles (EVs) are nanometer-sized, lipid bilayer-enclosed particles which carry bioactive material and mediate intercellular communication. Bioactive molecules on EVs surface may convey rapid and specific signaling in the recipient cells. We have identified that vascular endothelial growth factor-C (VEGF-C), the master lymphangiogenic growth factor, is associated with EVs produced by pancreatic cancer cells. EV-VEGF-C contributes to pancreatic cancer metastasis via promoting lymphangiogenesis and tumor cell invasion ability. We further identified that tumor suppressor dual specificity phosphatase-2 (DUSP2) controls VEGF-C at multiple levels including transcription, maturation, and extracellular vesicle (EV)-associated secretion. Our findings underscore the critical importance of DUSP2-VEGF-C axis in pancreatic cancer early metastasis.

Wei-Hsuan Hsu, Ph.D. (徐瑋萱)**Current position and professional experiences**

- | | |
|------------------|---|
| 2020 ~ Present | The 2nd Council Member , Taiwan Society for Extracellular Vesicles |
| 2018/8 ~ Present | Assistant Professor , National Cheng Kung University Department of Food Safety / Hygiene and Risk Management |
| 2015/6 ~ 2018/7 | Researcher , Industrial Technology Research Institute Biomedical Technology and Device Research Labs |
| 2014/9 ~ 2015/3 | Postdoctoral Researcher , Purdue University Department of Medical Sciences |
| 2013/9 ~ 2014/8 | Postdoctoral Researcher , National Taiwan University Department of Biochemical Science and Technology |

**Research interest**

1. Food microbiology
2. Food fermentation and biotechnology
3. Microorganisms and health

Short research summary

We study the communication of microorganisms and the bi-directional regulation between microbes and the host, especially gut. Specific probiotics are selected to regulate gut microbiota and to act as a target for disease therapeutics. We investigate the function of extracellular vesicles derived from probiotics and gut microbiota as well as their application on biomedicine and food science

Publications

1. Bao-Hong Lee, She-Ching Wu, Tang-Long Shen, Yi-Yun Hsu, Chia-Hsiu Chen, Wei-Hsuan Hsu*. 2020. The applications of Lactobacillus plantarum-derived extracellular vesicles as a novel natural antibacterial agent for improving quality and safety in tuna fish. Food Chem. 340, 128104.
2. Bao-Hong Lee, Wei-Hsuan Hsu, Cheng-Hui Lin. 2019. The anti-bacterial and anti-adherent effects of Pentraxin-3 on porcine kidney epithelial PK15 cells against Staphylococcus aureus infection. Int. J. Pept. Res. Ther. 25, 645-652.
3. Wei-Hsuan Hsu, Yu-Chun Lin, Bo-Rui Chen, She-Ching Wu*, Bao-Hong Lee*. 2018. The neuronal protection of a zinc-binding protein isolated from oyster. Food Chem. Toxicol. 114, 61-68.
4. Liang-Tzung Lin, Ying-Jang Lai, She-Ching Wu, Wei-Hsuan Hsu*, Chen-Jei Tai*. 2018. Optimal conditions for cordycepin production in surface liquid-cultured Cordyceps militaris treated with porcine liver extracts for suppression of oral cancer. J. Food Drug Anal. 26, 135-144.
5. Rui Zhang, Sherri Y. Huang, Kay Ka-Wai Li, Yen-Hsing Li, Wei-Hsuan Hsu, GuangJun Zhang, Chun-Ju Chang, Jer-Yen Yang*. 2017. Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through β -TrCP-mediated proteasome degradation. Oncotarget 8, 49869-49881.
6. Chia-Woei Wang, Wei-Hsuan Hsu, Chen-Jei Tai*. 2017. Antimetastatic effects of cordycepin mediated by the inhibition of mitochondrial activity and estrogen-related receptor α in human ovarian carcinoma cells. Oncotarget 8, 3049-3058.

7. Yeu-Ching Shi, Kai-Sian Lin, Yi-Fen Jhai, Bao-Hong Lee, Yifan Han, Zhibin Cui, Wei-Hsuan Hsu*, She-Ching Wu*. 2016. Miracle fruit (*Synsepalum dulcificum*) exhibits as a novel anti-hyperuricaemia agent. *Molecules* 21, 140.
8. Wei-Hsuan Hsu, Bao-Hong Lee, Tzu-Ming Pan*. 2015. Leptin-induced mitochondrial fusion mediates hepatic lipid accumulation. *Int. J. Obes.* 39, 1750-1756.
9. Yifan Han, Zhibin Cui, Yen-Hsing Li, Wei-Hsuan Hsu*, Bao-Hong Lee*. 2015. In vitro and in vivo anticancer activity of pardaxin against proliferation and growth of oral squamous cell carcinoma. *Mar. Drugs* 14, 2.
10. Yu-Ying Chang, Wei-Hsuan Hsu, Tzu-Ming Pan*. 2015. Monascus secondary metabolites monascin and ankaflavin inhibit activation of RBL-2H3 cells. *J. Agric. Food Chem.* 63, 192-199.
11. Ya-Yun Tan#, Wei-Hsuan Hsu#, Tsung-Wei Shih, Chih-Hui Lin, Tzu-Ming Pan*. 2014. Proteomic insight into the effect of ethanol on citrinin biosynthesis pathway in *Monascus purpureus* NTU 568. *Food Res. Int.* 64, 733-742. (#Co-first author)
12. Wei-Hsuan Hsu, Bao-Hong Lee, Tzu-Ming Pan*. 2014. Monascin attenuates oxidative stress-mediated lung inflammation via peroxisome proliferator-activated receptor-gamma (PPAR- γ) and nuclear factor-erythroid 2 related factor 2 (Nrf-2) modulation. *J. Agric. Food Chem.* 62, 5337-5344.
13. Wei-Hsuan Hsu, Tzu-Ming Pan*. 2014. Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus *Monascus* spp. *Appl. Microbiol. Biotechnol.* 98, 4853-4863. (Review).
14. Wei-Hsuan Hsu, Tzu-Ming Pan*. 2014. A novel PPAR γ agonist monascin potentially applied in diabetes prevention. *Food Funct.* 5, 1334-1340. (Review).
15. Wei-Hsuan Hsu, Tin-Hong Chen, Bao-Hong Lee, Ya-Wen Hsu, *Tzu-Ming Pan. 2014. Monascin and ankaflavin act as natural AMPK activators with PPAR α agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. *Food Chem. Toxicol.* 64, 94-103.

Development and Application of Extracellular Vesicles Derived from Probiotics

Wei-Hsuan Hsu

Department of Food Food Safety / Hygiene and Risk Management

National Cheng Kung University, Taiwan

Extracellular vesicles (EVs) secretion is necessary and conserved situation that across all domains of life. Prokaryotes and eukaryotes release nano-sized and spherical extracellular vesicles (EVs) with lipid-bilayer that encased with proteins, DNA, different classes of RNAs, lipids, toxins, enzymes, and other cargo that they deliver to extracellular environment to communicate. Few studies have evaluated the function of EVs derived from bacteria and researched the role of EVs among microbes. It's reported that the EVs derived from protiotics such as *Lactobacillus* species and the next generation probiotics in the intestine such as *Akkermansia muciniphila* and *Bacteroides fragilis* can improve intestinal inflammation-related diseases and adjust immune function. We establish the isolation method of EVs derived from protiotics and characterize the EVs. The occurrence of leaky gut is associated with the enterobacteria, this study investigated whether EVs secreted by probiotics can inhibit the growth of enterobacteria, and further clarify their possible molecular mechanisms to understand the links and communication between bacteria. The results showed that the EVs derived from different probiotics should have specificity for the regulation of intestinal bacteria. It was concluded that the EVs derived from probiotics selectively enter bacteria and specifically affect the growth of enterobacteria. It is expected that the new reagents will be developed to treat intestinal related diseases.

HY. Elizabeth Chou, Ph.D. (周涵怡)

Current position and professional experiences

- 2015/8 ~ Present **Associate Professor**, Graduate Institute of Oral Biology, National Taiwan University
- 2015/8 ~ Present **Jointly Appointed Associate Research Fellow**, Center for Biotechnology, National Taiwan University
- 2007/8 ~ Present **Associate Research Fellow**, Department of Dentistry, NTU Hospital



Research interest

1. Oral stem cell biology
2. Exosome biology
3. Biomedical engineering application

Short research summary

Dr. Han-Yi E. Chou serves as Associate Professor at the Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University. She received her Ph.D. degree from the Institute of Molecular Medicine of the National Taiwan University, and completed her post-doctoral fellowship at the Department of Pathology of NTU Hospital. Dr. Chou is interested in the biological control for homeostasis upon environmental stress and, if this fails, how it conducts to pathological outcomes. Her team has been focusing on the molecular basis linking chronic stress responses to the promotion of stemness properties, with aim to translate the biological logistics underlying these findings into novel applications through engineering and tailored design of biomedical devices.

Publications

1. Healing kinetics of diabetic wounds controlled with charge-biased hydrogel dressings. Venault A, Bai YW, Dizon GZ, Chou HY, Chiang HC, Lo CT, Zheng J, Aimare P and Chang Y*. *J Mater Chem B*. 2019; 7: 7184
2. Self-powered ultrasensitive glucose detection based on graphene multi-heterojunctions. Chang C, Lin W, Liao Y, Chou HY* and Chen YF*. *Lasers Electro-Optics*. 2018; AM4P:4. (* Equal Corresponding Author)
3. TIF1 β is phosphorylated at serine 473 in colorectal tumor cells through p38 mitogen-activated protein kinase as an oxidative defense mechanism. Shen TW, Chou HY and Kato M*. *Biochem Biophys Res Comm*. 2017; 292(3):310.
4. Chitosan-assisted differentiation of porcine adipose tissue-derived stem cells into glucose-responsive insulin-secreting clusters. Liu HY, Chen CC, Lin YY, Chen YJ, Liu BH, Wong SC, Wu CY, Chang YT, Chou HY* and Ding ST*. *Plos One*. 2017; Mar. (* Equal Corresponding Author)
5. A portable microfluidic device for the rapid diagnosis of cancer metastatic potential which is programmable for temperature and CO₂. Yu IF, Yu YH, Chen LY, Fan SK, Chou HY* Yang JT*. *Lab Chip*. 2014; 14(18):3621. (* Equal Corresponding Author)
6. A biocompatible open-surface droplet manipulation platform for detection of multi-nucleotide polymorphism. Huang CJ, Fang WF, Ke MS, Chou HY*, Yang JT*. *Lab Chip*. 2014; 14(12):2057. (* Equal Corresponding Author)
7. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, Yu SL, Yuan SS, Chen YJ, Lin CY,

Invited Speeches *Disease Biomarker & Mechanism – Moderator*
(TPS & TSEV) Hall I Section IV 11/15 13:30-14:55

Pan SH, Chou HY, Chen YJ, Chang GC, Chu WC, Lee YM, Lee JY, Lee PJ, Li KC, Chen HW and Yang PC. Nat Commun. 2014; 5:3472.

8. Interaction between Salt-inducible Kinase 2 and Protein Phosphatase 2A regulates the activity of Calcium/Calmodulin-dependent Protein Kinase I and Protein Phosphatase Methylesterase-1. Lee CW, Yang FC, Chang HY, Tan BC, Chou HY and Lee SC. J Biol Chem. 2014; 289:21108.

Cheng-Chih Hsu, Ph.D. (徐丞志)

Current position and professional experiences

- 2015 ~ Present **Faculty member**, Department of Chemistry,
National Taiwan University
- 2014 ~ 2015 **Postdoctoral research fellow**, Department of
Chemistry, Stanford University



Research interest

1. Mass spectrometry imaging
2. Ambient ionization mass spectrometry
3. Clinical mass spectrometry
4. Human microbiota metabolomics

Honors and Awards

1. 2020 Young Scholar Research Award of Taiwan Society for Mass Spectrometry
2. 2019 MOST Young Scholar Fellowship – Columbus Program
3. Top 40 Under 40 Power List 2018 of the Analytical Scientist
4. Future Tech Breakthrough Award 2018 at MOST Future Tech Exhibition
5. 2016 Recruiting Outstanding Young Scholar Award, FAOS
6. 2015 Mass Spectrometry Imaging (MSI) Award

Publications

1. Y.-C. Huang, H.-H. Chung, E. P. Dutkiewicz, C.-L. Chen, H.-Y. Hsieh, B.-R. Chen, M.-Y. Wang,* C.-C. Hsu,* "Predicting Breast Cancer by Paper Spray Ion Mobility Spectrometry Mass Spectrometry and Machine Learning." *Anal. Chem.* 2020, 92, 1653-1657. (Front Cover)
2. T.-H. Kuo, E. P. Dutkiewicz, J. Pei,* C.-C. Hsu,* "Ambient Ionization Mass Spectrometry Today and Tomorrow: Embracing Challenges and Opportunities." *Anal. Chem.* 2020, 92, 2353-2363.
3. T.-H. Kuo, C.-T. Yang, H.-Y. Chang, Y.-P. Hsueh,* C.-C. Hsu,* "Nematode-Trapping Fungi Produce Diverse Metabolites during Predator–Prey Interaction." *Metabolites.* 2020, 10, 117.
4. P. Huang, C.-Y. Huang, T.-C. Lin, L.-E. Lin, E. Yang, C. Lee,* C.-C. Hsu,* P.-T. Chou,* "Towards the Rational Design of Universal Dual Polarity Matrix for MALDI Mass Spectrometry." *Anal. Chem.* 2020, 92, 7139-7145.
5. L.-E. Lin, C.-L. Chen, Y.-C. Huang, H.-H. Chung, Y.-J. Peng, S.-T. Ding, M.-Y. Wang, T.-L. Shen, C.-C. Hsu,* "Precision Biomarker Discovery Powered by Microscopy Image Fusion-assisted High Spatial Resolution Ambient Ionization Mass Spectrometry Imaging." *Anal. Chim. Acta* 2020, 1100, 75-87.
6. Y.-L. Gao, Y.-J. Wang, H.-H. Chung, K.-C. Chen, T.-L. Shen, C.-C. Hsu,* "Tandem mass spectral similarity networking as a dereplication strategy for metabolic products of medicinal herbs in cancer cells." *Rapid Commun. Mass Spectrom.* 2020, 34, e8549.
7. T.-H. Kuo, H.-H. Chung, H.-Y. Chang, C.-W. Lin, M.-Y. Wang, T.-L. Shen, C.-C. Hsu,* "Deep Lipidomics and Molecular Imaging of Unsaturated Lipid Isomers: A Universal Strategy Initiated by mCPBA Epoxidation." *Anal. Chem.* 2019, 91, 11905-11915.
8. T.-H. Kuo, H.-C. Huang, C.-C. Hsu,* "Mass Spectrometry Imaging Guided Molecular Networking to Expedite Discovery and Structural Analysis of Agarwood Natural Products." *Anal. Chim. Acta* 2019, 1080, 95-103.

Invited Speeches *Disease Biomarker & Mechanism – Speaker*
(TPS & TSEV) Hall I Section IV 11/15 13:30-14:55


9. Q. Lyu, T.-H. Kuo, C. Sun, K. Chen, C.-C. Hsu,* Xian Li* “Comprehensive Structural Characterization of Phenolics in Litchi Pulp Using Tandem Mass Spectral Molecular Networking”, *Food. Chem.* 2019, 282, 9-17.
10. W.-K. Wu, C.-C. Chen, P.-Y. Liu, S. Panyod, B.-Y. Liao, P.-C. Chen, H.-L. Kao, H.-C. Kuo, C.-H. Kuo, H.T. Chiu, R.-A. Chen, H.-L. Chuang, Y.-T. Huang, H.-B. Zou, C.-C. Hsu, T.-Y. Chang, C.-L. Lin, C.-T. Ho, H.-T. Yu, L.-Y. Sheen*, M.-S. Wu* “Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice”, *Gut* 2019, 68, 1439-1449.
11. K.-H. Huang, T.-H. Tu, S.-C. Wang, Y.-T. Chan,* C.-C. Hsu,* “Micelles Protect Intact Metallo-supramolecular Block Copolymer Complexes from Solution to Gas Phase during Electrospray Ionization”, *Anal. Chem.* 2018, 90, 7691-7699.
12. Wang, F.; Yang, P.; Choi, J.; Antovski, P.; Zhu, Y.; Xu, X.; Kuo, T.-H. Lin, L.-E. Kim, D.N.H.; Huang, P.-C.; Xu, H.; Lee, C.-F. Wang, C.;* Hsu, C.-C.;* Chen, J.;* Weiss, P.;* Tseng, H.-R.* “Cross-Linked Fluorescent Supramolecular Nanoparticles for Intradermal Controlled Release of Antifungal Drug – A Therapeutic Approach for Onychomycosis”, *ACS Nano* 2018, 12, 6851-6859.
13. L.-E. Lin, P.-R. Su, H.-Y. Wu, C.-C. Hsu,* “A Simple Sonication Improves Protein Signal in Matrix-assisted Laser Desorption Ionization Mass Spectrometry Imaging.” *J. Am. Soc. Mass Spectrom.* 2018, 29,796-799.
14. Hsieh, H.-Y.; Li, L.-H.; Hsu, R.-Y.; Kao, W.-F.; Huang, T.-C.; Hsu, C.-C.* “Quantification of Endogenous Cholesterol in Human Serum on Paper Using Direct Analysis in Real Time Mass Spectrometry.” *Anal. Chem.* 2017, 89, 6146-6152.
15. C.-C. Hsu, M. Baker, T. Gaasterland, M. Meehan, E. R. Macagno,* P. C. Dorrestein,* “Top-Down Atmospheric Ionization Mass Spectrometry Microscopy Combined With Proteogenomics.” *Anal. Chem.* 2017, 89, 8251-8258.

Ambient Mass Spectrometry and Machine Learning in Disease Diagnosis

Cheng-Chih Hsu

Department of Chemistry, National Taiwan University, Taiwan

Mass spectrometry (MS) provides a wealth of chemical information. In our laboratory we combined MS-based metabolite and lipid profiling with machine learning to different clinical applications. First we use paper spray ionization (PSI) coupled with chip-based field asymmetry ion mobility spectrometry (FAIMS) to rapidly obtained the molecular features of breast core-needle biopsy. The predictive LASSO model gave a total accuracy close to 90% by training with about a hundred of patient breast samples. Later we utilized such strategy for real-time diagnosis of breast core-needle biopsy obtained from NTU Cancer Center. The tissue can be classified as benign or tumor within 10 minutes upon surgery. Secondly we utilized multimodal desorption electrospray ionization (DESI) mass spectrometry imaging (MSI)-microscopy image fusion to boost the spatial resolution of MSI. By such predictive molecular imaging we were able to find dozens of more potential lipid biomarkers that can be used to determine the tumor margins. We further utilized machine learning algorithms to explore if the dust chemical components from the environments can be used to give insights of the health status of household members. Lastly, we developed a molecular diagnostic veterinary platform using mobile mini-MS, in which the metabolite profiles of chicken stools were utilized to predict if the poultry were infected with parasites.




“Predicting Breast Cancer by Paper Spray Ion Mobility Spectrometry Mass Spectrometry and Machine Learning.” *Anal. Chem.* **2020**, *92*, 1653-1657. (Featured as Front Cover)
<https://pubs.acs.org/doi/10.1021/acs.analchem.9b03966>

Wen-Hung Kuo, M.D., Ph.D. (郭文宏)

Current position and professional experiences

- 2014/8 ~ Present **Clinical associate professor**, College of Medicine, National Taiwan University
- 1998/8 ~ Present **Visiting staff**, Department of Surgery, National Taiwan University Hospital



Research interest

1. General surgery
2. Breast surgery
3. Sonography
4. Translational research

Short research summary

Wen-Hung Kuo, Council of the Breast Cancer Society of Taiwan, is a Clinical Associate Professor of Surgery at the National Taiwan University College of Medicine and visiting staff at department of surgery and breast care center of national Taiwan university hospital, Taipei, Taiwan. Dr Kuo got his MD and PhD from the National Taiwan University College of Medicine.

Dr. Kuo has dedicated his career to the diagnosis and treatment of breast cancer. His areas of research include: molecular profiling of breast cancer, computer-aid diagnosis of breast ultrasound, serum biomarker for early detection of breast cancer and genetic susceptibility in early onset breast cancer.

Publications

1. Chiu LY*, Kuo WH*, Chen CN, Chang KJ, Chen A. A 2-Phase Merge Filter Approach to Computer-Aided Detection of Breast Tumors on 3-Dimensional Ultrasound Imaging. *J Ultrasound Med.* 2020 Jun 21. doi: 10.1002/jum.15365. Online ahead of print. (*Co-first author)
2. Huang M, Li HY, Liao HW, Lin CH, Wang CY, Kuo WH*, Kuo CH*. Using post-column infused internal standard assisted quantitative metabolomics for establishing prediction models for breast cancer detection. *Rapid Commun Mass Spectrom.* 2020 Apr;34 Suppl 1:e8581. doi: 10.1002/rcm.8581. Epub 2020 Feb 5. PMID: 31693758(*corresponding author)
3. Tai YL, Chu PY, Lee BH, Chen KC, Yang CY, Kuo WH, Shen TL. Basics and applications of tumor-derived extracellular vesicles. *J Biomed Sci.* 2019 May 11;26(1):35.
4. Hsiao FH, Kuo WH, Jow GM, Wang MY, Chang KJ, Lai YM, Chen YT, Huang CS. The changes of quality of life and their correlations with psychosocial factors following surgery among women with breast cancer from the post-surgery to post-treatment survivorship. *Breast.* 2019 Apr;44:59-65.
5. Hsu SM, Kuo WH, Kuo FC, Liao YY. Breast tumor classification using different features of quantitative ultrasound parametric images. *Int J Comput Assist Radiol Surg.* 2019 Apr;14(4):623-633. doi: 10.1007/s11548-018-01908-8. Epub 2019 Jan 8.
6. Chan SH, Tsai KW, Chiu SY, Kuo WH, Chen HY, Jiang SS, Chang KJ, Hung WC, Wang LH. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer. *Mol Cancer Ther.* 2019 Jan;18(1):147-161.
7. Chang JW, Kuo WH, Lin CM, Chen WL, Chan SH, Chiu MF, Chang IS, Jiang SS, Tsai FY, Chen CH, Huang PH, Chang KJ, Lin KT, Lin SC, Wang MY, Uen YH, Tu CW, Hou MF, Tsai SF, Shen CY, Tung SL, Wang LH. Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to

Invited Speeches Disease Biomarker & Mechanism – Speaker
(TPS & TSEV) Hall I Section IV 11/15 13:30-14:55

- suppress metastasis via GAS7-CYFIP1-mediated signaling pathway. *Oncogene*. 2018 Jul;37(30):4137-4150.
8. Tseng CW, Kuo WH, Chan SH, Chan HL, Chang KJ, Wang LH. Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the α -Ketoglutarate Signaling Pathway. *Cancer Res*. 2018 Jun 1;78(11):2799-2812.
 9. Hsiao FH, Jow GM, Kuo WH, Wang MY, Chang KJ, Lai YM, Chen YT, Huang CS. A longitudinal study of diurnal cortisol patterns and associated factors in breast cancer patients from the transition stage of the end of active cancer treatment to post-treatment survivorship. *Breast*. 2017 Dec; 36:96-101.
 10. Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM, Lee WH. Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β -hydroxybutyrate. *Nat Commun*. 2017 Mar; 8:14706.
 11. Hsieh MS, Lien HC, Hua SF, Kuo WH, Lee YH. Clear cell hidradenoma of the breast with MAML2 gene rearrangement. *Pathology*. 2017 Jan;49(1):84-87.
 12. Tsui PH, Chen CK, Kuo WH, Chang KJ, Fang J, Ma HY, Chou D. Small-window parametric imaging based on information entropy for ultrasound tissue characterization. *Sci Rep*. 2017 Jan 20;7:41004.
 13. Lai SF, Chen YH, Kuo WH, Lien HC, Wang MY, Lu YS, Lo C, Kuo SH, Cheng AL, Huang CS. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. *Ann Surg Oncol*. 2016 Nov;23(12):3860-3869.
 14. Wu LA, Kuo WH, Chen CY, Tsai YS, Wang J. The association of infrared imaging findings of the breast with prognosis in breast cancer patients: an observational cohort study. *BMC Cancer*. 2016 Jul 27;16:541.
 15. Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, Wang MY, Liu CY, Cheng FT, Yeh MH, Li HY, Yang YH, Hsu YH, Fan SC, Li LY, Yu SL, Chang KJ, Chen PL, Ni YH, Huang CS. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. *Oncotarget*. 2016 Feb;7(7):8310-20.
 16. Wang J, Wang MY, Kuo WH, Chen KL, Shih TT. Proton MR Spectroscopy of Normal breasts: Association of Risk Factors for Breast Cancer with Water and Lipid Composition of the Breast. *Magn Reson Imaging*. 2016 May;34(4):524-8.
 17. Lin CH, Chen IC, Huang CS, Hu FC, Kuo WH, Kuo KT, Wang CC, Wu PF, Chang DY, Wang MY, Chang CH, Chen WW, Lu YS, Cheng AL. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. *Sci Rep*. 2015. Dec; 5:17879.
 18. Yao-Yin Chang* , Wen-Hung Kuo* , Jui-Hui Hung, Chien-Yueh Lee, Yung-Hua Lee, Ya-Chu Chang Wen-Chun Lin, Cheng-Ying Shen , Chiun-Sheng Huang , Fon-Jou Hsieh , Liang-Chuan Lai, Mong-Hsun Tsai , King-Jen Chang and Eric Y Chuang. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. *Molecular Cancer*. 2015 Feb; 14:36. (*Co-first author)
 19. Hsiao FH, Kuo WH, Jow GM, Chang KJ, Yang PS, Lam HB, Lee JJ, Huang CS, Liu YF, Lai YM. Habitual sleep-wake behaviors and lifestyle as predictors of diurnal cortisol patterns in young breast cancer survivors: A longitudinal study. *Psychoneuroendocrinology*. 2015 Mar; 53: 60-8.

Clinical Application of Circulation Extracellular mi-RNA in Breast Cancer

Wen-Hung Kuo

National Taiwan University Hospital, Taipei, Taiwan

The characteristic of cancer cells is continuously changing during cancer progression; however, there is often lacking clinical biomarkers for detection, monitoring and prediction of cancer development over time, which leads to higher mortality of cancer patients. Liquid biopsies (i.e. blood, urine, saliva etc.) with less invasive, low risk as well as time- and cost-effective features, compared to standard tissue biopsy, seem to match this clinical unmet need. Due to the emerging role critical for tumor formation and progression, in this current proposal, we attempt to use a large-scaled serum cohort from normal, benign (DCIS) as well as varied stages of ER+/PR+, HER2+, ER+/PR+/HER2+ and triple negative (TN) patients, to establish the signatures of circulation miRNAs in related to the early and malignant development of breast cancer. Our goal is to provide insightful information for cancer development and understanding of tumor-derived circulation extracellular miRNAs in cancer progression, subsequently these results can be translated to early detection and monitoring and even alternative therapeutic targets for breast cancer in complement with limited accessibility of standard tissue biopsies.

By compares each clinical group of tumor development, we found that there are 13 miRNAs with significantly different expression between non-cancer group (healthy and benign) and cancer group. Based on these miRNAs, an elastic net regression model was built and could be used to identify a cancer patient from non-cancer group (healthy and benign tumor). The performance evaluated by validation shows the prediction accuracy as 98.13%. In addition, its positive predictive value was 96.08% and negative predictive value was 100%, showing the potential of early detection of breast cancer.

Furthermore, we have also tried to analysis by clustering the miRNAs into blocks and finding the correlation between miRNA blocks and cancer development, which could let us take a view from whole miRNA expression data. There are several types of expression patterns between different clinical groups and some of which imply the non-random changing as the development of breast cancer.

Tzu-Heng Wu, Ph.D. (吳子珩)

Current position and professional experiences

- 2020/1 ~ Present **Chief Executive Officer**, PlasmonicTron, Taiwan
- 2018/7 ~ Present **Co-founder**, PhaseLab Instrument, France
- 2019/12 ~ Present **Invited Member**, Association of Chemical Sensor in Taiwan (ACST)
- 2017/6 ~ 2018/6 **Postdoctoral researcher**, Universite de Technologie de Troyes (2018-2019)



Research interest

1. Aptamer sensing strategy
2. Bioinformatics
3. Plasmonic sensors

Short research summary

Dr. Tzu-Heng Wu is currently the Chief Executive Officer of PlasmonicTron (Taiwan), and also the co-founder of PhaseLab Instrument (Paris, France). Dr. Wu received his double Ph.D degrees from both National Taiwan University and Université de Technologie de Troye (France). Dr. Wu's work focuses mainly on aptamer-based sensing strategy toward both proteins and nucleic acids. Combining empirical validation and in-silico design algorithm, the team of Dr. Wu is looking for highly functional sensing probes to carry out diagnostic under complex environments. Besides from Dr. Wu's primary duties in PlasmonicTron as CEO, he is also board member of PhaseLab Instrument (PLi). Dr. Wu sets strategy for PLi towards immunotherapy-based application, targeting EU market.

Publications

- 1 Wu, T. H., Chang, C. C., Yang, C. H., Lin, W. Y., Ee, T. J., & Lin, C. W. "Hybridization Chain Reactions Targeting the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)." *International journal of molecular sciences*, 2020, 21(9), 3216.
- 2 Tzu-Heng WU, Chia-Cheng Chang, Julien Valiant, Aurélien BRUYANT and Chii-Wann LIN, "DNA biosensor combining single-wavelength colorimetry and a digital lock-in amplifier within a smartphone.", *Lab-On-a-Chip*, 2016, 23, 4527
- 3 Aurélien Bruyant, Julien Vaillant, Tzu-Heng Wu, Yunlong Zhu, Yi Huang and Abeer Al Mohtar "Interferometry Using Generalized Lock-in Amplifier (G-LIA): A Versatile Approach for Phase-Sensitive Sensing and Imaging" ("Optical Interferometry", Book chapter), ,Intech, 2016, ISBN 978-953-51-2956-1
- 4 Shih-Chung WEI, Pei-Tung YANG, Tzu-Heng WU, Yin-Lin LU, Frank GU, Kung-Bin Sung and Chii-Wann Lin. "Characteristic investigation of scanning surface plasmon microscopy for nucleotide functionalized nano-array" *Optical Express*, 2015, 23, 20104
- 6 CC Chang, CY Chen, TL Chuang, TH Wu, SC Wei, H Liao, CW Lin "Aptamer-based colorimetric detection of proteins using a branched DNA cascade amplification strategy and unmodified gold nanoparticles" *Biosensors and Bioelectronics* 2016, 78, 200-205
- 7 Aurelien BRUYANT, Julien VAIAINT, Tzu-Heng WU, Chii-Wann LIN "Apparatus and method for compact interferometric sensor based on bi-reflective layer" ,PCT, 2016
- 8 CC Chang, CY Chen, X Zhao, TH Wu" SC Wei, CW Lin, "Label-free colorimetric aptasensor for IgE using DNA pseudoknot probe" *Analyst* 2014, 139 (13), 3347-3351

**Engineered Aptamer Based Plasmonic Sensing
Toward Exosome Liquid Biopsy and Beyond**

Tzu-Heng Wu
PlasmonicTron, Taiwan

Exosome based liquid biopsy has great clinical potentials toward cancer metastasis diagnosis. Herein, we aim to discuss our recent advance on how aptamer, nucleic acid self-assembly and Surface Plasmon Resonance biosensor can be combined to build an excellent toolset toward exosome study. We will firstly discuss how aptamers can be engineered to have unique sensing properties towards exosomal surface protein, with a focus on surface integrin $\alpha_6\beta_4$. Exosomal surface Integrin has been proven by early stage work to be a vital indicator for organo-tropic metastasis. Through *in-silico* design and empirical validation via surface plasmon resonance biosensor, two novel integrin targeting aptamers are introduced herein, made from post-SELEX engineering. We will then explore how these engineered aptamers can be further leveraged with molecular self-assemblies to provide unprecedented molecular interaction capacities. As an example, bi-function integrin sensing probes are demonstrated, with a capacity to conduct chain reaction amplification upon capture of integrin. Finally, leveraging these unique exosome probes, highly sensitive detection can be undertaken using our automated Surface Plasmon Resonance system, simultaneously specifying the relevant physical parameters of the captured exosomes. With the above-mentioned results, we would like to finally explore the possibility to apply these technologies into a wider range of exosome applications.

受邀演講 Invited Speeches

台灣演化與計算生物學會 (TSECB)
Taiwan Society of Evolution and Computational Biology

台灣生物資訊與系統生物學會 (TBSB)
Taiwan Bioinformatics and Systems Biology Society

第二會議廳 Lecture Hall II



Hurng-Yi Wang, Ph.D. (王弘毅)

Current position and professional experiences

2015/8 ~ Present	Professor , Graduate Institute of Clinical Medicine, National Taiwan University
2010 ~ 2015	Associate Professor , Graduate Institute of Clinical Medicine, National Taiwan University
2006 ~ 2010	Assistant Professor , Graduate Institute of Clinical Medicine, National Taiwan University



Research interest

1. Population genetics
2. Molecular genetics
3. Comparative genomics
4. Virology

Short research summary

Dr. Hurng-Yi Wang is a Professor of Graduate Institute of Clinical Medicine at the National Taiwan University (NTU), Taiwan. Dr. Wang received his Ph.D degree from the National Taiwan Normal University. The researches in Dr. Wang's lab are concentrated on molecular evolution and population genetics. Currently, there are two major domains in his lab. The first one is virus related research. He focuses on patterns of viral diversity change within host, rate of viral evolution, and interaction between pathogen and host. The second domain is to understand the mechanisms that drive population differentiation including nature as well as tumor cell populations.

Publications

1. Chaw SM, Tai JH, Chen SL, Hsieh CH, Chang SY, Yeh SH, Yang WS, Chen PJ, **Wang HY***. The origin and underlying driving forces of the SARS-CoV-2 outbreak. *Journal of Biomedical Science*. 2020 27(1):1-12 (IF=5.762; Medicine, Research, and Experimental 20/136=12%)
2. Hsieh CH, Huang, CG, Wu WJ, **Wang HY***. A rapid insect species identification system using mini-barcode pyrosequencing. *Pest Management Science* 2020 76 (4), 1222-1227 (IF: 3.750; Entomology 7/101=7%)
3. Chen PY, Chuang YC, Wu UI, Sun HY, Wang JT, Sheng WH, Lo HJ, **Wang HY**, Chun YC, Chang SC. Clonality of fluconazole-nonsusceptible *Candida tropicalis* in bloodstream infections, Taiwan, 2011–2017. *Emerging Infectious Diseases*, 2019 25(9): 1668. (IF:6.259, Infectious Disease 7/93=8%)
4. Chen YA, Lien JC, Tseng LF, Cheng CF, Lin WY, Wang HY, Tsai KH. Effects of indoor residual spraying and outdoor larval control on *Anopheles coluzzii* from São Tomé and Príncipe, two islands with pre-eliminated malaria. *Malaria journal*, 2019, 18(1): 405. (IF:2.631, Infectious Disease, 53/93=57%)
5. Zhang Y, Li Y, Shen X, Zhu T, Tao Y, Li T, Li X, Wang D, Ma Q, Hu Z, Liu J, Zheng C, Ruan J, Cai J, Wu CI, **Wang HY***, and Lu X*. "Rapid generation of copy number variation may lead to very high genetic load in cancer cell population." *Molecular Biology and Evolution*, 2019, 36 (3), 541-552. (IF: 11.062; Genetics and heredity 7/177=4%)
6. Wu LL, Peng WH, Wu H-L, Miaw SC, Yeh SH, Yang HC, Liao PH, Lin JS, Chen YR, Hong YT, Chen PJ, **Wang HY***, and Chen DS*. Ly6C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. *Hepatology*, 2019, 69 (6), 2364-2380. (IF: 14.679;

Gastroenterology and hepatology 6/88=7%)

7. Wen H, **Wang HY**, He H and Wu CI*. “On the low reproducibility of cancer studies.” *National Science Review*, 2018, in press. (IF: 16.693; Multidisciplinary Sciences 3/71=4%)
8. **Wang HY**, Chen Y, Tong D, Ling S, Hu Z, Tao Y, Lu X and Wu CI*. “Is the evolution in tumors Darwinian or non-Darwinian?” *National Science Review*. 2018, 5: 15-17. (IF: 16.693; Multidisciplinary Sciences 3/71=4%)
9. Zhang Y, Shen X, Li Y, Zhu T, Tao Y, Li T, Wang D, Li X, Ma Q, Lu X*, **Wang HY***, Wu CI. Genetic load in cancer cell populations. *Cancer Research*, 2017, 77(13) Supplement: 514 (IF:9.727, Oncology, 19/244=8%)
10. Lin YY, Hsieh CH, Chen JH, Lu X, Kao JH, Chen PJ, Chen DS, **Wang HY***. “De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline.” *BMC Bioinformatics*. 2017, 18(1):223. (IF: 3.242; Mathematical and computational biology 9/59=15%)
11. **Wang HY***. Revealing the time-dependent evolution of the hepatitis B virus from a chain of sequentially infected chronic carriers. *Genes & Genetic Systems*. 90 (6), 359-359 (IF: 0.917; Genetics and Heridity 164/177=92%)
12. Wu CI*, **Wang HY**, Ling S, Lu X. “The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process.” *Annual Review of Genetics*. 2016, 50:347-369. (IF: 11.146; Genetics and heredity 5/177=3%)
13. Chiou HY, Jeng CR, **Wang HY**, Inoue S, Chan FT, Liao JW, Chiou MT, Pang VF*. “Pathology and molecular detection of rabies virus in ferret badgers associated with a rabies outbreak in Taiwan.” *Journal of Wildlife Diseases*. 2016, 52(1): 57-69. (IF: 1.187; Veterinary Sciences 66/142=46%)
14. Liu CJ*, Chen TC, Chen PJ, **Wang HY**, Tseng TC, Cheng HR, Liu CH, Chen DS and Kao JH*. “Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages.” *Journal of Gastroenterology and Hepatology*. 2015, 30(1): 172-7. (IF: 3.437; Gastroenterology & Hepatology 42/88=47 %)

Huai-Kuang Tsai, Ph.D. (蔡懷寬)

Current position and professional experiences

- 2015/11 ~ Present **Research Fellow**, Institute of Information Science, Academia Sinica
- 2016/8 ~ Present **Professor (Joint appointment)**, Genome and Systems Biology degree program, National Taiwan University
- 2016/8 ~ Present **Professor (Joint appointment)**, Department of Biological Science and Technology, National Chiao-Tung University



Research interest

1. Bioinformatics and computational biology
2. Gene regulation
3. Machine learning
4. Comparative genomics

Short research summary

Dr. Huai-Kuang Tsai is a Research Fellow at Institute of Information Science, Academia Sinica. He received the B.S., the M.S., and the Ph.D. degrees in Computer Science and Information Engineering from the National Taiwan University, Taipei, Taiwan, in 1996, 1998, and 2003, respectively. Dr. Tsai's research interests include computational biology, bioinformatics, gene regulation, comparative genomics, and machine learning. His current research mainly focuses on understanding fundamental regulatory mechanisms in cells. He aims to understand the dynamic interactions between *cis*- and *trans*- regulatory elements, the impact of these interactions on gene expression and the evolutionary signatures of genes and genomes.

Publications

1. Chiang, S., Shinohara, H., Huang, J.H., **Tsai, H.K.***, and Okada, M.* (2020) Inferring the transcriptional regulatory mechanism of signal-dependent gene expression via an integrative computational approach, *FEBS Letters*, DOI: 10.1002/1873-3468.13757.
2. Chong, S.Y., Sutler, S., Lin, J.J., Tsai, C.H., **Tsai, H.K.**, Biggins, S., Tsukiyama, T., Lo, Y.C., and Kao, C.F. (2020) H3K4 methylation at active genes mitigates transcription-replication conflicts during replication stress, *Nature Communications*, 11(809).
3. Lin, C.Y., Chao, J.L., **Tsai, H.K.**, Chalker, D., and Yao, M.C. (2019) Setting Boundaries for Genome-wide Heterochromatic DNA Deletions Through Flanking Inverted Repeats in *Tetrahymena thermophila*, *Nucleic Acids Research*, 47(10), 5181-92.
4. Huang, J.H., Kwan, S.Y., Tsai, T.Y., and **Tsai, H.K.*** (2018) Expansion of transcription factor binding sites for introducing lineage-specific motifs in the promoter regions, *Frontiers in Genetics*, 9, 571.
5. Shiau, C.K., Huang, J.H. and **Tsai, H.K.*** (2018) CATANA: Comprehensive Alternative Transcript Atlas based on Annotation, *Bioinformatics*, bty795.
6. Liu, W.H., Tsai, Z.T.Y., and **Tsai, H.K.*** (2017) Comparative genomic analyses highlight the contribution of pseudogenized protein-coding genes to human lincRNAs, *BMC Genomics*, 18, 786.

7. Ng, I.M., Huang, J.H., Tsai, S.C., and **Tsai, H.K.*** (2017) IsoPlot: a database for comparison of mRNA isoform variations in the fruit fly and mosquitoes, *Database*, 2017, bax069.
8. Cheng, J.H., Pan D., Tsai, Z.T.Y., and **Tsai, H.K.*** (2015) Genome-wide analysis of enhancer RNA in gene regulation across 12 mouse tissues, *Scientific Reports*, 5, 12648.
9. Tsai, Z.T.Y., Shiu, S.H.* , and **Tsai, H.K.*** (2015) Contribution of sequence motif, chromatin state, and DNA structure features to predictive models of transcription factor binding in yeast, *PLoS Computational Biology*, 11(8), e1004418.
10. Hung, C.L., Cheng, H.H., Hsieh, W.C., Tsai, Z.T.Y., **Tsai, H.K.**, Chu, C.H., Hsieh, W.P., Lai, C.H., and Wang, W.C.* (2015) The CrdRS two-component system in *Helicobacter pylori* responds to nitrosative stress, *Molecular Microbiology*, 97(6),1128-41.
11. Wang, T.Y. and **Tsai, H.K.*** (2014) MetaRank: Ranking Microbial Taxonomic Units or Functional Groups for Comparative Analysis of Metagenomes, *Encyclopedia of Metagenomics*, 1-7. Tsai, Z.T.Y., Chu, W.Y., Cheng, J.H., and **Tsai, H.K.*** (2014) Associations between intronic non-B DNA structures and exon skipping, *Nucleic Acids Research*, 42(2), 739-747.

**Deciphering the Multiple Facets of Gene Regulation via
Multi-omics Data Integration and Analysis**

Huai-Kuang Tsai

Institute of Information Science, Academia Sinica, Taiwan

Gene regulation involves the mechanisms that act to induce or repress the expression of a gene. These include structural/chemical changes to the genetic material, binding of transcription factors (TF) to specific DNA elements to regulate transcription, or mechanisms that modulate translation of mRNA. Recently, the abundance and diversity of multiple “omes” provide an excellent opportunity for understanding the regulatory mechanisms. In this talk, I will introduce the way our lab decipher the gene regulatory programs via applying integrative approaches to multi-omics data. I will first try to answer how TF binding motifs became introduced into the cis-regulatory DNA regions of the genome over evolutionary time. Then, I will put focus on the relationship between TF binding to promoter and gene splicing patterns. In the last part, I will illustrate the way we combine bilinear regression and kinetic modeling to decipher the signal-dependent gene regulation. If there is still time left, I will introduce our newly developed tool for the identification of candidate regulators associated with biological traits.

Yu-Wei Wu, Ph.D. (吳育瑋)

Current position and professional experiences

- 2020/2 ~ Present **Associate Professor**, Graduate Institute of Biomedical Informatics, Taipei Medical University
- 2016/10 ~ 2020/1 **Assistant Professor**, Graduate Institute of Biomedical Informatics, Taipei Medical University

**Research interest**

1. Metagenomics
2. Bioinformatics
3. Genomics
4. Machine learning

Short research summary

Dr. Yu-Wei Wu is an Associate Professor of the Graduate Institute of Biomedical Informatics at Taipei Medical University, Taiwan. Dr. Wu received his Ph.D. degree from School of Informatics and Computing at Indiana University. He then went to the Joint Bioenergy Institute at the Lawrence Berkeley National Laboratory to work as a postdoctoral research fellow before he came back to Taiwan. He has been working on resolving metagenomic problems using machine learning algorithms for more than 10 years. After joining Taipei Medical University he was also attempting to tackle the problem of predicting antimicrobial resistance activities for prokaryotic pathogens. His research interests include computational metagenomics, bioinformatics, machine learning, and anything related to prokaryotes.

Publications

1. Yi-Han Huang, Yu-Wei Wu, Jian-Ying Chuang, Yung-Chiao Chang, Hsiao-Fu Chang, Pao-Luh Tao, Horace H. Loh, Shiu-Hwa Yeh, "Morphine produces potent antinociception, sedation, and hypothermia in humanized mice expressing human mu-opioid receptor splice variants", *PAIN*, 161(6):1177-1190, 2020.
2. Herdiantri Sufriyana, Yu-Wei Wu, and Emily Chia-Yu Su, "Artificial intelligence-assisted prediction of preeclampsia: Development and external validation of a nationwide health insurance dataset of the BPJS Kesehatan in Indonesia", *EBioMedicine*, 54:102710, 2020.
3. Nai-Fang Chi, Tzu-Hao Chang, Chen-Yang Lee, Yu-Wei Wu, Ting-An Shen, Lung Chan, Yih-Ru Chen, Hung-Yi Chiou, Chung Y. Hsu, Chaur-Jong Hu, "Untargeted metabolomics predicts the functional outcome of ischemic stroke", *Journal of the Formosan Medical Association*, in press, 2020.
4. Herdiantri Sufriyana, Yu-Wei Wu, and Emily Chia-Yu Su, "Prediction of Preeclampsia and Intrauterine Growth Restriction: Development of Machine Learning Models on a Prospective Cohort", *JMIR Medical Informatics*, 8(5):e15411, 2020.
5. Te-Sheng Chang, Tzi-Yuan Wang, Tzu-Yu Hsueh, Yu-Wen Lee, Jiumn-Yih Wu, Chien-Min Chiang, Hsin-Mei Chuang, Wen-Xuan Cai, and Yu-Wei Wu*, "A Genome-Centric Approach Reveals a Novel Glycosyltransferase from the GA A07 Strain of *Bacillus thuringiensis* Responsible for Catalyzing 15-O-Glycosylation of Ganoderic Acid A", *International Journal of Molecular Sciences*, 20(20): 5192, 2019.
6. Te-Sheng Chang, Chien-Min Chiang, Yu-Han Kao, Jiumn-Yih Wu, Yu-Wei Wu, and Tzi-Yuan Wang,

- "A New Triterpenoid Glucoside from a Novel Acidic Glycosylation of Ganoderic Acid A via Recombinant Glycosyltransferase of *Bacillus subtilis*", *Molecules*, 24(19): 3457, 2019.
7. Yu-Wei Wu*, Shih-Hung Yang, Myung Hwangbo, and Kung-Hui Chu, "Analysis of *Zobellella denitrificans* ZD1 draft genome: Genes and gene clusters responsible for high polyhydroxybutyrate (PHB) production from glycerol under saline conditions and its CRISPR-Cas system", *PLoS ONE*, 14(9): e0222143, 2019.
 8. Ankita Kothari, Yu-Wei Wu, John-Marc Chandonia, Marimikel Charrier, Lara Rajeev, Andrea Rocha, Dominique Joyner, Terry Hazen, Steven Singer, and Aindrila Mukhopadhyay, "Large circular plasmids from groundwater plasmidomes span multiple incompatibility groups and are enriched in multi-metal resistance genes", *mBio*, 10(1):e02899-18, 2019.
 9. Shan-Hua Yang; Kshitij Tandon; Chih-Ying Lu; Naohisa Wada; Chao-Jen Shih; Silver Sung-Yun Hsiao; Wann-Neng Jane; Tzan-Chain Lee; Chi-Ming Yang; Chi-Te Liu; Vianney Denis; Yu-Ting Wu; Li-Ting Wang; Lina Huang; Der-Chuen Lee; Yu-Wei Wu; Hideyuki Yamashiro; Sen-Lin Tang, "Metagenomic, phylogenetic and functional characterization of predominant endolithic green sulfur bacteria in the coral *Isopora palifera*", *Microbiome*, 7:3, 2019.
 10. Shu-Miaw Chaw, Yu-Ching Liu, Yu-Wei Wu, Han-Yu Wang, Chan-Yi Lin, Chung-Shien Wu, Huei-Mien Ke, Lo-Yu Chang, Chih-Yao Hsu, Hui-Ting Yang, Edi Sudianto, Ming-Hung Hsu, Kun-Pin Wu, Ling-Ni Wang, James Leebens-Mack, and Isheng Tsai, "Stout camphor tree genome fills gaps in understanding of flowering plant genome evolution", *Nature Plants*, 5:63-73, 2019.
 11. Sean Wei, Yu-Wei Wu, Tzong-Huei Lee, Yi-Shiang Huang, Cheng-Yu Yang, Yi-Lung Chen, and Yin-Ru Chiang, "Microbial functional responses to cholesterol catabolism in denitrifying sludge", *mSystems*, 3:e00113-18, 2018.
 12. Xiaoyu Liang, Jason M. Whitham, Evert K. Holwerda, Xiongjun Shao, Liang Tian, Yu-Wei Wu, Vincent Lombard, Bernard Henrissat, Dawn M. Klingeman, Zamin K. Yang, Mircea Podar, Tom L. Richard, James G. Elkins, Steven D. Brown, and Lee R. Lynd, "Development and Characterization of Stable Anaerobic Thermophilic Methanogenic Microbiomes Fermenting Switchgrass at Decreasing Residence Times", *Biotechnology for Biofuels*, 11:243, 2018.
 13. Yu-Wei Wu* and Yu-Chuan Jack Li, "Development and implementation of computational models provides solutions for biomedical community", *Computer Methods and Programs in Biomedicine*, 159: A1, 2018.
 14. Jefferey Kimbrel, Nicholas Ballor, Yu-Wei Wu, Maude David, Terry C Hazen, Blake Simmons, Steven Singer, and Janet Jansson, "Microbial community structure and functional potential along a hypersaline gradient", *Frontiers in Microbiology*, 9:1492, 2018.
 15. Hsuan-Lin Her and Yu-Wei Wu*, "A pan-genome-based machine learning approach for predicting antimicrobial resistance activities of the *Escherichia coli* strains", *Bioinformatics*, 34(13): i89-i95, 2018.
 16. Harry R. Beller, Andria V. Rodrigues, Kamrun Zargar, Yu-Wei Wu, Avneesh K. Saini, Renee M. Saville, Jose H. Pereira, Paul D. Adams, Susannah G. Tringe, Christopher J. Petzold, and Jay D. Keasling, "Enzyme discovery for toluene synthesis in anoxic microbial communities", *Nature Chemical Biology*, 14: 451-457, 2018.
 17. Yu-Wei Wu*, "ezTree: an automated pipeline for identifying phylogenetic marker genes and inferring evolutionary relationships among uncultivated prokaryotic draft genomes", *BMC Genomics*, 19(Supp 1): 921, 2018.
 18. Sebastian Kolinko, Yu-Wei Wu, Firehiwot Tachea, Evelyn Denzel, Jennifer Hiras, Raphael Gabriel, Nora Baecker, Leanne Jade Chan, Stephanie Eichorst, Dario Frey, Qiushi Chen, Parastoo Azadi, Paul Adams, Todd Pray, Deepti Tanjore, Christopher Petzold, John Gladden, Blake Simmons, and Steven Singer, "A Bacterial Pioneer Produces Cellulase Complexes that Persist through Community Succession", *Nature Microbiology*, 3: 99-107, 2018.
 19. Alexander Sczyrba, Peter Hofmann ... Yu-Wei Wu ... Alice C McHardy, "Critical Assessment of

- Metagenome Interpretation—a benchmark of metagenomics software”, *Nature Methods*, 14(11): 1063-1071, 2017.
20. Yu-Wei Wu, Yiru Shao, Kamil Khanipov, George Golovko, Maria Pimenova, Yuriy Fofanov, and Kung-Hui Chu, “Draft Genome Sequence of *Zobellella denitrificans* ZD1 (JCM 13380), a salt-tolerant denitrifying bacterium capable of producing poly(3-hydroxybutyrate)”, *Genome Announcements*, 5(36): e00948-17, 2017.
 21. Yu-Wei Wu, Brendan Higgins, Chaowei Yu, Amitha P. Reddy, Shannon Ceballos, Larry D. Joh, Blake A. Simmons, Steven W. Singer, and Jean S. VanderGheynst, “Ionic liquids impact the bioenergy feedstock degrading microbiome and transcription of enzymes relevant to polysaccharide hydrolysis”, *mSystems*, 1(6): e00120-16, 2016.
 22. Ankita Kothari, Marimikel Charrier, Yu-Wei Wu, Stephanie Malfatti, Carol E. Zhou, Steven W. Singer, Larry Dugan, and Aindrila Mukhopadhyay, “Transcriptomic analysis of the highly efficient oil-degrading bacterium *Acinetobacter venetianus* RAG-1 reveals genes important in dodecane uptake and utilization”, *FEMS Microbiology Letters*, 363(20): fnw224, 2016.
 23. Jennifer Hiras, Yu-Wei Wu, Kai Deng, Carrie D. Nicora, Joshua T. Aldrich, Dario Frey, Sebastian Kolinko, Errol R. Robinson, Jon M. Jacobs, Paul Adams, Trent Northen, Blake A. Simmons, and Steven W. Singer, “Comparative community proteomics demonstrates the unexpected importance of an actinobacterial glycoside hydrolase family 12 for crystalline cellulose hydrolysis”, *mBIO*, 7(4): e01106-16, 2016. (co-First author)
 24. Jennifer Hiras, Yu-Wei Wu, Stephanie A Eichorst, Blake A Simmons, and Steven W Singer, “Refining the Phylum Chlorobi by Resolving the Phylogeny and Metabolic Potential of the Representative of a Deeply Branching, Uncultivated Lineage”, *ISME*, 10:833-845, 2016. (co-First author)
 25. Yu-Wei Wu*, Blake A Simmons, and Steven W Singer, “MaxBin 2.0: an automated binning algorithm to recover genomes from multiple metagenomic datasets”, *Bioinformatics*, 32(4): 605-607, 2016.
 26. William Nelson, Yukari Maezato, Yu-Wei Wu, Margaret Romine, and Stephen Lindemann, “Identification and resolution of microdiversity through metagenomic sequencing of parallel consortia”, *Applied and Environmental Microbiology Journal*, 82(1): 255-267, 2016.
 27. Kuei-Han Lin, Ben-Yang Liao, Hao-Wei Chang, Shiao-Wei Huang, Ting-Yan Chang, Cheng-Yu Yang, Yu-Bin Wang, Yu-Teh Kirk Lin, Yu-Wei Wu, Sen-Lin Tang, Hon-Tsen Yu, “Metabolic characteristics of dominant microbes and key rare species from an acidic hot spring in Taiwan revealed by metagenomics”, *BMC Genomics*, 16:1029, 2015.
 28. Yu-Wei Wu, Chijioke Joshua, Stephanie A Eichorst, John M Gladden, Blake A Simmons, and Steven W Singer, “Genomic Analysis of Xylose Metabolism in Members of the *Deinococcus-Thermus* Phylum from Thermophilic Biomass-Deconstructing Bacterial Consortia”, *BioEnergy Research*, 8(3): 1031-1035, 2015.

**Predicting Antimicrobial Resistance Activities from
the Bacterial Pan-genomes Using Machine Learning Algorithms**

Yu-Wei Wu

Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan

Antimicrobial resistance (AMR) is becoming a huge problem for everyone. Bacterial pathogens usually gain resistance to certain antibiotic drugs by acquiring antimicrobial resistance genes or variants from other bacteria; hence it is important to understand what the AMR genes are and how to dig them out. In this talk I am going to introduce our approach to mine novel AMR genes from collections of bacterial genomes. We have previously shown in our 2018 Bioinformatics paper that using only a subset of known AMR genes can achieve better prediction accuracies for AMR activities of the *E. coli*. However known AMR genes only account for a tiny proportion of the entire gene collection, and there may be more genes potentially connected to antimicrobial resistance. As a result we continue pursuing the discovery of novel AMR genes in four common bacterial pathogens and show that 1) unprecedented AMR genes indeed serve as better predictors for AMR activities, and 2) most of the discovered AMR genes are hypothetical proteins (i.e. unknown function). To find their functions, we employ a network-based approach to determine the grouping or clustering effects of the genes and attempt to assign genes with unidentified functions to their neighbors with high confidence. We hope that such efforts can contribute to the expansion of the AMR gene repertoire and may serve as good predictors for AMR pathogens.

Yu-Chao Wang, Ph.D. (王禹超)

Current position and professional experiences

- 2019/8 ~ Present **Associate Professor**, Institute of Biomedical Informatics, National Yang-Ming University
- 2013/8 ~ 2019/7 **Assistant Professor**, Institute of Biomedical Informatics, National Yang-Ming University

**Research interest**

1. Biomedical data analysis and AI in healthcare
2. Translational bioinformatics
3. Systems biology

Short research summary

Dr. Yu-Chao Wang is an Associate Professor of Biomedical Informatics at National Yang-Ming University (NYMU), Taiwan. Dr. Wang received his Ph.D. degree in electric engineering from National Tsing Hua University (NTHU), Taiwan, in 2010. His research interest focuses on multi-omics analysis for precision medicine. Specifically, omics data analysis and machine learning approaches are used to identify biomarkers for clinical applications and to unravel the underlying mechanisms of carcinogenesis.

Publications

1. Yeh YC, Lei HJ, Chen MH, Ho HL, Chiu LY, Li CP, **Wang YC***, "C-reactive protein (CRP) is a promising diagnostic immunohistochemical marker for intrahepatic cholangiocarcinoma and is associated with better prognosis" *American Journal of Surgical Pathology*, 41(12):1630-1641, 2017.
2. Lyu GY, Yeh YH, Yeh YC*, **Wang YC***, "Mutation load estimation model as a predictor of the response to cancer immunotherapy" *npj Genomic Medicine*, 3:12, 2018.
3. Yeh YC, Ho HL, Wu YC, Pan CC, **Wang YC***, Chou TY*, "AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma" *Modern Pathology*, 33(3):391-403, 2020.
4. Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, **Wang YC**, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH*, "PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy" *Journal for ImmunoTherapy of Cancer*, 8:e000485, 2020.
5. Pan CC*, Yeh YC, **Wang YC**, Chang YH, "Differential expression analysis of clear cell renal cell carcinomas in The Cancer Genome Atlas distinguishes an aggressive subset enriched with chromosomes 7 and 12 gains" *Histopathology*, 76(7):950-958, 2020.
6. Pan YR†, Wu CE†, **Wang YC†**, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JC, Chen MH*, Yeh CN*, "Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response" *Clinical & Translational Immunology*, 9:e1145, 2020. †co-first author
7. Wu CE, Yeh DW, Pan YR, Huang WK, Chen MH, Chang JW, Chen JS, **Wang YC***, Yeh CN*, "Chromosomal instability may not be a predictor for immune checkpoint inhibitors from a comprehensive bioinformatics analysis" *Life* (under revision).

Identification of Genomic Predictors for Treatment Response to Cancer Immunotherapy Using Omics Data Analysis

Yu-Chao Wang

Institute of Biomedical Informatics, National Yang-Ming University, Taiwan

Cancer is the leading cause of human deaths worldwide. Cancer therapeutics are intensively studied, and immune checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies represent one of the novel promising therapeutic approaches. ICIs are now widely used in various cancers and have achieved impressive success in cancer treatment, resulting in a new era of anti-cancer therapy. However, treatment response is only observed in a subset of patients. Therefore, exploration of predictive biomarkers is critical to optimize the benefits of ICIs in patients.

Currently, several potential biomarkers have been identified, including tumor mutational burden (TMB), microsatellite instability (MSI) status, neoantigen burden, PD-L1 expression, CD8⁺ T-cell density, and interferon- γ gene signature. Among these, TMB and MSI status have been identified as effective indicators of patients who might benefit from immunotherapy. However, MSI-high status is observed relatively infrequently, leading to limited use of MSI as a predictive biomarker in clinical practice. TMB is defined as the total number of mutations in the tumor. Whole exome sequencing (WES), which allows comprehensive measurement of TMB, is considered as the gold standard for TMB determination. However, high cost, long turnaround time, infrastructure requirements and bioinformatics demands have prevented WES from routine clinical practice. Therefore, we developed a computational framework to construct a TMB estimation model to accurately estimate TMB with the genetic information on a small number of genes. Even so, how to determine the TMB threshold to stratify TMB-high patients would be another problem. Since the TMB distribution varies for different cancer types, it may not be appropriate to use a fixed TMB threshold to identify TMB-high patients across different tumors. In view of this, another strategy is to develop a gene panel by selecting a small number of genes which mutation is associated with well-established predictive biomarkers. We established a DNA damage repair gene panel which alteration is associated with TMB and MSI in different cancers. The altered gene panel accounted for approximately 30% of various cancers and had a 60% predicted response rate in patients with a mutated gene panel undergoing treatment with ICIs. Hopefully, we can use omics data analysis to develop a reliable tool that can be used to predict the response to ICIs in cancer patients and guide the appropriate administration of ICIs in clinical practice.

Invited Speeches

Population Genomics – Speaker

(TSECB & TBSB) Hall II Section I 11/14 10:40-12:05

Shaw-Jenq Tsai, Ph.D. (蔡少正)

Current position and professional experiences

- | | |
|----------------|--|
| 2019 ~ Present | Chair Professor , Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan |
| 2001 ~ Present | Director , Bioinformatic Center, National Cheng Kung University |
| 2016 ~ 2020 | President , The Chinese Physiological Society |
| 2019 ~ Present | President, Asian Society of Endometriosis and Adenomyosis |
| 2011 ~ Present | Ambassador , World Endometriosis Society |



Research interest

1. Hypoxia-mediated epigenome regulation
2. Mechanisms of drug resistance in cancer
3. Endometriosis
4. Translational medicine

Short research summary

Professor Shaw-Jenq (Sean) Tsai received his PhD degree from the University of Wisconsin-Madison, USA in 1997. He then joined the Department of Physiology at the National Cheng Kung University, Taiwan, as an assistant professor in 1998. He was promoted to distinguished professor in 2008 in recognition of his great academic achievements. Professor Tsai also served as the Director-General of Department of Life Sciences, Ministry of Science and Technology, Taiwan during 2014-2017. Professor Tsai's research focuses on investigating molecular mechanisms underlying important human diseases, including cancer, polycystic ovarian syndrome, and endometriosis. He has published more than one hundred papers in prestigious journals such as Nature, Nature Communications, Journal of Clinical Investigation, Journal of Pathology, Cancer Research, Nucleic Acids Research, and Journal of Clinical Endocrinology & Metabolism. Those papers have been cited more than 5000 times with an H-index of 46. The outstanding research performance enables Professor Tsai to be awarded the "2014 Distinguished Scientist" by Society for Experimental Biology and Medicine and elected as a fellow in 2018. Professor Tsai serves as editorial board member of many journals including Journal of Endocrinology, Journal of Molecular Endocrinology, Reproductive Medicine & Biology, and is the Asian editor of Experimental Biology and Medicine.

Publications

1. WN Li, KY Hsiao, CA Wang, N Chang, PL Hsu, MH Wu*, SJ Tsai* Extracellular vesicle-associated VEGF-C as a novel target for endometriosis. **Proc Natl Acad Sci U S A**, 117 (41):25859-25868, Oct. 13, 2020.
2. PS Chen, WT Chu, PL Hsu, SC Lin, IC Peng, CY Wang, SJ Tsai* Pathophysiological implications of hypoxia in human diseases. **J Biomed Sci** 27: 63, 2020 May 11.
3. CA Wang, YH Chang, PC Hou, YJ Tai, WN Li, PL Hsu, **SR Wu**, CF Li, YS Shan, SJ Tsai* DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination. **J Extracell Vesicles** 9 (1): 1746529, 2020 April 4.
4. TM Chen, MC Lai, YH Li, YL Chan, CH Wu, YM Wang, CW Chien, SY Huang, H. S Sun*, SJ Tsai* hnRNPM induces translation switch under hypoxia to promote colon cancer development. **EBioMedicine** 2019 Mar 6. pii: S2352-3964(19)30138-0. doi: 10.1016/j.ebiom.2019.02.059

5. PL Hsu, J Jou, SJ Tsai* TYRO3: a potential therapeutic target in cancer. **Exp Biol Med** 244: 83–9, 2019
6. SC Lin, HC Lee, CT Hsu, YH Huang, WN Li, PL Hsu, MH Wu*, SJ Tsai* Targeting anthrax toxin receptor 2 ameliorates endometriosis progression. **Theranostics**; 9(3): 620-632, 2019. doi: 10.7150/thno.30655
7. JL Fu, KY Hsiao, HC Lee, WN Li, N Chang, MH Wu*, SJ Tsai* Suppression of COUP-TFII upregulates angiogenin and promotes angiogenesis in endometriosis **Hum Reprod** 33 (8): 1517-27, 2018 Aug 1. doi: 10.1093/humrep/dey220.
8. KY Hsiao, HS Sun, SJ Tsai* Circular RNA - New member of noncoding RNA with novel functions. **Exp Biol Med** (Maywood) 242(11):1136-1141.
9. SC Lin, HC Lee, PC Hou, JL Fu, MH Wu, SJ Tsai* Targeting hypoxia-mediated YAP1 nuclear translocation ameliorates pathogenesis of endometriosis without compromising maternal fertility. **J Pathol** 242: 476–487. doi: 10.1002/path.4922, 2017
10. PC Hou, YH Li, SC Lin, SC Lin, JC Lee, PW Lin, JP Liou, JY Chang, CC Kuo, YM Liu, HS Sun, SJ Tsai* Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. **Cancer Res**, 77 (16): 4305-4316. doi: 10.1158/0008-5472.CAN-16-2990, 2017
11. KY Hsiao, YC Lin, SK Gupta, N Chang, L Yen, H. S Sun*, SJ Tsai* Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. **Cancer Res** 77:2339-2350. May 1, doi: 10.1158/0008-5472.CAN-16-1883, 2017 (Hot paper, high-cite paper)
12. SC Lin, KY Hsiao, N Chang, PC Hou, SJ Tsai* Loss of dual specificity phosphatase-2 promotes angiogenesis and metastasis via upregulation of interleukin-8 in colon cancer. **J Pathol** 241: 638–648, 2017
13. CW Chien, PC Ho, HC Wu, YL Chang, SC Lin, PW Lin, JC Lee, YJ Chang, HS Sun, SJ Tsai* Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. **Oncogene** 35(45):5872-5881, 2016
14. KY Hsiao, MH Wu, N Chang, SH Yang, CW Wu, HS Sun, SJ Tsai* Coordination of AUF1 and miR-148a to destabilize DNA methyltransferase 1 mRNA under hypoxia in endometriosis. **Mol Hum Reprod** 21:894-904, 2015
15. CA Wang, SJ Tsai* 2015 The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. **Exp Biol Med** (Maywood) 240(6):718-24, 2015
16. KY Hsiao, SC Lin, MH Wu*, SJ Tsai* Pathological functions of hypoxia in endometriosis. **Front Biol Sci** 7: 309-321, 2015
17. SC Lin, WL Liao, JC Lee, SJ Tsai* Hypoxia-regulated gene network in drug resistance and cancer progression. **Exp Biol Med** 239:779-792, 2014
18. SC Lin, YH Li, MH Wu, YF Chang, DK Lee, S Tsai, MJ Tsai, and SJ Tsai* Suppression of COUP-TFII by proinflammatory cytokines contributes to the pathogenesis of endometriosis. **J Clin Endocrinol Metab** 99(3): E427-37, 2014.
19. TM Chen, YH Shih, JT Tseng, MC Lai, Ch Wu, YH Li, SJ Tsai*, and HS Sun* Overexpression of FGF9 in colon cancer cells is mediated by hypoxia-induced translational activation. **Nucleic Acids Res** 42:2932-44, 2014
20. HM Chen, YH Lin, YM Cheng, LYC Wing, SJ Tsai* Overexpression of integrin-β1 promotes leiomyomal cell spreading and proliferation. **J Clin Endocrinol Metab** 98:E837-46, 2013.
21. MH Wu, PC Chuang, YJ Lin, SJ Tsai* Suppression of annexin A2 by prostaglandin E₂ impairs phagocytic ability of peritoneal macrophage in women with endometriosis. **Hum Reprod** 28:1045-53, 2013 (recommended by Faculty 1000 of Medicine)
22. J Qin, SP Wu, F Dai, X Xie, CM Cheng, C J Creighton, A Frolov, Gustavo Ayala4, X Lin, XH Feng, MM Ittmann, SJ Tsai, MJ Tsai, S Y Tsai Inhibition of TGF-β-dependent growth barrier by COUP-TFII to promote prostate tumor growth and metastasis. **Nature** 493: 236-240, 2013

Hsin-Chou Yang, Ph.D. (楊欣洲)

Current position and professional experiences

2018/1 ~ Present	Research Fellow , Institute of Statistical Science, Academia Sinica
2008/2 ~ Present	Core Faculty , Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica
2011/2 ~ Present	Core Faculty , Translational Medicine Program, Degree Program, Academia Sinica
2016/12 ~ Present	Core Faculty , Data Science Program, Degree Program, Academia Sinica & National Taiwan University
2017/12 ~ Present	Joint Associate Professor , Institute of Public Health, National Yang-Ming University
2018/8 ~ Present	Joint Professor , Department of Statistics, National Cheng Kung University
2019/7 ~ Present	Coordinator , Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica



Research interest

1. Statistical genomics
2. Bioinformatics
3. Genetic epidemiology

Short research summary

Dr. Hsin-Chou Yang received his Ph.D. in Statistics from the National Tsing Hua University, Taiwan in 2002. Dr. Yang became a Postdoctoral Fellow at Institute of Biomedical Sciences, Academia Sinica from Oct. 2002 to Jun. 2006 and shifted his research from ecological statistics to statistical genetics and genetic epidemiology. In Jul. 2006, Dr. Yang joined Institute of Statistical Science, Academia Sinica as an Assistant Research Fellow and his research interest shifted to statistical genomics, genome medicine, and omics research. Dr. Yang was promoted to Association Research Fellow and Research Fellow at Mar. 2011 and Jan. 2018, respectively. Dr. Yang has devoted to developing novel statistical/bioinformatics methodologies and analysis tools for the omics (genomics, transcriptomics, epigenomics, and metabolomics) and pharmaco-omics data as well as to answering practical biomedical and biological issues via close collaborations with epidemiologists, clinicians, and geneticists. He won several titles including Career Development Award of Academia Sinica (2011), Elected member of Global Young Academy (2013), Junior Research Investigators Award, Academia Sinica (2013), Outstanding Young Alumni Award of National Cheng Kung University (2016), Future Technology Breakthrough Award of Ministry of Science and Technology (2018), Elected member of International Statistical Institute (2019), and Contribution Award of Chinese Institute of Probability and Statistics (2019). He has joint appointments in National Cheng Kung University and National Yang Ming University. He is the Associate Editor and Review Editor for three international journals and served as reviewers for more than 40 international journals and 140 papers. He is the Member of the Institution Review Board (IRB) in National Health Research Institute and Academia Sinica. He also serves as the Review Panel Member of Department of Nature Sciences and Sustainable Development, Ministry of Science and Technology and Panel Member of Mathematics Research Promotion Center, Ministry of Science and Technology.

Publications (Selective publications in the past 5 years, * Corresponding author)

1. [Yang, H.-C.](#), Chu, S.-K., Kuo, H.-W., Wang, S.-C., Liu, S.-W., Ho, I.-K. and Liu, Y.-L.* (2016/03). Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on *CYP2B6*, *SPON1*, and *GSG1L* associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. *PLoS Genetics* **12**, e1005910.
 2. Huang, M.-C., Chuang, T.-P., Chen, C.-H., Wu, J.-Y., Chen, Y.-T., Li, L.-H.* and [Yang, H.-C.](#)* (2016/03). An integrated analysis tool for hybridization intensities and genotypes using new-generation population-optimized human arrays. *BMC Genomics* **17**, 266. (<https://rdcu.be/6i0w>)
 3. Liang, Y.-J., Lin, Y.-T., Chen, C.-W., Lin, C.-W., Chao, K.-M., Pan, W.-H. and [Yang, H.-C.](#)* (2016/06). SMART: Statistical Metabolomics Analysis – an R tool. *Analytical Chemistry* **88**, 6334-6341.
 4. [Yang, H.-C.](#)* and Lin, Y.-T. (2016/11). Homozygosity disequilibrium and its gene regulation. *BMC Proceedings* **10**, 159-163. (<http://rdcu.be/mHtp>)
 5. [Yang, H.-C.](#), Chen, I.-C., Tsay, Y.-C., Li, Z.-R., Chen, C.-H., Hwu, H.-G. and Chen, C.-H.* (2017/04). Using an event-history with risk-free model to study the genetics of alcoholism. *Scientific Reports* **7**, 1975. (<http://rdcu.be/r18K>)
 6. Chu, S.-K. and [Yang, H.-C.](#)* (2017/09). Interethnic DNA methylation difference and its implications in pharmacoepigenetics. *Epigenomics* **9**, 1437-1454.
 7. [Yang, H.-C.](#)* and Chen, C.-W. (2018/09). Homozygosity disequilibrium associated with treatment response and its methylation regulation. *BMC Proceedings* **12**, 45. (<https://rdcu.be/6Z4m>)
- Chen, C.-W. and [Yang, H.-C.](#)* (2019/01). OPATs: Omnibus p-value association tests. *Briefings in Bioinformatics* **20**, 1-14.

**Population Pharmacogenomics:
Enrichment of Ancestry-Informative Markers in Pharmacogenetic Loci**

Hsin-Chou Yang

Institute of Statistical Science, Academia Sinica, Taiwan

Recent studies have pointed out the essential role of genetic ancestry in population pharmacogenetics. In this study, we analyzed the whole-genome sequencing data from The 1000 Genomes Project (Phase 3) and the pharmacogenetic information from Drug Bank, PharmGKB, PharmaADME, and Biotransformation. We found that ancestry-informative markers were enriched in pharmacogenetic loci (PGx), suggesting that trans-ancestry differentiation must be carefully considered in population pharmacogenetics studies. Ancestry-informative PGx were located in both protein-coding and non-protein-coding regions, illustrating that a whole-genome analysis is necessary for an unbiased examination over PGx. Finally, those ancestry-informative PGx that targeted multiple drugs were often a functional variant, which reflected their importance in biological functions and pathways. This study developed an efficient algorithm for an ultrahigh-dimensional principal component analysis, created genetic catalogues of ancestry-informative markers and genes, established a high-accuracy prediction panel of genetic ancestry, explored pharmacogenetic patterns, and constructed a genetic ancestry pharmacogenomic database “Genetic Ancestry PhD”.

Hsiao-Pei Lu, Ph.D. (呂曉沛)

Current position and professional experiences

- 2019/2 ~ Present **Assistant Professor**, Department of
Biotechnology and Bioindustry Sciences,
National Cheng Kung University
- 2012/8 ~ 2019/1 **Postdoctoral Fellow**, Institute of Oceanography,
National Taiwan University



Research interest

1. Microbial ecology
2. Microbial evolution
3. Molecular genetics
4. Bioinformatics

Short research summary

Dr. Lu is now an Assistant Professor at the National Cheng Kung University (NCKU), Tainan, Taiwan. She received her M.S. and Ph.D. degrees from the National Taiwan University (NTU), Taipei, Taiwan. Dr. Lu is a molecular microbial ecologist with education and training in zoology and marine science. Dr. Lu's research interests are associated with microbial community ecology & microbial genome evolution. She applies meta-omics approaches (such as metagenomics, metatranscriptomics, and metabolomics) and bioinformatics tools (including phylogenetic and statistical analyses) to investigate microbe-involved systems. Her research aims are to develop new analytical methods and suitable theoretical concepts which can better interpret microbial biodiversity and biogeography.

Publications

1. **Hsiao-Pei Lu***, Yung-Hsien Shao, Jer-Horng Wu, and Chih-hao Hsieh. (2020). System performance corresponding to bacterial community succession after a disturbance in an autotrophic nitrogen removal bioreactor. *mSystems* 5: e00398-20.
2. Po-Yu Liu, An-Chi Cheng, Shiao-Wei Huang, **Hsiao-Pei Lu**, and Hon-Tsen Yu*. (2020). Body-size scaling is related to gut microbial diversity, metabolism and dietary niche of arboreal folivorous flying squirrels. *Scientific Reports* 10: 7809.
3. Wan-Hsuan Cheng, **Hsiao-Pei Lu**, Chung-Chi Chen, Sen Jan, and Chih-hao Hsieh*. (2020). Vertical beta-diversity of bacterial communities depending on water stratification. *Frontiers in Microbiology* 11: 449.
4. **Hsiao-Pei Lu**, Yi-Chun Yeh, Fuh-Kwo Shiah, Gwo-Ching Gong, and Chih-hao Hsieh*. (2019). Evolutionary constraints on species diversity in marine bacterioplankton communities. *The ISME Journal* 13: 1032–1041.
5. **Hsiao-Pei Lu**, Po-Yu Liu, Yu-bin Wang, Ji-Fan Hsieh, Han-Chen Ho, Shiao-Wei Huang, Chung-Yen Lin, Chih-hao Hsieh, and Hon-Tsen Yu*. (2018). Functional characteristics of the flying squirrel's cecal microbiota under a leaf-based diet, based on multiple meta-omic profiling. *Frontiers in Microbiology* 8: 2622.
6. Wenxue Wu, **Hsiao-Pei Lu**, Akash Sastri, Yi-Chun Yeh, Gwo-Ching Gong, Wen-Chen Chou, and Chih-Hao Hsieh*. (2018). Contrasting the relative importance of species sorting and dispersal limitation in shaping marine bacterial versus protist communities. *The ISME Journal* 12: 485-494.

7. **Hsiao-Pei Lu***, Yi-Chun Yeh, Akash Sastri, Fuh-Kwo Shiah, Gwo-Ching Gong, and Chih-hao Hsieh. (2016). Evaluating community-environment relationships along fine to broad taxonomic resolutions reveals evolutionary forces underlying community assembly. *The ISME Journal* 10: 2867-2878.
8. **Hsiao-Pei Lu**, Yung-Chih Lai, Shiao-Wei Huang, Huang-Chi Chen, Chih-hao Hsieh, and Hon-Tsen Yu*. (2014). Spatial heterogeneity of gut microbiota reveals multiple bacterial communities with distinct characteristics. *Scientific Reports* 4: 6185.
9. **Hsiao-Pei Lu**, Yu-bin Wang, Shiao-Wei Huang, Chung-Yen Lin, Martin Wu, Chih-hao Hsieh, and Hon-Tsen Yu*. (2012). Metagenomic analysis reveals a functional signature for biomass degradation by cecal microbiota in the leaf-eating flying squirrel (*Petaurista alborufus lena*). *BMC Genomics* 13: 466.

**The Application of Metagenomics, Metatranscriptomics,
and Metabolomics on Ecological Issues**

Hsiao-Pei Lu

Department of Biotechnology and Bioindustry Sciences,
National Cheng Kung University, Tainan, Taiwan

Recent technological advances, including high-throughput sequencing and mass spectrometry platforms, have allowed us to thoroughly characterize the diversity and composition of genetic materials and chemical compounds; however, due to the complexity of organisms and their derivatives in natural environments, it is still difficult to apply multi-omics approaches on ecological issues. Here, I will introduce two case studies to share experiences in data analysis of metagenomics, metatranscriptomics, and metabolomics for investigating microbe-compound relationships.

In the first case, we focus on forest ecosystems, using the gut microbiota of leaf-eating flying squirrels as a model to explore how symbiotic microbes help the host adapt to a high-fiber, toxin-rich diet. In the second case, we focus on ocean ecosystems, using the marine bacterioplankton as a model to explore how microbes respond to nutrient upwelling and further affect the flux of dissolved organic matter. These exploratory studies based on metagenomics, metatranscriptomics, and metabolomics would provide new insights which allow to form molecular-based hypotheses regarding functional contributions of microorganisms in natural environments.

Shih Sheng Jiang, Ph.D. (江士昇)

Current position and professional experiences

2017/7 ~ Present	Assistant Investigator , National Institute of Cancer Research, NHRI	
2011/3 ~ 2017/6	Project Assistant Investigator , National Institute of Cancer Research, NHRI	
2015/8 ~ Present	Adjunct Assistant Professor , Biotechnology Center/Ph.D. Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung, Taiwan	
2012/8 ~ Present	Adjunct Assistant Professor , Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan	
2006/1 ~ 2012/6	Research Associate , National Institute of Cancer Research, NHRI	
2003/9 ~ 2005/12	Research Associate , President's Laboratory, NHRI	
2000/5 ~ 2003/8	Postdoctoral Fellow , Division of Molecular and Genomic Medicine, NHRI	

Research interest

1. Cancer genomics
2. Bioinformatics
3. Cancer biology
4. Molecular biology
5. Cancer immunology

Short research summary

Dr. Shih Sheng Jiang is a Principal Investigator of National Institute of Cancer Research at the National Health Research Institutes (NHRI), Taiwan. Dr. Jiang received his Ph.D. degree from the National Tsing Hua University, Taiwan and has been involved in genomic researches for more than 15 years. Dr. Jiang's research focuses on the utilization of genomics and bioinformatics approaches to identify biomarkers of cancers for early detection, diagnosis, and prognosis, as well as to unveil the underlying mechanisms of those cancer biomarkers to pave the way for better cancer treatments.

Publications

1. Li, Y. L., Chen, C. H., Chen, J. Y., Lai, Y. S., Wang, S. C., Jiang, S. S.*, and Hung, W. C.* (2020) Single-cell analysis reveals immune modulation and metabolic switch in tumor-draining lymph nodes. *Oncoimmunology* 9, 1830513
2. Kuo, C. L., Chou, H. Y., Chiu, Y. C., Cheng, A. N., Fan, C. C., Chang, Y. N., Chen, C. H., Jiang, S. S., Chen, N. J., and Lee, A. Y. (2020) Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. *Cancer Lett* 474, 138-150
3. Wu, Y. J., Ko, B. S., Liang, S. M., Lu, Y. J., Jan, Y. J., Jiang, S. S., Shyue, S. K., Chen, L., and Liou, J. Y. (2019) ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma. *Cell Death Dis* 10, 408
4. Lin, C. Y., Wang, B. J., Chen, B. C., Tseng, J. C., Jiang, S. S., Tsai, K. K., Shen, Y. Y., Yuh, C. H., Sie, Z. L., Wang, W. C., Kung, H. J., and Chuu, C. P. (2019) Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc. *Cancers (Basel)* 11
5. Cho, C. Y., Chung, S. Y., Lin, S., Huang, J. S., Chen, Y. L., Jiang, S. S., Cheng, L. C., Kuo, T. H., Lay, J.

- D., Yang, Y. Y., Lai, G. M., and Chuang, S. E. (2019) PTBP1-mediated regulation of AXL mRNA stability plays a role in lung tumorigenesis. *Sci Rep* 9, 16922
6. Chen, M. H., Chou, W. C., Hsiao, C. F., Jiang, S. S., Tsai, H. J., Liu, Y. C., Hsu, C., Shan, Y. S., Hung, Y. P., Hsich, C. H., Chiu, C. H., Liu, T. C., Cho, S. F., Liu, T. W., and Chao, Y. (2019) An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. *Oncologist*
 7. Chan, S. H., Tsai, K. W., Chiu, S. Y., Kuo, W. H., Chen, H. Y., Jiang, S. S., Chang, K. J., Hung, W. C., and Wang, L. H. (2019) Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer. *Mol Cancer Ther* 18, 147-161
 8. Wang, L. T., Jiang, S. S., Ting, C. H., Hsu, P. J., Chang, C. C., Sytwu, H. K., Liu, K. J., and Yen, B. L. (2018) Differentiation of Mesenchymal Stem Cells from Human Induced Pluripotent Stem Cells Results in Downregulation of c-Myc and DNA Replication Pathways with Immunomodulation Toward CD4 and CD8 Cells. *Stem Cells* 36, 903-914
 9. Sung, Y. J., Kao, T. Y., Kuo, C. L., Fan, C. C., Cheng, A. N., Fang, W. C., Chou, H. Y., Lo, Y. K., Chen, C. H., Jiang, S. S., Chang, I. S., Hsu, C. H., Lee, J. C., and Lee, A. Y. (2018) Mitochondrial Lon sequesters and stabilizes p53 in the matrix to restrain apoptosis under oxidative stress via its chaperone activity. *Cell Death Dis* 9, 697
 10. Liu, S. C., Hsu, T., Chang, Y. S., Chung, A. K., Jiang, S. S., OuYang, C. N., Yuh, C. H., Hsueh, C., Liu, Y. P., and Tsang, N. M. (2018) Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. *Nat Commun* 9, 5105
 11. Lin, C. Y., Jan, Y. J., Kuo, L. K., Wang, B. J., Huo, C., Jiang, S. S., Chen, S. C., Kuo, Y. Y., Chang, C. R., and Chuu, C. P. (2018) Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5. *Cancer Sci* 109, 3564-3574
 12. Chen, C. H., Jiang, S. S.,* Chang, I. S., Wen, H. J., Sun, C. W., and Wang, S. L.* (2018) Association between fetal exposure to phthalate endocrine disruptor and genome-wide DNA methylation at birth. *Environ Res* 162, 261-270
 13. Chen, C. C., Chen, L. L., Li, C. P., Hsu, Y. T., Jiang, S. S., Fan, C. S., Chua, K. V., Huang, S. X., Shyr, Y. M., Chen, L. T., and Huang, T. S. (2018) Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development. *Oncoimmunology* 7, e1424612
 14. Chang, J. W., Kuo, W. H., Lin, C. M., Chen, W. L., Chan, S. H., Chiu, M. F., Chang, I. S., Jiang, S. S., Tsai, F. Y., Chen, C. H., Huang, P. H., Chang, K. J., Lin, K. T., Lin, S. C., Wang, M. Y., Uen, Y. H., Tu, C. W., Hou, M. F., Tsai, S. F., Shen, C. Y., Tung, S. L., and Wang, L. H. (2018) Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway. *Oncogene*
 15. Wang, S. H., Chang, J. S., Hsiao, J. R., Yen, Y. C., Jiang, S. S., Liu, S. H., Chen, Y. L., Shen, Y. Y., Chang, J. Y., and Chen, Y. W. (2017) Tumour cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial endothelial-mesenchymal transition of lymphatic endothelial cells. *Oncogene* 36, 1503-1515
 16. Tsai, H. J., Jiang, S. S., Hung, W. C., Borthakur, G., Lin, S. F., Pemmaraju, N., Jabbour, E., Bomalaski, J. S., Chen, Y. P., Hsiao, H. H., Wang, M. C., Kuo, C. Y., Chang, H., Yeh, S. P., Cortes, J., Chen, L. T., and Chen, T. Y. (2017) A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. *Sci Rep* 7, 11253
 17. Li, S. M., Chen, C. H., Chen, Y. W., Yen, Y. C., Fang, W. T., Tsai, F. Y., Chang, J. L., Shen, Y. Y., Huang, S. F., Chuu, C. P., Chang, I. S., Hsiung, C. A., and Jiang, S. S.* (2017) Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma. *Sci Rep* 7, 11893
 18. Cheng, A. N., Fan, C. C., Lo, Y. K., Kuo, C. L., Wang, H. C., Lien, I. H., Lin, S. Y., Chen, C. H., Jiang, S. S., Chang, I. S., Juan, H. F., Lyu, P. C., and Lee, A. Y. (2017) Cdc7-Dbf4-mediated

phosphorylation of HSP90-S164 stabilizes HSP90-HCLK2-MRN complex to enhance ATR/ATM signaling that overcomes replication stress in cancer. *Sci Rep* 7, 17024

19. Chang, I. S., Jiang, S. S., Yang, J. C., Su, W. C., Chien, L. H., Hsiao, C. F., Lee, J. H., Chen, C. Y., Chen, C. H., Chang, G. C., Wang, Z., Lo, F. Y., Chen, K. Y., Wang, W. C., Chen, Y. M., Huang, M. S., Tsai, Y. H., Su, Y. C., Hsieh, W. S., Shih, W. C., Shieh, S. H., Yang, T. Y., Lan, Q., Rothman, N., Chen, C. J., Chanock, S. J., Yang, P. C., and Hsiung, C. A. (2017) Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. *Am J Respir Crit Care Med* 195, 663-673 (co-first author)
20. Su, C. M., Wang, M. Y., Hong, C. C., Chen, H. A., Su, Y. H., Wu, C. H., Huang, M. T., Chang, Y. W., Jiang, S. S., Sung, S. Y., Chang, J. Y., Chen, L. T., Chen, P. S., and Su, J. L. (2016) miR-520h is crucial for DAPK2 regulation and breast cancer progression. *Oncogene* 35, 1134-1142
21. Peng, H. Y., Jiang, S. S., Hsiao, J. R., Hsiao, M., Hsu, Y. M., Wu, G. H., Chang, W. M., Chang, J. Y., Jin, S. L., and Shiah, S. G. (2016) IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma. *Mol Oncol* 10, 895-909
22. Lin, S. C., Chou, Y. T., Jiang, S. S., Chang, J. L., Chung, C. H., Kao, Y. R., Chang, I. S., and Wu, C. W. (2016) Epigenetic Switch between SOX2 and SOX9 Regulates Cancer Cell Plasticity. *Cancer Res* 76, 7036-7048
23. Chou, C. P., Jiang, S. S., Pan, H. B., Yen, Y. C., Tseng, H. H., Hung, Y. T., Wang, S. H., Chen, Y. L., and Chen, Y. W. (2016) Endothelial cell colony forming units derived from malignant breast diseases are resistant to tumor necrosis factor-alpha-induced apoptosis. *Sci Rep* 6, 37450
24. Cheng, C. W., Hsiao, J. R., Fan, C. C., Lo, Y. K., Tzen, C. Y., Wu, L. W., Fang, W. Y., Cheng, A. J., Chen, C. H., Chang, I. S., Jiang, S. S., Chang, J. Y., and Lee, A. Y. (2016) Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma. *Mol Carcinog* 55, 499-513
25. Chen, J. Y., Li, C. F., Chu, P. Y., Lai, Y. S., Chen, C. H., Jiang, S. S., Hou, M. F., and Hung, W. C. (2016) Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1. *Oncotarget* 7, 27689-27710
26. Chen, K. Y., Hsiao, C. F., Chang, G. C., Tsai, Y. H., Su, W. C., Chen, Y. M., Huang, M. S., Tsai, F. Y., Jiang, S. S., Chang, I. S., Chen, C. Y., Hsiung, C. A., Chen, C. J., Yang, P. C., and Group, G. S. (2015) Estrogen Receptor Gene Polymorphisms and Lung Adenocarcinoma Risk in Never-Smoking Women. *J Thorac Oncol* 10, 1413-1420

**Dissecting Tumor Microenvironment Using Gene Expression Profiling Data
for Prognostic Biomarkers of OSCC**

Shih Sheng Jiang

National Institute of Cancer Research (NICR), National Health Research Institutes (NHRI), Taiwan

Oral squamous cell carcinomas (OSCC) are squamous cell carcinomas of the head and neck occurring at the oral cavity. OSCC are among the most prevalent malignancies in the world. The five-year survival rates range from 30% to 60%, making it among the worst for all types of cancers. Despite the advances in therapeutic methods, the prognosis of OSCC has not been significantly improved during the past several decades, mainly due to lack of effective biomarkers for predicting prognosis and proficient treatment strategies. To address such issues, it is advised to i) obtain biomarkers capable of identifying patients at high risk of disease progression and ii) to better understand the cellular and molecular mechanisms via which those biomarkers are functionally involved in the disease progression, and eventually one can invent tailored treatment strategies accordingly. In this talk, I will share our experience on prognosis biomarker development for OSCC of advanced stage based on genome-wide analyses of both bulk-tissue gene expression profiling (microarray, NanoString and RNAseq) data as well as single-cell RNAseq data. Pathway analysis at single-cell resolution has provided us insights into the mechanisms how alteration in cellular function or abundance of some candidate cell types could possibly account for poor prognosis and/or disease progression of OSCC.

H. Sunny Sun, Ph.D. (孫孝芳)**Current position and professional experiences**

- 2016/8 ~ Present **Director/Professor**, Institute of Molecular Medicine, National Cheng Kung University
- 2011/8 ~ Present **Director**, Center for Genomic Medicine, National Cheng Kung University
- 2015/2 ~ 2016/7 **Associated Vice President**, Office of Research and Development, National Cheng Kung University

**Research interest**

1. Genomic medicine
2. Bioinformatics
3. Molecular genetics
4. Comparative genomics

Short research summary

Dr. Sunny Sun is a Professor and Director of Molecular Medicine at the National Cheng Kung University (NCKU), Taiwan. Dr. Sun received her Ph.D degree from the University of Wisconsin-Madison in the United State and has been involved in genomic researches for the past ~20 years. Dr. Sun's research interest focuses on the application of computational strategy and advanced molecular biology techniques to identify genes responsible for various human diseases and study the regulation of gene expression in physiological and pathological conditions. In addition to her primary role in the University, Dr. Sun is also the Director of Center for Genomic Medicine in NCKU, in which she leads a team to provide services for clinical diagnosis and supports for clinical research.

Publications

1. Kai-Chiang Liang, Joseph T. Tseng, Shaw-Jenq Tsai and **H. Sunny Sun***. 2015. Characterization and distribution of repetitive elements in association with genes in the human genome. *Computational Biology and Chemistry* 57:29-38.
2. Kuei-Yang Hsiao, Meng-Hsing Wu, Ning Chang, Shang-Hsun Yang, Chun-Wei Wu, **H. Sunny Sun*** and Shaw-Jenq Tsai*. 2015. Coordination of AUF1 and miR-148a to destabilize DNA methyltransferase 1 mRNA under hypoxia in endometriosis *Mol Hum Reprod.* 21(12):894-904.
3. Wei-Hsuan Yen, Wu-Sian Ke, Jan-Jong Hung, Tsung-Ming Chen, Jia-Shing Chen, **H. Sunny Sun***. 2016. Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma. *Cancer Medicine* 5(3):465-77.
4. Chun-Wei Chien, Pei-Chi Hou, Han-Chung Wu, Yu-Ling Chang, Shih-Chieh Lin, Shau-Chieh Lin, Bo-Wen Lin, Jenq-Chang Lee, Yu-Jia Chang, and **H. Sunny Sun*** and Shaw-Jenq Tsai*. 2016. Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. *Oncogene* 10;35(45):5872-5881.
5. Ming-Chih Lai, Chiao-May Chang, and **H. Sunny Sun***. 2016. Hypoxia Induces Autophagy through Translational Up-Regulation of Lysosomal Proteins in Human Colon Cancer Cells. *PLoS ONE* 11(4):e0153627.
6. Kuei-Yang Hsiao, Ya-Chi Lin, Sachin Kumar Gupta, Ning Chang, Laising Yen, **H. Sunny Sun***, and Shaw-Jenq Tsai*. 2017 Non-coding effects of circular RNA CCDC66 promotes colon cancer growth and metastasis. *Cancer Research* 77(9):2339-2350.

7. Kuei-Yang Hsiao, **H. Sunny Sun** and Shaw-Jenq Tsai. 2017. Circular RNA – New member of noncoding RNA with novel functions. *Experimental Biology and Medicine* 242(11):1136-1141.
8. Nithila A. Joseph, Shiow-Her Chiou*, Zoe Lung, Cheng-Lin Yang, Tze-Yi Lin, Hui-Wen Chang, **H. Sunny Sun*** Sachin Kumar Gupta, Laising Yen, Shulhn-Der Wang, and Kuan-Chih Chow*. 2018. The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. *Journal of Hematology & Oncology* 11(1):74.
9. Tsung-Ming Chen, Ming-Chih Lai, Yi-Han Li, Ya-Ling Chan, Chih-Hao Wu, Yu-Ming Wang, Chun-Wei Chien, San-Yuan Huang, **H. Sunny Sun***, and Shaw-Jenq Tsai*. 2019. hnRNPM induces translation switch under hypoxia to promote colon cancer development. *EBioMedicine*. 41: 299–309.
10. Chia-Liang Tsai, **H. Sunny Sun**, Yu-Min Kuo, Ming-Chyi Pai. 2019. The role of physical fitness in cognitive-related biomarkers in persons at genetic risk of familial Alzheimer’s disease. *Journal of Clinical Medicine* 8(10), 1639 ; doi:10.3390/jcm8101639.
11. Chan-I Su, Yu-Ting Kao, Chao-Chen Chang, Yao Chang, Tzong-Shiann Ho, **H. Sunny Sun**, Yi-Ling Lin, Michael M. C. Lai, Yu-Huei Liu, and Chia-Yi Yu, 2020, DNA-induced 2'3'-cGAMP enhances haplotype-specific human STING cleavage by dengue protease. 2020. *PNAS*, 117 (27) 15947-15954.
12. Chun-Hsien Chu, Jia-Shing Chen, Pei-Chin Chuang, Chia-Hao Su, Ya-Ling Chan, Ying-Ju Yang, Yu-Ting Chiang, Yu-Ya Su, Po-Wu Gean, **H. Sunny Sun***. 2020. TIAM2S as a novel regulator for serotonin level enhances brain plasticity and locomotion behavior. *The FASEB Journal*. 34:3267–3288.
13. Ya-Ling Chan, Wei-Chung Lai, Jia-Shing Chen, Joseph Ta-Chien Tseng, Pei-Chin Chuang, Jonathan Jou, Chung-Ta Lee and **H. Sunny Sun***. 2020. TIAM2S Mediates Serotonin Homeostasis and Provokes a Pro-Inflammatory Immune Microenvironment Permissive for Colorectal Tumorigenesis. *Cancers* 12(7):1844.
14. Yen-An Tang, Lin-Yen Wang, Chiao-May Chang, I-Wen Lee, Wen-Hui Tsai*, **H. Sunny Sun***. 2020. Novel compound heterozygous mutations in CRTAP cause rare autosomal recessive osteogenesis imperfecta. *Frontiers in Genetics*, 14 August 2020, DOI: 10.3389/fgene.2020.00897.
15. Yi-Han Li, Tsung-Ming Chen, Shang-Hsun Yang, Bu-Miin Huang, Chia-Ching Wu, Jih-Ing Chuang, Shaw-Jenq Tsai* and **H. Sunny Sun***. 2020. The male sex-determination gene SRY binds to human fibroblast growth factor 9 (FGF9) promoter and upregulates FGF9 expression. *Biology of reproduction* (Accepted).
16. Vo-Minh-Hoang Bui, Clément Mettling, Jonathan Jou, **H. Sunny Sun***. 2020. Genomic amplification of chromosome 20q13.33 is the early biomarker for the development of sporadic colorectal carcinoma. *BMC Genomics* (accepted).

Hsueh-Fen Juan, Ph.D. (阮雪芬)**Current position and professional experiences**

- 2020/7 ~ Present **Distinguished Professor**, Department of Life Science, Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University (NTU), Taiwan
- 2020/4 ~ Present **Key Director**, Taiwan AI Labs

**Research interest**

1. Systems biology
2. Proteomics
3. Bioinformatics
4. Transcriptomics
5. Synthetic biology
6. Cancer biology

Short research summary

Dr. Hsueh-Fen Juan is Distinguished Professor of National Taiwan University. She received her BS and MS degree in Botany and PhD in Biochemical Sciences from National Taiwan University (NTU). She worked as a research scientist at Japan International Research Center for Agricultural Sciences (Tsukuba, Japan) and a postdoctoral research fellow at Institute of Biological Chemistry, Academia Sinica (Taipei, Taiwan). She started her academic career as an assistant professor at Department of Chemical Engineering, National Taipei University of Technology and as an adjunct assistant professor at Department of Computer Science and Information Engineering at NTU in 2002. She moved to NTU as an assistant professor at Department of Life Science in 2004. She was promoted to associate professor in 2006, full professor in 2009 and became distinguished professor at Department of Life Science and Graduate Institute of Biomedical Electronics and Bioinformatics in 2020. Dr. Juan studied synthetic biology with Professor Hirotada Mori (NIST, Japan) in 2006 and Dr. James C. Liao (UCLA, USA) during 2007-2008. Dr. Juan joined the national teams for repurposed drugs against SARS in 2003 and SARS-CoV-2 in 2020 using bioinformatics and big data analysis. Since Dr. Juan made significant contributions through systems biology approach to development of methodology and cancer therapy, she received several awards "Taiwan's Ten Outstanding Young Persons", FY2011 JSPS Invitation Fellowship Program for Research in Japan, K. T. Li Breakthrough Award by Institute of Information and Computing Machinery, USA Emerging Information and Technology Association (EITA) Service Award, and Ministry of Science and Technology (MOST) Outstanding Research Award. She serves as the editor of Scientific Reports (Nature Research).

Publications

1. Chen, T.-F., Chang, Y.-C., Hsiao, Y., Lee, K.-H., Hsiao, Y.-C., Lin, Y.-H., Tu, Y.-C. E., Huang, H.-C., Chen, C.-Y.*, Juan, H.-F.* (2020) "DockCoV2: a drug database against SARS-CoV-2" *Nucleic Acids Research* Oct 9. doi: 10.1093/nar/gkaa861.
2. Chang, Y.-W., Hsu, C.-L., Tang, C.-W., Chen, X.-J., Huang, H.-C.*, Juan, H.-F.* (2020) "Multiomics reveals ectopic ATP synthase blockade induces cancer cell death via a lncRNA-mediated phospho-signaling network" *Molecular and Cellular Proteomics* Aug 11:mcp.RA120.002219.
3. Wu, A. Y.-T., Sun, Y.-C., Chen, Y.-J., Chou, S. T.-Y., Guo, V., Chien, J. C.-Y., Ko, J. J.-S., Yang, A. L., Huang, H.-C., Chuang, J.-C., Wu, S., Ho, M.-R., Ericsson, M., Lin, W.-W., Cheung, C. H. Y., Juan, H.-

- F., Ueda, K., Chen Y., Lai C. P.-K. (2020) "Multi-resolution imaging using bioluminescence resonance energy transfer identifies distinct biodistribution profiles of extracellular vesicles and exomeres with redirected tropism" *Advanced Science* 7: 2001467.
4. Cheung, H. Y. C., Hsu, C.-L., Lin, T.-Y., Chen, W.-T., Wang, Y.-C., Huang, H.-C.*, Juan, H.-F.* (2020) "ZNF322A-mediated protein phosphorylation induces autophagosome formation through modulation of IRS1-AKT glucose uptake and HSP-elicited UPR in lung cancer" *Journal of Biomedical Science* 27(1):75.
 5. Wang, W.-H., Hsu, C.-L., Huang, H.-C.*, Juan, H.-F.* (2020) "Quantitative phosphoproteomics reveals cell alignment and mitochondrial length change under cyclic stretching in lung cells" *International Journal of Molecular Sciences* 21(11):E4074.
 6. Yin, C.-F., Kao, S.-C., Hsu, C.-L., Cheung, C. H.Y., Chang, Y.-W., Huang, H.-C.*, Juan, H.-F.* (2020) "Phosphoproteome analysis reveals dynamic heat shock protein 27 phosphorylation in tanshinone IIA-induced cell death" *Journal of Proteome Research* 19(4):1620-1634.
 7. Hsieh, C.-H., Cheung, C. H. Y., Liu, Y.-L., Hou, C.-L., Hsu, C.-L., Huang, C.-T., Yang, T.-S., Chen, S.-F., Chen, C.-N., Hsu, W.-M.*, Huang, H.-C.*, Juan, H.-F.* (2019) "Quantitative proteomics of Th-MYCN transgenic mice reveals aurora kinase inhibitor altered metabolic pathways and enhanced ACADM to suppress neuroblastoma progression" *Journal of Proteome Research* 18(11):3850-3866.
 8. Cheung, H. Y. C., Hsu, C.-L., Tsuei, C.-Y., Kuo, T.-T., Huang, C.-T., Hsu, W.-M., Chung, Y.-H., Wu, H.-Y., Hsu, C.-C., Huang, H.-C.*, Juan, H.-F.* (2019) "Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy" *Cell Death & Disease* 10:786.
 9. Wu, P.-Y., Yu, I.-S., Lin, Y.-C., Chang, Y.-T., Chen, C.-C., Lin, K.-H., Tseng, T.-H., Kargren, M., Tai, Y.-L., Shen, T.-L., Liu, Y.-L., Wang, B.-J., Chang, C.-H., Chen, W.-M., Juan, H.-F., Huang, S.-F., Chan, Y.-Y., Liao, Y.-F., Hsu, W.-M., Lee, H. (2019) "Activation of aryl hydrocarbon receptor by kynurenine impairs progression and metastasis of neuroblastoma" *Cancer Research* 79(21):5550-5562.
 10. Huang, C.-T., Hsieh, C.-H., Lee, W.-C., Liu, Y.-L., Yang, T.-S., Hsu, W.-M., Oyang, Y.-J., Huang, H.-C.*, Juan, H.-F.* (2019) "Therapeutic targeting of non-oncogene dependencies in high-risk neuroblastoma" *Clinical Cancer Research* 25(13):4063-4078.
 11. Huang, C.-T., Hsieh, C.-H., Chung, Y.-H., Oyang, Y.-J., Huang, H.-C.*, Juan, H.-F.* (2019) "Perturbational gene-expression signatures for combinatorial drug discovery" *iScience* 15:291-306 (Cell Press).
 12. Yang, T.-W., Sahu, D., Chang, Y.-W., Hsu, C.-L., Hsieh, C.-H., Huang, H.-C.*, Juan, H.-F.* (2019) "RNA-binding proteomics reveals MATR3 interacting with lncRNA SNHG1 to enhance neuroblastoma progression" *Journal of Proteome Research* 18: 406-416.
 13. Chang, J.-Y., Yu, W.-H., Juan, H.-F.*, Huang, H.-C.* (2018) "Dynamics of alternative polyadenylation in human preimplantation embryos" *Biochemical and Biophysical Research Communications* 504(4):727-733.
 14. Huang, C.-T., Hsieh, C.-H., Oyang, Y.-J., Huang, H.-C.*, Juan, H.-F.* (2018) "A large-scale gene expression intensity-based similarity metric for drug repositioning" *iScience* 7: 40-52. (Cell Press)
 15. Cheung, H. Y. C., Hsu, C.-L., Chen, K.-P., Chong, S.-T., Huang, H.-C.*, Juan, H.-F.* (2017) "MCM2-regulated functional networks in lung cancer by multi-dimensional proteomic approach" *Scientific Reports* 7(1):13302.
 16. Hsu, C.-L., Wang, J.-K., Lu, P.-C., Huang, H.-C.*, and Juan, H.-F.* (2017) "DynaPho: a web platform for inferring the dynamics of time-series phosphoproteomics" *Bioinformatics* 33(22):3664-3666.
 17. Cheung, C. H.-Y., Juan, H.-F.*. (2017) "Quantitative Proteomics in Lung Cancer" *Journal of Biomedical Science* 24:37.
 18. Jen, J., Lin, L.-L., Lo, F.-Y., Chen, H.-T., Liao, S.-Y., Tang, Y.-A., Hsu, H.-S., Salgia, R., Hsu, C.-L., Huang, H.-C., Juan, H.-F.*, Wang, Y.-C.* (2016) "Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer"

Invited Speeches

Artificial Intelligence – Speaker

(TSECB & TBSB) Hall II Section III 11/15 10:30-11:55

Oncogene 35(18):2357-69.

AI for Drug Repositioning

Hsueh-Fen Juan

Department of Life Science, Graduate Institute of Biomedical and Bioinformatics,
National Taiwan University, Taipei, Taiwan
Taiwan AI Labs, Taipei, Taiwan

In the big data era, the artificial intelligent (AI) and network medicine offer cutting-edge applications to drug repositioning. Drug repositioning is the process of finding new uses for existing approved drugs, and is believed to offer great benefits over de novo drug discovery. The current state of the COVID-19 pandemic is a global health crisis; drug repositioning enables rapid clinical trials and regulatory review for COVID-19 therapy. One of the best-known ways is to block enzymes essential for virus replication. By performing molecular docking analyses, we develop a drug database for SARS-CoV2, named as DockCoV2 which focuses on predicting the binding affinity of FDA-approved and Taiwan National Health Insurance (NHI) drugs with seven proteins including spike, 3CLpro, PLpro, RdRp, N protein, ACE2 and TMPRSS2. DockCoV2 also provides validation information to help users understand which drugs have already been reported to be effective against MERS or SARS-CoV. DockCoV2 is available at <https://covirus.cc/drugs/>. Additionally, by systematically analyzing a large compendium of compound-perturbed data obtained from the Library of Integrated Network-based Cellular Signatures (LINCS), a project initiated by the US National Institute of Health, we identified potentially effective drugs for COVID-19 and experimentally confirmed that the predicted compounds significantly inhibited SARS-CoV-2 replication at nanomolar, non-toxic concentrations.

Chien-Yu Chen, Ph.D. (陳倩瑜)

Current position and professional experiences

- 2013/8 ~ Present **Professor**, Department of Biomechanics Engineering, National Taiwan University
- 2019/2 ~ 2020/1 **Chief Scientist**, Genomic AI team, Taiwan AI Labs
- 2008/8 ~ 2013/7 **Associate Professor**, Department of Biomechanics Engineering, National Taiwan University
- 2005/8 ~ 2008/7 **Assistant Professor**, Department of Biomechanics Engineering, National Taiwan University



Research interest

1. Bioinformatics
2. Machine learning
3. Regulatory networks
4. Genomic medicine

Short research summary

Chien-Yu Chen received the B.S. degree in Electrical Engineering from National Taiwan University in 1996, the M.S. degree in Electrical Engineering from the Stanford University in 1998, and the Ph.D. degree in Computer Science and Information Engineering from National Taiwan University in 2003. She is currently a Professor of the department of Biomechanics Engineering, National Taiwan University. Dr. Chen's lab mainly focuses on developing machine learning-based algorithms to solve problems of molecular biology, including predicting pathogenicity of regulatory variants, haplotyping, quantifying transcript expression, predicting cell type-specific enhancer activity, etc.

Publications

1. Ting-Fu Chen#, Yu-Chuan Chang#, Yi Hsiao#, Ko-Han Lee#, Yu-Chun Hsiao, Yu-Hsiang Lin, Yi-Chin Ethan Tu, Hsuan-Cheng Huang, **Chien-Yu Chen***, Hsueh-Fen Juan*, DockCoV2: a drug database against SARS-CoV-2, *Nucleic Acids Research*, gkaa861, 2020.
2. Yu-Chuan Chang, June-Tai Wu, Ming-Yi Hong, Yi-An Tung, Ping-Han Hsieh, Sook Wah Yee, Kathleen M. Giacomini, Yen-Jen Oyang, **Chien-Yu Chen*** & for the Alzheimer's Disease Neuroimaging Initiative, GenEpi: gene-based epistasis discovery using machine learning, *BMC Bioinformatics*, 21:68, 2020.
3. Jou-Ho Shih, Hsin-Yi Chen, Shin-Chih Lin, Yi-Chen Yeh, Roger Shen, Yaw-Dong Lang, Dung-Chi Wu, **Chien-Yu Chen**, Ruey-Hwa Chen, Teh-Ying Chou, and Yuh-Shan Jou*, Integrative analyses of noncoding RNAs reveal the potential mechanisms augmenting tumor malignancy in lung adenocarcinoma, *Nucleic Acids Research*, Volume 48, Issue 3, 1175–1191, 2019.
4. Ping-Han Hsieh, Yen-Jen Oyang, and **Chien-Yu Chen***, Effect of *de novo* transcriptome assembly on transcript quantification, *Scientific Reports*, 9:8304, 2019.
5. Yu-Yu Lin, Ping Chun Wu, Pei-Lung Chen, Yen-Jen Oyang, Chien-Yu Chen*, HAHap: a read-based haplotyping method using hierarchical assembly, *PeerJ* 6:e5852, 2018.
6. Chien-Yueh Lee#, Ping-Han Hsieh# (equal contribution), Li-Mei Chiang, Amrita Chattopadhyay, Kuan-Yi Li, Yi-Fang Lee, Tzu-Pin Lu, Liang-Chuan Lai, En-Chung Lin, Hsinyu Lee, Shih-Torng Ding, Mong-Hsun Tsai, **Chien-Yu Chen***, Eric Y. Chuang*, Whole-genome *de novo* sequencing reveals

- unique genes that contributed to the adaptive evolution of the Mikado pheasant, *GigaScience*, Volume 7, Issue 5, 2018.
7. Chia-Lin Chung, Jiaye Lee, Mitsuteru Akiba, Hsin-Han Lee, Tzu-Hao Kuo, Dang Liu, Huei-Mien Ke, Toshiro Yokoi, Marylette Roa, Meiyeh Lu, Ya-Yun Chang, Pao-Jen Ann, Jyh-Nong Tsai, **Chien-Yu Chen**, Shean-Shong Tzean, Yuko Ota, Tsutomu Hattori, Norio Sahashi, Ruey-Fen Liou, Taisei Kikuchi, Isheng J. Tsai, Comparative and population genomics landscape of *Phellinus noxius*: a hypervariable fungus causing root rot in trees, *Molecular Ecology*, 10 October 2017.
 8. Tian-Sin Fan, Ruey-Meei Wu, Pei-Lung Chen, Ta-Fu Chen, Huei-Ying Li, Yin-Hung Lin, **Chien-Yu Chen**, Meng-Ling Chen, Chun-Hwei Tai, Hang-I. Lin, Chin-Hsien Lin*, Clinical heterogeneity of LRRK2 p.I2012T mutation, *Parkinsonism & Related Disorders*, Vol. 33, 36–43, 2016.
 9. Ju-Chun Hsu*, Yu-Yu Lin, Chia-Che Chang, Kuo-Hsun Hua, Mei-Ju May Chen, Li-Hsin Huang, and **Chien-Yu Chen**, Discovery of Organophosphate Resistance-Related Genes Associated with Well-known Resistance Mechanisms of the Diamondback Moth (*Plutella xylostella*) by RNA-Seq. *Journal of Economic Entomology*, 109 (3): 1378-1386, 2016.
 10. Mao-Sen Liu, Tony Chien-Yen Kuo, Chia-Yun Ko, Dung-Chi Wu, Kuan-Yi Li, Wu-Jui Lin, Ching-Ping Lin, Yen-Wei Wang, Roland Schafleitner, Hsiao-Feng Lo, **Chien-Yu Chen***, and Long-Fang Oliver Chen*, Genomic and transcriptomic comparison of nucleotide variations for insights into bruchid resistance of mungbean (*Vigna radiata* [L.] R. Wilczek). *BMC Plant Biology*, 16:46, 2016.
 11. Mei-Ju May Chen#, Li-Kai Chen(#:equal contribution), Yu-Shing Lai, You-Yu Lin, Dung-Chi Wu, Yi-An Tung, Kwei-Yan Liu, Hsueh-Tzu Shih, Yi-Jyun Chen, Yan-Liang Lin, Li-Ting Ma, Jian-Long Huang, Po-Chun Wu, Ming-Yi Hong, Fang-Hua Chu, June-Tai Wu*, Wen-Hsiung Li*, and **Chien-Yu Chen***, Integrating RNA-seq and ChIP-seq Data to Characterize Long Non-coding RNAs in *Drosophila melanogaster*, *BMC Genomics*, 17:220, 2016.
 12. Hsing-Yu Chen, En-Jung Hsieh, Mei-Chun Cheng, **Chien-Yu Chen**, Shih-Ying Hwang and Tsan-Piao Lin, ORA47 regulates JA and ABA biosynthesis and signaling through binding to a novel cis-element, *New Phytologist*, 211(2):599-613, 2016.
 13. Kuo-I Lin*, Kuo-Hsuan Hung, Shin-Tang Su, **Chien-Yu Chen**, Pang-Hung Hsu, Po-Chun Wu, Hsin-Yu Chen, Fan-Ru Lin, Ming-Daw Tsai, Shang-Yi Huang, Wan-Jung Wu, and Mei-Ju May Chen, Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells, accepted by *Cell Death and Differentiation*, 2016.
 14. Samia Elfekih, **Chien-Yu Chen**, Ju-Chun Hsu, Mahdi Belcaid, and David Haymer*, Identification and preliminary characterization of chemosensory perception-associated proteins in the melon fly *Bactrocera cucurbitae* using RNA-seq, *Scientific Reports*, 6:19112, 2016.
 15. Tony Chien-Yen Kuo, Chia-Cheng Hu, Ting-Ying Chien, Mei-Ju May Chen, Hai-Tung Feng, Long-Fang O. Chen, **Chien-Yu Chen*** and Ju-Chun Hsu*, Discovery of Genes Related to Formothion Resistance in Oriental Fruit Fly (*Bactrocera dorsalis*) by a Constrained Functional Genomics Analysis, *Insect Molecular Biology*, 24(3):338-47, 2015.

Whole Genome Sequencing Data Analysis Using Deep Learning

Chien-Yu Chen

Department of Biomechatronics Engineering, National Taiwan University, Taiwan

In recent years, deep learning has been largely applied to analyzing various types of epigenomic data owing to its capability in capturing complicated structural patterns in regulatory regions. This facilitates the process of annotating abundant non-coding variants discovered in personal whole genome sequencing (WGS) data. In this talk, I will present a deep neural network model that utilizes DNase data to predict the H3K27ac peaks as the active enhancers in selected cell types. We propose joint training of multiple cell types to boost the model performance in predicting cross-cell type enhancer activities. The results demonstrated that by incorporating more datasets across different cell types, the complex regulatory patterns could be captured by the deep learning models and the prediction accuracy can be largely improved. In addition, I will also present an autoML framework, ezGeno, that can further improve the prediction performance by automatically searching the best network architecture. In the end of the talk, how the constructed models can be used in annotating the variants derived from WGS will be briefly explained.

Jia-Ming Chang, Ph.D. (張家銘)**Current position and professional experiences**

- 2016/02 ~ Present **Assistant Professor**, Department of Computer Science, National Cheng Chi University
- 2014/01 ~ 2016/01 **Post-doc**, Institute of Human Genetics (IGH), CNRS, France
- 2008/10 ~ 2013/03 **PhD**, Centre for Genomic Regulation and UPF, Spain

**Research interest**

1. Sequence analysis
2. Phylogenetics
3. Bioinformatics
4. Comparative genomics

Short research summary

Dr. Jia-Ming Chang is an Assistant Professor of Department of Computer Science at the National Cheng Chi University (NCCU), Taiwan. Dr. Chang received his Ph.D degree from Center of Genomic Regulation in Barcelona, Spain and has been involved in bioinformatics researches for the past ~10 years. Dr. Chang's research interest focuses using computational approach to predict protein function prediction, the effect of multiple sequence analysis on downstream phylogenetics reconstruction and computational epigenetics.

Publications

1. Yang Ming Lin, Ching-Tai Chen, Jia-Ming Chang* (2019, Dec). MS2CNN: Predicting MS/MS spectrum based on protein sequence by Deep Convolutional Neural Networks. *BMC Genomics*, 20, 906.
2. Naihui Zhou et al. (include Jia-Ming Chang) (2019, Nov). The CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens. *Genome Biology*, 20, 244.
3. Jia-Ming Chang*, Evan W. Floden, Javier Herrero, Olivier Gascuel, Paolo Di Tommaso, Cedric Notredame* (2019, Feb). Incorporating alignment uncertainty into Felsenstein's phylogenetic bootstrap to improve its reliability. *Bioinformatics*, <https://doi.org/10.1093/bioinformatics/btz082>.
4. Yuki Ogiyama, Bernd Schuettengruber, Giorgio L. Papadopoulos, Jia-Ming Chang, Giacomo Cavalli (2018, Jul). Polycomb-Dependent Chromatin Looping Contributes to Gene Silencing during *Drosophila* Development. *Molecular Cell*, 71, 1-16.
5. Quentin Szabo, Daniel Jost, Jia-Ming Chang, Diego I. Cattoni, Giorgio L. Papadopoulos, Boyan Bonev, Tom Sexton, Julian Gurgo, Caroline Jacquier, Marcelo Nollmann, Frédéric Bantignies, Giacomo Cavalli (2018, Feb). TADs are 3D structural units of higher-order chromosome organization in *Drosophila*. *Science Advances*, 4(2), eaar8082.
6. Diego I. Cattoni, Andrés M. Cardozo Gizzi, Mariya Georgieva, Marco Di Stefano, Alessandro Valeri, Delphine Chamoussset, Christophe Houbroun, Stephanie Déjardin, Jean-Bernard Fiche, Inma González, Jia-Ming Chang, Thomas Sexton, Marc A. Marti-Renom, Frédéric Bantignies, Giacomo Cavalli, Marcelo Nollmann (2017, Nov). Single-cell absolute contact probability

detection reveals chromosomes are organized by multiple low-frequency yet specific interactions. *Nature communications*, 8(1), 1753.

7. Maria Chatzou, Cedrik Magis, Jia-Ming Chang, Carsten Kemena, Giovanni Bussotti, Ionas Erb, Cedric Notredame (2016, Nov). Multiple sequence alignment modeling: methods and applications. *Briefings in Bioinformatics*, 17(6):1009-1023.
8. Evan W. Floden, Paolo Di Tommaso, Maria Chatzou, Cedrik Magis, Cedric Notredame, Jia-Ming Chang* (2016, Jul). PSI/TM-Coffee: a web server for fast and accurate multiple sequence alignments of regular and transmembrane proteins using homology extension on reduced databases. *Nucleic Acids Research*, 44 (W1): W339-W343.
9. Meng-Shin Shiao\$, Jia-Ming Chang\$, Wen- Lang Fan, Mei-Yeh Jade Lu, Cedric Notredame, Shu Fang, Rumi Kondo, Wen- Hsiung Li (2015, Oct). Expression divergence of chemosensory genes between *Drosophila sechellia* and its sibling species and its implications for host shift. *Genome Biology and Evolution*, 7(10):2843-2858. \$Joint-first author
10. Jia-Ming Chang, Paolo Di Tommaso, Vincent Lefort, Olivier Gascuel, Cedric Notredame (2015, Jul). TCS: a web server for multiple sequence alignment evaluation and phylogenetic reconstruction. *Nucleic Acids Research*, 43(W1):W3-6.

Computational Protein Function Prediction

Jia-Ming Chang

Dep. of Computer Science, National Chengchi University, Taiwan

Biological data has grown explosively with the advance of next-generation sequencing. However, annotating protein function with wet lab experiments is time-consuming. Fortunately, computational function prediction can help wet labs formulate biological hypotheses and prioritize experiments. We have developed, GODoc, a novel and effective strategy to incorporate a training procedure into the k-nearest neighbor algorithm (instance-based learning) which is capable of solving the Gene Ontology (GO) multiple-label prediction problem, which is especially notable given the thousands of GO terms. In the CAFA3 competition (68 teams), GODoc ranks 10th in Cellular Component Ontology. In the term-centric task, GODoc performs third and is tied for first for the biofilm formation of *Pseudomonas aeruginosa* and the long-term memory of *Drosophila melanogaster*, respectively. Besides GO prediction, we present PSLCNN, a model using deep neural networks to predict protein subcellular localization for eukaryotes and prokaryotes. Compared with the state-of-the-art tools, PSLCNN achieves the best performance for prokaryotes and is comparable for eukaryotes.

References

- GODoc
 - 2019 Genome biology The CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens team: NCCUCS
 - 2019 BMC bioinformatics GODoc: A High-Throughput Protein Function Prediction using the Novel k-nearest-neighbor and Voting algorithms
- PSLCNN
 - 2019 TAAI PSLCNN: Protein Subcellular Localization Prediction for Eukaryotes and Prokaryotes Using Deep Learning
 - 2013 PLoS one Efficient and interpretable prediction of protein functional classes by Correspondence Analysis and Compact Set Relations
 - 2008 Proteins PSLDoc: Protein subcellular localization prediction based on gapped-dipeptides and probabilistic latent semantic analysis

Chau-Ti Ting, Ph.D. (丁照棣)

Current position and professional experiences

2020 ~ Present	Professor , Department of Life Science, National Taiwan University, Taiwan
2006 ~ 2020	Associate Professor , Department of Life Science, National Taiwan University, Taiwan
2004 ~ 2006	Associate Professor , Department of Life Science, National Tsing Hua University, Taiwan
2000 ~ 2004	Assistant Professor , Department of Life Science, National Tsing Hua University, Taiwan



Research interest

1. Molecular evolution
2. Population genetics and genomics
3. Speciation
4. *Drosophila* genetics

Short research summary

Dr. Chau-Ti Ting is a Professor of Department of Life Science at the National Taiwan University, Taiwan. Dr. Ting received her Ph.D. degree from the National Taiwan University and has been involved in population genetics and genomics researches for more than 20 years. Dr. Ting's research interest focuses on the genetics changes during species formation and her team has applied advanced molecular genetic techniques to investigate the phenotypic consequences and fitness differences. Her work on population genomics has also revealed the evolutionary dynamics of segmental duplications and the evolutionary forces acting on these segmental duplications. In addition to her primary role in research and teaching, Dr. Ting is also the Director of Center for International Academic Exchanges in College of Life Science.

Publications

1. Burlyaeva M, Vishnyakova M, Gurkina M, Konstanin K, Lee CR, **Ting CT**, Schafleitner R, Nuzhdin S, Samsonova M, von Wettberg E. 2019 Collections of Mungbean [*Vigna radiata* (L.) R. Wilczek] and urdbean [*V. mungo* (L.) Hepper] in Vavilov Institute (VIR): traits diversity and trends in the breeding process over the last 100 years. *Genet Resour Crop Evol* 66: 767–781. (doi.org/10.1007/s10722-019-00760-2).
2. Li J, Jiang L, Wu CI, Lu X*, Fang S*, and **Ting CT***. 2019. Small segmental duplications in *Drosophila*—High rate of emergence and elimination. *Genome Biol Evol* 11: 486–496. (doi.org/10.1093/gbe/evz011)
3. Chen, C K, Yu CP, Li SC, Wu SM, Lu MJ, Chen JH, Chen RD, Ng SC, **Ting CT***, and Li WH*. 2017. Identification and evolutionary analysis of long non-coding RNAs in zebra finch. *BMC Genomics* 18: 117. (doi: 10.1186/s12864-017-3506-z)
4. Chen CK, Ng CS, Wu SM, Chen JJ, Cheng PL, Wu P, Lu MJ, Chen DR, Chuong CM, Cheng HC*, **Ting CT*** and Li WH*. 2016. Regulatory differences in natal down development between altricial zebra finch and precocial chicken. *Mol Biol Evol* 33: 2030–2043.
5. Yang H, He B, Ma H, Tsaur SC, Ma C, Wu Y, **Ting CT**, Zhang YE*. 2015. Expression profile and gene age jointly shaped the genome-wide distribution of premature termination codons in *Drosophila* populations. *Mol Biol Evol* 32: 216-28

Invited Speeches *Genomics of Pathogens – Speaker*

(TSECB & TBSB) Hall II Section IV 11/15 13:30-14:55

Hung-Yi Wang, Ph.D. (王弘毅)

Current position and professional experiences

- | | |
|------------------|--|
| 2015/8 ~ Present | Professor , Graduate Institute of Clinical Medicine, National Taiwan University |
| 2010 ~ 2015 | Associate Professor , Graduate Institute of Clinical Medicine, National Taiwan University |
| 2006 ~ 2010 | Assistant Professor , Graduate Institute of Clinical Medicine, National Taiwan University |



Research interest

1. Population genetics
2. Molecular genetics
3. Comparative genomics
4. Virology

Short research summary

Dr. Hung-Yi Wang is a Professor of Graduate Institute of Clinical Medicine at the National Taiwan University (NTU), Taiwan. Dr. Wang received his Ph.D degree from the National Taiwan Normal University. The researches in Dr. Wang's lab are concentrated on molecular evolution and population genetics. Currently, there are two major domains in his lab. The first one is virus related research. He focuses on patterns of viral diversity change within host, rate of viral evolution, and interaction between pathogen and host. The second domain is to understand the mechanisms that drive population differentiation including nature as well as tumor cell populations.

Publications

1. Chaw SM, Tai JH, Chen SL, Hsieh CH, Chang SY, Yeh SH, Yang WS, Chen PJ, **Wang HY***. The origin and underlying driving forces of the SARS-CoV-2 outbreak. *Journal of Biomedical Science*. 2020 27(1):1-12 (IF=5.762; Medicine, Research, and Experimental 20/136=12%)
2. Hsieh CH, Huang, CG, Wu WJ, **Wang HY***. A rapid insect species identification system using mini-barcode pyrosequencing. *Pest Management Science* 2020 76 (4), 1222-1227 (IF: 3.750; Entomology 7/101=7%)
3. Chen PY, Chuang YC, Wu UI, Sun HY, Wang JT, Sheng WH, Lo HJ, **Wang HY**, Chun YC, Chang SC. Clonality of fluconazole-nonsusceptible *Candida tropicalis* in bloodstream infections, Taiwan, 2011–2017. *Emerging Infectious Diseases*, 2019 25(9): 1668. (IF:6.259, Infectious Disease 7/93=8%)
4. Chen YA, Lien JC, Tseng LF, Cheng CF, Lin WY, Wang HY, Tsai KH. Effects of indoor residual spraying and outdoor larval control on *Anopheles coluzzii* from São Tomé and Príncipe, two islands with pre-eliminated malaria. *Malaria journal*, 2019, 18(1): 405. (IF:2.631, Infectious Disease, 53/93=57%)
5. Zhang Y, Li Y, Shen X, Zhu T, Tao Y, Li T, Li X, Wang D, Ma Q, Hu Z, Liu J, Zheng C, Ruan J, Cai J, Wu CI, **Wang HY***, and Lu X*. "Rapid generation of copy number variation may lead to very high genetic load in cancer cell population." *Molecular Biology and Evolution*, 2019, 36 (3), 541-552. (IF: 11.062; Genetics and heredity 7/177=4%)
6. Wu LL, Peng WH, Wu H-L, Miaw SC, Yeh SH, Yang HC, Liao PH, Lin JS, Chen YR, Hong YT, Chen PJ, **Wang HY***, and Chen DS*. Ly6C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. *Hepatology*, 2019, 69 (6), 2364-2380. (IF: 14.679;

Gastroenterology and hepatology 6/88=7%)

7. Wen H, **Wang HY**, He H and Wu CI*. “On the low reproducibility of cancer studies.” *National Science Review*, 2018, in press. (IF: 16.693; Multidisciplinary Sciences 3/71=4%)
8. **Wang HY**, Chen Y, Tong D, Ling S, Hu Z, Tao Y, Lu X and Wu CI*. “Is the evolution in tumors Darwinian or non-Darwinian?” *National Science Review*. 2018, 5: 15-17. (IF: 16.693; Multidisciplinary Sciences 3/71=4%)
9. Zhang Y, Shen X, Li Y, Zhu T, Tao Y, Li T, Wang D, Li X, Ma Q, Lu X*, **Wang HY***, Wu CI. Genetic load in cancer cell populations. *Cancer Research*, 2017, 77(13) Supplement: 514 (IF:9.727, Oncology, 19/244=8%)
10. Lin YY, Hsieh CH, Chen JH, Lu X, Kao JH, Chen PJ, Chen DS, **Wang HY***. “De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline.” *BMC Bioinformatics*. 2017, 18(1):223. (IF: 3.242; Mathematical and computational biology 9/59=15%)
11. **Wang HY***. Revealing the time-dependent evolution of the hepatitis B virus from a chain of sequentially infected chronic carriers. *Genes & Genetic Systems*. 90 (6), 359-359 (IF: 0.917; Genetics and Heridity 164/177=92%)
12. Wu CI*, **Wang HY**, Ling S, Lu X. “The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process.” *Annual Review of Genetics*. 2016, 50:347-369. (IF: 11.146; Genetics and heredity 5/177=3%)
13. Chiou HY, Jeng CR, **Wang HY**, Inoue S, Chan FT, Liao JW, Chiou MT, Pang VF*. “Pathology and molecular detection of rabies virus in ferret badgers associated with a rabies outbreak in Taiwan.” *Journal of Wildlife Diseases*. 2016, 52(1): 57-69. (IF: 1.187; Veterinary Sciences 66/142=46%)
14. Liu CJ*, Chen TC, Chen PJ, **Wang HY**, Tseng TC, Cheng HR, Liu CH, Chen DS and Kao JH*. “Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages.” *Journal of Gastroenterology and Hepatology*. 2015, 30(1): 172-7. (IF: 3.437; Gastroenterology & Hepatology 42/88=47 %)

The Origin and Underlying Driving Forces of the SARS-CoV-2 Outbreak

Hung-Yi Wang


Graduate Institute of Clinical Medicine, National Taiwan University, Taiwan

The spread of SARS-CoV-2 since December 2019 has become a pandemic and impacted many aspects of human society. In this study, genetic variation of SARS-CoV-2 genomes and its related coronaviruses was analyzed. After correction for mutational bias, the excess of low frequency mutations on both synonymous and nonsynonymous sites was revealed which is consistent with recent outbreak of the virus. In contrast to adaptive evolution previously reported for SARS-CoV in its brief epidemic in 2003, our analysis of SARS-CoV-2 genomes shows signs of relaxation of selection. The sequence similarity of the spike receptor binding domain between SARS-CoV-2 and a sequence from pangolin is probably due to an ancient intergenomic introgression approximately occurred 40 years ago. The current outbreak of SARS-CoV-2 was estimated to have originated on 12/11/2019 (ranging 11/13/2019–12/23/2019). The effective population size of the virus showed approximately 20-fold increase from the onset of the outbreak to the lockdown of Wuhan (1/23/2020) and ceased to increase afterwards, demonstrating the effectiveness of social distancing on preventing virus spread. Genetic diversity of SARS-CoV-2 collected from China in early pandemic was two time higher than those derived from the rest of the world. In network analysis, haplotypes collected from Wuhan were at interior and have more mutational connections, both of which are consistent with the observation that the outbreak of cov-19 was originated from China. Among huge amount of mutations, there are 16 mutations with frequencies higher than 10%. Based on these 16 mutations, we defined three clusters. Cluster I includes C8782T, C17747T, A17858G, C18060T, and C28144T. Cluster II contains G11083T, C14805T, and G26144T. Cluster III, which contains C3037T, C14408T, and A23403G, is the largest cluster and can be divided into 2 subclusters, IIIa and IIIb. Cluster IIIa includes C1059T and G25563T, and IIIb has 3 consecutive mutations, G28881A, G28882A, and G28883C. While effect of A23403G (D614G in spike protein) has been demonstrated, the impact for the result of mutations require further investigations.

Ming-Der Lin, Ph.D. (林明德)

Current position and professional experiences

- 2016/8 ~ Present **Associate Professor**, Department of Molecular Biology and Human Genetics, Tzu Chi University
- 2010/2 ~ 2016/7 **Assistant Professor**, Department of Molecular Biology and Human Genetics, Tzu Chi University
- 2007/2 ~ 2010/1 **Assistant Professor**, Department of Life Sciences, Tzu Chi University



Research interest

1. Developmental biology
2. Molecular genetics

Short research summary

Dr. Ming-Der Lin is an Associate Professor of the Department of Molecular Biology and Human Genetics at the Tzu Chi University, Hualien, Taiwan. Dr. Lin received his Ph.D. degree from the National Taiwan University. One of Dr. Lin's research interests focuses on the germline development of *Drosophila*, biting midge, and other insects. Also, Dr. Lin adopts the zebrafish model to study traditional Chinese medicine's therapeutic effect on osteoporosis; and performs functional analyses on disease-causing genes by using both *Drosophila* and zebrafish as models.

Publications

1. Chun-I Chiu, Aaron J. Mullins, Kuan-Chih Kuan, Ming-Der Lin, Nan-Yao Su, Hou-Feng Li* (2020, Sep). Termite salinity tolerance and potential for transoceanic dispersal through rafting. *Ecological Entomology*, <https://doi.org/10.1111/een.12946>. (SCI, 26/101, Entomology).
2. Rui-Yi Chen, Bui Thi Ngoc Hieu, Gilbert Audira, Bao Lou*, Ming-Der Lin*, and Chung-Der Hsiao* (2020, Jul). Meta-Transcriptomic Analysis of RNAseq Data Reveals Pacu and Loach Fish with Unusually High Levels of Myoglobin Expression in Skeletal Muscles. *Animals*, 10(7), 1130. (SCI, 14/142, Veterinary Sciences).
3. Yi-Mei Lee, Po-Hsun Chiang, Jen-Ho Cheng, Wei-Hong Shen, Chao-Han Chen, Mei-Ling Wu, Yi-Lu Tian, Chao-Heng Ni, Ting-Fang Wang, Ming-Der Lin*, and Tze-Bin Chou* (2020, May). *Drosophila* decapping protein 2 modulates the formation of cortical F-actin for germ plasm assembly. *Developmental Biology*, <https://doi.org/10.1016/j.ydbio.2020.01.013>. (SCI, 13/43, Developmental Biology).
4. Rakesh Roy, Ren-In You, Ming-Der Lin, and Nien-Tsung Lin* (2020, Apr). Mutation of the Carboxy-Terminal Processing Protease in *Acinetobacter baumannii* Affects Motility, Leads to Loss of Membrane Integrity, and Reduces Virulence. *Pathogens*, 9(5), 322. (SCI, 45/133, Microbiology).
5. Szu-Chieh Wang, Yung-Hao Ching, Preethi Krishnaraj, Guan-Yu Chen, Anna Shiny Radhakrishnan, Hsien-Min Lee, Wu-Chun Tu, and Ming-Der Lin* (2020, Feb). Oogenesis of Hematophagous Midge *Forcipomyia taiwana* (Diptera: Ceratopogonidae) and Nuage Localization of Vasa in Germline Cells. *Insects*, 11(2), 106. (SCI, 18/101, Entomology).
6. Chia-Yin Chiang, Yung-Hao Ching, Ting-Yan Chang, Liang-Shuan Hu, Yee Siang Yong, Pei Ying

Invited Speeches **Genomics of Pathogens – Speaker**

(TSECB & TBSB) Hall II Section IV 11/15 13:30-14:55

- Keak, Ivana Mustika, Ming-Der Lin*, and Ben-Yang Liao* (2020, Jan). Novel Eye Genes Systematically Discovered through an Integrated Analysis of Mouse Transcriptomes and Phenome. *Computational and Structural Biotechnology Journal*, Volume 18, 2020, Pages 73-82. (SCI, 43/297, Biochemistry & Molecular Biology).
7. Preethi Krishnaraj, Yu Chang, Tsung-Jung Ho, Nai-Chen Lu, Ming-Der Lin*, Hao-Ping Chen* (2019, Jan). In vivo pro-angiogenic effects of dracorhodin perchlorate in zebrafish embryos: A novel bioactivity evaluation platform for commercial dragon blood samples. *Journal of food and drug analysis*, Volume 27, Issue 1, January 2019, Pages 259-265. (SCI, 13/139, Food Science and Technology).
 8. Wan-Yu Liao, Lee-Fong Lin, Ming-Der Lin, Sheng-Che Hsieh, Althea Yi-Shan Li, Yueh-Shiah Tsay, and Ming-Lun Chou* (2018, Jul). Overexpression of *Lilium formosanum* MADS-box (LFMADS) Causing Floral Defects While Promoting Flowering in *Arabidopsis thaliana*, Whereas Only Affecting Floral Transition Time in *Nicotiana tabacum*. *International Journal of Molecular Sciences*, 19:2217-2244. (SCI, 90/292, Biochemistry and Molecular Biology).
 9. Yu-Chung Lin, Kuan-Ting Wu, Zhe-Rui Lin, Elena Perevedentseva, Artashes Karmenyan, Ming-Der Lin, Chia-Liang Cheng* (2016, Apr). Nanodiamond for biolabelling and toxicity evaluation in the zebrafish embryo in vivo. *J Biophotonics*, Volume 9, Issue 8, Pages 827–836; doi: 10.1002/jbio.201500304. (SCI, 10/90, Optics).
 10. Szu-Chieh Wang, Hao-Jen Hsu, Gee-way Lin, Ting-Fang Wang, Chun-che Chang*, Ming-Der Lin* (2015, Sep). Germ plasm localisation of the HELICc of *Vasa* in *Drosophila*: analysis of domain sufficiency and amino acids critical for localisation. *Scientific Reports*, 5:14703. (SCI, 5/57, Multidisciplinary Sciences).

**The Genome of *Prorhinotermes Flavus*:
A Termite Species with High Salinity Tolerance**

Ming-Der Lin

Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan
Department of Life Sciences, Tzu Chi University, Hualien, Taiwan
Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan

Prorhinotermes flavus is a dampwood termite with unique habitats. They are found in coastal areas of islands or continents ranging over the Indian and the Pacific Ocean, including Taiwan. Though a few genomes of termite species have been sequenced, a high salinity tolerant termite species has not been explored. Here, we performed *de novo* assembly of *P. flavus* by using a hybrid assembly pipeline. The high-quality genome was obtained by 1. Building a genome draft by 10X Genomic Supernova assembly, 2. Scaffolding by SSPACE (Illumina mate-pair) and SSPACE-LongRead (PacBio longread), 3. Error correction using Illumina reads by Pilon, 4. Inter scaffolding and gap filling by Hi-C and our developing tool Tinker. The final assembly of the *P. flavus* genome is about 974 Mb. The scaffold N50 length is 29 Mb, and 32 scaffolds can comprise 90 % of the genome. Accordingly, we established a *P. flavus* database that provides a user-friendly interface for visualization of the genomic structure together with the information of transcriptome profiling among different castes and sexes. While *P. flavus* can be easily cultured on Petri dishes and produce a substantial amount of progenies, our high-quality genome assembly could grant *P. flavus* a great potential to be an emerging model of eusocial insects for exploring basic biological questions related to caste development, developmental processes of hemimetabolous insect, and termite eusociality.

Invited Speeches **Genomics of Pathogens – Speaker**

(TSECB & TBSB) Hall II Section IV 11/15 13:30-14:55

Chuan Ku, Ph.D. (顧銓)

Current position and professional experiences

- 2019/1 ~ Present **Assistant research fellow**, Institute of Plant and Microbial Biology, Academia Sinica
- 2020/8 ~ Present **Adjunct assistant professor**, Institute of Ecology and Evolutionary Biology, National Taiwan University
- 2020/8 ~ Present **Jointly appointed assistant professor**, Genome and Systems Biology Degree Program, National Taiwan University and Academia Sinica



Research interest

1. Eukaryote evolution
2. Giant viruses
3. Marine microalgae
4. Comparative genomics

Short research summary

Dr. Chuan Ku is an Assistant Research Fellow at Institute of Plant and Microbial Biology, Academia Sinica, Taiwan. He received his doctoral degree in 2016 from the University of Düsseldorf, Germany where his research focused on the prokaryotic origins of eukaryotic genes. Later Dr. Ku did his postdoctoral research as an EMBO long-term fellow at Department of Plant and Environmental Sciences, Weizmann Institute of Science, Israel, where he started to work on marine calcifying microalgae and giant viruses of eukaryotes. His current research focuses on ancient evolution of giant viruses and eukaryotes, genomics of microalgae, host-virus interactions, and single-cell omics of expression regulation.

Publications

1. **Chuan Ku**, Uri Sheyn, Arnau Sebé-Pedrós, Shifra Ben-Dor, Daniella Schatz, Amos Tanay, Shilo Rosenwasser, Assaf Vardi (2020): A single-cell view on alga-virus interactions reveals sequential transcriptional programs and infection states. *Science Advances* 6(21): eaba4137. DOI: 10.1126/sciadv.aba4137
2. **Chuan Ku***, Tsu-Wang Sun (2020): Did giant and large dsDNA viruses originate before their eukaryotic hosts? *Proceedings of the National Academy of Sciences of the United States of America* 117(6): 2747-2748. DOI: 10.1073/pnas.1919860117
3. **Chuan Ku***, Arnau Sebé-Pedrós* (2019): Using single-cell transcriptomics to understand functional states and interactions in microbial eukaryotes. *Philosophical Transactions of the Royal Society B* 374(1786): 20190098. DOI:10.1098/rstb.2019.0098
4. **Chuan Ku**, Noa Barak-Gavish, Mark Maienschein-Cline, Stefan J. Green, Assaf Vardi (2018): Complete genome sequence of *Sulfitobacter* sp. strain D7, a virulent bacterium isolated from an *Emiliania huxleyi* algal bloom in the North Atlantic. *Microbiology Resource Announcements* 7(19): e01379-18. DOI:10.1128/MRA.01379-18
5. Noa Barak-Gavish, Miguel Frada, **Chuan Ku**, Peter A. Lee, Giacomo R. DiTullio, Sergey Malitsky, Asaph Aharoni, Stefan J. Green, Ron Rotkopf, Elena Kartvelishvily, Uri Sheyn, Daniella Schatz, Assaf Vardi (2018): Bacterial virulence against an oceanic bloom-forming phytoplankter is mediated by algal DMSP. *Science Advances* 4(10): eaau5716. DOI: 10.1126/sciadv.aau5716

6. William F. Martin, Mayo Roettger, **Chuan Ku**, Sriram G. Garg, Shijulal Nelson-Sathi, Giddy Landan (2017): Late mitochondrial origin is an artefact. *Genome Biology and Evolution* 9(2): 373-379. DOI:10.1093/gbe/evx027
7. **Chuan Ku***, William F. Martin* (2016): A natural barrier to lateral gene transfer from prokaryotes to eukaryotes revealed from genomes: the 70% rule. *BMC Biology* 14:89. DOI:10.1186/s12915-016-0315-9
8. **Chuan Ku**, Shijulal Nelson-Sathi, Mayo Roettger, Filipa L. Sousa, Peter J. Lockhart, David Bryant, Einat Hazkani-Covo, James O. McInerney, Giddy Landan, William F. Martin (2015): Endosymbiotic origin and differential loss of eukaryotic genes. *Nature* 524:427-432. DOI:10.1038/nature14963
9. **Chuan Ku**, Shijulal Nelson-Sathi, Mayo Roettger, Sriram Garg, Einat Hazkani-Covo, William F. Martin (2015): Endosymbiotic gene transfer from prokaryotic pangenomes: Inherited chimerism in eukaryotes. *Proceedings of the National Academy of Sciences of the United States of America* 112(33): 10139-10146. DOI:10.1073/pnas.1421385112

Genome Content Evolution in Giant Viruses of Eukaryotes

Chuan Ku

Institute of Plant and Microbial Biology, Academia Sinica, Taiwan

The expanding collection of giant viruses discovered to date has revolutionized our view of viral genomes. The Nucleo-Cytoplasmic Large DNA Viruses (NCLDVs), which cause smallpox, African Swine Fever, algal deaths, and other diseases, have the largest genomes among viruses (up to 2.8 Mb) and infect diverse eukaryotic hosts across various ecosystems. While several hypotheses have been proposed on their origin(s) and evolution, most analyses to date have been limited to phylogenetic reconstruction using a few core genes and do not take into account the vast majority of the protein-encoding sequences. To provide a comprehensive view of the relationships among NCLDVs, we integrated comparative and network analyses of gene clusters to complement phylogenetic inferences based on individual genes. Despite extreme variation in their gene contents, we detected significant sharing of gene clusters between NCLDV families that are distant in the core gene tree. Notable differences exist between the core gene phylogenies and gene sharing patterns among genomes of giant viruses infecting aquatic amoebae and algae. Our results shed light upon the roles of host factors on the expansive genome evolution of eukaryotic giant viruses.

受邀演講 Invited Speeches

台灣基因醫學暨生物標記學會 (TGMBS)
Taiwan Genomics Medicine and Biomarker Society

台灣精準醫學學會 (TPMS)
Taiwan Precision Medicine Society

第三會議廳 Lecture Hall III





SCIEX 多體學整合分析驅動精準醫學研究解決方案

常規的定量檢驗

QTRAP® 系統



優於免疫法或光譜法的檢驗利器，進行生物標誌物的定量分析以精確監測健康狀態

CHROMSYSTEMS®
DIAGNOSTICS BY HPLC & LC-MS/MS 試劑盒套組的搭配，降低學習質譜分析技術的入門門檻

固醇類賀爾蒙 | 藥物濃度監測 | 維生素D



高解析質譜儀系統

在雲端進行生物資訊與大數據體學研究的交叉應用



TripleTOF® 系統與 OneOmics™

發現/篩查式檢驗



台灣塞爾克斯應用生技有限公司 (SCIEX Taiwan Private Limited)

地址：11493 臺北市內湖區堤頂大道二段89號3樓

網站：www.sciex.com | SCIEXNow™；0800-818-978 (免付費電話)

Wan-Chi Tsai, Ph.D. (蔡婉琪)

Current position and professional experiences

- 2019/8 ~ Present **Associate Vice President, Global Affairs/
Director, Division of Planning & Development,**
Office of Global Affairs, Kaohsiung Medical
University
- 2017/8 ~ Present **Associate Professor, Department of Medical
Laboratory Science and Biotechnology,**
Kaohsiung Medical University



Research interest

1. Tumor biology
2. Natural products
3. Molecular genetics

Short research summary

Dr. Wan-Chi Tsai, is an Associate Professor of the Department of Medical Laboratory Science and Biotechnology of Kaohsiung Medical University (KMU), Taiwan. She received her bachelor's degree from KMU in 2000 and the Ph.D. degree from National Cheng Kung University in 2006. She conducted her postdoctoral fellowship at College of Pharmacy of Ohio State University in U.S. for two years to study the therapeutic potential of small molecules against prostate, breast, and pancreatic cancer. She served as an assistant professor at Chung Shan Medical University from 2008 to 2010, and transferred to KMU in 2011. Her primary research focus is on the therapeutic advantages of marine/herbal natural products and synthetic ruthenium-based small molecules in the treatment of oral and pancreatic cancer.

Publications

1. Wen-Chi Yang*, Sheng-Fung Lin, Shu-Chen Wang, Wan-Chi Tsai, Chun-Chieh Wu and Shih-Chi Wu. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. *International Journal of Molecular Sciences*. 2020; 21: 3033.
2. Ming-Hui Yang, Marcelo Chen, Hsiao-Hsuan Mo, Wan-Chi Tsai, Yu-Chi Chang, Chin-Chuan Chang, Ko-Chin Chen, Hsin-Yi Wu, Cheng-Hui Yuan, Che-Hsin Lee, Yi-Ming Arthur Chen* and Yu-Chang Tyan*. Utilizing Experimental Mouse Model to Identify Effectors of Hepatocellular Carcinoma Induced by HBx Antigen. *Cancers (Basel)*. 2020 Feb 10;12(2).
3. Shin-Chen Pan, Che-Yu Li, Chia-Yi Kuo, Yi-Zih Kuo, Wei-Yu Fang, Yu-Hsuan Huang, Tzu-Chin Hsieh, Hung-Ying Kao, Yuan Kuo, Ya-Rong Kang, Wan-Chi Tsai, Sen-Tien Tsai* & Li-Wha Wu*. The p53-S100A2 Positive Feedback Loop Negatively Regulates Epithelialization in Cutaneous Wound Healing. *Sci Rep*. 2018 Apr 3;8(1):5458.
4. Wan-Chi Tsai, Hui-Fang Tsai, Yinuan Wong, Jui-Yen Hong, Shwu-Jen Chang, Ming-Wei Lee*. Preparation and characterization of Gellan gum/Glucosamine/Clioquinol film as oral cancer treatment patch. *Mater Sci Eng C Mater Biol Appl*. 2018 Jan 1;82:317-322.
5. Ping-Jen Chen, Charles Lung-Cheng Huang, Shih-Feng Weng, Ming-Ping Wu, Chung-Han Ho, Jhi-Joung Wang, Wan-Chi Tsai, Ya-Wen Hsu. Relapse insomnia increases greater risk of anxiety and depression: evidence from a population-based 4-year cohort study. *Sleep Med*. 2017 Oct;38:122-129.


Invited Speeches *Cell & Immune Therapy – Moderator* (TGMBS & TPMS) *Hall III Section I 11/14 10:40-12:05*

6. Yi-Jin Chen, Wen-Hung Wang, Wan-Yu Wu, Chia-Chi Hsu, Ling-Rung Wei, Sheng-Fan Wang, Ya-Wen Hsu, Chih-Chuang Liaw, Wan-Chi Tsai*. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways. *PLoS One*. 2017 Aug 22;12(8):e0183368.
7. Wan-Chi Tsai, Li-Yuan Bai, Yi-Jin Chen, Po-Chen Chu, Ya-Wen Hsu, Aaron M. Sargeant, and Jing-Ru Weng*. OSU-A9 inhibits pancreatic cancer cells by modulating p38-JAK-STAT3 signaling. *Oncotarget*. 2017 Apr 25;8(17):29233-29246.
8. Nai-Ming Chen[†], Albrecht Neesse[†], Moritz Lino Dyck, Alexander O. Koenig, Clara Lubeseder-Martellato, Thore Winter, Hanibal Bohnenberger, Julia Kitz, Jochen Gaedcke, Marian Grade, Jin-San Zhang, Wan-Chi Tsai, Thomas Stief, Jens Siveke, Philipp Ströbel, Steven A. Johnsen, Volker Ellenrieder and Elisabeth Hessmann*. Context-dependent NFATc1 promoter editing in pancreatic plasticity. *Gastroenterology*. 2017 May;152(6):1507-1520.e15.
9. Wen-Hung Wang[†], Yu-Hsuan Kuo[†], Ling-Ya Chu, Chia-Ying Lee, Yu-Chang Tyan, Zong-Shiow Chen and Wan-Chi Tsai*. Anti-cancer Effects of *Salvia miltiorrhiza* Alcohol Extract on Oral Squamous Carcinoma Cells. *Evidence-Based Complementary and Alternative Medicine*. 2017;2017:5364010.
10. Shih-Cheng Chen, Ming-Hui Yang, Tze-Wen Chung, Ting-Syuan Jhuang, Jean-Dean Yang, Ko-Chin Chen, Wan-Jou Chen, Ying-Fong Huang, Shiang-Bin Jong, Wan-Chi Tsai, Po-Chiao Lin, and Yu-Chang Tyan*. Preparation and Characterization of Hyaluronic Acid-Polycaprolactone Copolymer Micelles for the Drug Delivery of Radioactive Iodine-131 Labeled Lipiodol. *BioMed Research International*. 2017;2017:4051763.
11. Sheng-Fan Wang*, Sung-Pin Tseng, El-Wui Loh, Wen-Hung Wang, Ming-Chun Li, Kuan-Hsuan Chen, Wan-Chi Tsai, Yuan-Ming Lee, Huan-Yuan Chen, Fu-Tong Liu, Yi-Ming Arthur Chen*, Jason C. Huang*. Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model. *Developmental and Comparative Immunology*. 2017 Feb;67:8-17.
12. Wan-Chi Tsai, Mark Daniel de Luna, Hanna Lee Bermillo-Arriesgado, Cybelle Futralan, James Colades and Meng-Wei Wan. Competitive fixed-bed adsorption of Pb(II), Cu(II) and Ni(II) from aqueous solution using chitosan coated bentonite. *International Journal of Polymer Science*. Volume 2016 (2016), Article ID 1608939, 11 pages
13. Ya-Ju Hsieh, Sung-Pin Tseng, Yu-Hsuan Kuo, Tain-Lu Cheng, Chiao-Yu Chiang, Yew-Min Tzeng*, Wan-Chi Tsai*. Ovatodiolide of *Anisomeles indica*, exerts the anti-cancer potential on pancreatic cancer cell lines through STAT3 and NF- κ B regulation. *Evidence-based Complementary and Alternative Medicine*. 2016;2016:8680372.
14. Wan-Chi Tsai, Sonia Ibarra-Buscano, Chi-Chuan Kan, Cybelle Morales Futralan, Maria Lourdes P. Dalida, Meng-Wei Wan*. Removal of copper, nickel, lead, and zinc using chitosan-coated montmorillonite beads in single- and multi-metal system. *Desalination and Water Treatment*. 2016;57(61): 9799-9812.

Thai-Yen Ling, Ph.D. (林泰元)

Current position and professional experiences

Present	Associate Professor , Institute of Pharmacology, College of Medicine, National Taiwan University
2005 ~ 2006	Postdoctoral Fellow , Genomics Research Center, Academia Sinica, Taipei, Taiwan
2003 ~ 2005	Postdoctoral Fellow , Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan
2000 ~ 2002	Postdoctoral Fellow , Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

**Research interest**

1. Stem cell biology
2. Regeneration medicine
3. Tissue engineering
4. Signal transduction

Honors

第 17 屆國家新創獎 - 學研新創績獎

第 16 屆國家新創獎 - 學研新創

2012- ISSCR Travel Ward

Honorable Mention Award for “Competition for Originality in Biotechnology”: by the Industrial Development Bureau, Ministry of Economic Affairs, 2009

Post-doctoral research fellow scholarship, Academia Sinica 2003-2005

Publications

1. Huang AP, Hsu YH, Wu MS, Tsai HH, Su CY, **Ling TY**, Hsu SH, Lai DM. (2020) Potential of stem cell therapy in intracerebral hemorrhage. *Mol Biol Rep.* Jun;47(6):4671-4680. doi: 10.1007/s11033-020-05457-9. Epub 2020 May 15.
2. Tsai TH, Ling TY, Lee CH. (2020) Adoption of Regulations for Cell Therapy Development: Linkage Between Taiwan and Japan. *Clin Transl Sci.* May 14. doi: 10.1111/cts.12813.
3. Sun YJ, Hsu CH, **Ling TY**, Liu L, Lin TC, Jakfar S, Young IC, Lin FH. (2020) The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer. *Biofabrication.* Mar 27;12(2):025031. doi: 10.1088/1758-5090/ab78ee.
4. Chiu PC, Liou HC, **Ling TY**, Shen LJ. (2020) Development of a Neuroprotective Erythropoietin Modified With a Novel Carrier for the Blood-Brain Barrier. *Neurotherapeutics.* Mar 6. doi: 10.1007/s13311-020-00845-2.
5. Chao TL, Gu SY, Lin PH, Chou YT, **Ling TY**, Chang SY. (2020) Characterization of Influenza A Virus Infection in Mouse Pulmonary Stem/Progenitor Cells. *Front Microbiol.* Jan 21;10:2942.
6. Lin SC, Liou YM, **Ling TY**, Chuang YH, Chiang BL. (2019) Placenta-Derived Mesenchymal Stem Cells Reduce the Interleukin-5 Level Experimentally in Children with Asthma. *Int J Med Sci.* 20;16(11):1430-1438.
7. Weng CF, Chen LJ, Lin CW, Chen HM, Lee HH, **Ling TY**, Hsiao FY. (2019) Association between the Risk of Lung Cancer and Influenza: A Population-Based Nested Case-Control Study. *Int J Infect Dis.* pii: S1201-9712(19)30315-7.

8. Su LJ, Lin HH, Wu MS, Pan L, Yadav K, Hsu HH, **Ling TY**, Chen YT, Chang HC. (2019) Intracellular Delivery of Luciferase with Fluorescent Nanodiamonds for Dual-Modality Imaging of Human Stem Cells. *Bioconjug Chem.* 30(8):2228-2237.
9. Liou YM, Wei TY, **Ling TY**, Lin SC, Yang YH, Chiang BL, Chuang YH. (2019) Differential effects of mesenchymal stem cells on T cells isolated from childhood allergies and autoimmune diseases. *Allergy*. doi: 10.1111/all.13838.
10. Ho SY, **Ling TY**, Lin HY, Liou JT, Liu FC, Chen IC, Lee SW, Hsu Y, Lai DM, Liou HH. (2017) SDF-1/CXCR4 Signaling Maintains Stemness Signature in Mouse Neural Stem/Progenitor Cells. *Stem Cells Int.* doi: 10.1155/2017/2493752.
11. Su LJ, Wu MS, Hui YY, Chang BM, Pan L, Hsu PC, Chen YT, Ho HN, Huang YH, **Ling TY**, Hsu HH, Chang HC. (2017) Fluorescent nanodiamonds enable quantitative tracking of human mesenchymal stem cells in miniature pigs. *Sci Rep.* doi: 10.1038/srep45607.
12. Cheng NC, Lin WJ, **Ling TY**, Young TH. (2017) Sustained Release of Adipose-Derived Stem Cells by Thermosensitive Chitosan/Gelatin Hydrogel for Therapeutic Angiogenesis. *Acta Biomater.*, S1742-7061 (17): 30069-7.
13. Tsao PN, Matsuoka C, Wei SC, Sato A, Sato S, Hasegawa K, Chen HK, **Ling TY**, Mori M, Cardoso WV, Morimoto M. (2016) Epithelial Notch signaling regulates lung alveolar morphogenesis and airway epithelial integrity. *Proc Natl Acad Sci U S A.*, 113(29): 8242-7.
14. Gu SY, Ho CC, Huang YK, Chen HW, Wang YC, Kuo CY, Teng SC, Fu WM, Yang PC, Wu CW, Peng FC, **Ling TY*** (2016) Acquisition of tumorigenic potential and enhancement of angiogenesis in pulmonary stem/progenitor cells through Oct-4 hyperexpression. *Oncotarget*, 7 (12): 13917-31.
15. Yang KC, Kitamura Y, Wu CC, Chang HH, **Ling TY**, Kuo TF. (2016) Tooth Germ-Like Construct Transplantation for Whole-Tooth Regeneration: An In Vivo Study in the Miniature Pig. *Artif Organs*, 40(4): E39-50.
16. Chiu CJ, **Ling TY**, Chiang BL. (2015) Lung-derived SSEA-1+ stem/progenitor cells inhibit allergic airway inflammation in mice. *Allergy*, (70): 374-83.
17. Chang TS, Wu YC, Chi CC, Su WC, Chang PJ, Lee KF, Tung TH, Wang J, Liu JJ, Tung SY, Kuo LM, Ho HN, **Ling TY**, Huang YH. (2015) Activation of il6/igfir confers poor prognosis of hbv-related hepatocellular carcinoma through induction of oct4/nanog expression. *Clin Cancer Res.*, 21(1): 201-10.
18. **Ling TY**, Liu YL, Huang YK, Gu SY, Chen HK, Ho CC, Tsao PN, Tung YC, Chen HW, Cheng CH, Lin KH, Lin FH. (2014) Differentiation of lung stem/progenitor cells into alveolar pneumocytes and induction of angiogenesis within a 3D gelatin--microbubble scaffold. *Biomaterials*, 35(22): 5660-9.
19. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, **Ling TY**, Yu SL, Yuan SS, Chen YJ, Lin CY, Pan SH, Chou HY, Chen YJ, Chang GC, Chu WC, Lee YM, Lee JY, Lee PJ, Li KC, Chen HW, Yang PC. (2014) Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. *Nat Commun.*, 5: 3472.
20. Huang YH, Lin MH, Wang PC, Wu YC, Chiang HL, Wang YL, Chang JH, Huang YK, Gu SY, Ho HN, **Ling TY*** (2014) Hypoxia inducible factor 2 α /insulin-like growth factor receptor signal loop supports the proliferation and Oct-4 maintenance of mouse germline stem cells. *Mol Hum Reprod.*, 20(6): 526-37.
21. Su TH, Liu CJ, Yang HC, Jeng YM, Cheng HR, Liu CH, Tseng TC, **Ling TY**, Chen PJ, Chen DS, Kao JH. (2014) Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. *J Gastroenterol.*, 49(2): 356-62.
22. Kang KH, **Ling TY**, Liou HH, Huang YK, Hour MJ, Liou HC, Fu WM. (2013) Enhancement role of host 12/15-lipoxygenase in melanoma progression. *Eur J Cancer.*, 49(12): 2747-59
23. Chang JH, Au HK, Lee WC, Chi CC, **Ling TY**, Wang LM, Kao SH, Huang YH, Tzeng CR. (2013) Expression of the pluripotent transcription factor OCT4 promotes cell migration in endometriosis. *Fertil Steril.*, 99(5): 1332-39.
24. Tai YY, Chen RS, Lin Y, **Ling TY**, Chen MH (2012) FGF-9 accelerates epithelial invagination for

- ectodermal organogenesis in real time bioengineered organ manipulation. *Cell Commun Signal.*, 10(1): 34.
25. Wu YC, **Ling TY**, Lu SH, Kuo HC, Ho HN, Yeh SD, Shen CN, Huang YH. (2012) Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. *Cancer Res.*, 72(19): 4963-73.
 26. Lu SH, Yen YK, **Ling TY**, Cheng KT, Shu JA, Au HK, Huang YH. (2010) Capacitation suppression by mouse seminal vesicle autoantigen involves a decrease in plasma membrane Ca²⁺-ATPase (PMCA)-mediated intracellular calcium. *J Cell Biochem.*, 111(5): 1188-98.
 27. Huang CJ, Chien YL, **Ling TY**, Cho HC, Yu J, Chang YC. (2010) The influence of collagen film nanostructure on pulmonary stem cells and collagen-stromal cell interactions. *Biomaterials*, 31(32): 8271-80.
 28. Yang RB, Au HK, Tzeng CR, Tsai MT, Wu P, Wu YC, Ling TY, Huang YH (2010) Characterization of a novel cell-surface protein expressed on human sperm. *Hum Reprod.*, 25(1): 42-51.
 29. Huang YH, Chin CC, Ho HN, Chou CK, Shen CN, Kuo HC, Wu TJ, Wu YC, Hung YC, Chang CC, **Ling TY**. (2009) Pluripotency of mouse spermatogonial stem cells maintained by IGF-1- dependent pathway. *FASEB J.*, 23(7): 2076-87.
 30. Cheng CJ, Wu YC, Shu JA, **Ling TY**, Kuo HC, Wu JY, Chang EE, Chang SC, Huang YH. (2007) Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. *J Biomed Sci.*, 14(6): 797-807.
 31. **Ling TY**, Kuo MD, Li CL, Yu AL, Huang YH, Wu TJ, Lin YC, Chen SH and Yu J (2006) Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS-CoV infection in vitro. *Proc. Natl. Acad. Sci. U.S.A.*, 103 (26): 9530–35.

The Pharmacology of Cellular Therapy

Thai-Yen Ling

Department of Pharmacology, College of Medicine, NTU, Taiwan

In the past years, the concept of “a drug” has been regarded as low molecular weight organic compounds, so-called “small molecules” and larger biomolecules, such as peptide drugs and monoclonal antibodies. However, over the past decade, these traditional concepts have been improved on the development of new drugs based upon cells, which we refer to here as cellular therapies. The examples were tisagenlecleucel (CTL019, Kymriah) and axicabtagene ciloleucel (Yescarta), which were approved by FDA in August and October, 2017, respectively. In Pharmaceutical industry, drugs used in the clinical setting require production that adheres to current Good Manufacturing Practices (cGMP) to ensure the safety, purity, and potency from batch to batch. Like all drugs, understanding the pharmacology for the products of cellular therapies is critical to their effective application in the clinical setting.

Kuo-Hsiang Chuang, Ph.D. (莊國祥)

Current position and professional experiences

- 2017 ~ Present **Associate Professor**, Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan
- 2012 ~ 2017 **Assistant Professor**, Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan



Research interest

1. Antibody engineering
2. Immunotherapy
3. Autoimmune disease
4. Molecular imaging

Short research summary

Dr. Kuo-Hsiang Chuang completed his Ph.D. degree in Kaohsiung Medical University in 2010, and his advisor is Dr. Tian-Lu Cheng. Dr. Chuang has 18-year experiences on genetic engineering and antibody drug development technology. After entering Taipei Medical University as an assistant professor in February 2012, he is committed to the development of multifunctional antibody drugs, novel tumor-specific T cell technology platform, novel protein drugs for treatment of autoimmune diseases, and a variety of tandem-repeated protein technologies that can be applied to enhance the sensitivity of immunoassay technology. Currently, Dr. Chuang is an associate professor at Taipei Medical University and the CEO and founder of CytoArm Co., Ltd.

Publications

1. Chen YJ, Chen M, Cheng TL, Roffler SR, Lin SY, Hsu HL, Wang CH, Chen CY, Kao AP, Cheng JJ, **Chuang KH***. Simply mixing poly-protein G with detection antibodies enhances the detection limit and sensitivity of immunoassays. *Analytical Chemistry* 2019 Jul 2;91(13):8310-8317 **IF: 6.35** [7/84 (7.7%); CHEMISTRY, ANALYTICAL]
2. Lu YC, Chuang CH, **Chuang KH (3rd)**, Chen IJ, Huang BC, Lee WH, Huang HE, Li JJ, Cheng YA, Cheng KW, Wang JY, Hsieh YC, Lin WW, Cheng TL*. Specific activation of pro-Remicade enhances selectivity and safety of rheumatoid arthritis therapy. *PLOS Biology* 2019 Jun 13;17(6):e3000286. **IF: 8.386** [3/87 (2.9%); BIOLOGY]
3. Chen YJ, Chen M, Hsieh YC, Su YC, Wang CH, Cheng CM, Kao AP, Wang KH, Cheng JJ, **Chuang KH***. Development of a highly sensitive enzyme-linked immunosorbent assay (ELISA) through use of poly-protein G-expressing cell-based microplates. *Scientific Reports* 2018 Dec 14;8:17868 **IF: 4.011** [15/69 (21.1%); MULTIDISCIPLINARY SCIENCES]
4. Su CY, Chen M, Chen LC, Ho YS, Ho HO, Lin SY, **Chuang KH***, Sheu MT*. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. *Drug Delivery* 2018 May;25(1):1066-1079. **IF: 3.829** [60/267 (22.3%); PHARMACOLOGY & PHARMACY]
5. Lee CJ, Wang CC, Chen M, **Chuang KH (4th)**, Cheng TL, Jian TY, Wang YM, Huang TH, Liao KW, Tzou SC. Development of an inflammatory tissue-selective chimeric TNF receptor. *Cytokine* 2019 Jan;113:340-346. **IF: 3.078** [113/193 (58.3%); CELL BIOLOGY]

6. Chen M, Cheng KW, Chen YJ, Wang CH, Cheng TC, Chang KC, Kao AP, **Chuang KH***. Real-time imaging of intestinal bacterial β -glucuronidase activity by hydrolysis of a fluorescent probe. **Scientific Reports** 2017 Jun 9;7(1):3142. **IF: 4.011** [15/69 (21.1%); MULTIDISCIPLINARY SCIENCES]
7. Hao WR, Chen M, Chen YJ, Su YC, Cheng CM, Hsueh HY, Kao AP, Hsieh YC, Chang J, Tseng MY, **Chuang KH***. Poly-protein G-expressing bacteria enhance the sensitivity of immunoassays. **Scientific Reports** 2017 Apr 20;7(1):989. **IF: 4.011** [15/69 (21.1%); MULTIDISCIPLINARY SCIENCES]
8. Su YC, Burnouf PA, **Chuang KH (3rd)**, Chen BM, Cheng TL, Roffler SR. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. **Nature communications** 2017 Jun 8;8:15507. **IF: 11.878 [5/69 (6.5%)]**; MULTIDISCIPLINARY SCIENCES]
9. Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, **Chuang KH***, Cheng TL*. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. **Scientific Reports** 2016 Dec 19;6:39119. **IF: 4.011** [15/69 (21.1%); MULTIDISCIPLINARY SCIENCES]
10. Huang WC, Burnouf PA, Su YC, Chen BM, **Chuang KH (5th)**, Lee CW, Wei PK, Cheng TL, Roffler SR. Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. **ACS Nano**. 2016 Jan 26;10(1):648-62. **13.903** [14/172 (7.8%), CHEMISTRY & MULTIDISCIPLINARY]
11. Lin WW, Hsieh YC, Cheng YA, **Chuang KH (4th)**, Huang CC, Chuang CH, Chen IJ, Cheng KW, Lu YC, Cheng TC, Wang YT, Roffler SR, Cheng TL. Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules. **Analytical Chemistry** 2016 Dec 20;88(24):12371-12379. **IF: 6.35** [7/84 (7.7%); CHEMISTRY, ANALYTICAL]
12. Chen BM, Su YC, Chang CJ, Burnouf PA, **Chuang KH (5th)**, Chen CH, Cheng TL, Chen YT, Wu JY, Roffler SR. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. **Analytical Chemistry** 2016 Nov 1;88(21):10661-10666. **IF: 6.35** [7/84 (7.7%); CHEMISTRY, ANALYTICAL]

Novel Anti-cancer Armed T Cell Therapeutic Technology

Kuo-Hsiang Chuang

Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan

Chimeric antigen receptor (CAR) T cell technology has been the most well-known cellular immunotherapy in recent years due to its substantial success in the treatment of hematological tumors in clinical practice. However, the gene transfer technology used in current CAR T cells is still mainly based on retrovirus or lentivirus systems, which poses a potential carcinogenic risk. Additionally, the laborious protocols for manufacturing and quality control of CAR T cell products take almost 30 days, and some patients may die before the products are completed.

In this study, we present a non-genetic engineering technology for rapidly manufacturing cancer-specific T cells. By using anti-cancer/anti-CD3 bispecific antibody with the unique structure to culture human peripheral blood mononuclear cells, cancer-specific BsAb-armed T cells can be rapidly generated with a purity of over 90% in 7 days. The BsAb-armed T cells efficiently accumulated at tumor sites in vitro and in vivo. The release of cytotoxins (perforin and granzyme) and cytokines (TNF- α and IFN- γ) from the BsAb-armed T cells dramatically increased after they contacted cancer cells, causing the effective elimination of the cells in vitro and in vivo. Importantly, the BsAb-armed T cells did not cause obvious cytokine release syndrome or tissue toxicity in mouse models.

Collectively, the BsAb-armed T cell technology, as compared to current CAR-T cell technology, represents a simple, time-saving, highly safe, and economical method to generate highly pure cancer-specific effector T cells, thereby providing an affordable T cell immunotherapy to patients

Chi-Kuan Chen, M.D., Ph.D. (陳冀寬)**Current position and professional experiences**

2019/12 ~ Present	General Manager , ProMD Inc
2019 ~ Present	Secretary General , Taiwan Precision Medicine Society
2013 ~ 2019	Director , Department of Laboratory Medicine, Mackay Memorial Hospital, Taipei and Tamsui, Taiwan
2017 ~ 2019	Director , Precision Medicine Center, Mackay Memorial Hospital, Taipei
2018 ~ 2019	Director , Department of Pathology, School of Medicine, Mackay Medical College

**Research interest**

1. Hematopathology
2. Molecular diagnosis & precision medicine
3. Immunomodulation and immune cell therapy
4. Bioethic and biobanking
5. IVDD clinical trial
6. Quality system for ISO 9001, ISO 13485, ISO 14971, ISO 15189, ISO 17025

Short research summary

Dr. GQ Chen is a Medical Physician professional with proven experience in surgical pathology, laboratory medicine, molecular pathology, and precision medicine. He has strong expertise in translating medicinal science into clinical practice, bridging basic biotechnology into laboratory application, introducing medical knowledge to common people. He also well experienced in planning and connecting R&D discipline to clinical trial and IND.

Industrial Cooperation Projects

1. Invented and filed patents over the field of histopathology, molecular pathology, implanted medical device, medical ethic, and biomedical database.
2. In charged of Molecular Diagnostic R&D Lab & Pilot Manufacturing Project, came out ten more oncogenic somatic mutations detecting kits, sold to local medical centers molecular pathology labs, and directed some medical device clinical trials.
3. Became specialized on ISO 9001, ISO 15189, ISO 17025, ISO 14155, ISO 13485, and ISO 14971, covering regulations from basic quality system, good laboratory practice, good clinical trial practice, and good manufacturing practice in medical device.
4. Served as the science and technology topic of the Ministry of Economic Affairs "Infectious Diseases Intelligent Automation Inspection System Development Project"(A+ Project) General Counsel, about to produce the world's first unmanned microbiological testing automation system for clinical testing laboratories

Pitfalls in Autologous Immune Cell Therapy

Chi-Kuan Chen

BioRay Health Group, Taiwan

Autologous immune cell therapy takes the patient's own immune cells, increases the number through in vitro cell culture technology, and then transfuses them to the patient's circulation vessels. It is a way to passively enhance the number and activity of immune cells. It has been widely used in cancer adjuvant treatment, balance self immunity, and even prevent cancer. Immune cells drawn from patients are usually in a chaotic and abnormal microenvironment. In a relatively nutritious and healthy culture situation in vitro, they can usually recover their activity and increase their number smoothly. Once the immune cells are reinfused into the patient, they are again exposed to the same adverse microenvironmental effects. These proliferated immune cells usually cannot survive smoothly, and the cell survival half-life is usually no more than one week. Therefore, the effect of autologous immune cell therapy in clinical adjuvant treatment of cancer will be greatly limited. We will discuss how to improve the improper immune microenvironment in patients and enhance the clinical effect of autologous immune cell therapy.

實驗室級超純水系統



LIGHT
AND
HANDY

EASY
CHANGE

EASY
OPERATION

EASY
MAINTENANCE

Lab water purification systems

design for general laboratory application

您~絕對值得擁有自己的超純水系統!

獅柏股份有限公司

Tel: (02)2219-0378

Fax: (02)2219-0226

www.lionbio.com.tw

154 info@lionbio.com.tw

Ming-Yii Huang, M.D., Ph.D. (黃旻儀)

Current position and professional experiences

- 2019/9 ~ Present **Associate Dean**, School of Medicine, Kaohsiung Medical University
- 2016/2 ~ Present **Professor**, College of Medicine, Kaohsiung Medical University
- 1999/8 ~ Present **Attending staff**, Department of Radiation Oncology, Kaohsiung Medical University Hospital
- 2014/8 ~ 2018/7 **Vice Director**, Center for Biomarkers and Biotech Drugs (CBBD), Kaohsiung Medical University



Research interest

1. Radiation oncology
2. Molecular biology
3. Pharmacogenomics
4. Radiation biology

Short research summary

Dr. Ming-Yii Huang is a Professor and Medical Doctor at the Kaohsiung Medical University (KMU), Taiwan. Dr. Huang received her MD, Ph.D degree from the KMU and has been involved in cancer researches for the past ~18 years. Dr. Huang's research interest focuses on the develop mRNA molecular markers for the detection of circulating tumor cells in various human cancers. And identification of novel genes involved in the carcinogenesis, the therapeutic efficacy prediction of various human cancers receiving radiation therapy.

Publications

1. **Ming-Yii Huang**, Hsin-Hua Lee, Ching-Wen Huang, Chun-Ming Huang, Cheng-Jen Ma, Tzu-Chieh Yin, Hsiang-Lin Tsai, Chee-Yin Chai, Yi-Ting Chen, Jaw-Yuan Wang*. **2020**. ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation *Oncology Letters*. 20:212. doi.org/10.3892/ol.2020.12075.
2. Chun-Ming Huang, **Ming-Yii Huang**, Ching-Wen Huang, Hsiang-Lin Tsai, Wei-Chih Su, Wei-Chiao Chang, Jaw-Yuan Wang*, Hon-Yi Shi*. **2020**. Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. *Scientific Reports*. 28;10(1):12555. doi: 10.1038/s41598-020-69345-9.
3. Wen-Chin Chiu†, Pen-Tzu Fang†, Yi-Chen Lee, Yen-Yun Wang, Yu-Han Su, Stephen Chu-Sung Hu, Yuk-Kwan Chen, Yu-Tong Tsui, Ying-Hsien Kao, **Ming-Yii Huang***, Shyng-Shiou F. Yuan*. **2020**. DNA repair protein Rad51 induces tumor growth and metastasis in esophageal squamous cell carcinoma via a p38/Akt dependent pathway. *Annals of Surgical Oncology*. 27(6):2090-2101. doi: 10.1245/s10434-019-08043-x. Epub 2019 Nov 20.
4. Hsin-Hua Lee, Chien-Hung Chen, Kuei-Hau Luo, Hung-Yi Chuang, Chih-Jen Huang, Yuan-Kai Cheng, Frank Chen, Shih-Hsun Kuo, **Ming-Yii Huang***. **2020**. Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer. *Scientific Reports*. 9;10(1):4342. doi: 10.1038/s41598-020-61403-6.

5. **Ming-Yii Huang**, Ching-Wen Huang, Jaw-Yuan Wang*. **2020**. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *Kaohsiung Journal of Medical Sciences*. 36(3):152-159. doi: 10.1002/kjm2.12161. Epub 2019 Dec 9. Review.
6. Chun-Ming Huang, Ching-Wen Huang, Cheng-Jen Ma, Yung-Sung Yeh, Wei-Chih Su, Tsung-Kun Chang, Hsiang-Lin Tsai, **Ming-Yii Huang***, Jaw-Yuan Wang*. **2020**. Predictive Value of FOLFOX-based Regimen, Long Interval, Hemoglobin Levels and Clinical Negative Nodal Status, and Post-chemoradiotherapy CEA Levels for Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy. *Journal of Oncology*. 28;2020:9437684. eCollection 2020. doi.org/10.1155/2020/9437684. eCollection 2020.
7. Hsin-Hua Lee, Chien-Hung Chen, Hung-Yi Chuang, Yu-Wei Huang, **Ming-Yii Huang***. **2019**. Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases. *Scientific Reports*. 14;9(1):16834. doi: 10.1038/s41598-019-53456-z.
8. Chien-Hung Chen, Hsin-Hua Lee, Hung-Yi Chuang, Jen-Yu Hung, **Ming-Yii Huang***, Inn-Wen Chong*. **2019**. Combination of whole brain radiotherapy with epidermal growth factor receptor tyrosine kinase inhibitors improves overall survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. *Cancers (Basel)*. 31;11(8). pii: E1092. doi: 10.3390/cancers11081092.
9. Chia-Cheng Su, Kun-Lin Hsieh, Po-Len Liu, Hsin-Chih Yeh, Shu-Pin Huang, Shih-Hua Fang, Wei-Chung Cheng, Kuan-Hua Huang, Fang-Yen Chiu, I-Ling Lin, **Ming-Yii Huang***, Chia-Yang Li*. **2019**. AICAR induces apoptosis and inhibits migration and invasion in prostate cancer cells through an AMPK/mTOR-dependent pathway. *International Journal of Molecular Sciences*. 3;20(7). pii: E1647. doi: 10.3390/ijms20071647.
10. Chih-Jen Huang, **Ming-Yii Huang**, Ming-Chen Paul Shih, Kai-yuan Cheng, Ka-Wo Lee, Tzu-Ying Lu, Shyng-Shiou Yuan, Pen-Tzu Fang*. **2019**. Post-radiation sinusitis is associated with recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. *Radiation Oncology*. 11;14(1):61. doi: 10.1186/s13014-019-1261-9. PMID: 30971260.
11. Chih-Jen Huang, **Ming-Yii Huang**, Pen-Tzu Fang, Frank Chen, Yu-Tsang Wang, Chung-Ho Chen, Shyng-Shiou Yuan, Chun-Ming Huang, Kuei-Hau Luo, Hung-Yi Chuang, Yen-Yun Wang, Hsin-Hua Lee*. **2019**. Randomized double-blind, placebo-controlled trial evaluating oral glutamine on radiation-induced oral mucositis and dermatitis in head and neck cancer patients. *American Journal of Clinical Nutrition*. 1;109(3):606-614. doi: 10.1093/ajcn/nqy329.
12. Chia-Cheng Su, Kun-Lin Hsieh, Po-Len Liu, Hsin-Chih Yeh, Shu-Pin Huang, Shih-Hua Fang, Wei-Chung Cheng, Kuan-Hua Huang, Fang-Yen Chiu, I-Ling Lin, **Ming-Yii Huang***, Chia-Yang Li*. **2019**. AICAR induces apoptosis and inhibits migration and invasion in prostate cancer cells through an AMPK/mTOR-dependent pathway. *International Journal of Molecular Sciences*. 3;20(7). pii: E1647. doi: 10.3390/ijms20071647.
13. **Ming-Yii Huang†**, Chia-En Tu†, Shu-Chi Wang, Yung-Li Hung, Chia-Cheng Su, Shih-Hua Fang, Chi-Shuo Chen, Po-Len Li, Wei-Chung Cheng, Yu-Wei Huang, Chia-Yang Li*. **2018**. Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia. *BMC Complementary and Alternative Medicine*. 15;18(1):221. doi: 10.1186/s12906-018-2287-5.
14. **Ming-Yii Huang**, Hsin-Hua Lee, Hsiang-Lin Tsai, Ching-Wen Huang, Yung-Sung Yeh, Cheng-Jen Ma, Chun-Ming Huang, Chiao-Yun Chen, Joh-Jong Huang*, Jaw-Yuan Wang*. **2018**. Comparison of Efficacy and Safety of Preoperative Chemoradiotherapy in Locally Advanced Upper and Middle/Lower Rectal Cancer. *Radiation Oncology*. 27;13(1):53. doi: 10.1186/s13014-018-0987-0.
15. Kuo-Hua Lin†, **Ming-Yii Huang†**(equal first author), Wei-Chung Cheng, Shu-Chi Wang, Shih-Hua Fang, Hung-Pin Tu, Chia-Cheng Su, Yung-Li Hung, Po-Len Liu, Chi-Shuo Chen, Yu-Ting Wang, and Chia-Yang Li*. **2018**. RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment. *Scientific Reports*. 8;8(1):2672. doi: 10.1038/s41598-018-21065-x.

Chun-Ying Wu, M.D., Ph.D., M.P.H., L.L.M., L.L.B. (吳俊穎)

Current position and professional experiences

- 2019/8 ~ Present **Director**, Professor, Institute of Biomedical Informatics, National Yang-Ming University
- 2017/10 ~ Present **Chief**, Division of Translational Research, Taipei Veterans General Hospital
- 2014/8 ~ Present **Joint Appointment Researcher**, National Institute of Cancer Research, National Health Research Institutes

**Research interest**

1. Digestive cancers translational research
2. Big data research and health outcome assessment
3. Microbiome research and bionanochip development
4. Empirical study of medical malpractice

Short research summary

Prof. Wu establishes Taiwan Microbiome Consortium and currently serves as the first President in the consortium. Prof. Wu is now the Editor-in-Chief of *Advances in Digestive Medicine* (the joint official journal of GEST, DEST & TASL), editorial member of *Gut*, Vice-Secretary General of the Digestive Endoscopy Society of Taiwan, the executive of the Taiwan Liver Cancer Association, and the control board of the Taiwan Evidence-based Medicine Association. Prof. Wu has published many articles in top ranking journals such as *JAMA*, *J Clinical Oncology*, *Gastroenterology*, *JAMA Intern Med*, *Gut*, *J of Hepatology*, *Hepatology*, *Annals of Surgery*, *Gastrointest Endoscopy*, *Radiology*, *Biosens Bioelectron*, etc. Prof. Wu owns several patents, such as gastric cancer screening, hepatitis B virus quantitative detection methods, microbiota to treat metabolic syndrome, etc. Prof. Wu is the winner of “2016 National Innovation Award”, Taiwan Institute for Biotechnology & Medicine Industry; “2015 Outstanding Research Award”, Ministry of Science & Technology; and “2015 Emerging Leadership Award”, Asia-Pacific Digestive Week.

Publications

1. **Wu CY***, Ho HJ, Wu CY, Chen YJ, Lee TY, Hsu YC, Lin JT. Association between proton pump inhibitor use and mortality in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor. *Gut* (in press) (SCI, **IF 19.819**, 3/88)
2. Cheng WY, **Wu CY**, Yu J. The role of gut microbiota in cancer treatment: friend or foe? *Gut* 2020 Oct; 69(10): 186-76 (SCI, **IF 19.819**, 3/88).
3. Chen YJ, Lee WH, Ho HJ, Tseng CH, **Wu CY***. An altered fecal microbial profiling in rosacea patients compared to matched controls. *J Formos Med Assoc* 2020 May 20;S0929-6646(20)30172-8 (SCI, **IF 3.008**, 42/165).
4. Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, **Wu CY***. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C. *Clin Gastroenterol Hepatol* 2020 April 28;S1542-3565(20)30533-4 (SCI, **IF 8.549**, 10/88).
5. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, **Wu CY***. Association of daily aspirin therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B. *JAMA Intern Med* 2019 May 1; 179(5): 633-40 (SCI, **IF 18.652**, 7/165).

6. Tseng CH, **Wu CY***. The gut microbiota in obesity (review).
J Formos Med Assoc 2019 Mar; 118 Suppl 1: S3-S9 (SCI, **IF 3.008**, 42/165)
7. Yeo YH, Ho HJ, Yang HI..., **Wu CY***, Nguyen MH. The HBsAg seroclearance rate and predictors in adults with chronic hepatitis B: a systematic review and meta-analysis.
Gastroenterology 2019 Feb; 156(3): 635-46 (SCI, **IF 17.373**, 4/88).
8. Chen YJ, Ho HJ, Tseng CH, Lai ZL, Shieh JJ, **Wu CY***. Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients.
Exp Dermatol 2018 Dec;27(12):1336-43 (SCI, **IF 3.368**, 15/68)
9. Lai ZL, Tseng CH, Ho HJ, Cheung CKY, Lin JY, Chen YJ, Cheng FC, Hsu YC, Lin JT, El-Omar EM, **Wu CY***. Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. **Sci Rep** 2018 Oct 23; 8(1): 15625 (SCI, **IF 3.998**, 17/71)
10. Hsu YC, Yip TCF, Ho HJ, Wong VWS, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GLH, **Wu CY***. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. **J Hepatol** 2018 Aug; 69(2): 278-85 (SCI, **IF 20.582**, 2/88)
11. Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, **Wu CY***. Effect of nucleos(t)ide analogue therapy on risk of intrahepatic cholangiocarcinoma in chronic hepatitis B.
Clin Gastroenterol Hepatol 2018 Jun; 16(6): 947-54.e4 (SCI, **IF 8.549**, 10/88)
12. Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, **Wu CY***. First-line *Helicobacter pylori* eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. **Gut** 2018 Jan; 67(1): 20-7 (SCI, **IF 19.819**, 3/88)
13. Leung WK, Hsiu JH, Lin JT, Wu MS, **Wu CY***. Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study.
Gastroint Endosc 2018 Jan; 87(1): 119-27 (SCI, **IF 6.890**, 16/88)
14. Lee TY, Wu JC, Yu SH, Lin JT, Wu MS, **Wu CY***. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically non-cirrhotic non-alcoholic fatty liver disease.
Int J Cancer 2017 Oct 1; 141(7): 1307-14 (SCI, **IF 5.145**, 59/244).
15. **Wu CY**, Chang YT, Juan CK, Shieh JJ, Lin YP, Liu HN, Lin JT, Chen YJ. Risk of inflammatory bowel disease in rosacea patients: results from a nationwide cohort study.
J Am Acad Dermatol 2017 May; 76(5): 911-7 (SCI, **IF 8.277**, 1/68).
16. Wang ST, Ho HJ, Lin JT, Shieh JJ, **Wu CY*** (**corresponding author**). Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Cell Death & Disease 2017 Feb 23; 8(2): e2626 (SCI, **IF 6.304**, 40/195)
17. Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, **Wu CY*** (**corresponding author**), Lin JT. Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in e antigen-negative patients.
Clin Gastroenterol Hepatol 2016 Oct; 14(10): 1490-8 (SCI, **IF 8.549**, 10/88).
18. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, **Wu CY*** (**corresponding author**). Association between nucleos(t)ide analogues and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma following radiofrequency ablation.
Hepatology 2016 May; 63(5): 1517-27 (SCI, **IF 14.679**, 6/88).
19. **Wu CY**, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study.
Gut 2016 Apr; 65(4): 693-701 (SCI, **IF 19.819**, 3/88)
20. Chen CC, Lai ZL, Wang GJ, **Wu CY*** (**corresponding author**). Polymerase chain reaction-free detection of hepatitis B virus DNA using a nanostructured impedance biosensor.
Biosens Bioelectron 2016 Mar 15; 77:603-8 (SCI, **IF 10.257**, 2/27, Electrochemistry).
21. Tseng CH, Lin JT, Ho HJ, Lai ZL, Wang CB, Tang SL, **Wu CY***. Gastric microbiota and predicted gene function are altered after subtotal gastrectomy in patients with gastric cancer.
Sci Rep 2016 Feb 10; 6:20701 (SCI, **IF 4.122**, 12/64)

Invited Speeches

(TGMBS & TPMS) Hall III Section II 11/14 14:40-16:05

Microbiota – Speaker

Gut Microbiota, FMT and Human Diseases

Chun-Ying Wu

Director, Institute of Biomedical Informatics, National Yang-Ming University, Taiwan

Chief, Division of Translational Research, Taipei Veterans General Hospital, Taiwan

Human intestinal tract harbors a complex microbial community with approximately 100 trillion cells, about 10 times of the number of human cells and 100 times of the number of human genes. This complex microbial community is called gut microbiota. The development of next generation sequencing technologies makes it possible to explore the composition of gut microbial community, most of them are not cultivable. Human microbiota can be considered as the second genome of human beings.

Gut microbiota is stabilized in the first years after birth via the vertical transmission from parents and close contact with family members. Environmental factors, such as diet, medication, exercise, etc., further shape gut microbiota characteristics thereafter. Each subject's gut microbiota is unique, but changes with time. Gut microbiota interacted with human immune system and triggers several inflammatory related pathways, which are associated with many human diseases, such as obesity, metabolic syndrome, cancers, autoimmune diseases, cardiovascular diseases, neurological and psychiatric diseases, etc.

Fecal microbiota transplantation (FMT) is the translocation of gut microbiota to treat human diseases by re-colonization of normal gut microbiota in patients. A couple of human diseases have been treated successfully by FMT in recently randomized clinical trials. FMT has been demonstrated to be superior than traditional antibiotics treatment in patients with refractory pseudomembranous colitis, infected by *Clostridium difficile*. FMT is also approved to be effective in some subset of patients with inflammatory bowel diseases. There are many ongoing clinical trials to examine the efficacy and safety of FMT in treating obesity, metabolic diseases, psychiatric diseases, cancer and autoimmune diseases.

Gut microbiota plays important roles in shaping and treating human diseases. Exploring the complicated interactions between gut microbiota and human diseases will provide many new diagnostic and therapeutic methods for human diseases and will be the most exciting fields of 21st century.

Ching-Hung Tseng, Ph.D. (曾景鴻)

Current position and professional experiences

- 2017/9 ~ Present **General Manager**, Germark Biotechnology Co., Ltd
- 2016/9 ~ 2017/8 **Research and Development Manager**, Germark Biotechnology Co., Ltd



Research interest

1. Gut microbiome
2. Microbial metagenomics
3. Comparative genomics
4. Bioinformatics

Short research summary

Dr. Tseng is now the General Manager in Germark Biotechnology Co., Ltd., Taichung, which provides the total solution to microbiome research from sample collection, DNA extraction, NGS sequencing, to downstream analysis with scientific rigor. Dr. Tseng received his Ph.D. degree from the Bioinformatics Program jointly hold by Taiwan International Graduate Program (TIGP) and National Yang-Ming University (NYMU) and involved in environmental microbiome studies during his Ph.D pursuit. Dr. Tseng's research interest focuses on the application of computational strategy to resolve microbial functionality, ecology, and interactions to their host environments, including human body.

Publications

1. Shan-Hua Yang, Ching-Hung Tseng, Hsueh-Ping Lo, Pei-wen Chiang, Hsing-Ju Chen, Jia-Ho Shiu, Hung-Chun Lai, Kshitij Tandon, Naoko Isomura, Takuma Mezaki, Hiromi Yamamoto and Sen-Lin Tang. (2020) Locality effect of coral-associated bacterial community in the Kuroshio Current from Taiwan to Japan. *Front Ecol Evol*, accepted. (as co-first author)
2. Li-Lin Liang, **Ching-Hung Tseng**, Hsiu J. Ho and Chun-Ying Wu. (2020) Covid-19 mortality is negatively associated with test number and government effectiveness. *Sci Rep*, 10:12567.
3. Yi-Ju Chen, Wei-Hsiang Lee, Hsiu J Ho, **Ching-Hung Tseng** and Chun-Ying Wu. (2020) An altered fecal microbial profiling in rosacea patients compared to matched controls. *J Formos Med Assoc*, doi: 10.1016/j.jfma.2020.04.034.
4. Yi-Ju Chen, Hsiu J. Ho, **Ching-Hung Tseng**, Zi-Lun Lai, Jeng-Jer Shieh and Chun-Ying Wu. (2018) Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients. *Exp Dermatol*, 27(12):1336-43.
5. Zi-Lun Lai, **Ching-Hung Tseng**, Hsiu J Ho, Cynthia KY Cheung, Jian-Yong Lin, Yi-Ju Chen, Fu-Chou Cheng, Yao-Chun Hsu, Jaw-Town Lin, Emad M El-Omar and Chun-Ying Wu. (2018) Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. *Sci Rep*, 8(1):15625. (as co-first author)
6. **Ching-Hung Tseng** and Chun-Ying Wu. (2018) The gut microbiome in obesity. *J Formos Med Assoc*, doi: 10.1016/j.jfma.2018.07.009.
7. Yu-Ting Wu, Cheng-Yu Yang, Pei-Wen Chiang, **Ching-Hung Tseng**, Hsiu-Hui Chiu, Isaam Saeed, Bayanmunkh Baatar, Denis Rogozin, Saman Halgamuge, Andrei Degermendzhi and Sen-Lin Tang. (2018) Comprehensive insights into composition, metabolic potentials, and interactions among archaeal, bacterial, and viral assemblages in meromictic Lake Shunet in Siberia. *Front Microbiol*, 9:1763.

8. Jia-Ho Shiu, Jiun-Yan Ding, **Ching-Hung Tseng**, Shueh-Ping Lou, Takuma Mezaki, Yu-Ting Wu, Hsiang-lu Wang and Sen-Lin Tang. (2018) A newly designed primer revealed high phylogenetic diversity of Endozoicomonas in coral reefs. *Microbes Environ*, 33(2):172-85.
9. Jia-Ho Shiu, Shashank Keshavmurthy, Pei-Wen Chiang, Hsing-Ju Chen, Shueh-Ping Lou, **Ching-Hung Tseng**, Hernyi Justin Hsieh, Chaolun A. Chen and Sen-Lin Tang. (2017) Dynamics of coral-associated bacterial communities acclimated to temperature stress based on recent thermal history. *Sci Rep*, 7(1):14933.
10. Shan-Hua Yang, **Ching-Hung Tseng**, Chang-Rung Huang, Chung-Pin Chen, Kshitij Tandon, Sonny T. M. Lee, Pei-Wen Chiang, Jia-Ho Shiu, Chaolun A. Chen and Sen-Lin Tang. (2017) Long-term survey is necessary to reveal various shifts of microbial composition in corals. *Front Microbiol*, 8:1094. (as co-first author)
11. Bayanmunkh Baatar, Pei-Wen Chiang, Denis Yu Rogozin, Yu-Ting Wu, **Ching-Hung Tseng**, Cheng-Yu Yang, Hsiu-Hui Chiu, Bolormaa Oyuntsetseg, Andrey G. Degermendzhy and Sen-Lin Tang. (2016) Bacterial communities of three saline meromictic lakes in central Asia. *PLoS ONE*, 11(3): e0150847.
12. Shan-Hua Yang, Sonny T. M. Lee, Chang-Rung Huang, **Ching-Hung Tseng**, Pei-Wen Chiang, Chung-Pin Chen, Hsing-Ju Chen and Sen-Lin Tang. (2016) Prevalence of potential nitrogen-fixing, green sulfur bacteria in the skeleton of reef-building coral *Isopora palifera*. *Limnol Oceanogr*, 61(3):1078-86.
13. **Ching-Hung Tseng**, Jaw-Town Lin, Hsiu J. Ho, Zi-Lun Lai, Chang-Bi Wang, Sen-Lin Tang and Chun-Ying Wu. (2016) Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer. *Sci Rep*, 6:20701.
14. **Ching-Hung Tseng**, Pei-Wen Chiang, Hung-Chun Lai, Fuh-Kwo Shiah, Ting-Chang Hsu, Yi-Lung Chen, Liang-Saw Wen, Chun-Mao Tseng, Wung-Yang Shieh, Isaam Saeed, Saman Halgamuge and Sen-Lin Tang. (2015) Prokaryotic assemblages and metagenomes in pelagic zones of the South China Sea. *BMC Genomics*, 16(1):219-34.

The Gut Microbiome in Human Health and Diseases, a Recent Perspective

Ching-Hung Tseng


Germark Biotechnology Co., Ltd, Taichung, Taiwan

In the past two decades, the sheer number of studies tackling the intestinal microbiota reveals its immense intimacy to human health, and to disease pathogenesis when it is disrupted. Descriptive microbiota association investigations have motivated the integration of multi-omics approaches into this nascent field to resolve causative mechanisms behind observed association. With the supports from techniques in metagenomics, metabolomics, culturomics, and animal inoculation, microbiome-derived metabolites have been discovered one after another as central messengers mediating host metabolism. To translate these discoveries into real-world applications, several microbiome-directed interventions (including targeted and untargeted) have been continuously put on trial for validation. In addition to academic progress, an overview of contemporary microbiome industry will be discussed, together with future challenges and potential needs for microbiome therapy development to address interpersonal response variation.

Ting-Yuan Hsu M.D., O.M.D., Ph.D. (許庭源)

Current position and professional experiences

- | | |
|------------------|---|
| 2018 ~ Present | Consulting Physician , An-Ho Clinic, Kaohsiung, Taiwan |
| 2011/12 ~ 2018/7 | Director , BioRay Biotech Inc |
| 1997/6 ~ 2011/6 | Associate Professor , Chinese Medicine Institute, China Medical University, Taichung, Taiwan |
| 1996/6 ~ 2001/6 | Director , Pediatric Department, Hua Ji Hospital, Chiayi, Taiwan |
| 1993/9 ~ 1996/5 | Attending Physician , Pediatrics, St. Paul Hospital, Taoyuang, Taiwan |
| 1990/6 ~ 1993/8 | Residency , Mackay Memorial Hospital, Taipei |
| 1987/6 ~ 1988/5 | Internship , Mackay Memorial Hospital, Taipei |



Research interest

1. Immunology
2. Pediatrics
3. Division of rheumatology

Short research summary

1. Establishment of an animal model for the study of atopic dermatitis I led a team established first animal model for atopic dermatitis induced by allergen
2. Prevention and treatment of allergic disease by direct allergen-gene transfer I led a team successfully demonstrated that direct gene transfer (gene therapy) could treat and prevent IgE-mediated allergenic diseases including atopic dermatitis and airway hyperreactivity. This is a major breakthrough in the treatment of allergic diseases
3. To investigate the working mechanisms of tradition Chinese medicine in the treatment of allergic diseases
4. To select anti-allergy probiotic strain for clinical application
5. Development of Cordyceps and Taiwanfungus in the good agriculture practice
6. To develop biomarkers for heat pattern diagnosis by microarray technology

Publications

1. Hsu CH, Lin SP, and Huang FU. Computerized Dymorphology Database Mackay (CDDM). Acta Paed Sin 1993;35:19-26.
2. Hsu CH, Lee HC, Chiu NC, and Huang FY. Duplex Doppler Assessment of Visceral and Cerebral Blood Flow Velocity in Newborns. J Formos med Assoc 1993;92:803-6.
3. Hsu CH, Chen MR, Hwang FY, Kao HA, Hung HY, and Hsu CH. Efficacy of plasmin-treated Intravenous Gamma-globulin for therapy of Kawasaki Syndrome. Pediatr Infect Dis J 1993;12:509-12.SCI
4. Hsu CH, Lee HC, Huang FY. Duplex ultrasonographic assessment of gut blood flow velocity. J Ultrasonund Med 1994;13:15-18.SCI
5. Hsu CH, Chua KY, Huang SK, Chiang IP, and Hsieh KH. Development and Characterizations of a murine Dermatitis Model. J Allergy and Clin Immunol 1995;95:806.SCI
6. Hsu CH, Chua KY, Huang SK, Chiang IP, and Hsieh KH. Glutathione S-transferase induces murine dermatitis that resembles human allergic dermatitis. Clinical and Experimental Allergy

- 1996;26:1329-1337.SCI
7. Hsu CH, Chua KY, Huang SK, and Hsieh KH et al. Immunoprophylaxis of Allergen-induced IgE synthesis and Airway hyperresponsiveness by genetic immunization. *Nature Medicine* 1996;2:540-544.SCI
 8. Hsu CH, Chua KY, Huang SK, and Hsieh KH et al. Inhibition of allergen-specific IgE by direct gene transfer. *International Immunology* 1996;8: 1405-1411.SCI
 9. Hsu CH, Chua KY, Huang SK, and Hsieh KH. Glutathione S-transferase induces murine dermatitis that resembles human allergic dermatitis. *Adv Exp Med Biol.* 1996;409:33-7. SCI
 10. Hsu CH et al The association between disease patterns in Chinese Medicine and serum ECP in allergic rhinitis *Chin Med Coll J* 1999; 8: 12-26.
 11. Hsu CH, Shyu YY, and Li MH. The mechanisms of anti-asthmatic formulae in traditional Chinese medicine in the treatment of allergen-induced airway inflammation. *J Chin Med* 2000; 11:111-121
 12. Hsu CH, Lu CM, Huang HW, La MT, and Li MH. Allergic asthma animal model with cold and heat “zheng”. *J Chin Med* 2001; 12:155-164.
 13. Hsu CH et al Gene expression in heat Zheng of allergic asthma by microarray biochip *J Chin Med* 2002; 13:97-109.
 14. Hsu CH et al. High eosinophil cationic protein level in asthmatic patients with "Heat" Zheng . *Am J Chin Med* 2003; 31.:277-283 SCI
 15. Yu MC , Lee CH, Lai CH ,Chiang IP ,Wang YY, and Hsu CH. The hepatoprotective effect of traditional Chinese medicine in galatosamine –induced acute hepatotoxicity . *J Chin Med* 2003; 14 :99-108.
 16. Lu CM, Yu MC ,Chen YH , Hsiao MH , Chen KJ ,Huang PT ,Wang YY, and Hsu CH Gene expression in "Heat" Zheng pattern of allergic asthma. *J Chin Med* 2003;14:109-121.
 17. Su SY, Lee CH, Lai CW, Wang YY, Lai MC, Yu MT, and Hsu CH. Antioxidative effects and estrogenic activity of Chinese herbs Charming-Queen tea. *J Chin Med* 2003;14:193-203.
 18. Kao SH, Hsu CH, Su SN, Hor WT, Chang T WH, Chow LP. Identification and immunologic characterization of an allergen, alliin lyase, from garlic (*Allium sativum*). *J Allergy Clin Immunol.* 2004 ;113:161-8. SCI
 19. Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. *Pediatr Allergy Immunol.* 2004;15:152-8. SCI
 20. Hsu CH, Lin SS, Liu FL, Su WC, Yeh SD. Oral administration of a mite allergen expressed by zucchini yellow mosaic virus in cucurbit species downregulates allergen-induced airway inflammation and IgE synthesis. *J Allergy Clin Immunol.* 2004;113:1079-85. SCI
 21. Hsu CH, Lu CM, Chang TT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. *Pediatr Allergy Immunol.* 2005;16:76-81. SCI
 22. Chang TT, Huang CC, Hsu CH. Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma. *Phytother Res.* 2006;20:342-47. SCI
 23. Chang YC, Lin CC, Hsu CH. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic acid bacteria. *Vaccine*, 2006;24:5931-36. SCI
 24. Chang TT, Huang CC, Hsu CH. Inhibition of mite-induced immunoglobulin E synthesis, airway inflammation, and hyperreactivity by herbal medicine STA-1. *Immunopharmacology and Immunotoxicology.* 2006;28: 683-95. SCI
 25. Production of Active Nonglycosylated Recombinant B-Chain of Type-2 Ribosome-Inactivating Protein from *Viscum articulatum* and Its Biological Effects on Peripheral Blood Mononuclear Cells. *Evid Based Complement Alternat Med.* Lu TL, Chuang JY, Yang JS, Chiu ST, Hsiao NW, Wu MC, Hsu CH. 2011;2011:283747-16. SCI
 26. Daily Intake of Probiotics with High IFN- γ /IL-10 Ratio Increases the Cytotoxicity of Human Natural Killer Cells: A Personalized Probiotic. *J. Immun. Research.* Yu-Hsuan Ho, Yu-Chiu Lu,

Hung-Cheng Chang, Shin-Yi Lee, Min-Fen Tsai, Yu-Ting Huang, and Ting-Yuan Hsu. 2014; Volume 2014, Article ID 721505, 7 pages

27. Ho Y-H, Lu Y-C, Chang H-C, Lee S-Y, Tsai M-F, Huang Y-T, et al. Daily intake of probiotics with high IFN- γ /IL-10 ratio increases the cytotoxicity of human natural killer cells: A personalized probiotic approach. *Journal of immunology research*. 2014;2014.
28. Ho Y-H, Huang Y-T, Lu Y-C, Lee S-Y, Tsai M-F, Hung S-P, et al. Effects of gender and age on immune responses of human peripheral blood mononuclear cells to probiotics: A large scale pilot study. *The journal of nutrition, health & aging*. 2017;21(5):521–6.
29. Fang S, Cheng D, Huang Y, Hsu T, Lu H. A pilot study of the influence of probiotics on hair toxic element levels after long-term supplement with different Lactic Acid bacteria strains. *J Prob Health*. 2018;6:1–8.

Integrative Treatments of Advanced Cancers by Combined Both Cytokine-induced Killer Cell and Personalized Probiotic Therapy

Ting-Yuan Hsu

Department of Research and Development, BioRay Biotech Inc. Kaohsiung,

Many studies have demonstrated that cytokine-induced killer cells (CIK) have potent cytotoxic activities against both solid and hematologic tumors such as leukemia, lung cancer, hepatoma, and ovarian cancer in a MHC-unrestricted cytolytic effect, and having potential synergy with surgery, chemotherapy and radiotherapy. In addition, side effects of CIK infusions were very minor. However, there are some obstacles impeding treatment efficacy: (1) biological response to gut microbes may vary in different individuals; this responses can enhance clinical curative effects? (2) insufficient amount and short life span of effector CIK cells may compromise therapeutic efficacy; (3) sensitive examination for real-time evaluating the efficacy is not accessible.


To solve aforementioned problems and create groundbreaking immunotherapy, we accordingly established T-cell antigen reviving system (T-CARS), Kinetic Amplified Cytokine induced Killer cell (KA-CIK) and circulating tumor cells (CTC) assay. T-CARS utilizes our patented microfluidic system to identify quickly personalized probiotic antigen to effectively facilitate T-cell activity. Oral administration of personalized probiotic strain can double CIK cytotoxicity activity after 30-day treatment and most importantly prolong CIK cells life span to 90-day after infusion in patients. KA-CIK technology simulates virtual circulation to yield remarkably higher amount of anti-tumor active CIK cells than traditional culture method which provided standardized system to produce high qualities and quantities of cell for treatment within 14 days. Besides, high sensitivity CTC assay employs as low as 7.5 ml blood to determine free tumor cells in patients peripheral blood circulation. We therefore use KA-CIK system to provide patient with advanced cancers more than 1×10^{10} cells for each infusion that are enhanced by T-CARS from individual probiotic strain, and followed by measurement of the changes of CTC in peripheral blood after each infusion.

Our integrative CIK cell-based immunotherapy including T-CARS and KA-CIK has demonstrated potential in improving clinical outcomes and relieving the major side effects for standard treatment options. However, the number of transfused CIK cells and frequency of transfusion seem to play an important role in enhancing anti-tumor activity. The optimal protocol for each patient needs to be elucidated. And challenges are under investigation for synergy with other immunotherapy approaches, target therapies or even conventional chemotherapy.

Hei-Jen Jou, M.D., Ph.D. (周輝政)

Current position and professional experiences

- 2018/7 ~ Present **Principal Investigator**, Circulating Tumor Cell (CRC) & Genetic Laboratory, Taiwan Adventist Hospital (TAH)
- 2018/2 ~ Present **Senior Vice President**, Taiwan Adventist Hospital (TAH)
- 2011/1 ~ Present **Chief Strategy Officer**, Taiwan Adventist Hospital (TAH)
- 1996/7 ~ Present **Attending Physician**, Department of Obstetrics and Gynecology, Taiwan Adventist Hospital (TAH)
- 2012/8 ~ Present **Adjunct Associate Professor**, Graduate Institute of Nurse-Midwifery, National Taipei University of Nursing and Health Sciences (NTUNHS)
- 2004/2 ~ Present **Adjunct Assistant Professor**, College of Medicine, National Taiwan University (NTU)



Research interest

1. Circulating rare cell
2. Microfluidic chip

Short research summary

Dr. Jou Hei-Jen is the Senior Vice President and Chief Strategy Officer of the Taiwan Adventist Hospital (TAH), and the attending physician in obstetrics and gynecology. Dr. Jou obtained a bachelor's degree in medicine from the Department of Medicine of National Taiwan University (NTU) in 1985, and a master's degree in finance from the EMBA of NTU in 2001. He is currently a doctoral candidate in the International College of Semiconductor Technology, National Chiao Tung University.

In the past five years, Dr. Jou has been committed to the research of microfluidic chips and circulating rare cells. In addition to his primary roles in the Hospital, he is also a principal investigator of the circulating tumor cell and genetic laboratory in TAH, in which he leads a team to provide supports for clinical research and the development of precision medicine.

Publications

1. Huang, C. E., Ma, G. C., **Jou, H. J.**, Lin, W. H., Lee, D. J., Lin, Y. S., Chen, M. (2017). Noninvasive prenatal diagnosis of fetal aneuploidy by circulating fetal nucleated red blood cells and extravillous trophoblasts using silicon-based nanostructured microfluidics. *Mol Cytogenet*, 10, 44. doi: 10.1186/s13039-017-0343-3
2. Hung, H. W., Yang, P. Y., Yan, Y. H., **Jou, H. J.**, Lu, M. C., & Wu, S. C. (2016). Increased postpartum maternal complications after cesarean section compared with vaginal delivery in 225 304 Taiwanese women. *J Matern Fetal Neonatal Med*, 29(10), 1665-1672. doi: 10.3109/14767058.2015.1059806
3. **Jou, H. J.**, Siao, R. Y., Tsai, Y. S., Chen, Y. T., Li, C. Y., & Chen, C. C. (2014). Postdischarge rehospitalization and in-hospital mortality among Taiwanese women with hip fracture. *Taiwan J Obstet Gynecol*, 53(1), 43-47. doi: 10.1016/j.tjog.2012.04.042

4. Chien, P. L., Su, H. F., Hsieh, P. C., Siao, R. Y., Ling, P. Y., & **Jou, H. J.** (2013). Sleep Quality among Female Hospital Staff Nurses. *Sleep Disord*, 2013, 283490. doi: 10.1155/2013/283490
5. Chen, Y. C., Tsao, L. I., Huang, C. H., Yu, Y. Y., Liu, I. L., & **Jou, H. J.** (2013). An Internet-based health management platform may effectively reduce the risk factors of metabolic syndrome among career women. *Taiwan J Obstet Gynecol*, 52(2), 215-221. doi: 10.1016/j.tjog.2013.04.011
6. Yang, T. S., Wang, S. Y., Yang, Y. C., Su, C. H., Lee, F. K., Chen, S. C., Tseng, C. Y., **Jou, H. J.**, Huang, J. P., Huang, K. E. (2012). Effects of standardized phytoestrogen on Taiwanese menopausal women. *Taiwan J Obstet Gynecol*, 51(2), 229-235. doi: 10.1016/j.tjog.2012.04.011
7. **Jou, H. J.**, Hung, H. W., Yan, Y. H., & Wu, S. C. (2012). Risk factors for blood transfusion in singleton pregnancy deliveries in Taiwan. *Int J Gynaecol Obstet*, 117(2), 124-127. doi: 10.1016/j.ijgo.2011.11.028
8. **Jou, H. J.**, Hsu, I. P., Liu, C. Y., Chung, S. H., Chen, S. M., & Gau, M. L. (2010). Awareness and use of folic acid among pregnant women in Taipei. *Taiwan J Obstet Gynecol*, 49(3), 306-310. doi: 10.1016/S1028-4559(10)60066-6
9. **Jou, H. J.**, Hsu, I. P., Huang, H. T., Liu, I. L., Chien, P. L., Li, I. C., . . . Chen, S. M. (2010). A hospital-based therapeutic lifestyle program for women with metabolic syndrome. *Taiwan J Obstet Gynecol*, 49(4), 432-437. doi: 10.1016/S1028-4559(10)60094-0
10. **Jou, H. J.**, & Huang, H. T. (2009). Metabolic syndrome: menopausal women and the health care challenge. *Taiwan J Obstet Gynecol*, 48(3), 205-209. doi: 10.1016/S1028-4559(09)60291-6

Hung-Cheng Lai, M.D., Ph.D. (賴鴻政)**Current position and professional experiences**

- 2013/11 ~ Present **Director/Professor**, Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University
- 2013/11 ~ Present **Vice Superintendent**, Shuang Ho Hospital, Taipei Medical University
- 2014/8 ~ 2020/7 **Chair**, Department of OB/ GYN, Shuang Ho Hospital, Taipei Medical University

**Research interest**

1. Epigenetic biomarker
2. Cancer organoids
3. Robotic surgery

Short research summary

My research interest focuses on two themes: “Epigenetics” and “Cancer Stem Cells”. The long term goal is to discover novel diagnostic markers and therapeutic targets. In epigenetics, we are using genome-wide approaches to discover novel DNA methylation in Gynecological cancers, and trying to translate these DNA methylation markers to clinical diagnostics. Novel genes of interest undergo functional characterization from molecular biology to cell biology and animal studies. In addition, we have successfully established cancer organoids from primary tumors. Translational investigation of cancer organoids is ongoing. Clinically, I am a board-certified Gynecologic Oncologist and a pioneer robotic gynecological surgeon in Asia.

Publications

1. Liew PL, Huang RL, Wu TI, Liao CC, Chen CW, Su PH, Wang HC, Weng YC, Lai HC*. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. *Clinical Epigenetics*. 2019 Nov 28;11(1):170
2. Wu TI, Huang RL, Su PH, Mao SP, Wu CH, Lai HC*. Ovarian Cancer Detection by DNA Methylation in Cervical Scrapings. *Clinical Epigenetics*. 2019 Nov 27;11(1):166
3. Su PH, Lai HC, Huang RL, Chen LY, Wang YC, Wu TI, Chan MWY, Liao CC, Chen CW, Lin WY, Chang CC. Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer. *Sci Rep*. 2019 Jun 24;9(1):9195.
4. Chung VY, Tan TZ, Ye J, Huang RL, Lai HC, Kappei D, Wollmann H, Guccione E, Huang RY. The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. *Commun Biol*. 2019 Jul 24;2(1):272.
5. Chen CW, Chang HC, Huang TF, Liao CC, Huang RL, Lai HC. Transition from multiport to single-site surgery: A single institution experience in robotic supracervical hysterectomy for benign gynecological diseases. *Taiwan J Obstet Gynecol*. 2019 Jul;58(4):514-519.
6. Li SS, Ip CKM, Tang MYH, Tang MKS, Tong Y, Zhang J, Hassan AA, Mak ASC, Yung S, Chan TM, Ip PP, Lee CL, Chiu PCN, Lee LTO, Lai HC, Zeng JZ, Shum HC, Wong AST. Sialyl Lewisx-P-selectin cascade mediates tumor-mesothelial adhesion in ascitic fluid shear flow. *Nat Commun*. 2019 Jun 3;10(1):2406.
7. Chen LY, Huang RL, Chan MW, Yan PS, Huang TS, Wu RC, Suryo Rahmanto Y, Su PH, Weng YC, Chou JL, Chao TK, Wang YC, Shih IM, Lai HC*. TET1 reprograms the epithelial ovarian cancer

- epigenome and reveals casein kinase 2 α as a therapeutic target. *J Pathol.* 2019 Mar 18.
8. Cheng FHC, Lin HY, Hwang TW, Chen YC, Huang RL, Chang CB, Yang W, Lin RI, Lin CW, Chen GCW, Mai SY, Lin JM, Chuang YM, Chou JL, Kuo LW, Li C, Cheng ASL, Lai HC, Wu SF, Tsai JC, Chan MWY. E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness. *Cancer Sci.* 2019 Mar;110(3):1085-1095.
 9. Su PH, Hsu YW, Huang RL, Chen LY, Chao TK, Liao CC, Chen CW, Wu TI, Mao SP, Balch C, Lai HC*. TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. *Cancer Lett.* 2019 May 28;450:53-62.
 10. Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer. *Cancer Sci.* 2019 Mar;110(3):1105-1116.
 11. Chen HJ, Huang RL, Liew PL, Su PH, Chen LY, Weng YC, Chang CC, Wang YC, Michael Chan WY, Lai HC* GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells. *Int J Cancer.* 2018 Jul 14. doi: 10.1002/ijc.31750.
 12. Maggie Tang, Patrick Yue, Philip Ip, Huang RL, Lai HC, Annie NY Cheung, Ka Yu Tse, Hextan Ngan, and Alice Wong. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. *Nature Communication.* 11 June 2018
 13. Huang RL, Chen HJ, Chen LY, Chao TK, Lin WY, Liew PL, Su PH, Weng YC, Wang YC, Liao CC, Hsu YW, Chen Wang H, Lai HC*. Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis. *Int J Cancer.* 2018 May 7. doi: 10.1002/ijc.31580.
 14. Liew PL, Huang RL, Weng YC, Fang CL, Hui-Ming Huang T, Lai HC*. Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors. *Int J Cancer.* 2018 Feb 16. doi: 10.1002/ijc.31324.
 15. Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, Lai HC*, The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. *J Gynecol Oncol.* 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
 16. Chang PY, Liao YP, Wang HC, Chen YC, Huang RL, Wang YC, Yuan CC, Lai HC*. An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. *Oncotarget* 2017 Jun. 8(32): 53432-53449.
 17. Chao TK, Huang TS, Liao YP, Huang RL, Su PH, Shen HY, Lai HC, Wang YC. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. *PLoS One* . 2017 Jul 28;12(7)
 18. Su PH, Hsu YW, Huang RL, Weng YC, Wang HC, Chen YC, Tsai YJ, Yuan CC, Lai HC*. Methyloomics of nitroxidative stress on precancerous cells reveals DNA methylation alteration at the transition from in situ to invasive cervical cancer. *Oncotarget.* 2017; 8.65281-65291
 19. Hsu YW, Huang RL, Su PH, Chen YC, Wang HC, Liao CC, Lai HC*. Genotype-specific methylation of HPV in cervical intraepithelial neoplasia. *J Gynecol Oncol.* 2017 Jul;28(4).e56.
 20. Deng S, Wong CKC, Lai HC, Wong AST. Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/ β -catenin signaling and epithelial-to-mesenchymal transition. *Oncotarget.* 2017 Apr 18;8(16):25897-25914. (SCI)
 21. Adrienn Kocsis, Zsuzsa Schaff, Róbert Koiss, Balázs Járjay, Gábor Sobel, Károly Pap, István Székely, Hung-Cheng Lai, Tamás Ferenci, Tibor Takács, Miklós Nyíri, Csaba Jeney, Márta Benczik, Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women. *Int J Cancer,* 2017 Mar 1;140(5):1119-1133
 22. Huang RL, Su PH, Liao YP, Wu TI, Hsu YT, Lin WY, Wang HC, Weng YJ, Ou YC, Tim H. M. Huang, Lai HC* Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. *Clin Cancer Res.* 2017 Jan 1;23(1):263-272.
 23. Lin CK, Bai MY, Hu TM, Wang YC, Chao TK, Weng SJ, Ma KH, Lai HC*. Preclinical evaluation of a

- nano-formulated, antihelminthic niclosamide in ovarian cancer. *Oncotarget* 2016 Feb 23;7(8):8993-9006. doi: 10.18632/oncotarget.7113.
24. Wang PH, Sun HD, Lin H, Wang KL, Liou WS, Hung YC, Chiang YC, Lu CH, Lai HC, Chang TC; Taiwanese Gynecologic Oncology Group. Outcome of patients with recurrent adult-type granulosa cell tumors – A Taiwanese Gynecologic Oncology Group study. *Taiwan J Obstet Gynecol.* 2015 Jun;54(3):253-9. doi: 10.1016/j.tjog.2014.12.007.
 25. Par Bahadur Pun; Liao YP; Su PH; Wang HC; Chen YC; Hsu YW; Huang RL; Chang CC, Lai HC*. Triage of high-risk human papillomavirus-positive women by methylated POU4F3. *Clinical Epigenetics*, 2015 Aug 21;7(1):85.
 26. Chang CC, Ou YC, Wang KL, Chang TC, Cheng YM, Chen CH, Chu TY, Hsu ST, Liou WS, Chang YY, Wu HH, Chen TH, Lai HC*. Triage of Atypical Glandular Cell by SOX1 and POU4F3 Methylation: A Taiwanese Gynecologic Oncology Group (TGOG) Study. *PLoS One*. 2015 Jun 9;10(6):e0128705. doi: 10.1371/journal.pone.0128705. eCollection 2015
 27. Chang CC, Huang RL, Liao YP, Su PH, Hsu YW, Wang HC, Tien CY, Yu MH, Lin YW, Lai HC*. Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. *BMC Cancer*. 2015 May 19;15(1):418.
 28. Jadhav RR, Ye Z, Huang RL, Liu J, Hsu PY, Huang YW, Rangel LB, Lai HC, Roa JC, Kirma NB, Huang TH, Jin VX. Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer. *Clin Epigenetics*. 2015 Feb 24;7(1):13. doi: 10.1186/s13148-015-0045-9.
 29. Chou JL, Huang RL, Jacqueline Shay, Chen LY, Lin SJ, Pearly S. Yan, Chao WT, Lai YH, Lai YL, Chao TK, Lee CI, Tai CK, Wu SF, Kenneth P. Nephew, Tim H.-M. Huang, Lai HC* and Michael W.Y. CHAN* Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients. *Clinical Epigenetics* 2015 Jan 14;7(1)

王子豪教授紀念講座 (Memorial Lecture for Prof. Tzu-Hao Wang)**FemTech: Precision Women Health**

Hung-Cheng Lai

Department of Obstetrics and Gynecology, School of Medicine, College of Medicine,
Taipei Medical University, Taiwan

Technology developed for female health (Female technology; FemTech) is burgeoning. Cancer and infertility are two crucial diseases threatening women's health. The concept and development of precision diagnostics may lead to a new cancer screening and reproduction assessment. Using methylomic approaches, we have developed DNA methylation biomarkers for cervical cancer screening, which has been approved by TFDA in 2016 (Cervi-M). Recently, a registration trial of DNA methylation biomarkers for endometrial cancer, an increasing incidence in Taiwan and worldwide, was completed with an expected positive result (MPap). The latest research reveals a potential panel for implantation prediction after an embryo transfer in infertility treatment, which may substantially improve assisted reproduction technology's efficiency. Precision diagnostics by DNA methylation biomarkers are paving a new way in women's health and create an opportunity for a startup.

Ni-Chung Lee, M.D., Ph.D. (李妮鍾)**Current position and professional experiences**

2016 ~ Present **Clinical Associate Professor**, Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

2006 ~ Present **Attending Physician**, Department of Medical Genetics and Pediatrics, NTUH

**Research interest**

1. Molecular genetics
2. Gene therapy

Short research summary

Dr. Ni-Chung Lee is a Clinical Associate Professor at the National Taiwan University Hospital (NTUH). She had her PhD degree from NTU. Her research interests include the diagnosis and treatment of pediatric patients with rare diseases. In the diagnosis, she involves in the clinical application of next generation sequencing for pediatric rare diseases. About the treatment, she conducted gene therapy researches for AADC deficiency, Pompe disease and several rare diseases.

Publications

1. Kuo CW, Hwu WL, Chien YH, Hsu C, Hung MZ, Lin IL, Lai F, Lee NC*. Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes. *Mol Genet Genomic Med.* 2020 Aug 14:e1455.
2. Kao HJ, Chiang HL, Chen HH, Fan PC, Tu YF, Chou YY, Hwu WL, Lin CL, Kwok PY, Lee NC*. De novo mutation and skewed X-inactivation in girl with BCAP31-related syndrome. *Hum Mutat.* 2020 Jul 11.
3. Fan SP, Lee NC, Lin CH. Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification. *Mov Disord.* 2020 Aug;35(8):1457-1462.
4. Fang WQ, Hwu WL, Chien YH, Yang SY, Chieh JJ, Chang LM, Huang AC, Lee NC*, Chiu MJ. Composite Scores of Plasma Tau and β -Amyloids Correlate with Dementia in Down Syndrome. *ACS Chem Neurosci.* 2020 Jan 15;11(2):191-196.
5. Lee CT, Tung YC, Hwu WL, Shih JC, Lin WH, Wu MZ, Kuo KT, Yang YL, Chen HL, Chen M, Su YN, Jong YJ, Liu SY, Tsai WY, Lee NC*. Mosaic paternal haploidy in a patient with pancreatoblastoma and Beckwith-Wiedemann spectrum. *Am J Med Genet A.* 2019 Sep;179(9):1878-1883.
6. Yu MH, Tsang MH, Lai S, Ho MS, Tse DML, Willis B, Kwong AK, Chou YY, Lin SP, Quinzii CM, Hwu WL, Chien YH, Kuo PL, Chan VC, Tsoi C, Chong SC, Rodenburg RJT, Smeitink J, Mak CC, Yeung KS, Fung JL, Lam W, Hui J, Lee NC*, Fung CW, Chung BH. Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. *NPJ Genom Med.* 2019 Aug 5;4:18.
7. Lee NC, Hsu WC, Chang LM, Chen YC, Huang PT, Chien CC, Chien YH, Chen CL, Hwu WL, Lee PL. REM sleep and sleep apnea are associated with language function in Down syndrome children: An analysis of a community sample. *J Formos Med Assoc.* 2019 Aug 1.
8. Wu ET, Hwu WL, Chien YH, Hsu C, Chen TF, Chen NQ, Chou HC, Tsao PN, Fan PC, Tsai IJ, Lin SP, Hsieh WS, Chang TM, Chen CN, Lee CH, Chou YY, Chiu PC, Tsai WH, Hsiung HC, Lai F, Lee NC*. Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients With Severe Illnesses. *Pediatr Crit Care Med.* 2019 Jul 1.

9. Tseng CH, Chien YH, Lee NC, Hsu YC, Peng SF, Tseng WI, Hwu WL. Gene therapy improves brain white matter in aromatic l-amino acid decarboxylase deficiency. *Ann Neurol*. 2019 May;85(5):644-652.
10. Ho SY, Chien YH, Tsai LK, Muramatsu S, Hwu WL, Liou HH, Lee NC*. Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency. *Front Cell Neurosci*. 2019 Jan
11. Hsu RH, Chien YH, Hwu WL, Chang IF, Ho HC, Chou SP, Huang TM, Lee NC*. Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population. *Orphanet J Rare Dis*. 2019 Jan 7;14(1):6.
12. Lee NC, Chien YH, Hwu WL. A review of aromatic l-amino acid decarboxylase (AADC) deficiency in Taiwan. *Am J Med Genet C Semin Med Genet*. 2019 Jan 7.
13. Luo S, Valencia CA, Zhang J, Lee NC, Slone J, Gui B, Wang X, Li Z, Dell S, Brown J, Chen SM, Chien YH, Hwu WL, Fan PC, Wong LJ, Atwal PS, Huang T. Biparental Inheritance of Mitochondrial DNA in Humans. *Proc Natl Acad Sci U S A*. 2018 Nov 26.
14. Mak CC, Leung GK, Mok GT, Yeung KS, Yang W, Fung CW, Chan SH, Lee SL, Lee NC, Pfundt R, Lau YL, Chung BH. Exome sequencing for paediatric-onset diseases: impact of the extensive involvement of medical geneticists in the diagnostic odyssey. *NPJ Genom Med*. 2018 Aug 6;3:19.
15. Hsu RH, Hwu WL, Chen M, Chung IF, Peng SS, Chen CY, Cheng WC, Chien YH, Lee NC*. Next-generation sequencing identifies TRPV4-related skeletal dysplasia in a boy with progressive bowlegs. *Pediatr Neonatol*. 2018 Apr 13. pii: S1875-9572(17)30574-0.
16. Hsu RH, Lin WD, Chao MC, Hsiao HP, Wong SL, Chiu PC, Chu SY, Ke YY, Lau BH, Chien YH, Hwu WL, Tsai FJ, Wang CH, Lee NC*. Congenital generalized lipodystrophy in Taiwan. *J Formos Med Assoc*. 2019 Jan;118(1 Pt 1):142-147.
17. Kruszka P, Porras AR, de Souza DH, Moresco A, Huckstadt V, Gill AD, Boyle AP, Hu T, Addissie YA, Mok GTK, Tekendo-Ngongang C, Fieggen K, Prijoles EJ, Tanpaiboon P, Honey E, Luk HM, Lo IFM, Thong MK, Muthukumarasamy P, Jones KL, Belhassan K, Ouldin K, El Bouchikhi I, Bouguenouch L, Shukla A, Girisha KM, Sirisena ND, Dissanayake VHW, Paththinige CS, Mishra R, Kisling MS, Ferreira CR, de Herreros MB, Lee NC, Jamuar SS, Lai A, Tan ES, Ying Lim J, Wen-Min CB, Gupta N, Lotz-Esquivel S, Badilla-Porras R, Hussen DF, El Ruby MO, Ashaat EA, Patil SJ, Dowsett L, Eaton A, Innes AM, Shotelersuk V, Badoe Ě, Wonkam A, Obregon MG, Chung BHY, Trubnykova M, La Serna J, Gallardo Jugo BE, Chávez Pastor M, Abarca Barriga HH, Megarbane A, Kozel BA, van Haelst MM, Stevenson RE, Summar M, Adeyemo AA, Morris CA, Moretti-Ferreira D, Linguraru MG, Muenke M. Williams-Beuren syndrome in diverse populations. *Am J Med Genet A*. 2018 May;176(5):1128-1136.
18. Tung YC, Lee NC, Hwu WL, Liu SY, Lee CT, Chien YH, Tsai WY. SHOX deficiency in short Taiwanese children: A single-center experience. *J Formos Med Assoc*. 2018 Oct;117(10):909-914.
19. Lee NC, Hwu WL, Muramatsu SI, Falk DJ, Byrne BJ, Cheng CH, Shih NC, Chang KL, Tsai LK, Chien YH. A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. *Mol Neurobiol*. 2018 Jun;55(6):5299-5309.
20. Lee NC, Chien YH, Hwu WL. A Review of Biomarkers for Alzheimer's Disease in Down Syndrome. *Neurol Ther*. 2017 Jul;6(Suppl 1):69-81.
21. Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu SI, Byrne BJ, Hwu WL. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. *Lancet Child Adolesc Health*. 2017 Dec;1(4):265-273.
22. Lee NC, Yang SY, Chieh JJ, Huang PT, Chang LM, Chiu YN, Huang AC, Chien YH, Hwu WL, Chiu MJ. Blood Beta-Amyloid and Tau in Down syndrome: A Comparison with Alzheimer's Disease. *Front. Aging Neurosci.*, 2017 Jan 17;8:316.

兒童罕病的精準醫療 – 機會與挑戰**Precision Medicine for Critically Ill Children – Opportunities and Challenges**

Ni-Chung Lee

Department of Pediatrics and Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

Critical illness in infants and children, especially those caused by genetic diseases, is one of the most challenging fields in maternal and children health. In the intensive care units patients are threatened by death or serious sequelae; but specific diagnosis won't be established. Because precise managements in respective of the disease are not possible, the prognosis of patients can be poor even though large amount of medical resources are consumed. Our team employs rapid whole exome sequencing (WES), for in time diagnosis of critical illness in infants and children. The work flow encompasses collaboration between clinical and bench work, establishment of clinical network, WES technical improvements to increase speed and efficiency, clinical reading of WES, and development of WES clinical reading program with artificial intelligence assistance We run trio (patient and parents) samples to increase diagnostic yields. The time from sample collection to pivotal report is 6 working days with a diagnostic yield around 50%. We create a new standard for clinical care for critically ill children in Tawian. With this, we hope to improve the care of our children.

Pi-Yueh Chang, Ph.D. (張璧月)**Current position and professional experiences**

- 2019/6 ~ Present **Technical Director,**
Department of laboratory medicine, Linkou
Chang Gung Memorial Hospital
- 2018/3 ~ Present **Assistant professor,**
Department of Medical Biotechnology and
Laboratory Science, Chang Gung University
- 2008/7 ~ 2019/5 **Deputy Chief Technologist,**
Department of laboratory medicine,
Linkou Chang Gung Memorial Hospital

**Research interest**

1. Clinical molecular diagnosis
2. Tumor marker exploration
3. ELISA kit development

Short research summary

Pi-Yueh Chang is a Director at Department of Laboratory Medicine in Linkou Chang Gung Memorial Hospital and an Assistant Professor at the Department of Medical Biotechnology and Laboratory Science, Chang Gung University. Mrs. Chang has been in charge the Clinical Molecular Diagnostic Lab for the past 15 years and implemented more than 30 laboratory-developed molecular tests for clinical use, such as molecular tests for emerging infectious pathogens and tests for single-gene caused rare diseases. In recent year, her team turned to develop multigene tests for common diseases such as epilepsy, obesity, gout, heart disease, cleft palate, or deafness by next generation sequencer or MassArray platform. And her research interests focus on exploration of genetic cancer markers especially for colorectal cancer.

Publications

1. **Pi-Yueh Chang**, Yung-Bin Kuo, Tsu-Lan Wu, Chun-Ta Liao, Yu-Chen Sun, Tzu-Chen Yen, Err-Cheng Chan. Association and Prognostic Value of Serum Inflammation Markers in Patients with Leukoplakia and Oral Cavity Cancer. Clin Chem Lab Med 2013;51:1291-300
2. Chao-Hua Fu, Wei-ting Chen, **Pi-Yueh Chang** *, Ming-Ta. Michael Lee, Ming-Shien Wen. Revalidation of CoaguChek XS Plus System for INR Monitoring in Taiwanese Patients: Effects of Clinical and Genetic Factors. Biomed J 2014;37:380-5 * Corresponding
3. Ying-Hao Wen, **Pi-Yueh Chang**, Chen-Ming Hsu, Hsin-Yao Wang, Cheng-Tang Chiu, Jang-Jih Lu. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: results from a 12-year experience. Clin Chim Acta 2015;450:273-76
4. Kuang-Hui Yu, Tien-Ming Chan, Ping-Han Tsai, Ching-Hui Cheng, **Pi-Yueh Chang** *. Diagnostic Performance of Serum IgG4 Levels in Patients With IgG4-Related Disease. Medicine 2015; 94:e1707 (IF:1.206) * Corresponding
5. **Pi-Yueh Chang**, Cheng-Tao Yang, Ching-Hui Cheng, Kuang-Hui Yu. Diagnostic Performance of Anti-cyclic Citrullinated Peptide and Rheumatoid Factor in Patients with Rheumatoid Arthritis. Int J Rheum Dis 2016;19(9):880-6
6. **Pi-Yueh Chang**, Chia-Chun Chen, Yu-Sun Chang, Wen-Sy Tsai, Jeng-Fu You, Geng-Ping Lin, Ting-Wen Chen, Jinn-Shiun Chen, Err-Cheng Chan. MicroRNA-223 and microRNA-92a in stool and

plasma samples act as complementary biomarkers to increase colorectal cancer detection. *Oncotarget* 2016 Mar 1; 7(9):10663-75. Doi:10.18632

7. **Pi-Yueh Chang**, Jinn-Shiun Chen, Nai-Chung Chang, Shih-Cheng Chang, Mei-Chia Wang, Shu-Hui Tsai, Ying-Hao Wen, Wen-Sy Tsai, Err-Cheng Chan, Jang-Jih Lu. NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing. *Oncotarget* 2016 Jun 21;7(25):37566-80. doi: 10.18632
8. Hsiu-Huei Peng, Nai-Chung Chang, Kuo-Ting Chen, Jang-Jih Lu, **Pi-Yueh Chang**, Shih-Cheng Chang, Yah-Huei Wu-Chou, Yi-Ting Chou, Wannii Phang, Po-Jen Cheng. Nonsynonymous variants in MYH9 and ABCA4 are the most frequent risk loci associated with nonsyndromic orofacial cleft in Taiwanese population. *BMC Med Genet* 2016;17:59
9. Mei-Chia Wang, Chih-Liang Wang, Tai-Long Chen, John Wen-Cheng Chang, Jang-Jih Lu, **Pi-Yueh Chang***, Chiu-Chian Chiou*. Predicting Outcomes of EGFR-Targeted Therapy in Non-Small Cell Lung Cancer Patients Using Pleural Effusions Samples and Peptide Nucleic Acid Probe Assay. *Clin Chem Lab Med* 2017;55(12):1979-86. *Corresponding
10. **Pi-Yueh Chang**, Jinn-Shiun Chen, Shih-Cheng Chang, Mei-Chia Wang, Nai-Chung Chang, Ying-Hao Wen, Wen-Sy Tsai, Wei-Hsiu Liu, Hsiu-Ling Liu and Jang-Jih Lu. Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer. *Oncotarget* 2017;8(42):72352-62.
11. Kuang-Hui Yu, **Pi-Yueh Chang**, Shih-Cheng Chang, Yah-Huei Wu-Chou, Li-An Wu, Ding-Pin Chen, Fu-Sung Lo, and Jang-Jih Lu. A comprehensive analysis of the association of common variants of ABCG2 with gout. *Sci Rep* 2017;7(1):9988. doi: 10.1038/s41598-017-10196-2
12. Hsin-Shih Wang, Chia-Lung Tsai, **Pi-Yueh Chang**, Angel Chao, Ren-Chin Wu, Shun-Hua Chen, Chin-Jung Wang, Chih-Feng Yen, Yun-Shien Lee, Tzu-Hao Wang Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. *PLoS ONE* 2018,13(1): e0190573.
13. Wei-Hsiu Liu; **Pi-Yueh Chang#**; Shih-Cheng Chang; Jang-Jih Lu; Che-Ming Wu. Mutation Screening in Non-syndromic Hearing Loss Patients with Cochlear Implant by Massive Parallel Sequencing in Taiwan. *PLOS ONE* 2019,14(1) : e0211261, <https://doi.org/10.1371/journal.pone.0211261>, # co-first author
14. **Pi-Yueh Chang**, Chia-Chun Chen, Jy-Ming Chiang, Shih-Cheng Chang, Mei-Chia Wang, Jinn-Shiun Chen, Wen-Sy Tsai, Jeng Fu You and Jang-Jih Lu. A Simple and Highly Specific MassARRAY-Based Stool DNA Assay to Prioritize Follow-up Decisions in Fecal Immunochemical Test-Positive Individuals. *Cancers* 2019, 11, 423; doi:10.3390/cancers11030423
15. **Pi-Yueh Chang**, Shih-Cheng Chang, Mei-Chia Wang, Jinn-Shiun Chen, Wen-Sy Tsai, Jeng Fu You, Chia-Chun Chen, Hsiu-Ling Liu, Jy-Ming Chiang. Pathogenic germline mutations of DNA repair pathway components in early-onset sporadic colorectal polyp and cancer patients 2020 (under revision)

我會得癌症嗎？遺傳性癌症基因檢測經驗分享**Am I Susceptible to Cancer?**

Pi-Yueh Chang

Department of Laboratory Medicine, Chang Gung Memorial Hospital at LinKou Taoyuan, Taiwan

Sometimes, certain types of cancer seem to run in some families because family members share certain behaviors or exposures such as smoking or obesity. However, in some cases the cancer is caused by an abnormal gene that is being passed along from generation to generation and we often referred it to "inherited cancer". Only about 5% to 10% of all cancers result directly from gene defects inherited from a parent. In this talk, I will introduce: (1) Clinical definition of family cancer syndrome which considering the onset age, how many cases of the same type of cancer in the pedigree, whether more than one type of cancer occurred in a single person et al. (2) Genes specifically associated with inherited cancer, using hereditary breast and ovarian cancer syndrome and Lynch syndrome as examples. (3) How do we identify cancer-predisposed individuals by multigene panel testing on next generation sequencing platform? What's the optimal gene content in the panel? How do we make sure the high complexity genetic testing been performed accurately? How do we interpretate the gene test results for risk assessment? (4) What is the clinical performance of the hereditary cancer panel test based on sensitivity and cost-effectiveness point of view? Finally, I will share the experience of offering inherited cancer panel service in Linkou Chang Gung Memorial Hospital.

Jang-Jih Lu, M.D., Ph.D. (盧章智)

Current position and professional experiences

- 2011 ~ Present **Director and Professor**, Department of Laboratory Medicine, LinKou Chang Gung Memorial Hospital
- 2019 ~ 2021 **President**, Taiwan Precision Medicine Society
- 2012 ~ 2018 **President**, Taiwan Society of Clinical Pathologist and Laboratory Medicine
- 2012 ~ 2015 **President**, Taiwan Association of Histocompatibility
- 2001 ~ 2021 **Executive Council**, Taiwan Society of Microbiology
- 2008 ~ 2011 **Director and Professor**, Department of Laboratory Medicine, China Medical University Hospital, Taichung
- 2003 ~ 2008 **Director and Professor**, Division of clinical Pathology, Department of Pathology, Tri-Service General Hospital

**Research interest**

1. Clinical microbiology
2. Infectious diseases
3. Molecular epidemiology, antimicrobial drug resistance and molecular diagnosis
4. Laboratory management and accreditation

Short research summary

My main research contributions focus on the field of clinical microbiology to address the clinical and epidemiological important questions involving in bacterial infectious diseases. I continuously investigate many clinically significant bacterial pathogens including gram-positive bacteria (methicillin-resistant *Staphylococcus aureus*, *S. lugdunensis*, *S. haemolyticus*, Group B *Streptococcus* and vancomycin-resistant *Enterococcus faecium*), *Campylobacter spp.*, and *Candida albicans*. My another main research is to develop and validate a rapid and accurate method for detecting antimicrobial resistance or typing strains by using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry and artificial intelligence / machine learning (ML) methods. One of my major achievements was to use tumor markers and ML technology for more accurate and subjective cancer screening. The results of the study had been patented (Pub. No. 發明第 I630501, Pub. date : 2018/07/21) (USA, Filing No. 15/382,212, Filing date : 2016/12/16) and transferred to 20/20 GeneSystems Inc.

Publications

1. Wang HY, Chung CR, Wang Z, Li S, Chu BY, Horng JT, **Lu JJ***, Lee TY. A large-scale investigation and identification of methicillin-resistant *Staphylococcus aureus* based on peaks binning of matrix-assisted laser desorption ionization-time of flight MS spectra. *Brief Bioinformatics*. 2020. Jul 16:bbaa138. Doi: 10.1093/bib/bbaa138. Online ahead of print. PMID: 32672791.
2. Wang HY, Chen CH, Shi S, Chung CR, Wen HY, Wu MH, Lebowitz MS, Zhou J, **Lu JJ***. Improving Multi-Tumor Biomarker Health Check-up Tests with Machine Learning Algorithms. *Cancers (Basel)*. 2020 Jun 1;12(6)1442. doi: 10.3390/cancers12061442. PMID: 32492934.
3. Lin LC, Ge MC, Liu TP, **Lu JJ*** 2020. Molecular epidemiological survey of prophages in MRSA isolates in Taiwan. *Infect Drug Resist*. 2020 Feb 24;13:635-641.

4. Wang SH, Chen CC, Lee CH, Chen XA, Chang TY, Cheng YC, Young JJ, **Lu JJ***. 2020. Fungicidal and anti-biofilm activities of trimethylchitosan-stabilized silver nanoparticles against *Candida* species in zebrafish embryos. *Int J Biol Macromol*. 2020 Jan 15;143:724- 731.
5. Yang SL, Wen YH, Wu YS, Wang MC, Chang PY, Yang S, **Lu JJ***. 2019. Diagnosis of *Pneumocystis pneumonia* by real-time PCR in patients with various underlying diseases. *J Microbiol Immunol Infect*. 2019 Oct 7. pii: 1684-1182(19)30147-1. doi: 10.1016/j.jmii.2019.08.012. [Epub ahead of print] PMID 31635929
6. Chung CR, Wang HY, Lien F, Tseng YJ, Chen CH, Lee TY, Liu TP, Horng JT, **Lu JJ***. 2019. Incorporating Statistical Test and Machine Intelligence Into Strain Typing of *Staphylococcus haemolyticus* Based on Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. *Front Microbiol*. 2019 Sep 13;10:2120. doi: 10.3389/fmicb.2019.02120. eCollection 2019. PMID 31572327
7. Wang HY, Hung CC, Chen CH, Lee TY, Huang KY, Ning HC, Lai NC, Tsai MH, Lu LC, Tseng YJ, **Lu JJ***. 2019. Increase *Trichomonas vaginalis* detection based on urine routine analysis through a machine learning approach. *Sci Rep*. 2019 Aug 19;9(1):11074. doi: 10.1038/s41598-019-47361-8. PMID 31423009.
8. Tsai MH, Lin LC, Hsu JF, Lai MY, Huang HR, Chiang MC, **Lu JJ***. 2019. Rapid identification of invasive fungal species using sensitive universal primers-based PCR and restriction endonuclease digestions coupled with high-resolution melting analysis. *J Microbiol Immunol Infect*. 2019 Oct;52(5):728-735.
9. Chang SC, Lin LC, Ge MC, Liu TP, **Lu JJ***. 2019. Characterization of a novel, type II staphylococcal cassette chromosome mec element from an endemic oxacillin-resistant *Staphylococcus lugdunensis* clone in a hospital setting. *J Antimicrob Chemother*. 2019 May 18. pii: dkz189. doi: 10.1093/jac/dkz189. [Epub ahead of print]
10. Tseng YJ, Huang CE, Wen CN, Lai PY, Wu MH, Sun YC, Wang HY, **Lu JJ***. 2019. Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. *Int J Med Inform*. 2019 Aug;128:79-86. doi:10.1016/j.ijmedinf. 2019.05.003. Epub 2019 May 7.
11. Chang PY, Chen CC, Chiang JM, Chang SC, Wang MC, Chen JS, Tsai WS, You JF, **Lu JJ***. 2019. A Simple and Highly Specific MassARRAY-Based Stool DNA Assay to Prioritize Follow-up Decisions in Fecal Immunochemical Test-Positive Individuals. *Cancers (Basel)*. 2019 Mar 25;11(3). pii: E423. doi: 10.3390/cancers11030423.
12. Tsai MH, Hsu JF, Lai MY, Lin LC, Chu SM, Huang HR, Chiang MC, Fu RH, **Lu JJ***. 2019. Molecular Characteristics and Antimicrobial Resistance of Group B Streptococcus Strains Causing Invasive Disease in Neonates and Adults. *Front Microbiol*. 2019 Feb 18;10:264. doi: 10.3389/fmicb.2019.00264. eCollection 2019.
13. Yeh HC, **Lu JJ***, Chang SC, Ge MC. 2019. Identification of microbiota in peri-implantitis pockets by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Sci Rep*. 2019 Jan 28;9(1):774. doi: 10.1038/s41598-018-37450-5. **(Equally contributed with first author)**
14. Liu WH, Chang PY, Chang SC, **Lu JJ***, Wu CM. 2019. Mutation screening in non-syndromic hearing loss patients with cochlear implantation by massive parallel sequencing in Taiwan. *PLoS One*. 2019 Jan 25;14(1):e0211261. doi: 10.1371/journal.pone.0211261. eCollection 2019.
15. Ge MC, Kuo SF, Chang SC, Chien CC, You HL, **Lu JJ***. 2019. Antimicrobial Susceptibility and Virulence Surveillance of *Campylobacter* spp. Isolated From Patients in Two Tertiary Medical Centers in Taiwan. *Front Microbiol*. 2019 Jan 7;9:3186. doi: 10.3389/fmicb.2018.03186. eCollection 2018.
16. Wang HY, **Lu JJ**, Chang CY, Chou WP, Hsieh JC, Lin CR, Wu MH. 2019. Development of a high sensitivity TaqMan-based PCR assay for the specific detection of *Mycobacterium tuberculosis* complex in both pulmonary and extrapulmonary specimens. *Sci Rep*. 2019 Jan 14;9(1):113. doi: 10.1038/s41598-018-33804-1. **(Equally contributed with first author)**

Chen-Wen Yen, Ph.D. (嚴成文)

Current position and professional experiences

Professor, Department of Mechanical and Electro-Mechanical Engineering, Sun Yat-Sen University, Kaoshing, Taiwan



Research interest

1. Machine learning
2. Sleep medicine
3. Intelligent medical diagnostic systems
4. Physiological signal processing

Short research summary

1. 2011, 2011, 2015, 2017, Distinguished Teaching Award, National Sun Yat-sen University
2. 2013, 2014, National Instrument Engineering Impact Awards
3. 2018, Two National Innovators Awards
4. 2018, Associate Vice President for Research & Development, National Sun Yat-sen University
5. Excellent Teacher Award, Ministry of Education, Taiwan

Publications

1. Hong CY, Guo LY, Song R, Nagurka ML, Sung JL, Yen CW, 2016, "Assessing postural stability via the correlation patterns of vertical ground reaction force components," Biomed Eng Online. Vol. 15, 90.
2. Hong CY, Guo LY, Song R, Nagurka ML, Sung JL, Yen CW, 2017, "Developing a low cost treadmill vi dynamic modeling," Journal of Healthcare Engineering, Article ID 9875471.
3. Lin NH, Hsu CY, Luo Y, Nagurka ML, Sung JL, Hong CY, Yen CW, 2107, "Detecting rapid eye movement sleep using a single EEG signal channel," Expert Systems with Applications, 2017, Vol. 87, 220-227.
4. Liu CH, Lee PL, Chen YL, Yen CW, 2020, "Developing postural stability measures by using Kinect to assess body joint coordinatin patterns," Sensors (Basel). Vol. 20(5).

睡眠醫學遇上機器學習**When Sleep Medicine Meets Machine Learning****嚴成文**

高雄國立中山大學 機械與機電工程學系

對機器學習而言，睡眠既是目的也是手段。以手段而言，機器學習的挑戰主在於建立評估睡眠品質的客觀指標，幫助大家了解自己的各項作為是否有助於達到一夜好眠的目的。所以以目的而言，由於許多疾病都會影響睡眠，機器學習的主要功能在於如何由睡眠中的各項生理訊號萃取出能客觀評估疾病嚴重度的量化特徵，追蹤病情的變化，進而協助規劃有效的介入方式。報告中將以多個實例來說明研究的規劃，並具體描述目前的困難。

Chin-An Yang, M.D., Ph.D. (楊晶安)**Current position and professional experiences**

- 2019/8 ~ Present 中國醫藥大學醫學系實驗診斷科專任副教授
(院校合聘)
- 2018/12 ~ Present 中國醫藥大學新竹附設醫院檢驗科主任
- 2018/12 ~ Present 中國醫藥大學新竹附設醫院臨床病理科暨兒
科(過敏免疫風濕次專科)主治醫師
- 2019/8 ~ Present 中國醫藥大學新竹附設醫院教學部主任
- 2019 ~ Present 台灣臨床病理暨檢驗醫學會中區副秘書長
台灣精準醫學會中區副秘書長
- 2020/2 ~ Present 國立清華大學生醫工程與環境科學系合聘副
教授
- 2007/9 ~ 2011/1 德國柏林洪堡大學醫學免疫研究所博士
- 2011/7 ~ 2014/7 台大醫院小兒部住院醫師

**Research interest**

1. Laboratory medicine
2. Immunology
3. Molecular genetics
4. Bioinformatics

Short research summary

My research focuses on complex immune diseases and cancers using multi-cohort and multi-omics approaches. The aims of our studies are to understand the underlying mechanisms, to identify diagnostic biomarkers, and to build up prognostication models. Another part of my research is related to clinical laboratory automation.

Publications

1. Yang CA, Li JP, Yen JC, Lai IL, Ho YC, Chen YC, Lan JL, Chang JG (2018, Sep). lncRNA NTT/PBOV1 Axis Promotes Monocyte Differentiation and Is Elevated in Rheumatoid Arthritis. *International Journal of Molecular Sciences*, 2018 Sep 18;19(9).pii: E2806.
2. Yang CA, Bauer S, Ho YC, Sotzny F, Chang JG, Scheibenbogen C (2018, Aug). The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome. *Journal of Transnational Medicine*, 2018 Aug 17;16(1):231.
3. Yang CA, Chou IC, Cho DY, Lin CY, Huang HY, Ho YC, Liu TY, Li YH, Chang JG. (2018, May). Whole exome sequencing in Dandy-Walker variant with intellectual disability reveals an activating CIP2A mutation as novel genetic cause. *Neurogenetics*, 2018 Aug;19(3):157-163.
4. Yang CA, Huang HY, Yen JC, and Chang JG. (2018, May). Prognostic value of RNASEH2A-, CDK1-, and CD151-related pathway gene profiling for kidney cancers. *International Journal of Molecular Sciences*, 2018 May 28;19(6).
5. Chin-An Yang, Chao Liang, Chia-Li Lin, Chiung-Tzu Hsiao, Ching-Tien Peng, Hung-Chih Lin, Jan-Gowth Chang (2017, Sep). Impact of *Enterobius vermicularis* infection and mebendazole treatment on intestinal microbiota and host immune response. *Plos Neglected Tropical Diseases*, 2017 Sep 25;11(9):e0005963.
6. Chin-An Yang, Jiunu-An Lin, Ci-Wen Chang, Kang-Hsi Wu, Su-Peng Yeh, Cheng-Mao Ho, Jan-

Gowth Chang (2016, Oct). Selection of GP. Mur antigen negative RBC for blood recipients with anti-“Mia” records decreases transfusion reaction rate in Taiwan. *Transfusion Medicine*, 2016 Oct;26(5):349-354.

7. Chin-An Yang, Bor-Luen Chiang (2015, Jun). Inflammasomes and human autoimmunity: A comprehensive review. *Journal of Autoimmunity*, 2015 Jul;61:1-8.
8. Chin-An Yang, Shin-Tsung Huang, Bor-Luen Chiang (2015, Feb). Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages. *Rheumatology*, 2015 Feb;54(2):324-31.
9. Chin-An Yang, Bor-Luen Chiang (2015, Jan). Toll-like receptor 1 N248S polymorphism affects T helper 1 cytokine production and is associated with serum immunoglobulin E levels in Taiwanese allergic patients. *Journal of Microbiology, Immunology and Infection*, 2017 Feb;50(1):112-117.
10. 專書論文：楊晶安，何承懋，張建國（2017年10月）。第七章 檢驗與診斷推理及治療決策。臨床推理-現代觀與教學應用（ISBN：978-986-93670-9-7）（p.117~131）。台北：台灣艾思唯爾。

精準用藥：從高維度次世代定序資訊分析談起
Drug Selection Using High-dimensional NGS Data Analysis

楊晶安

中國醫藥大學新竹附設醫院, 台灣

在精準醫學時代，執行次世代定序相較以前方便很多，臨床醫師有機會利用此項技術為病人的檢體做多體學的分析。每位病人都是獨立的個體，即使得到同一種感染，或是得到同一種癌症，也可能有著不同的生理特徵及藥物反應，甚至同一人體內不同微環境內的細胞，隨著時間，也可能產生不同的變化。以多體學的角度分析這些異質性，能提供臨床寶貴的資訊，用以達到個人化醫療。但次世代定序的資料十分龐大，如何從中分析出真正與疾病相關的用藥資訊是關鍵。本演講將從精準醫學檢驗和臨床醫師的角度討論高維度次世代定序資訊分析可能遇到的判讀問題，提供次世代定序與臨床癌症指引整合的癌症範例，分享尋找癌症替代路徑相關標的的過程，並討論如何利用免疫高通量分析尋找嚴重新冠肺炎病人可能的診斷及治療方式。

Eric Pok Yang, Ph.D. (楊博鈞)**Current position and professional experiences**

2020/9 ~ Present	Chief Business Officer , Quark Biosciences, Inc.
2018/5 ~ Present	Secretary General , Precision Medicine & Molecular Diagnostics Industry Association (PMMD Taiwan)
2016/8 ~ 2020/8	Vice President , Quark Biosciences, Inc.
2015/6 ~ 2016/7	Director , Application and Business Development, Quark Biosciences, Inc.
2015/1 ~ 2015/5	Manager , Business Development, Quark Biosciences, Inc.
2005 ~ 2007	Howard Hughes Postdoctoral Fellow , Harvard Medical School

**Research interest**

1. Clinical diagnostics tools
2. Cancer biomarkers
3. Non-coding RNA

Short background summary

Dr. Eric Pok Yang joined Quark Biosciences in 2015 and was appointed Chief Business Officer in 2020. As a serial entrepreneur passionate in building world class brands, he currently oversees the company's marketing strategy and corporate development. Since joining Quark, Dr. Yang has successfully launched a number of products in precision oncology and reproductive healthcare.

Dr. Yang majored in Biochemistry at the University of California, Los Angeles (UCLA). After receiving his bachelor's degree, he joined the laboratory of Guillaume Chanfreau at UCLA to further his studies in Molecular Biology and Biochemistry. His doctoral thesis focused on deciphering the biogenesis of essential non-coding RNAs responsible for the modifications of ribosomal RNAs. Dr. Yang continued his research in long non-coding RNAs as a Howard Hughes Medical Institute Scholar at Harvard Medical School.

Publications

1. A Novel Multi-Gene Detection Platform for the Analysis of miRNA Expression. Science Report. Chia-Hsun Hsieh, Wei-Ming Chen, Yi-Shan Hsieh, Ya-Chun Fan, **Pok Eric Yang**, Shih-Ting Kang, Chun-Ta Liao.
2. miPrimer: an empirical-based qPCR primer design method for small noncoding microRNA. RNA. Shih-Ting Kang, Yi-Shan Hsieh, Chi-Ting Feng, Yu-Ting Chen, **Pok Eric Yang**, Wei-Ming Chen.
3. MSL complex is attracted to genes marked by H3K36 trimethylation using a sequence-independent mechanism. Molecular Cell. Erica Larschan, Artyom A Alekseyenko, Andrey A. Gortchakov, Shouyong Peng, Bing Li, **Pok Yang**, Jerry L Workman, Peter J Park, Mitzi I Kuroda
4. Noncoding RNAs and intranuclear positioning in monoallelic gene expression. Cell. **Pok Kwan Yang**, Mitzi I Kuroda.
5. Cotranscriptional recruitment of the pseudouridylsynthetase Cbf5p and of the RNA binding protein Naf1p during H/ACA snoRNP assembly. Molecular and Cellular Biology. **Pok Kwan Yang**, Coralie Hoareau, Carine Froment, Bernard Monsarrat, Yves Henry, Guillaume Chanfreau
6. The Shq1p.Naf1p complex is required for box H/ACA small nucleolar ribonucleoprotein particle

biogenesis. *Journal of Biological Chemistry*. **Pok Kwan Yang**, Giuseppe Rotondo, Tanya Porras, Pierre Legrain, Guillaume Chanfreau.

7. Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. *Oncogene*. Eri S Srivatsan, Rita Chakrabarti, Kayvan Zainabadi, Svetlana D Pack, Payam Benyamini, Marc S Mendonca, **Pok Kwan Yang**, Kevin Kang, Daria Motamedi, Mark P Sawicki, Zhengping Zhuang, Rachel A Jesudasan, Ulla Bengtsson, Chi Sun, Bruce A Roe, Eric J Stanbridge, Sharon P Wilczynski, J Leslie Redpath.

The Various Diagnostic Technologies for Precision Target Therapy

Eric P. Yang

Quark Biosciences, Taiwan

In the past few years, targeted therapy has become a mainstay in cancer treatment. With increasing amount of genomic data being generated, more cancer drugs are being developed each targeting specific gene alteration. As a result of the many options available, the goal for the clinicians is to identify patients with the alteration that will benefit from the treatment. While traditional methodologies are most used, newer and more sophisticated molecular diagnostic tools are now at the physicians' disposal. Here we examined various novel technologies that can be employed to detect mutations/rearrangements to aid precision target therapy.

Invited Speeches

(TGMBS & TPMS)

Target Therapy – Moderator

Hall III Section IV 11/15 13:30-14:55

科技新知分享

**New Frontiers in the Development of
Science and Biotechnology**

New Frontiers in the Development of Science and Biotechnology

日期 Date	11月14日 Nov. 14	時間 Time	12:40-13:20	地點 Position	第一會議廳 Lecture Hall I
公司名稱	台灣賽默飛世爾科技股份有限公司 Thermo Fisher				
演講主題	Orbitrap Exploris™ Mass Spectrometry – The Preferred Platform for Proteomics				
演講人	<p>簡芷薇 Chih-Wei Chien, PhD Application Scientist Center of Excellence for Applications & Training, SEA & TW Chromatography & Mass Spectrometry Division, Thermo Fisher Scientific, Taiwan</p> <p>Dr. Chien received her Ph.D. in Chemistry from National Tsing-Hua University, Taiwan in 2013. She worked as a postdoctoral researcher at Carnegie Institution for Science, Stanford, CA, USA in 2016, working on Immuno-precipitation–Mass Spectrometry (IP-MS) approach in the study of protein-protein interactome, related to brassinosteroid signaling in Arabidopsis. She has extensive experience in MS-based approaches to study quantitative proteomics in various biological specimens analysis as well as biomarker discovery in cancers. Prior to joining the biotechnology industry, she then joined Meribank Biotechnology Co., Ltd and was mainly responsible for the precision medicine project in maternal diseases. She has delineated stem cell multi-omic profiling in preterm birth and discovered the novel biomarkers for further in-vitro diagnostic application. She joined Thermo Fisher Scientific to explore more innovative applications and marketing in life science mass spectrometry.</p>				
演講摘要	<p>The new benchmark for proteomics requires the precise quantitation of all identified proteins, setting the foundation for bolder hypotheses and deeper understanding. Orbitrap mass spectrometers offer leading mass spectrometry (MS) technology for identifying and quantifying complex proteomics samples over a wide dynamic range. With established sample preparation, chromatographic separation and integrated data analysis tools, Orbitrap mass spectrometers enable researchers to successfully analyze diverse sample matrices with industry-leading sensitivity.</p> <p>Herein, we present the Orbitrap Exploris™ high-resolution, accurate-mass (HRAM) LCMS, with the power of built-in intelligence, sensitivity and selectivity delivers depth of analysis, to the lowest levels. Besides, the FAIMS Pro™ interface works seamlessly with next-generation MS technologies to enhance selectivity and enable the identification and quantitation of higher numbers of proteins than ever before. Combining HRAM instrumentation with differential ion mobility methods and orthogonal gas-phase separation techniques can reduce the complexity of accumulating and analyzing precursor ions, increasing proteome coverage, decreasing interference and improving quantitative confidence. The Orbitrap Exploris™ mass spectrometer can be helpful to obtain high confidence identifications, deeper proteome coverage, and enhanced biological knowledge generation.</p>				

New Frontiers in the Development of Science and Biotechnology

日期 Date	11月14日 Nov. 14	時間 Time	12:40-13:20	地點 Position	第三會議廳 Lecture Hall III
公司名稱	台灣科睿唯安股份有限公司 Clarivate™				
演講主題	使用 AI 工具加速研究創新				
演講人	<p>趙紫薇 科睿唯安 解決方案顧問 現為科睿唯安生命科學解決方案顧問，提供生命科學及智權的市場數據收集、分析及解讀，協助客戶解析靶點評估、產品選題、市場調查及競爭產品監控等商業決策。在加入科睿唯安之前，趙顧問曾任職於專利事務所及企業，參與專利申請、授權、技轉等業務。趙顧問於臺灣大學生物化學暨分子生物學研究所取得碩士學位，並在 2014 年通過中國專利代理人考試。近期報告：</p> <ul style="list-style-type: none"> • 《2018 年監管審批與世界接軌》 • 《罕見病藥物的機會與挑戰》 • 《2018 年全球新藥觀察暨 2019 年重磅預測》 • 《2020 最值得關注的重磅藥物》 • 《重磅藥物的研發早期特徵與授權獲利模式》 • 《新藥開發商品化之考慮-市場研究、競爭者分析、價值主張》 				
演講摘要	<p>使用 AI 工具不僅是進年來各大藥廠的趨勢，實務上在早期 pathway 及靶點選擇時即可導入 AI 工具，將繁瑣的數據評估工作交由 AI 代勞。在本演講及新知分享中，趙顧問將以實例說明研究者使用 AI 工具及可加速選擇合適的標的及研究設計；此外，AI 工具亦可應用在藥物上市成功率及時程預估，幫助給予計劃補助的單位合適並謹慎評估補助對象及其競品上市時程及成功率差異，合理調整補助產品組合(Portfolio)以達成最優效益。</p>				

New Frontiers in the Development of Science and Biotechnology

日期 Date	11月15日 Nov. 15	時間 Time	12:30-13:10	地點 Position	第一會議廳 Lecture Hall I
公司名稱	法德利科技股份有限公司 VtR Inc./Groupe Dassault				
演講主題	全球疫情帶來的醫藥產業新秩序—數據為王、有「它」就強！				
演講人	<p>李佩力 博士 美國伊利諾大學厄巴納-香檳分校植物病理學研究所 博士 現職：法德利科技股份有限公司 科學長</p> <p>經歷：創源生物科技股份有限公司 副總經理、分子視算股份有限公司 副總經理、法國達梭系統 (Dassault Systèmes BIOVIA)全球生物資訊與科學資訊首席講師、國際藥物工程學會(International Society for Pharmaceutical Engineering, ISPE)會員</p>				
演講摘要	<p>數位時代的現代醫藥產業 Tidal Change – Modern Pharma in the Digital Age</p> <p>數據、大數據、數據科學、數據分析學 – 你搞懂了嗎？ From Data, Big Data to Data Science and Data Analytics – Your precious data is worth more than you think</p> <p>疫情如何改變了醫藥產業 – 而且回不去了？ Life before pandemic and how COVID-19 changes everything – Pharma's perspective</p> <p>「它」如何幫助你度過難關並在產業新常態中勝出 What you can do about it and how Tableau can help?</p>				

New Frontiers in the Development of Science and Biotechnology

日期 Date	11月15日 Nov. 15	時間 Time	12:30-13:10	地點 Position	第三會議廳 Lecture Hall III
公司名稱	凱杰生物科技有限公司 QIAGEN				
演講主題	QIAGEN 實現 NGS 樣本定序到數據分析解決方案 QIAGEN Digital DNA sequencing, a total NGS solution to rapid diagnosis and annotate complex variants from oncology and hereditary disease.				
主持人	翁振哲先生 凱杰生物科技業務經理				
演講人	張量凱先生 凱杰生物科技應用技術支援專員				
演講摘要	<p>Somatic cancer : 針對不同表型之乳癌病患篩選位點並提供用藥資訊- a live case study</p> <p>Hereditary disease : 以 Trio 家族性遺傳性分析評斷多表型遺傳症狀之變異位點 - a live case study</p>				

學會資訊

Information of Societies





Taiwan Proteomics Society

台灣蛋白質學會

Taiwan Proteomics Society

關於學會

台灣蛋白質學會自 2003 年成立以來，透過積極推動各項教育訓練與籌辦學術會議達到：落實專業人才的培育、提供國內學生與學者展現研究成果的平台、促進國際合作與交流的機會、提升產業界與學術界之間的連結。為提升年輕學者的學術國際觀，學會每年也提撥預算，用以補助年輕學者參與此領域之重要國際會議。誠摯歡迎蛋白質體與代謝體領域的新血加入，支持學會之永續經營，以推廣更豐富多元的學術活動。

109 年度會員大會與第七屆理監事選舉

- 今年度會員大會因疫情因素延期，並視情況擇日舉行。
- TPS 第六屆理監事三年任期將於 2020 年 12 月結束，因疫情因素，第七屆理監事將採通訊投票選出。選票預計 11/20 前寄發給當年度已繳交年費之非學生有效會員，請會員收到選票後一週內寄回。選舉結果將以 email 告知會員並同時公佈於學會網站。

會員與會費

	一般會員		團體會員
	社會人士	學生	
入會費	0	0	0
常年會費	1,050 元 / 年	550 元 / 年	10,000 元 / 年



*歡迎登入學會網站線上填寫會員資料及繳費 <https://reurl.cc/RdRZY9>

*會員參與國際會議可申請學會獎助金補助 (相關辦法公布於學會網站)

第六屆 台灣蛋白質學會 組織成員

理事長 余兆松
 常務理事 阮雪芬 張權發
 理事 吳韋訥 吳慧芬 呂濟宇 邱繼輝 許邦弘 陳怡婷 陳威戎 陳健生
 陳逸然 辜韋智 蔡有光 戴桓青
 常務監事 游佳融
 監事 林榮耀 陳玉如 廖寶琦 賴建成
 秘書長 朱俐潔
 秘書 蔡淑娟 (03) 211-8800 ext. 3130



<https://www.proteomics.org.tw/>



<https://www.facebook.com/TPSpot/>



台灣生物資訊與系統生物學會 Taiwan Bioinformatics and Systems Biology Society

學會緣起

21世紀藉由基因體及蛋白質體技術的蓬勃發展，人們解開了生物系統內龐大且複雜的核酸及蛋白質數據，而這些傲人成果的背後，代表著海量數據的運算。生物資訊學迅速結合後基因體多項新技術發展，解開生物系統內龐大而複雜的數據，引發生物科技與分子醫學研究方法的革命，並產生多方面巨大之影響，其中包括著人類在生物及醫學領域的新契機與面臨的新挑戰。『台灣生物資訊與系統生物學會』於2000年12月建立，成立的宗旨即是希望透過跨領域的合作與資源整合，加速台灣生物資訊學的發展及推廣，進而提昇台灣在生技醫學領域的研發能量，如精準醫療、健康醫療大數據應用、基因檢測及微生物菌相分析等領域之研究。有鑒於此，我們誠摯邀請所有對生物資訊及系統生物學有興趣的人、系所與公司行號加入我們的行列。讓大家都藉藉此平台進行交流及利用本學會各項資源。

入會方式

入會資格：凡年滿十八歲、贊同本會宗旨、並完成會費繳交者。

入會費：個人會員貳佰元，團體會員壹仟元，學生會員壹佰元。

常年費：個人會員陸佰元，團體會員伍仟元，學生會員貳佰元。

收款行：兆豐國際商業銀行竹科新安分行 收款帳號：02009028049

戶名：台灣生物資訊與系統生物學會

*匯款後請 Email 至 tbsb.tw@gmail.com，標題請輸入【入會繳費】

近期活動

APBC2021 The 19th Asia Pacific Bioinformatics Conference

February 3rd-5th, 2021

National Cheng Kung University, Tainan, Taiwan

活動網址: <http://www.binfo.ncku.edu.tw/APBC2021/>



現任理監事

理事長 孫孝芳

副理事長 阮雪芬

常務理事 熊昭

理事 蔡少正 許聞廉 何信瑩 劉玉凡 莊樹諄 江士昇 朱俐潔

常務監事 呂平江

監事 張偉嶠 張憶壽



台灣基因醫學暨生物標記學會

Taiwan Genomic Medicine and Biomarker Society

各位會員、先進們大家好！

「2020 多體學及精準醫學聯合會議 暨 109 年台灣基因醫學暨生物標記學會年會」將於今日在林口長庚大學舉辦。此次大會活動得以順利籌辦，要特別感謝主辦的台灣蛋白體學會，與協辦的台灣生物資訊暨系統生物學會、台灣演化與計算生物學會、台灣精準醫學學會、與台灣胞外體學會。在這全球受到新冠肺炎疫情的嚴重衝擊的一年，本著維繫學術交流的考量，堅持舉辦本次的會議，相當的不容易。一個活動能夠順利籌辦，要感激的人實在太多太多。剩下的，就是希望踴躍參與活動的會員、學員及各界先進，在親臨現場之後，能仔細感受到活動籌辦團隊的用心，給予指教與鼓勵。

有鑑於近年來生物醫學研究發展急遽，人類及各種生物基因體遺傳因子也持續完成解碼，基因醫學及生物標記等相關研究更彰顯其重要性；本會係以推動國內基因醫學暨生物標記研究，並建構完善應用發展平台，落實各項基因醫學新知與新技術之臨床醫學診治應用，有效協助國人健康維護、提升臨床醫療照護成效，啟動現代醫學全新紀元為宗旨。本會成立轉眼已經多年，一直以來得以穩步成長，除了顧問的指導，所有理監事對學會的發展，集思廣益，熱情參與外，全體會員積極參與每個活動與學員們的支持與鼓勵，更是推動學會進步的最大動力。歡迎有志一同之學、研、業界人士加入本學會，共同為台灣基因醫學暨生物標記學會的未來發展而努力。


在此，謹代表學會感激所有對本會支持或有所批評指導的各界人士，有了大家的支持與督促，學會將會更加努力前進，在未來發展的過程中，加倍凝聚會員的力量，激發所有潛在的爆發力。最後，謹以最誠摯的心，歡迎並感激所有參與籌辦及蒞臨與會的嘉賓，更預祝此次大會順利圓滿，與會者都能滿載而歸，不虛此行。

學會報名網址：



台灣基因醫學暨生物標記學會理事長

鄭添祿



台灣演化與計算生物學會

Taiwan Society of Evolution and Computational Biology

學會簡介

本學會為非營利之社會團體。旨在推廣演化及計算生物學相關之技術研發、教育及應用。現代演化論應用到許多計算技巧，而計算生物學亦需要有演化的理念基礎。本學會亦將致力於聯繫國內外相關組織並推動學術及技術之國際交流平台。促進國內相關之知識管理及生技產業發展。

本次會議演講

特別演講：Genomic Evolution and Adaptation in Africa: Implication for Health and Disease

時間：2020/11/15 (日) 9:10-10:00

講者：Prof. Sarah A. Tishkoff

David and Lyn Silfen University Professor, Department of Genetics, University of Pennsylvania

Section I Population Genomics 時間：2020/11/14 (六) 10:40-12:05

Section IV Genomics of Pathogens 時間：2020/11/15 (日) 13:30-14:55

入會方式

個人會員：凡贊同本會宗旨、年滿二十歲、具有行為能力、從事或有志於演化或計算生物學研究與應用之個人，為個人會員。

團體會員：凡贊同本會宗旨之公私機構或團體，從事或有志於演化或計算生物學研究教學與應用之公私機構或團體，為團體會員。

入會費：

	個人會員			團體會員
	一般個人	助理及學生會員	博士後會員	
入會費	NT 100-	NT 100-	NT 100-	NT 10,000-
常年會費	NT 1,000-	NT 300-	NT 500-	NT 10,000-
終身會員	NT 12,000-	NA	NA	NT 120,000-

現任理監事

理事長	丁照棟
常務理事	丁照棟 阮雪芬 莊樹諄
理事	黃禎祥 呂美擘 陳倩瑜 蔡怡陞 廖本揚 張家銘
常務監事	王子元
監事	李文雄 方淑
秘書長	王弘毅





關於學會

胞外體在動植物和微生物的基礎科學重要性越來越被顯現，提供科學家對於解釋生命現象不同的角度和視窗；同時，也開始被應用在產業上，包含液態檢體之生物標識、藥物傳輸系統甚至治療。台灣有許多優秀的學者、活力創新的學生、高度的跨領域合作能量、完整的研究資源和基礎，要在胞外體的研究上或是產業應用開發上，我們應該非常有競爭力。台灣胞外體學會(TSEV)自 2017 開始籌劃、2018 年成立自今，逐漸成長；期間，學會舉辦和推廣許多國內外有關胞外體的學術活動及工作坊，推廣胞外體相關前瞻研究進展和產業資訊，逐漸看到了胞外體研究在台灣的迅速擴散，實現了台灣胞外體學會的宗旨。同時，台灣投入胞外體研究的學者和成果也在國際逐漸曝光和受到肯定，也成為亞太胞外體學會成員之一。台灣胞外體學已成台灣在胞外體研究和國際及產業鏈結的重要推手，目標和責任越趨重大。正如胞外體做為體內細胞間交流的重要媒介，每一位參與胞外體研究的人，絕對不吝嗇相互的交流，也是必然的性格特性。

入會方式

入 會 資 格：贊同本會宗旨，檢附資料並完成會費繳交者。

入 會 費(新台幣)：個人會員參佰元、學生會員壹佰元、團體會員參仟元。

常年會費(新台幣)：個人會員參佰元，一次繳交新台幣貳仟元得成為終身會員，不需再繳交常年會費、學生會員壹佰元、團體會員參仟元。

收 款 行：華南銀行台大分行

收 款 帳 號：154-10-009245-1

戶 名：台灣胞外體學會

匯款完成後請 email 至學會信箱 tsevtw@gmail.com，請註明【入會費用】

現任理監事

理 事 長	沈湯龍	理 事	郭文宏
常務理事	湯銘哲	理 事	徐瑋萱
常務理事	賴品光	常務監事	黃富楠
理 事	張金堅	監 事	何佳安
理 事	陳致真	監 事	許藝瓊
理 事	林劭品		



台灣精準醫學學會 Taiwan Precision Medicine Society

學會簡介

「台灣精準醫學學會」，英文名稱為「Taiwan Precision Medicine Society (TPMS)」，於 2015 年成立，為從事精準醫學之專家學者及臨床從業人員組成的非營利團體。以聯絡從事精準醫學之相關人士，共同促進精準醫學之研究發展及臨床應用，以及提高精準醫學範疇所涉及之疾病診療與研究水準為宗旨。本學會致力於提升精準醫學之水準，並舉辦精準醫學之教育訓練及舉辦學術演講與討論會，促進精準醫學之研究發展與應用及建立精準醫學之專科醫師與諮詢師制度與資格審核。

加入學會

入會費：個人會員貳千元，團體會員貳萬元，於入會時繳納。

常年會費：個人會員壹仟元，團體會員貳萬元，於入會時繳納。

個人會員、團體會員、學生會員、終身會員入會方式請參考學會網站。

精準醫學專科醫師/諮詢師訓練與認證

110 年精準醫學專科醫師/諮詢師訓練開始報名。

早鳥報名有優惠，詳細報名辦法請上學會網站查詢!

台灣精準醫學學會

會址：33305 桃園市龜山區復興街 5 號 K 棟 B1 (林口長庚醫院檢驗醫學部)

電話：0966-630-686 / 03-3281200-5140

<http://www.tpms.org.tw>




交通地圖

Maps

交通地圖 Maps

交通地圖 Maps

交通資訊 (長庚大學)




校園平面圖



交通地圖 Maps

會場：第二醫學大樓



晚宴：長庚高爾夫球場



交通地圖 Maps

校車時刻表

Linkou branch \longleftrightarrow Chang Gung University Shuttle Bus Time Table						
項次	星期一至星期五(Mon.~Fri.)		星 期 六 (Sat.)		星期(例假)日(Sun.and Holidays)	
	總 院	校 區	總 院	校 區	總 院	校 區
	Linkou branc	Chang Gung University	Linkou branc	Chang Gung University	Linkou branc	Chang Gung University
1	06:20	06:30	06:20	06:30	*07:00	*07:20
2	06:30	06:40	*06:50	*07:15	⊕07:30	⊕07:40
3	06:40	06:50	*07:35	*07:55	*08:00	*08:20
4	*06:50	*07:10	08:15	08:25	⊕09:20	⊕09:30
5	⊕07:15	⊕07:25	08:45	08:55	⊕09:50	⊕10:00
6	*07:35	*07:55	09:20	09:30	⊕10:20	⊕10:30
7	⊕07:40	⊕07:50	*09:25	*09:45	*10:50	*11:10
8	⊕08:10	⊕08:20	09:50	10:00	*12:00	*12:20
9	08:15	08:25	10:20	10:30	*12:50	*13:10
10	08:45	08:55	10:50	11:00	*14:00	*14:20
11	09:20	09:30	*11:00	*11:20	*15:10	*15:30
12	09:50	10:00	11:20	11:30	15:40	15:50
13	10:20	10:30	*11:40	*12:00	*16:10	*16:30
14	10:50	11:00	⊕*12:05	⊕*12:25	16:10	16:20
15	⊕11:20	⊕11:30	*12:20	*12:40	16:40	16:50
16	*11:50	*12:10	⊕*12:40	⊕*13:00	*17:15	*17:35
17	12:30	12:40	*12:50	*13:10	17:40	17:50
18	⊕*12:40	⊕*13:00	*13:00	*13:20	18:10	18:20
19	13:20	13:30	⊕*13:15	⊕*13:35	*18:20	*18:40
20	13:50	14:00	13:40	13:50	18:40	18:50
21	14:20	14:30	14:10	14:20	*19:25	*19:45
22	14:50	15:00	14:40	14:50	19:40	19:50
23	⊕15:00	⊕15:10	*15:10	*15:30	20:10	20:20
24	⊕15:10	⊕15:20	*15:40	*16:00	*20:30	*20:50
25	*15:20	*15:40	*16:10	*16:30	20:40	20:50
26	⊕15:55	⊕16:05	16:30	16:40	21:10	21:20
27	⊕16:05	⊕16:15	17:00	17:10	*21:35	*21:55
28	*16:10	*16:30	17:30	17:40	22:10	22:20
29	16:20	16:30	⊕18:00	⊕18:10	*22:15	*22:35
30	⊕16:35	⊕16:45	18:30	18:40	22:40	23:00
31	16:50	17:00	*18:40	*19:00	*22:50	*23:10
32	17:10	17:20	19:00	19:10	23:10	23:30
33	17:20	17:30	19:30	19:40	*23:25	*23:45
34	⊕17:35	⊕17:45	20:00	20:10	23:40	23:50
35	17:50	18:00	*20:20	*20:40	00:10	00:20
36	18:20	18:30	21:00	21:10	*00:25	*00:45
37	18:50	19:00	21:40	21:50		
38	19:20	19:30	*21:50	*22:10		
39	19:45	19:55	22:10	22:20		
40	20:15	20:25	22:40	22:50	收假專車(林口總院發車)	
41	*20:50	*21:10	23:10	23:20)	
42	21:00	21:10	23:40	23:50	◎13:10	◎17:55
43	21:30	21:40	00:10	00:20	◎13:40	◎18:25
44	*21:55	*22:15	*00:25	*00:45	◎14:25	◎18:55
45	21:55	22:05			◎14:55	◎19:50
46	22:20	22:30			◎15:25	◎20:20
47	22:45	22:55			◎15:55	◎20:50
48	23:10	23:20			◎16:55	◎21:20
49	●23:40	●23:50			◎17:25	
50	00:10	00:20			◎以上專車僅於星期例假	
51	*00:25	*00:45			日及連續假期之收假日行	
					駛	

代號說明：

*：總院→社區→校區→總院	◎：收假日行駛
⊕：支援車輛，非社校區本線班車	●：總院→校區→社區

交通地圖 Maps

贊助廠商 Sponsors



Agilent Technologies







贊助廠商 Sponsors





生物資訊分析平台

服務內容	<ol style="list-style-type: none">1. RNA-seq data 標準分析2. Small RNA sequencing data 標準分析3. 外顯子定序(WES) data 標準分析4. 全基因體定序(WGS) data 標準分析5. Panel平台分析6. 16S metagenome sequencing data 標準分析7. Pathway analysis 標準分析8. 生物資訊客製化分析/整合(電洽)
平台特色	<ul style="list-style-type: none">➤ 由多名博士後研究員及資深分析工程師專案進行分析➤ 提供客製化分析與視覺化的整合➤ 專業高速運算叢集伺服器系統，提供最快速的服務➤ 多種跨體學生醫大數據之整合分析➤ 分析技術開發合作及產學合作



長庚大學分子醫學研究中心

Chang Gung Molecular Medicine Research Center

單位：生物資訊暨體學數據應用核心實驗室

網址：<https://cgmmrc.cgu.edu.tw/p/412-1029-9988.php>

聯絡人：張益峯 博士(分機：3941)

Email：ianyfchang@mail.cgu.edu.tw

蛋白質體服務平台

Proteomics Core Lab Service

質譜分析與多重蛋白質同步定量

Sample preparation

- Tryptic digestion¹
- Sample desalting²
- TiO₂ enrichment³

Mass spectrometry

- 1D LC-MS/MS⁴
- 2D LC-MS/MS⁵
- Data analysis⁶

Luminex-based immunodetection

- Protein detection⁷
- Autoantibody detection⁸



¹接受PAGE膠體內或水溶液樣品，目前預設為Trypsin切割蛋白體，若有其他需求可先告知。
²接受使用者已經切割完成的胜肽，但須經過去除鹽類的處理。³用於磷酸化蛋白體的分析。
⁴預設使用的質譜儀機型為Thermo Fisher LTQ ORBITRAP XL。⁵使用者須先完成SILAC、iTRAQ、TMT...蛋白質或胜肽的同位素標定。⁶報告以MicroSoft Office Excel形式發送。⁷使用BioRad、R&D、Luminex或相同原理的檢測試劑測定蛋白濃度。⁸使用者需提供重組蛋白做為自體抗原以偵測自體抗體的相對量。



長庚大學分子醫學研究中心

Chang Gung Molecular Medicine Research Center

單位：蛋白質體核心實驗室

網址：<https://cgmmrc.cgu.edu.tw/p/412-1029-9961.php>




聯絡人：張育勳 (分機：3542)

Email: proteomics@mail.cgu.edu.tw



生物資訊分析平台

服務內容	<ol style="list-style-type: none">1. RNA-seq data 標準分析2. Small RNA sequencing data 標準分析3. 外顯子定序(WES) data 標準分析4. 全基因體定序(WGS) data 標準分析5. Panel平台分析6. 16S metagenome sequencing data 標準分析7. Pathway analysis 標準分析8. 生物資訊客製化分析/整合(電洽)
平台特色	<ul style="list-style-type: none">➤ 由多名博士後研究員及資深分析工程師專案進行分析➤ 提供客製化分析與視覺化的整合➤ 專業高速運算叢集伺服器系統，提供最快速的服務➤ 多種跨體學生醫大數據之整合分析➤ 分析技術開發合作及產學合作



長庚大學分子醫學研究中心

Chang Gung Molecular Medicine Research Center

單位：生物資訊暨體學數據應用核心實驗室


網址：<https://cgmmrc.cgu.edu.tw/p/412-1029-9988.php>

聯絡人：張益峯 博士(分機：3941)

Email：ianyfchang@mail.cgu.edu.tw

基因體定序服務平台

Next Generation Sequencing Service



DNA sequencing

- 全外顯子組測序 (Whole exome sequencing)
- DNA 甲基化測序 (Methylation sequencing)
- 標的基因測序 (Targeted re-sequencing)
- 染色質免疫沉澱測序 (ChIP sequencing)

RNA sequencing

- PolyA RNA sequencing
- 核糖體RNA測序 (Ribosomal RNA sequencing)
- Coding RNA sequencing (capture-based RNA sequencing)
- 微小RNA測序 (Small RNA sequencing)

Liquid biopsy

- 細胞外游離DNA測序 (cfDNA target sequencing)
- 外吐小體微小RNA測序 (Exosome small RNA sequencing)
- 免疫譜測序 (Immune repertoire sequencing)
- 單細胞轉錄體測序 (Single cell RNA sequencing)

Metagenomics

- 細菌16S測序 (Bacterial 16S sequencing)
- 全基因組測序 (Whole genome sequencing)

Precision Medicine

- 藥物代謝基因檢測
- 腸道菌群定序分析
- 乳癌與卵巢癌基因篩檢
- 液態切片基因檢測
- 癌症標靶治療基因定序服務
- 心臟病用藥基因檢測
- 家族性高血脂基因檢測
- 心血管疾病基因檢測



病理核心實驗室服務平台

Pathology Service Platform

服務項目

1. 免疫組織化學染色 (Immunohistochemistry. IHC)
2. 顯色原位雜交染色 (Chromogen In Situ Hybridization. CISH)
3. 玻片掃描服務

服務特色

1. 提供免疫組織化學染色抗體測試結果之病理科醫師諮詢服務
2. 提供免疫組織染色常用抗體，減少查詢抗體及測試時間
3. 採用全自動化染色系統，減少人為染色誤差與縮短染色時間
4. 使用Leica compact polymer試劑組，提高偵測敏感度與降低非特异性背景訊號
5. 五片式全自動玻片掃描，可完成20X/40X高品質切片影像掃描

使用設備

1. Leica Bond MAX自動化免疫染色系統
2. Aperio ScanScope CS2病理組織切片全相式影像掃描儀
3. OLYMPUS DP71數位化顯微影像分析系統



長庚大學分子醫學研究中心

Chang Gung Molecular Medicine Research Center

單位：病理核心實驗室

網址：<https://cgmmrc.cgu.edu.tw/p/412-1029-9966.php>

聯絡人：李怡萱 (分機：3531)

Email: iloveart@mail.cgu.edu.tw

定量代謝體服務平台

Quantitative Metabolomics Service

收件評估

服務對象

長庚體系研究單位、各大專院校學研單位及廠商

客製化流程

檢測標的

小分子(< 2000 Dalton)代謝物檢測

樣品前處理

服務項目

1. 代謝物衍生化: 化學同位素標定之樣品前處理
(Chemical isotope labeling)
2. 特定小分子及代謝物定量檢測
3. 客製化代謝體學檢測平台
(metabolomics profiling analysis)

樣品檢測

服務特色

1. 提供唾液、尿液、組織及細胞等多樣化檢體萃取平台
2. 與國外實驗室技術合作，利用化學同位素標定方法，可全面性的分析代謝體學，並提供定性與準確定量的結果
3. 提供特定代謝物之定量分析

數據分析

儀器設備



Agilent 1290,
Infinity II LC system



Waters ACQUITY,
UPLC



Bruker ion trap,
HCT ultra



Bruker Qq-Tof,
Impact II

報告產出



長庚大學分子醫學研究中心

Chang Gung Molecular Medicine Research Center

單位：蛋白質體核心實驗室代謝體質譜分析平台

網址：<https://cgmmrc.cgu.edu.tw/p/412-1029-9968.php>

聯絡人：張育勳 (分機：3542)

Email: proteomics@mail.cgu.edu.tw

